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Abstract. 
Because there are no explicit principles for prioritizing 
resources for health care, the result is often irrational and 
obscure decision-making. This leads to inefficient uses of 
health resources. cost-utility analysis has been developed to 
better assess efficiency and health economists and decision- 
makers in many countries are increasingly interested in the 
technique. This study uses the technique on a small scale and 
assesses how it could contribute to the Thai health sector. 
A survey was conducted in Thailand which consisted of 
interviews and postal questionnaires, to collect quality of 
life valuation data. The EuroQol instrument was used together 
with the visual analogue scale and time trade-off scaling 
techniques. The survey acquired 354 interviews and 162 postal 
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responses. The effect of some variables, in particular the 
respondents, personal background, on the quality of life 
valuation data are analysed in the cardinal, ordinal and 
standardised data forms. 
Health experience, income and education were found to 
af f ect the valuation of most health states. However, only 
health experience was found to affect the standardised data, 
which were eventually employed in this cost-utility analysis. 
Four Thai health care programmes were selected for 
assessment; measles vaccination, rotavirus vaccination, BCG 
vaccination and anti-TB chemotherapy treatment programmes. In 
each programme, the key parameters in the computation 
included health benefits, side effects, clinical features of 
the diseases involved, and health programme costs. A 
transformation process turns the clinical features and side 
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effects into the correspondent EuroQol health states. As a 
result, the health benefits and side effects can be converted 
into the quality-adjusted-life-year (QALY) unit. 
The base-case analysis indicates that the anti-TB 
ambulatory short-course chemotherapy would cost 172.94 baht 
(US$ 6.85) per QALY; the measles vaccination, 435.53 baht 
(US$ 17.43); the BCG vaccination, 837.23 baht (US$ 33.23); 
the anti-TB hospitalised short-course treatment, 1456.17 baht 
(US$ 57.69) and the 3ýotavirus diarrhoea vaccination, 2182.68 
baht (US$ 86.63). These results are compared with those of 
other international cost-effectiveness studies as well as to 
assess a Thai health policy. The sensitivity analysis 
suggests that changes in some crucial parameters could alter 
the ranking. 
Also, the study preliminarily investigates some valuation 
models and tests the results both extensively with 
international valuation data and intensively with the Thai 
data. Finally, it proposes some criteria to assess the model. 
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Prologue 
Health care decision makers are increasingly concerned 
with the issue of efficiency due to a variety of factors such 
as rising health care costs, the availability of new medical 
technology and changes in illness pattern. This concern has 
gradually been translated into the economic study of health 
care in the hope that it would guide health resource 
utilisation towards efficiency. 
Cost-utility analysis, one of the methods of economic 
appraisal of health care that possess a straightforward 
method that is easy to understand, has been developed to 
better assess efficiency. It gains more consideration because 
compared with traditional economic evaluation approaches, its 
health benefit measurement has better comparability between 
health programmes and less biasedness between people. It is 
evident that cost-utility approach is increasingly employed 
at all levels. 
In attempting to apply cost-utility analysis to the Thai 
health sector, it is essential to understand the underlying 
concept, methodology, procedure and interpretation. It would 
be sensible to try the analysis on a small scale and assess 
how it could contribute to the sector before it is fully 
launched. This is what this study aims to do. If it works 
satisfactorily, it may repiace the old method of efficiency 
assessment or be combined with the existing one. As a result, 
this would encourage more cost-utility studies. 
This study could guide analysts how to perform cost- 
utility analysis. It may also show how the methodology can be 
adapted to suit his/her own study settings. For health care 
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decision-makers, the strengths and weaknesses of the approach 
and the results generated have to be appreciated. If the 
outcomes of this analysis are used, they should be included 
explicitly, systematically and rationally in the decision 
rule. 
The objective of the thesis.. 
This thesis has three objectives. First, at a general 
level, it demonstrates the performance of cost-utility 
analysis as applied to selected health programmes in 
Thailand. It is hoped that this would be a stepping stone to 
the analysis of other health programmes. 
Secondly, two specific issues are examined, concerning 
the methodology of cost-utility analysis and the findings of 
the evaluation of selected health programmes. one of the 
advantages of investigating the current methodology is to 
point out how appropriate the outcomes based on them are. The 
results could then be fed back to its development. Also, some 
can be recommended to be used in the analysis. Others could 
be added to the routine checklists for the standard of the 
analysis. This study selects which health programmes to 
analyse on the grounds that most of their economic 
evaluations at the international level have proved 
inconclusive. These programmes are also feasible in terms of 
cost-utility analysis in the context of Thailand. Therefore, 
this analysis could offer the outcome of an alternative 
approach to solve their unsettled efficiency issue. 
Thirdly, the intention to use the EuroQol instrument in 
the Thai health state valuation meets the objective of the 
international community promoting the measure (The EuroQol 
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Group, 1990). The EuroQol Group was set up by a group of 
researchers across countries to develop a standardised health 
state measure. 
a) The main objectives of the study. 
Since there has been no cost-utility study in Thailand, 
the study sets out to analyse some Thai public health 
programmes with appropriate and feasible methodology 
compatible with the Thai settings. 
It outlines the procedure, surveying the health state 
valuation, collecting the basic data required, computing the 
cost per QALY, interpreting the findings and applying the 
results to health policy. 
It describes an example of the analysis and lays the 
foundation for the analysis of more health programmes. The 
more such health programmes are analysed, the better the 
efficiency of the health resource allocation will be 
understood, the more ref ined the priority setting of the 
programmes will be, and the more sensible the decision- 
making, planning and implementation of health service 
provision will be. 
The development in modelling the quality of life 
valuation will be important to the health state measurement 
in the future since the huge cost of a valuation survey may 
be unjustified for it to make available the values for all 
the health states as needed. Therefore, the study 
preliminarily investigates some valuation models, tests the 
results and sets forward some criteria to assess the model. 
In the future, the survey could perhaps serve to provide the 
information for the valuation model and for the test of the 
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model result. 
b) The immediate goals of the analysis. 
The methodology of this approach, especially that of the 
quality of life valuation, increasingly varies. Therefore, 
the methodology employed becomes crucial to the result and 
the application. The empirical investigation of the current 
methodology plays an equally important role in assessing its 
suitability. It is argued that to make the cost-utility 
approach more explicit and rational, the potential normative 
influences on the results of the analysis should be turned 
into positive ones for as many value-laden issues as 
possible. 
Before proceeding to the cost-utility analysis, the study 
examines the effects on the quality of life valuation of some 
observable personal characteristics of the respondents. 
Therefore, the users of the result of this study become aware 
of their existence. In response to the current debate on 
"whose values should count", it explores if there are any 
differences between the valuation of different groups (e. g. 
doctors, health administrators, patients and healthy people) . 
Statistical techniques could suggest a suitable form of value 
aggregation through analysing respondents' valuation. 
These analyses would help analysts and decision-makers 
handle quality of life valuation data. Also, the findings 
contribute to understanding and developing the valuation 
methods. 
c) Health programme appraisal objective. 
On the following grounds, the study advocates the idea 
that all kinds of health programmes should be analysed by the 
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cost-utility method. First, all such programmes involve both 
health-related quality of life as well as the quantity of 
life (as the definition of health by WHO implies), no matter 
how small their magnitudes. Secondly, they consume and 
compete for health resources regardless of how unimportant 
they are. 
The crucial requirement for any health programme eligible 
for cost-utility analysis is that they are efficacious and 
effective. If they are not, there is no need to assess them 
since they should not be used anyway and will never be 
legitimate choices. 
Measles vaccination, rotavirus vaccination, BCG 
vaccination and anti-TB chemotherapy treatment programmes in 
the context of Thailand were chosen for assessment. Their 
comparisons can be formed as follows. BCG vaccination and 
anti-TB treatment represent a comparison between preventive 
and curative care that share the same objective of TB 
control. Measles and rotavirus vaccinations are two different 
measures for achieving the same end product (e. g. diarrhoea 
prevention). The same mode of protection delivery (e. g. 
vaccination) that is commonly used in controlling three 
different diseases (e. g. measles, rotavirus diarrhoea and 
tuberculosis) is compared. Above all, the inter-programme 
comparison ignoring their classification barriers and 
employing the common cost per QALY shows the trade-off 
between them in achieving the efficient use of health 
resources. 
Though these programmes have been widely studied with the 
cost-effectiveness and cost-benefit methods at the 
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international level, there is still scepticism about their 
overall cost-effectiveness. In many instances, they are 
inadequate as an aid to devising health resource allocations. 
The significance of this is that they are assessed by the 
cost-utility method. 
It is suspected that the BCG vaccination is neither 
effective nor cost-effective, as found in some clinical 
trials. In comparison, TB treatment is claimed to be an 
effective option for TB control and probably one of the most 
cost-effective options in developing countries. The 
comparison between rotavirus vaccination (despite its 
experimental status at the time of writing) and measles 
vaccination in lowering the morbidity and mortality incidence 
from diarrhoea has produced inconclusive findings. 
As a result, the existing outcomes fail to point 
decisively to the optimal funding and priority ranking of 
these programmes. For instance, rotavirus vaccination is more 
cost- effective in reducing diarrhoeal morbidity but less in 
preventing mortality than measles vaccination (Creese, 1983) . 
A combined measure of morbidity and mortality is suggested to 
be the solution to the contradictory outcome (Prescott et al, 
1983). By combining these two aspects of diseases into a 
common indicator and allowing for their duration, cost- 
utility analysis can resolve the obstacle and offer better 
conclusions and implications. 
It is apparent that the more these programmes are 
analysed with traditional economic evaluation methods in 
different populations, the more contradictory results are 
obtained. For they sharply differ in identifying, measuring 
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and valuing key parameters. They have incomparable coverage 
of the data collection and possess the distinctive degrees of 
the data accuracy. Therefore, this study attempts to analyse 
these programmes in a consistent way. They have compatible 
analysis procedure and therefore comparable results. 
Attention is paid to the issues of identification, 
measurement, estimation and valuation of vital parameters. 
The data sources are Thai health statistics. Secondary 
data available in some studies are also employed. For the 
unavailable Thai data, the data from more reliable, 
international sources are used. Their wide coverage reduces 
the number of assumptions, which could otherwise undermine 
the credibility of the analysis. Also, they are based on 
identical computation method. The government viewpoint is 
adopted because of the availability of government data and 
because it is the biggest provider of health services. 
Though the number of health programmes to be compared is 
small, the findings indicate their efficiency and rank their 
priority. The application of findings to reallocation could 
doubtless be of benefit if they are truly inefficient. 
d) The qlobal aim of the health-related qualitv of life 
valuation and cost-utility approach. 
The application of a health state measure to different 
populations is one of the keys to establishing it as a global 
measure. This study, based on the EuroQol instrument, is one 
of many studies contributing to achieving the EuroQol Group's 
objective of developing the instrument as a universally 
standard health state measure with regards to resource 
allocation. It would also serve a wider purpose as a health- 
related quality of life valuation in general. The 
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availability of valuation surveys using the EuroQol 
instrument can enable a comparison of valuation results in 
different populations. This also makes it possible to attempt 
modelling valuations at an international level. 
The study adds to a growing number of worldwide cost- 
utility studies. Such health programmes increase the stock of 
international economic evaluation studies. 
The organisation of the thesis. 
The organisation of the thesis follows the steps of the 
cost-utility analysis which this study undertakes. Chapter 
One introduces the cost-utility approach. It argues that this 
approach could bridge the gap between traditional economic 
evaluation approaches and contemporary alternative health 
resource uses, to which health benefit valuation in monetary 
terms is often inappropriate. The usual procedure is outlined 
and the methodology to date is reviewed. Unresolved problems 
are highlighted. Findings are interpreted and application 
areas discussed. Finally, the critical survey of cost-utility 
approach is presented. 
Chapter Two provides a background of the health state 
valuation containing a brief summary of various principal 
health-related quality of life measures and a full discussion 
of key scaling methods. Valuation collection in Thailand is 
surveyed, describing the implementation of the valuation 
survey in Thailand and reporting the outcome. Also discussed 
are criticisms of the EuroQol instrument. 
In Chapter Three, the effects of personal background 
variables on the Thai valuations are analysed. The results 
also have implications for the issuesý of whose values should 
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be used and how these values should be aggregated. The tests 
are applied to individual, as well as aggregate, units of 
observation. The data are investigated in the cardinal, 
ordinal and standardised forms in both analyses. 
Chapter Four presents the identification, measurement and 
estimation of the parameters used in this cost-utility 
analysis. It discusses the underlying concepts of 
identification and measurement of the health benefit effects, 
the side effects and the cost as well as the transformation 
method of the diseases and side effects into health states 
and QALY. The issues of discounting health care programmes 
are also addressed. This is followed by their estimations for 
the four health programmes and the implementation of 
conversion of clinical features into health states and QALY. 
Thd computation of the cost per QALY of the four 
programmes is shown in Chapter Five. The base-case results 
are presented, followed by those of the sensitivity analysis 
of some key variables and assumptions. The findings are 
compared with other international economic appraisal studies 
of these programmes. They are further used to assess 
Thailand's proposed health policy. 
Chapter Six makes a further inquiry into health state 
valuation. It compiles and compares outcomes of the valuation 
surveys with the EuroQol instrument in populations of 
different countries. Valuation models are tested extensively 
with these international data and intensively with the Thai 
data. 
Chapter Seven concludes the study. It discusses some 
issues arising from the analyses. It points out the 
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shortcomings and limitations of the cost-utility analysis. In 
addition, suggestions are proposed for improving the health- 
related quality of life valuation as well as other aspects of 
the cost-utility approach. It also lists further issues for 
research. Finally, it remarks on the prospect of the cost- 
utility approach in Thailand and at the international level. 
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Chapter 1 
The cost-utility approach to the assessment of health care 
This chapter introduces the cost utility approach to 
dealing with the inefficiency problem of health resource 
allocation. After pointing out the inadequacy of the 
traditional economic evaluation methods, it outlines the 
procedure of cost-utility analysis, discusses a variety of 
contemporary methodologies and considers its key problems. 
Also discussed are the use of results of cost-utility 
analysis and the ways in which is can be applied. The last 
section discusses criticisms of the technique and suggestions 
for resolving the remaining unsettled issues. 
1.1. The resource allocation problem in health sector. 
Priority-setting is a common problem in the health 
sector. It is necessary in view of the fact that there are 
insufficient resources available to do everything that might 
be beneficial. The problem appears at different levels from 
national health policies down to a routine job of individual 
practitioners. It could also be influenced by a variety of 
factors, including the economic situation of the community in 
question. However, economic criteria have played a relatively 
minor role in decision-making of health policy so far. For 
example, a public health policy may give to serious diseases 
precedence over less serious ones because the former produce 
more adverse consequences than the latter. Similarly, an 
observation of a doctor's practice could find that life- 
threatening cases are put before those that are not life- 
threatening. 
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More choices of health interventions have been created. 
The advance in medical technology provides more scope for 
achieving similar health outcomes or tackling the same health 
problems. Health concerns are increasing. We face new health 
problems such as environmental hazard, the control of which 
need to be covered in health sector. Likewise, health care 
tends to widen its coverage to new areas, previously not 
included in the health care system. For instance, care for 
the elderly in most developed countries has been developed 
after the welfare benefit system was established. This shows 
how the scope of health care widens over time. 
Under conditions of limited health care resources, these 
factors make the traditional priority-setting methods 
inadequate. It is unnecessary to spend more than necessary to 
attain a health objective when there exists a cheaper option 
to do so, for it prevents the excess from being used for 
other purposes. This is a typical characteristic of an 
inefficient allocation of health care resources. 
When an option with the least resource requirement is 
known and selected, the limited health fund could be 
redeployed for other purposes (even additionally in other 
non-health areas). The importance of the efficiency issue 
intensifies as it is recognised that most health care 
resources have the same ultimate objective, an improvement in 
health. 
Thai national policies have apparently determined 
priorities of health resource uses, although the underlying 
criteria are difficult to identify. For example, one policy 
clearly emphasised preventive care over curative care. The 
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Thai public health service system's confused criteria for 
priority-setting in allotting health resources was noted by 
the Fact Finding Commission (1987). It showed that the health 
programme priority of different levels of administration and 
that of different health agencies were inconsistent and 
incompatible, although they served the same government 
policies. The economic aspect has not received much attention 
in the government's priority-setting methods so far. 
In reviewing its recent master health plan, the 
government began to realise that more new and diversified 
health issues had to be dealt with. The programmes proposed 
included developing the health system infrastructure, 
improvement of health organisations, promotion of Primary 
Health Care and strengthening of laws related to health. At 
the operational level, numbers of patients with non- 
communicable and chronic diseases are rising and a population 
transitional change means an increase in the demand for 
health care for the elderly. Facing a surging number of 
problems, the government can no longer afford to ignore the 
efficiency aspect of health resource utilisation. Though the 
awareness of the inefficiency issue and the minimisation of 
the resource waste were mentioned in some health policies, 
they were not brought into effect. Guided among other 
decision criteria by the economic assessment, the priority- 
setting can indicate new lower cost programmes as well as 
identify which existing programmes are excessively expensive. 
In other words, it could distinguish between efficient and 
inefficient programmes. 
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1.2. The cost-utility approach as a rational solution to the 
inefficiency of health resource allocation. 
1.2.1. The conventional economic appraisal. 
From the economic viewpoint, the best use of any 
commodity including health resources can be guaranteed under 
the conditions of perfect competition. In other words, 
efficiency can be achieved without any government 
intervention, except to ensure that the market is perfectly 
competitive. However, most health care is not provided in 
such a situation. "Market failure" is the term used to 
describe this state of affairs. 
Efficiency can be defined as the condition that no one is 
made better off without at least one person being made worse 
off from the change under consideration. This is known as the 
Pareto optimum. The investigation of efficiency is termed 
economic evaluation (or appraisal or assessment). In 
practice, with the assumption of compensation between gainers 
and losers from the redistribution, cost-benefit analysis is 
the procedure by which to assess efficiency. Following the 
process of identification, measurement and valuation of the 
benefits and costs as well as discounting all items into the 
same time reference (i. e. the present value), the net of the 
two, which is usually converted into the same unit 
(e. g. monetary term), indicates the efficiency status. 
If the benefits and costs have a different unit, cost- 
effectiveness analysis is used to compare various 
alternatives with a similar outcome(s). This may reduce the 
comparability but still maintain the uniqueness of the 
benefit. Cost-benefit analysis can make a broader comparison 
between health programmes than cost-effectiveness analysis 
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because of a simpler measure of health benefits of the former 
(e. g. monetary terms). In economic terminology, efficiency 
assessed by cost-benefit analysis is referred to as 
allocative efficiency and that by cost-effectiveness analysis 
as technical efficiency. The final forms of their findings 
may be presented as a benefit-cost ratio and effectiveness- 
cost ratio. An option with the maximum ratio is the most 
efficient and the order of the efficiency for the rest is 
ranked on the basis of the ratio. 
As "do-nothing" is also one of the options, which happens 
of ten in the health sector, it is suggested that this should 
be included in the evaluation, particularly with cost- 
effectiveness analysis. Drummond et al (1987) illustrates the 
procedures of these approaches commonly employed in practice 
and provides a set of checklists for good and standard 
conduct. Mills (1985) reviews the application of the economic 
evaluation in developing countries. 
Though their underlying concept and framework are 
settled, the methodology, especially the estimation of some 
parameters, varies widely. In some early cost-benef it studies 
of health programmes, the loss of productivity from ill 
health avoided was normally considered as the benefit. The 
shadow pricing method was used to calculate the potential 
loss. Later, the concept of the value of life as well as the 
value of some. human body parts replaced the productivity 
loss. A number of new measurement methods were created. The 
willingness to pay method approximates the value of life from 
the willingness of individuals or institutions to trade a sum 
of wealth with a reduction in some probability of an ill- 
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health condition (usually death). The behaviour method 
estimates the life value by referring to real activities how 
they respond to the avoidance of health damage conditions 
with their financial sacrifices. The data can be acquired 
through a direct elicitation or from relevant published 
documents. 
The health benefit identified and measured in a cost- 
effectiveness study is broad since there exist a considerable 
number of unique health outcomes and a variety of objectives 
of the interventions. For example, it includes healthy years, 
mortality avoided, morbidity averted, cured cases and cases 
detected and treated. It also encounters methodological 
difficulties but to a lesser extent than cost-benefit 
analysis. Most cost- effectiveness studies could curtail some 
steps of health benefit measurement and valuation as well as 
some methodological difficulties by employing the data from 
relevant clinical trials. Normally, such trials provide 
reliable and scientifically sound results. 
It is now recognised that the cost-benefit approach is 
unfair to some population groups, like non-earning people, by 
neglecting their shares in the benefit computation. Also, 
there are many qualitative benefits that cannot be quantified 
and valued in monetary terms and that are totally left out of 
the calculation. Pain, suffering and mental and psychological 
outcomes are the most common examples. On the other hand, the 
definition of benefit in cost-effectiveness analysis is in 
many cases too narrowly defined for some decisions to be 
based on the findings. In some instances, the limited benefit 
from the study does not justify the cost. The methodology of 
44 
the two approaches does not really tackle a "spectrum" of 
health. They just deal partially with it in the simple forms 
of death, morbidity, disability, injury and debility. The 
quality of life hardly counts. 
The criticisms of the willingness to pay method are that 
the result could be influenced by other factors such as the 
attitude towards risk in addition to the intended variables 
and that the findings are likely to be misinterpreted and 
misused if the generalisation from a particular exercise 
towards the health resource allocation as a whole is not made 
known to the respondents involved. The drawbacks of the 
behavioral method are that in many instances it provides 
insufficient observations to make reliable results and that 
it sometimes cannot find proper cases for the health outcomes 
in consideration. Instead, it often uses the results from 
other relevant studies, the suitability of which are in 
doubt. 
1.2.2. Cost-utility analysis. 
An attempt to rectify these disadvantages leads to the 
development of a new approach to economic evaluation, known 
as cost-utility analysis. This method still maintains the 
welfare economic foundation and framework but improves some 
aspects of the process of benefit measurement. It seems to 
promote the economic evaluation of health care and play a 
growing role in health sector. 
Its major innovation lies in the area of health outcome 
measurement, which is the quality-adjusted-life year (QALY) . 
The QALY unit consists of two components. First, the quantity 
of life is considered as the length of life added by a health 
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intervention. In almost every health intervention, this 
aspect of life is unambiguously made known by medical and 
clinical evidence. Secondly, the quality of life concerns 
about the qualitative aspect of health. For example, an 
illness may affect physical health (e. g. ability to walk, 
selfcare and doing routine activities), mental health (e. g. 
pain, anxiety and depression) and social well-being (e. g. 
social life and family relationships). It is essential to 
know which impaired health dimensions of an ill person are 
averted by a health intervention and by how much (i. e. the 
severity). Some measurement methods of the health-related 
quality of life, normally represented by a health state 
classification, present the results in utility, as well as 
numerical, values. 
This new health outcome unit makes this approach flexible 
in the coverage of health programmes under comparison, that 
is, from a few alternative programmes sharing a common object 
to all the health programmes funded by a national health 
budget. It solves a classical problem of the trade-off 
between different aspects of health outcome, implicitly 
performed by decision makers facing diversifying health 
effects. As a result, cost-utility analysis is more useful 
than cost-effectiveness analysis. Since the two components of 
the QALY are natural health outcomes, it does not 
discriminate between people as obviously as and much as cost- 
benefit analysis does. Usually, a QALY gained is counted 
identically for all health service recipients. Moreover, all 
the health effects of health programmes compared--good and 
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harmful--can be included in the analysis, no matter how 
trivial. 
1.2.2.1. Usual procedure. 
In practice, the steps of conducting cost-utility 
analysis can be varied but the core steps remain similar. 
Health-related quality of life is relatively crucial with 
respect to the current state of the art since it has only 
recently been included in the analysis and since no standard 
measurements of the quality of life have been established 
yet. As a result, it could dictate some other steps. So the 
following pattern of steps taken in this study is proposed, 
starting with the quality of life issue. 
1) Health-related quality of life is to be identified, 
measured and valued. Clinical trial studies could provide 
such information, in addition to showing the efficacy and 
effectiveness conclusions of health programmes. However, in 
most cases, the trials cannot give all the details the 
analysts want. Fitzpatrick et al (1992) point out that a 
measurement instrument of the quality of life designed for 
one purpose might not be appropriate for being used in 
others. Usually quality of life is identified with reference 
to the standard concept of health (defined by the World 
Health Organisation) and measured by a health status 
measurement method in the operational form of health states. 
A change in health (that is, in health states) is central to 
the measurement task. Then, all the changes found are valued 
with a proper scaling method by selected respondents. 
Eventually, the quality of life from health programmes is 
quantified in terms of changes in health state values. 
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2) The identification and measurement of the quantity of 
life should be based on the same health state measure as used 
for the quality of life identification. However, this rarely 
happens at present. Therefore, the quantity of life measured 
in other health indices or instruments could be transformed 
into the one being used. The time scale is measured in the 
valuation (i. e. days, weeks and years). 
3) In a change in health state, the quantity of life is 
weighted by the quality of life (i. e. the multiplication of 
the quality of life and its corresponding time length). This 
gives rise to an amount of QALY. The QALY which occurs in the 
different time periods (i. e. on the basis of one year) is 
discounted into the present value counterpart. Then the sum 
of all the present values is the total benefit from a health 
programme. 
4) The side effects from the programme, also affecting 
the quality of life as well as the quantity, can be 
identified, measured, and valued by the same procedure 
described in 1) and the impacts on the quantity of life can 
be quantified as in 2) . Combining the two as 
done in 3) 
creates the QALY loss from the side effects. 
5) The net benefit is the difference between the health 
benefits (3) and the side effects (4). 
6) The cost of a health programme may be divided into 
direct, indirect and intangible costs. There is no definite 
rule about how comprehensively the programme cost should be 
measured. It depends on a variety of factors, including the 
purpose of the study, what viewpoint adopted (society, 
beneficiaries or government), the assumptions about health 
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care market and the dif f iculty of compiling the data. All the 
costs are valued in monetary terms. Some approximation 
methods may be needed for the costs arising from the non- 
marketable and non-tradable. They are subject to discounting. 
7) The comparison between the benefit and cost (i. e. steps 
5 and 6) is usually expressed in the form of the cost per 
QALY. By supposing the cost per QALY of a health programme is 
c dollars per QALY gained, it can be shown that the cost of 
rendering a year in the perfect health state by the programme 
equals to US$ c. 
The steps can be reshuffled provided that it does not 
adversely af f ect the analysis. For example, Spiegelhalter et 
al (1992) say that the quantity of life step could come 
before the quality of life one. The performance of some steps 
may be modified in accordance with a variety of factors (the 
cost of study, the availability of relevant economic 
evaluation studies, etc. ). 
1.2.2.2. Methodological variation. 
There is a considerable variation in the methodology used 
by most cost-utility studies. The key methodological 
variation in the identification, measurement, estimation and 
valuation are discussed as follows. 
a) Health-related quality of life measurement 
instrument. 
At present, the available instruments which are generic 
and widely implemented are the Quality of Well-Being Index, 
Sickness Impact Profile, Nottingham Health Profile, McMaster 
Health Index Questionnaire, Rosser Index and EuroQol. Their 
descriptors differ in the number and type of health 
dimensions, level of the dimensions, the number of statements 
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to be answered and the form of administering the 
questionnaire. Their valuation methods deviate in the scaling 
methods, the scale unit and the final form of the weightings. 
However, some studies comparing the results from different 
instruments indicate their convergence towards a trend 
(Buxton et al, 1988). 
b) Health-related quality of life scaling method. 
The popular scaling methods include magnitude estimation, 
visual analogue scale, categorical rating, standard gamble 
and time trade-off methods. They vary in their presentation 
(e. g. visual analogue feeling thermometer, choosing between 
the two choices and balancing two magnitudes of the two 
different things) and also in their criteria governing the 
valuation decisions and adjustors (e. g. probability, life time 
and the number of patients cured). Nevertheless, it is found 
that some scaling methods produces the similar results 
(Torrance,. 1988). 
c) Measurement of the health programme outcome. 
Ideally, the outcome is assessed by simply applying the 
instrument in consideration to the target subjects. But due 
to various factors, such as a long period of observing 
chronic patients, or an extraordinary cost of the measurement 
and ethical obstacles, the direct measurement method may not 
be possible. The alternatives are the conversion of existing 
outcome measures into the chosen instrument and the 
employment of experts, opinions about the outcomes formed on 
the basis of the instrument. 
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d) The health benefit unit. 
Recently, some health benefit units were claimed to be 
better than the QALY. The healthy-years -equivalent (HYE) has 
been designed to measure the utility value of a health 
profile (i. e. measuring the utility of all health states in 
various time periods involved in a certain health programme 
as a whole) in preference to the QALY, which measures 
separately the utility value of each health state (Mehrez et 
al, 1989). In other words, the utility function in the QALY 
unit is very specific whereas the HYE is so general that 
individuals with different types of the utility function 
could be reflected in the empirical valuation (Culyer et al, 
1992). However, the proposed unit is perhaps too complicated 
to be employed in practice and fully understood by decision 
makers. In addition, the allowance for some specific 
preferences may limit the comparability of the appraisal, 
undermining its applicability. 
e) Coverage of the health outcome measure. 
Although almost all studies incorporate the main health 
outcomes (particularly benefit effects), there is still 
variation in the coverage of the outcome measure, both health 
benefit and side effect. Some side effects are often missed 
out simply because there are no clinical trial studies 
providing their measurement. In some economic 'appraisals, 
insufficient literature review and data collection exclude 
some minor benefits and side effects. One of the solutions is 
to survey as many relevant studies as possible. As 
conflicting findings from the trials are not uncommon in some 
areas, it could highlight this issue if it exists. 
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Potentially different results and conclusions based on 
different trials would be notified in the study. It is also 
useful to update and reanalyse studies with new information. 
Cost-utility studies of health programmes against 
coronary heart diseases (CHD) are used here to highlight the 
methodological variations. These are appropriate examples 
because they are not only intended to serve the same purpose 
(i. e. reducing CHD) but also account for a large proportion of 
all the cost-utility studies undertaken to date (Gerard, 
1992). The programmes are coronary artery bypass graft (CABG) 
surgery (Williams, 1985; Weinstein et al, 1985), beta- 
adrenergic-antagonist (BAA) therapy (Weinstein et al, 1985; 
Goldman et al, 1988), anti-hypertensive treatment (Weinstein 
et al, 1985; Nissien et al, 1986), hypercholesterolemia 
treatment (Weinstein et al, 1985) and exercise (Hatziandren 
et al, 1988). 
The quantity of life is concerned mainly with the size of 
the effect (i. e. the number of health care recipients 
obtaining the benefit effects) and the extended length of 
life an average beneficiary receives. Nevertheless, the 
emphasis of the two may differ among the programmes due to 
the nature of the services. CABG surgery focuses on the long- 
run survival of the patients whereas the BAA therapy, anti- 
hypertensive treatment, hypercholesterolemic treatment and 
exercise aim at the reduction in CHD mortality and extra life 
expectancy. The outcome assessment of health programmes with 
spill-over effects on other diseases encounters the 
difficulty of not only accurately measuring the effects on 
the disease in consideration, but also dealing with the 
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effects on others. For example, the anti-hypertension 
treatment programme expects the additional benefit of stroke 
prevention and the exercise programme claims a reduction in 
other related illnesses but they are incapable of quantifying 
them. 
The quality of life measure for health outcomes is 
rudimentary since the health status measurement and valuation 
were unavailable at the time of most studies. The BAA therapy 
study focuses on the relief of angina and the prospect of 
returning to work. One study uses health profiles of each 
type of the disease and of post-treatment from the experts. 
By contrast, the others depend on the results of the clinical 
measures available. The quality of lif e is valued by the 
existing valuation data in one study and by the analysts 
themselves in the others. The exercise study assumes only two 
states of the quality of life. The onset of a non-fatal form 
of CHD is assigned 0.8 (healthy state = 1.0) and the injury 
from exercise, 0.9. 
The side effects of CABG are concerned mainly with the 
chance of the operative success (i. e. the death from the 
surgery) but little with other kinds. By contrast, for the 
anti-hypertensive treatment, the importance of the side 
effects exceeds that of the benefits. They are reported in 
the form of a variety of symptoms and signs. However, the 
matching quality of life measures is not indicated. The 
research does not bother to measure the side effects by 
assuming that the side effects could be offset by the 
indirect benefits (i. e. medical saving from the treatment). 
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Most of the analyses rely on effectiveness studies, 
notably randomised controlled trials. By contrast, the 
exercise programme employs a follow-up study of a 1000 
voluntary cohorts for 30 years. 
The direct costs are central to all the programmes while 
the indirect costs are optional and included in few studies. 
The CABG studies uses the treatment cost, excluding the cost 
of diagnostic tests prior to surgery. Constant costs 
regardless of the number of operations are assumed. The BAA 
therapy cost consists of the drug cost and fees for physician 
visits to monitor the drug administration. One study 
approximates the former with the average annual cost per 
patient surveyed from 10 drug stores in a city. The annual 
treatment cost is used in the hypercholesterolemic treatment. 
The exercise programme includes the direct cost (e. g. clothing 
and jogging shoes) and indirect cost (mainly time value). 
International studies of treatment effectiveness, which 
report the health outcomes, are covered in all the studies. 
Nevertheless, the way of handling the data in some studies is 
different from others. One of the BAA studies pools all the 
data available together whereas another follows a larger U. S. 
trial. 
The study population (i. e. the group[s] to which the 
programmes are intended to deliver services) differs in 
various studies, despite the fact that the CHD victims are 
similar. The findings might differ significantly among 
different study groups. The CABG surgery study categorises 
the operation recipients according to the severity of the 
disease (i. e. number of vessels damaged) . The BAA therapy 
54 
study classifies the patients into three groups with respect 
to their risk (high, medium and low), which is defined by the 
estimated risk of cardiac mortality in the 15-year period 
after myocardial infarction. Blood pressure, a simple 
clinical sign, is a main criterion to group the risk 
population for the anti -hypertension treatment. The exercise 
programme simply chooses 35-year-old men. 
The number and type of parameters, assumptions and 
conditions changed in their sensitivity analyses are normally 
altered one at a time. The BAA studies change the health 
benefit variable (both the extended length of life and the 
number of beneficiaries), cost and the mortality rate of the 
untreated. The anti -hypertensive study alters the discount 
rate and includes earning income among the health benefits. 
The exercise programme varies the discount rate, relative 
risk of CHD, prevalence rate of exercisers, quality of life 
values and cost. 
1.2.2.3. The problems with cost-utility analysis and some 
solutions. 
Since the valuation of health-related quality of life is 
a new issue in economic evaluation, a number of new problems 
and controversial issues emerge, despite the fact that some 
problems have been recognised for more than three decades in 
medicine and psychology. The subjective nature of the quality 
of life makes it impossible for it to be sensibly estimated 
from any variables other than the responses towards a value 
elicitation. In this respect, the cost-utility approach is 
more difficult and involves more effort than the other two 
economic appraisal methods. 
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As a result, in any study the following questions must be 
settled before the analysis can proceed. Moreover, the way in 
which these problems are handled should be made explicit so 
that the result users could fully understand. First, whose 
quality of life values should be acquired in the valuation 
procedure and incorporated into the analysis? Secondly, how 
good is the valuation outcome obtained? (Or, what is the 
quality of the valuation data obtained? ) Thirdly, how to 
incorporate them in the analysis? (Or how to aggregate them 
for a single index? ) These problems may not be solved 
theoretically but might be empirically resolvable. The 
empirical investigations of these issues are limited. Though 
the means to tackle these problems have been proposed and 
analysed, the established solutions are not available. 
a) Whose values should count? 
There are two basic views on the issue of whose values 
should count. One advocates that the quality of life values 
from some groups (e. g. doctors, patients and politicians) 
should represent the population. These values may come from 
a group Is own genuine values or f rom a group Is balancing 
values supplied by different people. Their experience, 
knowledge and/or authority conceivably makes their values 
reflect the reality (i. e. the vision of the quality of life). 
Muskin (1962) champions the socially-determined valuation by 
policy makers because health programmes normally generate 
positive externality, have no market pricing and lack the 
market mechanism. The other advocates the values of the 
general public, including the groups mentioned previously. 
Not only are health programmes usually financed by the 
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public, but also the potential health service recipients, 
excluded from the previous view, are incorporated into this 
one. The issue is often formed into a simple question; 
"Should direct beneficiaries, quality of life values or 
health care providers, or policy makers, or a whole 
population's be used and included in the health programme 
economic assessment? ". 
The criticism of the first view is that experience, 
knowledge, authority and familiarity cannot always guarantee 
an appropriate valuation since valuation is entirely a 
personal matter. Leger (1988) claims that doctors could be 
under the influence of some illness indications irrelevant to 
their patients. They were also found to underestimate the 
disability impact. It is possible for the patients to make 
the valuation in an overstated way to attract more resources 
to their care. It is found that patients with more disability 
tend to under-value the severity levels of their impairment 
while those with less do the opposite (Leger, 1988). 
Moreover, in using the valuation of some particular 
experts and/or patients, cost-utility analysis may become 
programme- specific because different health programmes would 
seek their own quality of life values. Unsurprisingly, this 
leads to the imposition of an extra cost of performing the 
analysis, and only health programmes with a justified net 
return can be carried out. As a result, this would limit the 
comparability between different health programmes, which is 
an advantage and objective of the analysis at the outset. 
The inability to understand and imagine the quality of 
life by the general public is a major reason, and therefore 
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a main criticism, for fear that their quality of life values 
would be irresponsible and unfounded. 
The nature of a health programme may be used to determine 
whose values are desirable. For example, preventive 
programmes should be based on policy-makers, valuation 
because such programmes affect everybody. For the treatment 
of some rare diseases, patients' and/or physicians' opinion 
might be appropriate due to their better understanding the 
illness consequences than others I. Public valuation would be 
suitable for the programmes associated with the life-style 
illness and the secondary preventive care (e. g. non- smoking 
campaign programme and breast cancer screening tests). 
However, this method may just solve the problem in a small 
number of health programmes. on a wider scale, the issue can 
be formed into an investigative question such as, "Is there 
any difference in the quality of life valuation among 
respondents? ", and an empirical analysis launched to examine 
it. 
To tackle the afore-mentioned groups potentially 
responsible for the value division, most analyses focus on 
the comparison between the valuation from doctors, health 
personnel, policy-makers, patients and common healthy people. 
By drawing the question parallel to an appropriate 
statistical procedure, the test for such comparison can be 
performed. It has been found that the difference in the 
valuation among various groups does not exist in every 
analysis. It is suggested from this conclusion that each 
cost-utility study has to assess this issue for its own 
surveyed values. For studies with the insignificantly divided 
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valuation, no decision-making is needed on this issue. By 
contrast, for one with significantly distinctive valuations, 
the decision could be made with the help of analysis 
findings. In order to measure the impact on the cost per QALY 
and priority ranking of choosing different group's values, 
the values should be tested in the sensitivity analysis 
section of the study. 
b) The quality of the valuation. 
Arguably, the outcome of the quality of life valuation 
can be biased by a number of factors. Fortunately, most 
doubts can be verified on empirical grounds. The fact that 
most scaling methods under real-life conditions violate their 
underlying assumptions undermines the reliability of the 
outcomes (Pliskin et al, 1980; Loomes et al, 1989). The 
personal background effects, which usually exist in opinion 
surveys and other non- experimental data collection, could 
make the outcomes invalid. The genuine values may change 
over time. The outcome at one point in time might not be 
appropriate for decision-making involved at any other 
time. 
Since no experimental studies have been developed to 
acquire unbiased values of the quality of life, the check for 
the biasedness of the outcome is now the only way to indicate 
its existence. Appropriate statistical methods could be 
employed to do the task. Moreover, if bias exists, the 
seriousness and sources could be assessed. This would help to 
determine the suitability of the valuation gathered to be 
used in the further steps. It moreover gives more confidence 
in the analysis result. 
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For any valuation survey, a reliability test can be built 
in to give some assurance of the trustworthiness of the 
outcome. However, it cannot provide the reliability result 
over time unless surveys are undertaken at more than one 
time. An alternative to the updating surveys is to forecast 
the future values. The assumption of unchanged values at 
present seems to be popular. 
c) The value aggregation. 
Since health resource allocation is impossible to decide 
on an individual basis, a single set of quality of life 
values, sometimes known as a summary measure, has to be 
deduced from a collection of individuals. Conceptually, there 
are many possible ways of aggregating the values. For 
example, one of the aggregations is the summation of all 
people's values for any quality of life condition according 
to a certain rule to which society sticks (Williams, 1983). 
A statistical method is employed to do the task. But the 
methods chosen depend on the value judgement of the decision- 
makers concerned. In addition, the aggregation is further 
complicated by taking into account various settings behind 
the quality of life values to be aggregated. For instance, 
Spiegelhalter et al (1992) point out that the summary measure 
is derived from the aggregation over uncertainty, over time 
and over groups of differing size. It could provide a typical 
set of the quality of life values, which in fact may not 
match the real behaviour of any evaluator. This is an 
inevitable consequence of the aggregation. 
The decision about the value aggregation can be made on 
the basis of the implications of the summary measure. For 
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example, if average values are acceptable, then it assumes 
that everyone's elicited values are taken into account and 
counted equally. on the other hand, an established opinion or 
a certain law may be in favour of majority rule (e. g. 50% or 
2/3 of the whole population) . Therefore, the median, a 
statistical indication for the majority, is preferable to the 
average. However, in reality it is impossible to get everyone 
involved in the valuation elicitation due to the 
unjustifiably high cost. The actual valuation of a whole 
population is never known. 
Therefore, statistical methods are introduced to 
approximate a whole population's valuation from samples. 
Hence the aggregation option should conform to the 
statistical indication of the samples' values so that the 
aggregation rule chosen could represent the whole 
population's. 
d) Other problems. 
Most cost-utility studies need the values for more health 
states than those supplied by a normal valuation survey. The 
values for unmeasured health states have to be given. 
Modelling the valuation of unmeasured health states based on 
measured ones is the most appropriate way to cope with the 
problem in the short-run. It would provide the analysis with 
the estimated values to carry out the computation. In 
addition, the valuation model may show how the respondents 
weight the component health dimensions in arriving at the 
composite valuation. Other problems may be less serious and 
could be handled satisfactorily by the sensitivity analysis 
to show how robust the findings are. 
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1.2.3. The use of the cost-utility analysis result. 
The problems encountered by this approach and the wide 
variety of dif f erences in the methodology, as seen in the 
previous section, point to the imperfection of this approach. 
As a result, use and interpretation should be handled with 
consideration of the background of the analysis. The major 
points for practical users to focus on are the issues open to 
debate. For example, it should be spotted whether the 
alternatives are incorporated extensively or not and whether 
the result is compatible with the users, assumptions and' 
choices over the issues. Moreover, the impacts, implications 
and consequences of the choices made in the analysis should 
be scrutinized. Because of these, an empirical study of the 
issues in cost-utility analysis is of more importance than a 
theoretical one. 
The result can be used in different areas. The economic 
application is fundamental. For other applications, 
additional information has to be included and/or the result 
adjusted. First, according to the economic concept, the 
result shows the efficiency of resource allocation. The 
optimal resource distribution among health programmes can be 
achieved when a QALY gained is created by the least-cost 
health programme. Otherwise, there would be a net gain by 
redirecting the resources from the high cost per QALY 
programmes towards the low ones. In the latter case, the 
total welfare condition of the people affected is supposed to 
be improved. 
Secondly, from the management viewpoint, the limited 
funding of health programmes should be spent in such a way 
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that top priority goes to the programme with the least-cost 
per QALY, the next priority to the second least-cost one, and 
so on until the fund runs out. As a result, the magnitude of 
the fund share for each eligible programme can be known and 
the combination of various programmes determined. In 
practice, a rise in the cost per QALY of the lowest cost per 
QALY programme due to its substantial use, either by higher 
marginal cost or by lower additional outcome or both, would 
cause it to lose efficiency status. Then the position of the 
new least cost per QALY moves to the first quantity of the 
next least cost per QALY programme. The process would repeat 
until the fund is used up. To do such an analysis, a great 
deal of information and effort are needed. 
Thirdly, the decision-making principle, which influences 
health policy and planning, could use the result to rank 
health programmes in addition to other existing criteria. The 
low cost per QALY programmes have a higher precedence than 
the high ones over the resource uses. Gerard (1992) briefly 
shows how to use the cost-utility analysis result for the 
reform in the UK health system. 
The result must not be misused to give precedence to the 
efficiency issue over other criteria and to dictate the 
decision-making rule. This is because the efficiency issue is 
not the only objective in the allocation of health resources 
in a society. For instance, equity issue may take precedence 
in the allocation over efficiency. In some health programmes, 
efficiency is regarded as more important than equity whereas 
in others, the opposite is true. Taking into account that 
both issues, as well as others, exist in the determination of 
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the decisions, the cost-utility analysis findings should be 
considered as indispensable guidelines in the issue of what 
and how the distribution of health resources ought to be in 
a society. 
Fourthly, it could be used in the evaluation of health 
care allocation and of its utilisation. Based on realistic 
information about the resources consumed and outcomes 
created, whether or not the resources allotted are efficient 
can be assessed retrospectively. In addition, the result may 
show the anticipated performance for the purpose of 
monitoring and possibly suggest improvements. 
Due to broad comparability, the cumulative findings for 
a health system are encouraging and usually summarised in a 
so-called league table. Tables 1 and 2 show the league tables 
for U. K. and the U. S. health care systems. The differences in 
the backgrounds and settings of the analyses should be 
examined before they can be put in the same table. The 
analysis result can be applied to two scopes; whole existing 
health resources and additional ones. The former, known as 
the restructuring of a health system, is so far less likely 
to happen than the latter. 
A common mistake made in the intertemporal comparison of 
some health programmes is to only extrapolate the cost onto 
the same time basis by, say, a medical care inflation index 
without considering the actual changes in the cost structure 
and the medical technology improvement in those programmes. 
A comparison of programmes analysed over a similar period 
could be more reliable than that made over a long time 
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Table 1: Cost per QALY for some health programmes in 
the UK. 
Health programme 
1. Pacemaker implantation for 
atrioventricular heart block 
2. Hip replacement 
3. Coronary artery bypass grafting for 
main vessel disease 
4. Kidney transplantation 
5. Heart transplantation 
6. Coronary artery bypass grafting for 
moderate angina with one vessel disease 
7. Hospital haemodialysis 
Cost per QALY 
M 
700 
750 
1040 
3000 
5000 
12000 
14000 
Source : McGuire et al (1988) 
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Table 2: Cost per QALY for some health programmes in 
the US. 
Health programme Cost per QALY* 
1. PKU screening less than zero 
2. Post-partum anti-D less than zero 
3. Ante-partum anti-D 1220 
4. Coronary artery bypass surgery 4200 
for left main coronary artery 
diseases 
5. Neonatal intensive care for 4500 
infants 1000-1499 g 
6. T4 (thyriod) screening 6300 
7. Treatment of severe hypertension 9400 
8. Treatment of mild hypertension 19100 
9. Estrogen therapy for postmenopausal 27000 
symptoms in women without a prior 
hysterectomy 
10. Neonatal intensive care for 31800 
infants 500-999 g 
11. Coronary artery bypass surgery for 36300 
single vessel disease with 
moderately severe angina 
12. School tuberculin testing 43700 
programmes 
13. Continuous ambulatory peritoneal 47100 
dialysis 
14. Hospital hemodialysis 54000 
Note All costs are converted into 1983 price 
(US$). 
Source : Torrance (1986). 
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period. Another error could arise from employing out-of-date 
parameter estimations including the valuation data. 
1.3. A critical survey of cost-utility approach. 
1.3.1. Criticisms of cost-utility analysis. 
The following are criticisms of cost-utility approach as 
a whole and in particular the health-related quality of life 
measure. Two main criticisms of the approach are that the 
QALY is an inadequate health outcome measure and the analysis 
includes undesirable ethical implications. There are problems 
and setbacks in the present concept, methodology and 
valuation obtained by the quality of life measure. 
Since many criticisms emerge as a result of applying this 
approach to social decision-making and health resource 
allocation criteria, this discussion is confined to health 
status indices with the purpose of resource allocation. 
1.3.1.1. The inadequacy problems of QALY. 
Mooney (1989) questions whether QALYs can measure 
outcomes of health services and of individual health care 
client's welfare as we wish them to. It is argued that the 
individual utility functions on which QALYs are based contain 
not only health status improvements but also other relevant 
elements (Mooney et al, 1991). Referring to the findings of 
other studies, they claim that, in some instances, 
information and participation in medical decision making are 
embraced in some patients' utility functions. They could 
produce utility and should count in terms of QALYS- 
The utility function assumed by the present QALY method 
is also criticised for being too specific to represent the 
true utility functions of individuals (Mehrez et al, 1989). 
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This allegation is supported by the discrepancy in health 
programme rankings between the respondents' actual valuation 
basis and the QALY results derived from it. 
The current QALY procedure gives rise to a social 
objective function which omits some of the important elements 
contained in usual public objectives of health care 
provision. The function does not take account of, for 
example, who receive the QALYs. It regards welfare as the 
only benefit from health interventions (Hope et al, 1993). A 
society may be concerned with who can benefit from health 
care provision and, apart from creating more QALYs, what 
health care can do. In other words, the individual utility 
functions on which the QALY method bases do not reflect the 
social objective function. Carr-Hill (1991) states that the 
QALY framework cannot sufficiently serve the need- or right- 
founded decisions. 
In addition, without convincing rationale supporting the 
aggregation of different health benefit values from different 
groups in society, the validity of summing up all the 
individuals' QALYs to achieve its maximum QALYs is 
questionable (Richardson, 1989; Loomes et al, 1989). 
The problem intensifies further if the measure is 
required to be compatible with both social and individual 
objective functions at the same time. Mooney (1989) points 
out that, in many cases, these two functions are obviously in 
conflict in not only health care but in other commodities as 
well. 
To overcome these problems, some state that the QALY 
method assumes health maximisation to be the only concern of 
68 
health services (Wagstaff, 1991). However, this assumption is 
still not plausible because all parties in a health service 
system lack perfect knowledge about health and health care 
which would enable them to maximise health. On the contrary, 
they tend to exhibit "bound rationality" (i. e. making 
rational choices that take into account decision- maker's 
cognitive limitations in terms of knowledge and computational 
capacity) (Mooney et al, 1991). 
The QALY approach could be rejected as a basis of 
decision-making on an individual level since it lacks two 
following aspects (Smith, 1987). First, it cannot deal with 
personal issues which are not only subtle and sensitive, but 
also variable. Secondly, the QALY findings cannot respond to 
patients' needs which vary from individual to individual, as 
opposed to the decisions of health professionals who take 
into account the detailed information of each case. Using the 
QALY principle could turn doctors into "calculating machines" 
(Seedhouse, 1988). 
Klein (1989) argues that the decision-making determined 
by a group's data cannot sensibly be applied to individual 
patients because there is the variation of health benefit 
gains (i. e. QALYs) within groups. It is possible that a 
patient with a potentially high yield in a low health benefit 
group is deprived of his treatment at the expense of a 
patient with a low return in a high health benefit group. 
Seedhouse (1988) disagrees with applying the QALY approach 
uniformly to everyone and suggests medical decisions should 
depend on specific circumstances. The use of the QALY 
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principle in allocating health care in society, in Harris's 
view (1987), is "dangerous and morally indefensible". 
As some regard the decision-making about the allocation 
of health resources as a political issue, Smith (1987) argues 
that the QALY principle, which mainly involves technical 
issues cannot sensibly replace the "responsible political 
discussion" basis. 
The meaning of the QALYs can be interpreted in such a way 
that they could cause protest from the public whose welfare 
is affected by the consequences of the health resource 
allocation according to the QALY principle. Nord (1992b) 
points out that this could happen due to the use of the 
health state index approach and life years as a unit of 
health outcome measurement. He also discusses four problems 
of alternative interpretations. 
First, the meaning of, the quality of life valuation 
result is unclear. To most people, the valuation result in 
terms of numbers has little meaning because they do not use 
them in everyday life. Moreover, there may be some 
difficulties with explaining such numbers to potential users 
of the result. 
Secondly, the value of health state may imply the value 
of life. A less healthy life may be regarded as a less 
valuable life. According to Seedhouse (1988), medical ethics 
rejects the value of varying degrees of quality of life in 
favour of the equal value of life on the grounds that there 
should be no difference between the value of different 
people's lives (no matter what their quality of life is). In 
other words, that the existence of each as a living person is 
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equally valuable. Everybody is equally eligible to concern 
and respect with regard to the health care distribution and 
the quality of treatment (Harris, 1987). 
Thirdly, the fact that the QALY approach does not take 
into account the prognosis of the treated patients (i. e. no 
consideration of starting and ending points of patients with 
health interventions) may overlook society's view that a 
small recovery for a patient in a severe health state may be 
preferred to a large improvement for a patient in a less 
severe health state or that patients in the same disorder 
state are equally entitled to treatment despite their 
potential health gains from health interventions. 
Fourthly, using life years as an abstract unit of health 
benefit to be maximised may alienate health professionals who 
care for living persons. In their eyes, the value of a 
patient's whole life restored by health care may not sensibly 
be evaluated by life years. Harris (1987) puts life before 
life years on the grounds that an individual's existence is 
the essential of almost everything. As a result, saving lives 
should take precedence over saving life years. 
The QALYs are seen by some sociologists as having a 
particular meaning created by economists (Mulkay et al, 
1987). This unit of health benefit measurement emerges from 
the social interaction between economists (and other social 
scientists) and lay people. According to them, this process 
has two drawbacks. First, the QALYs as well as the quality of 
life measurement cannot reflect people's genuine values. 
Secondly, the concept of health benefit and that of quality 
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of life preference offered by health economists could be 
different from those defined and understood by others. 
Insufficient information involving outcomes of health 
interventions is one of the basic problems for the QALY 
approach as an accurate basis for health resource allocation 
among diversified health programmes (Klein, 1989). The life 
expectancy findings of many existing health interventions as 
well as new ones are not available, neither are their quality 
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of life counterparts. 
Faced with these problems, it is advisable that the QALY 
method is assessed before being used in the practical 
environment as new medical technology is put to clinical 
trial (Klein, 1989). However, he is pessimistic about the 
performance of QALYs used under real-life conditions and 
suggests that the criteria of health resource priority- 
setting should be based on various rationality approaches, 
experiences and experimentation. He also warns against the 
dictation of science in the priority-setting criteria. 
1.3.1.2. Ethical problems of cost-utility analysis. 
Hope et al (1993) claim that decision-making about health 
interventions has a "major ethical component" . Hence, the 
ethical implications of the cost-utility method as a means of 
allocating health resources are considerable. 
Smith (1987) points out that decisions about which 
treatments are to be provided are decisions about who should 
be treated. The allegation that the cost-utility approach has 
been selected from many possible options on the basis of 
economic factors rather than human equality indicates that 
the principle of "justice as fairness" is violated by using 
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this approach as a health resource allocation criterion 
(Seedhouse, 1988). A serious charge is it could be used to 
legitimatize discrimination between people. 
Hope et al (1993) give a simple example of cardiac 
surgery to demonstrate the bias of the QALY principle against 
old people. Due to their high probability of operative 
mortality and morbidity and a short life expectancy (i. e. a 
small gain in life years), older people are likely to have 
less chance of receiving cardiac operations than younger 
people, and to be discriminated against. Harris (1987) 
endorses the view that the method is biased towards the young 
due to their potential to gain maximum QALYs. Race, sex and 
class are also believed to be grounds for discrimination in 
its application (Seedhouse, 1988) . Harris (1987) believes 
that the cost-utility approach would benefit the minority 
group of people at the expense of the majority. He also 
condemns the injustice in this approach. Justice may simply 
mean that a society does not allow systemic disadvantages to 
occur against a particular section of the community. Cost- 
utility approach, in contrast to this view, creates and 
maintains the disadvantages (e. g. to the old). Furthermore, 
the allocation of health care in accordance with this 
principle could violate the most basic civil rights (Harris, 
1987). 
Loomes et al (1989) claim that the cost per QALY ranking 
procedure does not take into account the distribution of 
QALYs gained between individuals. However, they concede that 
the problems of the equity issue in respect to QALYs--its 
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appropriate definition, measure and value--are substantial 
and are difficult to resolve. 
Four definitions of equity in the context of health and 
health care are explored by Wagstaff (1991) . "Equal treatment 
for equal need" requires that persons in equal needs of 
health care receive the same treatment regardless of personal 
backgrounds. "Equality of access" is interpreted that 
individuals should incur the same time and money costs in 
utilising health care facilities. Some call this "equality of 
opportunity". "Equality of health" is self-explanatory 
provided that health is well defined and can be measured. 
Ill-defined health can invalidate this definition. For 
example, Wagstaff (1991) states that if ... equality 
of health is interpreted to mean equality of 'expected QALYs 
remaining', the goal of equalising health may well not be 
feasible. " "Equity as equal constraints" uses environmental 
constraints faced by individuals to determine the inequity of 
health care distribution. 
Wagstaff concludes that only the "equality of health" 
definition would provide a basis for determining an equitable 
allocation of health care. This implies that, since the cost- 
utility approach is based on a health definition, it is 
possible that the equity condition of the allotted health 
resources derived from the analysis could be assessed. 
Seedhouse (1988) suggests that due to the undesirable 
ethical views generated by this approach, it should not be 
used solely and alternative methods should be included. 
Moreover, other moral and ethical considerations should be 
brought into the health care allocation decision-making for 
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instance through promoting more responsible, caring and 
humane individuals and organisations. 
1.3.1.3. The problems of the quality of life measure in 
cost-utility analysis. 
a) Conceptual problems. 
The most important criticism of the quality of life 
measure is that its concept of health is too limited to 
capture all the key health benefits. Donaldson et al (1988) 
show that the Rosser Index, consisting of only disability and 
distress, is insensitive to improvements (or reductions) in 
health status in evaluating long-term care for elderly 
people. As a result, the QALYs produced by this programme, 
which creates a minimum impact on life expectancy, are 
underestimated. Compared with care for acute illness, long- 
term care for elderly people is less able to compete for 
health resources. They also claim that the health status 
index based on the multi-attribute utility (MAU) 
classification system suffers similar problems when applied 
to some groups of major health service users (e. g. elderly 
people receiving long-term care). 
They demand separate criteria f or the health resource 
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allocation between health programmes with distinguished 
health outcomes (e. g. care [for elderly people] versus cure 
[for acute illness]) (Donaldson et al, 1989) . Loomes et al 
(1989) support the view and add that the Rosser Index's only 
29 health states are too insensitive to cover all states of 
health and thereby it overlooks real, vital health 
improvements of some patient groups. 
Single aggregated multi -dimensional measurement may cause 
the restriction of the health benefit assessment (Siegrist et 
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al, 1989). It is not sensible to use a single scale in 
combining all possible health evaluations which are affected 
by time, existing health problems, medical technology, 
different types of health care users and specific contexts 
(Carr-Hill, 1989). 
The concept and meaning of quality of life are criticised It 
as ill-defined. Mulkay et al (1987) argue that the responses 
obtained in an evaluation exercise should be treated as 
"reactions to socially defined situations" rather than 
"expression of stable underlying preferences". Siegrist et al 
(1989) state that the unfounded basis from which the 
dimensions of the quality of life measure are derived causes 
some scepticism. 
Donaldson et al (1989) point out that the "distress" in 
the Rosser Index may mean a number of different things (e. g. 
pain, misery, anxiety, low morale or loneliness). Before the 
QALYs can be employed as a health resource allocation 
principle, significant progress in defining and measuring 
various quality of life dimensions including disability and 
distress is essential. 
Richardson (1989) states that it is suitable to use 
"normal years" rather than "healthy years" as a unit of 
health outcome measurement. This is because "normal health", 
which has some levels of aches, pains, illness and chronic 
conditions, is more realistic than perfect health currently 
used as a reference health state in most measures. 
Respondents have different levels of difficulty in 
understanding, responding and answering different types of 
health dimension - They usually find their own emotional will- 
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being is more difficult to judge than their complaints about 
bodily symptoms (Siegrist et al, 1989). 
The health-related quality of life measure is advocated 
as context-specific simply because some parameters in 
particular circumstances have some influences on the quality 
of life (Siegrist et al, 1989; Carr-Hill, 1989). The 
influences can be divided into two main groups. The first and 
principal group consists of characteristics of disease (e. g. 
type, severity and prognosis of disease) and those of 
treatment. Weinstein (1988) considers the exclusion of the 
disease context in the Rosser Index to be its limitation and 
urges to give more attention in future research. Normand 
(1991) argues that comprehending the possible disease process 
surrounding the duration in consideration is essential to the 
sensible evaluation made for its quality of life. 
The second group comprises socio-demographic and 
psychological variables as well as other cultural 
backgrounds. Carr-Hill (1989) claims that patterns of health 
quality are shifting both among social groups and over time. 
The combination of various factors leads to constitute a 
proposed health-related quality of life measure as a 
,, distinct bio-psycho-social entity" (Siegrist et al, 1989). 
Though death is widely accepted as a state of health, its 
valuation by the same scale as other living states and their 
comparability is still debatable. Such a combination could 
discourage the raters from administering the health state 
assessment (Carr-Hill, 1992) . Carr-Hill (1989) states that 
some studies have found the influences of the chance of death 
from treatment upon the potential treatment recipients' 
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preferences. A relevant issue is whether the comparability 
between health interventions that prevent death and those 
that improve the quality of life is valid (Klein, 1989). 
b) Methodological problems. 
One of the main methodological problems of the present 
quality of life measurement is that the valuation tasks are 
carried out under conditions that violate key assumptions 
underlying the measurement. Therefore, the results obtained 
could be regarded invalid. It is criticised that insufficient 
evidence is provided to support the assumptions in the 
valuation exercises (Klein, 1989). 
Loomes et al (1989) give four pieces of evidence to show 
that the assumption of a constant proportional time trade-off 
is unsustainable. First, the absolute number of years 
remaining is taken into account in the trade-off decision. A 
study found that individuals are willing to choose to live on 
a shorter healthy life only if the life with ill health is 
greater than 5 years (McNeil et al, 1981). Secondly, a 
difference in the presumed duration of some health states in 
an evaluation exercise could result in significantly 
different values of those health states. Thirdly, it is 
possible that discount factors for living could play a part 
in valuing a health state differently between different 
periods of time. Finally, a person's life cycle preference 
can be responsible for disparate valuations of health states 
at various stages of life. This argument is based on the 
findings of the study by Wright (1986). 
The existence of risk in the decision-making about 
uncertain alternatives requires, among other things, two 
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conditions. First, an individual's risk attitudes towards 
uncertain duration of survival should be independent of the 
health state in consideration. This condition means that 
changes in health state must have no effect on the survival 
length, or the value assigned to a health state is 
independent of the duration of that state. Secondly, an 
individual Is risk attitudes towards an uncertain period of 
survival should be constantly proportional. It means that the 
length of life in a certainty alternative must vary by the 
same proportion as that of its uncertainty equivalent. 
Another way of expressing this proposition is that if one is 
willing to trade 3 years in an ill-health state for 2 healthy 
years, then one will be indifferent between 6 years in that 
state and 4 heathy ones. 
There is little direct evidence in the context of health 
to reject these two conditions in the valuation procedure. As 
a result, some findings from studies about risky prospects 
involving wealth are used by Loomes et al (1989) as indirect 
evidence to demonstrate the discordance of these conditions 
between theoretical and practical valuations. Both conditions 
may not be held as some individuals are found to be both risk 
averters and risk seekers. When one is in different health 
states, one may want to alter length of survival in a 
certainty equivalent choice other things being equal. Another 
possibility is that there is interaction between health 
states in different periods in a health profile. Loomes et al 
(1989) endorse this view and point out the likely effect of 
present health states upon future ones. If preferences of 
future health status would depend on those of past ones, the 
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health status indices which are based on the combination of 
many attributes over time (e. g. the multi-attribute utility 
health state classification) are likely to be invalid (Carr- 
Hill, 1989). Faced with a short period of survival, 
individuals often exhibit risk-aversion. In contrast, they 
may perform risk seeking when a long duration of survival is 
involved. As a result, they possess inconstant proportional 
risk attitudes towards survival length. 
According to Carr-Hill (1989), the first condition is 
crucial because with little or no support, it could undermine 
the comparability of health outcomes between health 
interventions which concern a variety of health states. Since 
the Rosser Index relies on these two assumptions, its 
credibility as a health outcome measure is damaged (Donaldson 
et al, 1989). 
As the problems of the expected utility theory, which 
underlies most current quality of life measurements, are 
increasingly found in other areas, they are related to the 
theory in the context of health and its relevant valuation 
techniques. 
Mooney (1989) summarises four key points of the expected 
utility theory in the context of the health-related quality 
of life valuation. 
a) Only health status is concerned. 
b) The utility of future (expected) health state is 
independent of that of present counterpart. 
c) The same change in health state is valued equally in 
magnitude no matter such a change is gain or loss. 
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d) one does not obtain the utility from the unchosen 
health states in the valuation elicitation. 
Mooney et al (1991) claim that utility can arise from the 
actions or decision processes of some patients. For example, 
patients who do not have to select among alternative health 
interventions but let doctors decide for them could obtain 
some preferences from avoiding difficult and tough decision- 
making or save some utilities which otherwise are lost in the 
decision process. Therefore, the neglect of this kind of 
preference in the established measurement methods could make 
the expected utility theory insufficient as the basis for the 
quality of life valuation. According to Loomes et al (1990), 
the application of the theory is improper or needs major 
change. 
The "framing effects" problem would occur. The result of 
an evaluation with gain prospect could differ from that with 
loss counterpart given the same final outcome. The "utility 
evaluation effects" problem arises when applying different 
valuation procedures or employing variants of the same 
procedure to assess the same object gives rise to distinctive 
valuation results. 
The "internal inconsistencies" problem which produces 
discrepancies within a valuation result could stem from bias 
factors. It could imply that health status is not the only 
determinant of the respondents' values. Also, a patient's 
ability to adjust to a new life-style or learn to cope with 
ill health may be responsible for discrepancies between 
simulated and actual valuations, which the present cost- 
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utility approach is unable to take into account (Loomes et 
al, 1990; Normand, 1991). 
The availability of various ways to evaluate the quality 
of life and the existence of disparate assessment results 
lead some critics to reject a unique way to measure the 
quality of life or a single set of quality of life values in 
the calculation of QALYs (Seedhouse, 1988). 
Involving the valuations from individuals in various 
walks of life and concerning health resource allocation 
between different people, the QALY approach inevitably makes 
interpersonal comparisons in society. Hope et al (1993) argue 
that the method loses its attractiveness because of its 
interpersonal comparisons of welfare between people. 
The interpersonal comparisons can be rejected on the 
grounds that different people exercise different means of 
giving utilities for health status (Seedhouse, 1988). The 
same critic adds that comparisons are impossible and 
inappropriate as each case is unique and therefore 
corresponding decisions cannot be generalised. 
Harris (1987) argues that the trade-off model between 
healthy and unhealthy life times based on individuals is not 
equivalent to and justifiable for the model for society as a 
whole. This is because the trade-off in the latter case is 
done in the context of different people. For instance, one 
person may prefer two healthy life years to three life years 
with an ill-health condition. But he may not agree to use 
this proportion in trading between his own life years and 
another person-'s. He may not want to sacrifice treatment to 
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anyone, no matter whether the treatment would make more 
benefits to any other than to him. 
Mooney et al (1991) accept that the problems of 
interpersonal comparisons of utility in cost-utility method 
are not and cannot be solved. However, they defend that all 
methods of allocation contain comparisons in the real world 
and that the QALY approach makes this issue more explicit 
than other principles. In addition, they stress that a 
particular drawback of the interpersonal comparisons in this 
approach is the neglect of different strengths of preferences 
between individuals due to the use of common finite 
references on a cardinal scale. For example, two individuals, 
preferences for a health state, measured by the time trade- 
off technique, are the same score of X/T (X= healthy life 
years and T= life years in that health states but the 
preferences for X or/and T of each individual could be 
different and are no longer considered in the measurement. 
Therefore, their differently perceived utilities gained by 
moving from that health state to the perfect health are 
disregarded. 
Loomes et al (1989) do not rule out the possibility of 
creating legitimate interpersonal comparisons in the cost- 
utility framework but ask whether individual preferences can 
be scaled and whether there is a means of aggregation of 
utilities compatible with the comparisons. 
Since there is a distinction between the valuation that 
assumes health intervention's effect on one's own welfare and 
one that assumes the impact on everyone else's, the problem 
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is which type of valuation is appropriate and consistent with 
the existing interpersonal comparisons of welfare. 
Loomes et al (1989) argue that the so-called egalitarian 
principle has a variety of valuation aggregation methods, 
including equal weightings. They stress that the equal 
weights for everyone is not necessarily the best aggregation 
method. Without an acceptable aggregation method, a 
conservative suggestion by them is to investigate the 
assumptions that underlie the method under consideration and 
the policy implications of various available methods. 
c) The problems of the existing valuation results. 
Mulkay et al (1987) play down the significance of the 
quality of life data in the cost-utility studies' conclusions 
and suggest practical actions. They claim without presenting 
a genuine case, that this is because the application of 
different background assumptions (which are possible and 
reasonable) to some set of the data could produce distinctive 
results. Hence, they suggest assessing the findings of the 
studies on the basis of their assumptions which make the data 
used meaningful. 
The quality of the valuation method depends on the data 
collection methods and the questionnaire types which 
influence its validity, reliability and sensitivity to change 
(Siegrist et al, 1989). (Validity means that an instrument 
can measure what is intended. Reliability is referred to as 
its ability to reproduce the same or similar result. The 
sensitivity to change describes its ability to detect the 
overall effect of health interventions. ) Carr-Hill (1989) 
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questions the validity and reliability of the valuation 
responses. 
The reliability of the quality of life valuation are most 
subject to criticisms which have foundations in the findings 
of other relevant studies. Donaldson et al (1988) argue that 
the valuation result could vary with time and differ with 
respect to health service types (e. g. maintenance of health 
versus health improvement activities) . They claim that the 
findings of most empirical quality of life studies are not 
generalizable. Mulkay et al (1987) add that there hardly is 
a link between what people respond in a valuation exercise 
and what they do in real life. Their two sensible reasons to 
support this remark are that the hypothetical conditions used 
in the valuation are too abstract and artificial compared to 
respondents, real life conditions and that the experimental 
valuation could change respondents' existing quality of life 
perceptions. These cast doubt over whether the valuations 
obtained in the context of experimental environment can be 
applied in reality (Carr-Hill, 1989). 
The issue of incomplete valuation responses is raised by 
Carr-Hill (1989). It is unclear how such responses are dealt 
with, interpreted and aggregated (e. g. whether they are 
dismissed as invalid or modified in a certain way) . Obviously 
they contain and convey some information. 
As it becomes clear that many valuation studies have 
found the valuation results differ between subgroups of 
respondents, the differential could pose a crucial problem if 
it is a result of the respondents' understanding of the 
measurement procedure rather than genuinely different 
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preferences. Mulkay et al (1987) describe two types of 
understanding that could cause the valuation to deviate from 
what is supposed by the analysts. The first is the 
understanding of the health context. Doctors, because of 
their training in this matter, could make a more subtle and 
delicate quality of life assessment than other non-health 
relevant groups. Backed by this belief, doctors, valuation 
can be regarded as a valid one and should be representative 
of the public's. The second is the understanding of the 
nature and requirements of the valuation technique. It is 
believed that doctors could understand the process better 
than others and thereby give more accurate and better 
valuations. 
Another criticism is that a narrow variation range of the 
valuation between most health states obtained by using the 
Rosser Index may decrease the role of quality of life in the 
QALYs and let life expectancy exert a major influence on the 
health outcome measurement (Mulkay et al, 1987). The small 
contribution could reduce the advantage of the QALY approach 
over other measures and add little additional information in 
the decision making process. Though this setback may be 
rectified in future, they still believe that a wider 
variation range of the values is artificial. 
The appropriate sample size and the desirable combination 
of respondents with various background characteristics for 
consistent and reliable valuations to be used routinely have 
yet to be determined. But a sample of 70 subjects and a 
substantial proportion of health care workers, which were 
used by an important study based on the Rosser Index (Kind et 
86 
al, 1982), are regarded by some as too small and partial 
(Carr-Hill, 1989; Wade, 1991). 
1.3.2. Responses to some of the criticisms. 
1.3.2.1. Responses to the inadequacy problems. 
There is occasionally confusion between health outcome 
and the process of health care provision (e. g. inputs and 
interactions between patients and health care providers). 
Taking account of individual personal backgrounds in the 
medical decision-making process can obscure the basic concept 
of the QALY unit as a health outcome measurement. This 
argument also applies to information available to patients 
and their participation in medical decision making. Though 
they could produce utility and be measurable in the patients I 
utility functions, they are hardly seen as health outcomes. 
The outcome measurement should be paid more attention 
than the measurement of process or intermediate utility as it 
is recognised that the shortage of the outcome information is 
still considerable (Gudex et al, 1991). 
Different quality of care for patients with different 
levels of service utilisation could in some instances mislead 
health professionals into thinking that some patients' 
quality of life is significantly different from, and uniquely 
incomparable to, others. 
Utility theory, as Mehrez et al (1989) claim, is a key to 
tackling the omission of some benefits from health care in 
individuals' utility functions. It can be employed to 
generate forms Of utility functions over health profiles and 
construct representations of health states for the evaluation 
process. They also add that this procedure could produce a 
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comprehensive measure of an individual Is preference and is a 
powerful tool due to having theoretical support. 
The direct ranking test of treatment options based on 
patients, preferences, which was suggested by Mehrez et al 
(1989), should be supplementary to, not in competition with, 
the cost-utility principle simply because health outcome is 
not equal to the preference over treatment alternatives. On 
the contrary, the preference representing the quality of life 
in the QALY procedure is part of the health outcome --QALYs. 
Recognising that there are many goals in the social 
objective of health care provision, it is not expected that 
the cost-utility analysis result is employed alone in the 
decision-making process with respect to health resource 
allocation. Harris (1987) seemingly places the principle of 
equal access to health care before the efficiency issue and 
in the same top rank as civil rights. 
In addition, most analysts do not intend to replace the 
political basis for the allocation by the cost-utility 
criterion (Williams, 1991) . In fact, this approach 
is 
basically designed for health policy analysis. Because it is 
similar to the decision-making framework, it is easily 
mistaken that the two are equivalent and findings based on 
the former could solve the problems of the latter. Moreover, 
it is the nature of the analysis that invites it to the 
unresolved political issues (Williams, 1991). 
The method may be useful in furnishing the political 
debates with some empirical and theoretical support. Its 
principle function is to assess the efficiency condition of 
88 
the health resource utilisation, which normally is one of the 
concerns in the allocation criteria. 
In order to prove the inadequacy of QALYs for the need- 
or right-based decisions, Williams (1991) argues that the 
following two questions should be answered. First, what are 
needs or rights? Secondly, how are , reasonable" levels of 
needs or rights to be determined without using a cost-per- 
QALY type principle? The failure to answer these two 
questions satisfactorily possibly indicates the invalidity of 
such decisions. Therefore, neither the QALY approach nor any 
other should be regarded as an inadequate basis for need- or 
right-founded decisions. 
Instead of answering the two questions above, Harris 
(1987) points out that the preference component in the QALYs 
violates the civil rights principle. Any health resource 
allocation rule without the preference guidance would deliver 
everyone an equal entitlement to be treated, which is based 
on their equal values of interests and desires. 
Harris (1987) accepts that cost-utility analysis as a 
decision-making device at individual level is useful and 
possesses assumptions compatible with individual and social 
maximisation objectives. 
It is conceded that the data insufficiency in the cost- 
utility procedure would be better tackled by collecting more 
data rather than by making assumptions. Nevertheless, 
gathering unavailable data in some areas other than economics 
poses a main snag (Williams, 1991). 
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1.3.2.2. Responses to the ethical problems. 
According to Harris (1987), cost-utility method gains 
moral and political supports owing to the acceptance of 
rational people's quality of life preferences. The strength 
of the QALY as a health outcome measure rests on a fusion of 
theoretical framework and the people's own desired choices. 
It is apparent that the difference between the medical 
ethics principle and the QALY approach lies in the unit of 
the valuation. In the former, the whole life counts whereas 
in the latter the part of life does (e. g. life time in 
healthy state or in ill-health state). It is very difficult 
to determine which is right or wrong since both depend on 
value judgement. 
In response to the argument that QALYs discriminate 
against old people in receiving health interventions, Hope et 
al (1993) contend th&t, considering the length of life spent, 
it is unfair to give old people privileges to live longer and 
let the young die early other things being equal. It is 
unjust for the young who have experienced a shorter life 
period than the old to be less entitled to more life years as 
a result of imposing measures against the discrimination than 
the old who have acquired almost maximum life span. The WHO's 
recommended policies for saving children's lives and reducing 
child mortality rates could implicitly favour health 
programmes towards the very young age groups. Yet no one 
accuses it of a discriminatory policy. 
Separating the priority- setting principle for health care 
provision for old people from that for the young (also any 
other personal factor prone to being used for discrimination) 
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is not a solution to lessen discrimination imposed by using 
a common cost-utility approach (and perhaps all other 
methods) but is a positive discrimination practice in itself. 
The mechanism (or dynamic characteristics) of the cost- 
utility approach makes it possible for the priority of 
treatments to change. For instance, suppose that in the 
future new treatments for some of the old's health problems 
lower the present cost per QALY and becomes more favourable 
than those for the young's at that time. The discrimination 
against the old would not remain. Nor would the creation of 
the permanently discriminatory structure do. 
Wagstaff (1991) disagrees with the accusation that cost- 
utility approach neglects the equity issue. He points out 
that the fact that a QALY is worth the same to everybody is 
"a kind of equality" in this approach. Mooney et al (1991) 
respond to the lack of the distribution issue in this method 
by interpreting that it assumes distribution questions are 
not of concern. 
Two equality aspects of the QALY procedure are 
highlighted by Williams (1987). The aggregation method that 
adds up dif f erent people Is QALYs to arrive at the community's 
QALYs indicates the equality of the value of the QALYs to 
everybody. Dead state carries the same degree of 
undesirability for everyone. 
Cost-utility approach could be modified by weighting 
different values to QALYs obtained by different people, as 
society wants to, in order for its equity aspect to be 
accepted (Wagstaff, 1991). The procedure can roughly be 
described as follows. The first step is to specify which 
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groups warrant special privileges. The second step is to 
assign appropriate weights for these groups (e. g. a higher 
weight to the young and a lower weight to those with self- 
damaged health behaviour) . The last is to maximise a weighted 
sum of the QALYs. Wagstaff (1991) point out that the problem 
of this procedure is how to obtain the appropriate weight for 
each group. The responses acquired from a direct valuation 
survey may be rejected on the grounds that it cannot make 
respondents differentiate between what is just and what is 
desirable. The latter is defined by justice plus the 
influences of their own selfish interests and social 
counterparts. Without a more satisfactorily devised option at 
present, Williams (1988a) suggests maintaining the "simple 
egalitarian rule" (i. e. the parity of a QALY's value to all) . 
Developing more responsible, moral and humane health 
professionals and relevant agencies might improve the quality 
of care and perhaps health outcomes but could not provide the 
solutions to the problems of injustice and discrimination in 
health care allocation. 
There are no direct solutions to the unsatisfactory 
ethical standing of cost-utility approach. In fact, no 
methods of allocating scarce health resources to various 
health interventions between people with different 
characteristics could meet all the ethical requirements 
(Harris, 1987). For example, drawing lots is a fair method of 
health care provision but impracticable and unacceptable. 
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1.3.2.3. Responses to the quality of life problems. 
a) Replies to the conceptual problems. 
The restriction imposed on some aspects of health outcome 
by the quality of life measure could be tackled at the 
expense of losing the comprehensiveness, which may be 
preferred by the decision makers. The balance of various 
aspects in any quality of life measure as part of the health 
resource allocation principle is determined by their frequent 
occurrence in eligible health interventions as perceived by 
patients (as well as potential ones) rather than by their 
existence (Williams, 1989). 
The more sensitive health outcome measure may not 
represent the decision-makers I position (Weinstein, 1988) . He 
also criticises a health outcome measure which has a high 
sensitivity but lacks the trade-off between the quality of 
life and life expectancy (e. g. Life Satisfaction Index) as an 
invalid basis for the allocation from the decision makers' 
viewpoint. According to Williams (1989), the trade-off part 
is necessary and important due to two reasons. One is that it 
is practical for far-reaching applications by busy 
practitioners. The other is that it is based on a definite 
pattern of measuring composite health benefit. 
Donaldson et al (1988) admit that due to the effect of 
the environment surrounding the elderly people with long-term 
care on health status, the validity of health status indices 
(both programme-specific and across-programme measures) are 
difficult to assess. 
Although the programme-specific health status indices 
used by Donaldson et al (1988) have an advantage of a higher 
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sensitivity in measuring disability of elderly people with 
long-term care than an across -programme counterpart like the 
Rosser Index, the omission of some genuine effects of the 
care such as distress in the programme- speci f ic indices could 
make them incomplete measures. Williams (1989) stresses that 
some programme- speci f ic measures omit survival impacts of 
health interventions for instance, which other indices can 
measure. 
Donaldson et al (1988) argue that the true distress (or 
psychological well-being) scale is unlikely to be scaled 
precisely because of the influence of recovery expectation 
from elderly people's disabilities. The distress dimension 
could possibly be underestimated by any current health status 
index. 
Therefore, it is possible that decision-makers could not 
make right decision based on incomplete findings produced by 
either the inaccurate across -programme health status index or 
the distress -omitted programme- specific index. If this is the 
case, the contention against using across -programme measures 
could be an argument for developing better and more precise 
scales for the distress dimension. If the distress aspect is 
found to be significant for elderly people's health, an 
across-programme index would gain support since it could 
trade off between the disability and distress dimensions. 
In addition, the possible bias in the distress scale 
could cast doubt over the impact of deaths and physical and 
mental frailty on the disability measurement by the 
programme-specific measures in Donaldson et al's study 
(1988). 
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Williams (1989) points out a main conceptual setback of 
programme-specific health status index. The index has 
arbitrary weighting of its components. So real changes may 
not be known. On the contrary, the artificial health impacts 
could stem from the numerical values given to the components. 
The programme-specific indices advocated by Donaldson et al 
(1988) are attacked on two accounts. First, each component is 
scaled independent of the others without any interactive 
effect. Secondly, most components carry the same maximum 
weight. 
A different conclusion from that of Donaldson et al 
(1988), based on the number of individuals affected (i. e. how 
many people have had their health improved, stabilised and 
worsened), could be made if the performance of all the 
individuals (i. e. their quality of life is counted as a 
single aggregate unit) is used for the comparison. The 
Modified Crichton Royal Behavioral Rating Scale and Life 
Satisfaction Index produced apparently the same results from 
the Rosser Index on the basis of median values of net health 
status changes over the periods concerned. 
The aggregate measurement is more appealing than the 
individual one from the health resource allocation viewpoint 
since the decision-makers are more interested in the health 
outcomes of all recipients in a health programme than 
individuals, health status movement. 
Applying a common set of quality of life measures for all 
health interventions is still controversial and likely to be 
decided on the basis of agreement between the parties 
concerned (Carr-Hill, 1989). 
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Also, whether or not disease context should be included 
in the quality of life measure in the QALY procedure is a 
debatable issue (Weinstein, 1988). 
Whether or not there is a distinction between the opinion 
and real behaviour due to a patient adjustable to health 
problems has to be empirically proved (Normand, 1991). 
b) Replies to the methodological problems. 
Since interpersonal comparisons of welfare have to be 
made unavoidably in any decision-making process for health 
resource distribution and since the controversy over this 
issue continues to be unresolved, to lessen the conflict is 
to keep the assumptions about the comparisons explicit. Gudex 
et al (1991) emphasise that value judgements underlying 
management and clinical practice is insufficiently 
investigated. 
From the policy analysis point of view, the QALY 
procedure clarifies the assumptions about interpersonal 
comparisons of utility made by decision-makers (Williams, 
1991). In the case that it is too difficult to be traced, the 
policy analysis models based on various reasonable 
assumptions should be explored. 
c) Replies to the problems of the valuation results. 
There are no practical "gold standards" for most 
technical issues such as the validity and reliability of the 
valuation results (as well as their generalisation to the 
population as a whole), the appropriate size and the 
constituents of the sample. Although in some cases the 
approximation can be quantified (e. g. the reliability of 
valuation of some health state between more than one interval 
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or the similarity level of values of repeated health state), 
the interpretation of the measurements still rests on one's 
opinion. 
The appropriate treatment of technical issues would 
evolve through learning experiences f rom a variety of the 
health status indices developed and administered, from 
accumulated past studies of a particular quality of life 
measurement and from other relevant valuation studies (e. g. 
psychological studies). 
At present, the analysts pay particular attention to the 
data collection process (Nord, 1991a). Through proper 
questionnaire design, valuation format and administering 
mode, the results obtained are hoped to possess the 
acceptable solutions to various technical issues. 
The application by postal survey of a health status index 
validated for an interview basis, for instance the Rosser 
Index, could alter its validity and reliability as evaluated 
in its original data collection mode. As a result, it is 
necessary to establish validity and reliability in every 
version. The tests for the two basic requirements may be 
hampered by such constraints as insufficient respondents' 
cooperation and resource limitations. These are really beyond 
the control of the analysts. 
Some obstacles remain unresolved. For example, the 
EuroQol Group (1992) could not find a proper means of 
combining dead state with other health states onto the same 
scale after some experimentation. 
Because of adjusting their methods to overcome these 
snags, some technical aspects of the valuation findings are 
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certainly not up to the high standard of some analysts. In 
addition, bettering some aspects of the result could worsen 
others (e. g. more inconsistency in the valuation could be as 
a result of including more health states to be scaled). 
The method with the best technical conditions, which is 
identified by exploring all alternative methods given the 
current state of the art, would be accepted by most people. 
1.3.3. Suggestions for some unresolved issues. 
Weighting between the criticisms and correspondent 
replies, as shown in the previous discussions, indicates that 
some problems remain with cost-utility approach. But they are 
not critical. Williams (1991) believes that misconception of 
the QALY approach, in particular its purpose, basically gives 
rise to its various misrepresentation and misleading. 
Therefore, they do not affect the applications of this method 
and the results obtained. As Williams (1991) states, there is 
no significant rival principle to this approach. On the 
contrary, the criticisms highlight various ambiguous points 
in the analysis and make the hidden issues explicit. As a 
result, they are of benefit to result users to realise its 
remaining weaknesses. 
The limitations highlighted in particular studies are, in 
most cases, trivial. As decision-making based on many studies 
is highly recommended and this is usually the case in 
reality, the shortcomings of individual studies become 
insignificant. 
The problems identified have become a challenge for 
analysts and induced more research studies into its 
development. Nobody denies the improvement potentiality of 
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this approach (Williams, 1991). A better and more acceptable 
analysis could be the result of testing the suggestions for 
unresolved issues, which are discussed below. 
Any suggestion, as Williams (1989) advises, should 
conform to the goal that it could guide decision-makers as to 
which health resources do the most good. 
1.3.3.1. Suggestions for the inadequacy issues. 
Referring to the model of the perfect agency relationship 
(i. e. the doctor acts as an agent in the interest of the 
patient) , Mooney et al (1991) believe that 
it is possible for 
the patient to maximise the utility derived from some aspects 
of health care in addition to the utility from health gain. 
This could improve the QALY method as a basis for decision- 
making at an individual level. 
Hence, they advocate exploring, on top of health change, 
what else is in the patient's utility function as outcomes 
from health interventions. It is hoped that their utilities 
could be integrated with the QALYs from health effect. Were 
they available, two immediate questions follow; what is the 
unit of utilities from these attributes and how are they 
combined to QALYs in practice? Also, it is urged to 
investigate the characteristics of the social welfare 
function. 
Williams (1991) comments that since, in reality, the 
roles of doctor and patient reverse the perfect agency 
relationship model, the existence of the patient's extra 
utility is indeed questionable. 
Mooney (1989) puts forward the Morgolis model in 
generating the individual's utility function as an 
99 
alternative to the current utility function assumed in the 
QALY approach which is concerned solely with utility from 
health status change. The model postulates that an individual 
possesses two (internal) utility functions. in the selfish 
utility function, or the conventional utility function, he 
obtains utility from directing resources to his own private 
health purposes. In the group- interested utility function, 
his contribution to resources distributed in accordance with 
the concerned group's health objectives gives him some 
utility. He allocates his resources between these two means 
of the utility production in such a way that his total 
utility is maximised. 
The group-interested utility function could explain such 
elements as uncertainty, irrationality, unpredictabilityi 
ignorance and externalities surrounding the pattern of the 
health care provision, in society, which the conventional 
individual utility function cannot account for. 
As an illustrative example by Mooney et al (1989), the 
group-interested utility functions determine the appropriate 
level of the equality of access for equal need for members of 
the group at the same time as one's selfish utility function 
reflects one's own value of health in terms of the utility 
maximisation from health interventions. 
A significant advantage of this model is that, to a 
certain extent, it could make the individual utility function 
consistent with the public welfare objective function (e. g. 
the equality of access in health care policy). 
However, there are some limitations. In practice, 
difficulty arises in the valuation process as more factors 
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are included and traded off. Different elements usually have 
different units which may not be familiar to respondents. 
They may cause some confusion. The validity of the valuation 
result could be in doubt. 
In order to be certain and confident that the QALY 
findings reflect respondents' utility, it is necessary, 
according to Mehrez et al (1989), to check the consistency 
between the treatment option ranking by the QALY result and 
that by the respondents' genuine preferences (which may 
simply be known by directly eliciting their preferences over 
the treatment alternatives). 
This test implicitly accepts the respondents I preferences 
over treatment options as a "gold standard" 
setting principle. If the result of thE 
acquired in practice and were approved, 
principle would be redundant. Moreover, 
popular with decision-makers than the QALY 
of the simplicity of its procedure. 
In the article of Mehrez et al (1989), 
of the priority- 
test could be 
then the QALY 
it may be more 
approach because 
two examples are 
provided'to highlight how conflicts between the two methods 
can happen. Given that the ranking treatment option method is 
so powerful that it is comparable to the QALY method, it 
should be interesting to note why they propose a new quality 
of life measure (Healthy-Years-Equivalent or HYE). 
The main superiority of the HYE to the QALY is in 
particular in the way it tackle the problem of the 
specificity of the individual utility function used in the 
QALY procedure. As a result, the priority-setting of health 
programmes based on the HYEs could reflect individual's 
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genuine and variant preferences, as opposed to that based on 
the QALYs possibly resulting in giving high precedence to 
less-preferred programmes. 
Its two shortcomings could prevent it from being widely 
used. First, its measurement unit of health outcome (i. e. 
utility) and the comparison unit of health care interventions 
(i. e. cost per unit of utility gained) may be strange and 
unpopular with both clinical and health programme appraisal 
decision-makers compared with QALYs and cost per QALY gained. 
Secondly, the feasibility of bringing the HYE procedure into 
operation could suffer from financial and respondents' 
cooperation problems. Its long and complex interviews could 
be a burden to willing subjects and incur considerable 
expense to the analysts. These problems may indirectly affect 
the validity and reliability of the responses obtained. In 
addition, the allowance for some specific preferences may 
limit the comparability between people and between health 
programmes serving different population groups, undermining 
its full application. 
Nord (1992b) outlines a new health outcome measure, the 
so-called Saved Young Life Equivalent (SAVE) as an 
alternative to the QALYs. A unit of the outcome (1 SAVE) is 
defined as "saving the life of a young person and restoring 
him or her to full health". The underlying argument for this 
unit is that, to most people, it is the greatest value that 
one can acquire from health care. 
In valuing the health outcome of a health intervention in 
terms of this unit, information such as various aspects of 
health outcome (e. g. quality of life change, survival length, 
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mortality risk, etc. ) personal backgrounds of typical 
patients and other relevant factors, significantly 
influencing the raters, decisions, are taken into account. 
The outcome of health intervention is valued compared with 
the reference health outcome by using the equivalence of 
numbers technique (i. e. to answer how many times (or what 
number) the outcome of this intervention is considered 
valuable as 1 SAVE). 
The SAVE approach could solve some difficulties in the 
QALY approach. First, since it rests on a more direct utility 
valuation than the QALY method does, it could reflect 
society's genuine preferences over health programmes better 
than the QALY procedure could. Secondly, it possesses a 
higher level of understandability in the valuation procedure 
because the measurement unit is comprehensible. Finally, it 
has more flexibility and higher levels of completeness, 
incorporating more relevant variables that, in respondents, 
views, can determine the appropriate valuations. This also 
results in avoiding the debates on the context-specific and 
disease-specific issues as well as ethical and distributional 
considerations because the answers to these matters can be 
embraced in respondents' values, independent of pre-arranged 
perceptions of the analysts. 
Some vital features of the QALY procedure are maintained 
in the SAVE approach. Both use numbers to represent 
valuations and compare different health interventions in 
similar cost per health gained ratios. 
Nevertheless, the SAVE approach has three major problems. 
First, the insufficient support for the reliability of the 
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past valuation results from the equivalence of numbers 
scaling technique in the context of health care leads to 
scepticism over the reliability of responses obtained from 
this method. Secondly, it is likely that respondents would 
face the presentation of excessive information, bearing on 
their decision-making process. Finally, applying the SAVE 
procedure to the huge number of health care interventions 
available so as to have a comprehensive ranking is an 
enormous and perhaps formidable task. A solution to the last 
problem is to use a valuation model. The validity of such a 
model can be tested by the precision level of the predictions 
it produces. 
The sharp difference between the QALY and SAVE methods is 
the unit of the measurement. The former, focusing in 
particular on health outcome, defines the unit in terms of 
life expectancy (time) adjusted by the quality of life 
(utility). By contrast, the latter measures not only health 
outcome but also the effects of health care process as well 
as other relevant variables (e. g. patient's characteristics 
and equity consideration) in the form of the social value 
(utility). 
As a result, the two approaches may serve different 
objectives. For instance, the cost per SAVE may not be 
regarded as an efficiency assessment tool while the cost per 
QALY may be since it is possible that the rule of rescue 
regardless of cost is the predominant criterion in the SAVE 
valuation findings and dictates the health resource 
allocation accordingly. 
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Hope et al (1993) comment that the SAVE approach does not 
make it clear to raters on what basis they should make their 
judgements. 
As Williams (1991) points out, an issue suggested by the 
advocates and critics of the QALY method alike is the urgency 
of collecting more vital data for the QALY calculation. 
1.3.3.2. Suggestions for the ethical issues. 
To find out what opinions people currently hold about the 
debatable ethical issues (e. g. the discrimination and equity 
problems) and to indicate the best way to take account of 
their views in health resource allocation could be a 
practicable solution to these issues, an alternative to the 
theoretically ethical considerations. Cost-utility method can 
serve these normative tasks (Williams, 1987). It must fulfil 
an objective function that contains the opinions of the 
people involved. The suggestion from its result is to be 
compared with that based on other principles which carry the 
people's views so as to assess whether the cost-utility 
method could deliver better outcomes. An empirical test for 
such a comparison would demonstrate how well the cost-utility 
approach is capable of resolving these pragmatic ethical 
problems. 
According to Hope et al (1993), the SAVE approach is one 
of the procedures that could tackle the discrimination issue 
explicitly by taking into account the opinion about the issue 
given by respondents. For example, it could devise a direct 
comparison of various health interventions for patients with 
different ages (e. g. 80-year-old versus 20-year-old). 
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The social welfare function (SWF) approach is introduced 
to cope with the two main objectives -efficiency and equity- 
of the health care provision (Wagstaff, 1991). Its most 
important aspect is to trade off between the two. In 
addition, other attributes of health care that society 
considers essential, for instance needs, can be incorporated 
into the function (McGuire et al, 1988). 
The appropriate efficiency-equity combination of health 
care provision could be obtained by maximising the SWF 
subject to resources and other constraints. Wagstaff (1991) 
describes this process in the context of QALYs. The desired 
distribution of additional QALYs among health programmes is 
determined first and then the most efficient option of each 
programme is identified. 
Similar to the SWF procedure is Donaldson et al's 
proposal (1988) . Their principle allows for QALY maximisation 
and the desired distribution pattern of health programmes to 
a certain extent. Acute care, long-term care, community care 
and primary care are four main categories into which the 
health care budget is allotted. Within each category, the 
priority of health programmes for funds is ranked using the 
QALY method. However, this still leaves a question of how to 
allocate the budget among the main categories. The 
consistency and compatibility between this unknown criterion 
and the QALY method have yet to be studied. 
1.3.3.3. Suggestions for the issues in the quality of 
life measure. 
a) Suggestions for the conceptual issues. 
Weinstein (1988) suggests that the QALY procedure should 
be developed in such a way that the valuation of health 
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status obtained takes into account age- and context-specific 
variations among people. 
The developments on both programme-specific and across- 
programme health outcome measures are important, as Donaldson 
et al (1988) urge, in the sense that their comparison could 
determine whether or not the across -programme measures could 
discriminate against some people when used in the decision- 
making process about health care allocation. 
According to Siegrist et al (1989), the quality of life 
valuation for the chronically ill is more complicated than 
that for other illnesses and thereby needs to be paid more 
attention in future in both clinical and policy-making 
contexts. With reference to long-term care for elderly 
people, Donaldson et al (1988) recommend dependency and life 
satisfaction as two quality of life measures. Their idea of 
these two dimensions stems from the objectives of the long- 
term care provider's policy in the UK, of which personal 
dignity and expression of personal preferences are two main 
components. If the disability dimension remains in the 
measure, then it should focus on the ability of individuals 
to perform daily activities. However, like the Rosser Index, 
the use of the long-term care objectives could be subject to 
the criticism that the measure is pre-determined by analysts. 
b) Suggestions for the methodological issues. 
Scaling a health profile could resolve the problem of the 
valuation conditions violating the assumptions underlying the 
measurement of separate health states in the QALY procedure. 
The HYE approach, as discussed earlier, is one of such 
methods. Respondents, attitude towards risk and time 
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preferences are taken into account in the measurement. 
Therefore, no unconvincing assumptions about them are needed. 
The valuation result obtained embodies each individual 
respondent's genuine views about these two attributes. 
Two alternative utility theories to the expected utility 
theory are put forward by Mooney (1989) as a basis for the 
quality of life scaling technique. Regret theory could 
incorporate the disutility of not selecting the choice with 
better outcome. Prospect theory could cope with ef f ect of 
current health status on valuations of other future health 
status. 
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Chapter 2 
The valuation of health states 
This chapter gives an overview of the health-related 
quality of life issue. The relevant measurements and scaling 
techniques to date are reviewed, some of which are selected 
to be used in this study. The details of the chosen 
instrument (e. g. the EuroQol instrument) and of the two 
scaling methods with some modifications are provided. It 
discusses criticisms of the EuroQol instrument. Whose 
valuations should count is addressed in the context of the 
Thai health sector. Finally, the valuation survey in Thailand 
is described thoroughly and the outcome presented. All of 
these offer an essential background for the analyses that 
follow throughout this study. 
2.1. Definition of health-related quality of life. 
There is no accurate definition of the health-related 
quality of life but the concept is derived from the health 
definition by the World Health Organisation. It builds on the 
subjective components of physical, mental and social well- 
being. In an objective form, health state is used as a 
representation of health. The health-related quality of life 
therefore depends on the health state approach in practice. 
Despite their different purposes of measuring the quality 
of life and the diverse techniques, all the health status 
instruments share the common core of the concept. Two 
examples, taken from the same source, support the 
observation. 
a. Health-related quality of life is "the level of well- 
being and satisfaction associated with events or conditions 
109 
in person's life as influenced by diseases, accidents or 
treatments" (Patrick et al, 1988) (my italics). 
b. Health-related quality of life is "the level of well- 
being and satisfaction associated with an individual's life 
and how this is affected by diseases, accidents and 
treatments" (Walker et al, 1988) (my italics). 
From these definitions, there are two fundamental 
respects required in the quality of life measurement. First, 
the quality of life concept focuses on an individual's level 
of well-being in relation to their surrounding diseases, 
accidents and treatments. Secondly, it is necessary to 
measure the degree of satisfaction in all those possible 
levels of the well-beings. The scaling method i's essentially 
devised to convert the respondents, satisfaction into 
numerical values of health states. The desirable method 
should confer a set of the values which reflects the 
relationship among the health states in consideration. A 
cardinal scaling approach, for instance, can rank the states 
and indicate how far apart any health state is from the 
others. 
In practice, a variety of interpretations of the health- 
related quality of life fulfil these two accounts. Therefore, 
many health state measures exist. Three main issues divide 
the measures. First, what activities, events or conditions in 
a person's life constitute the level of well-being? Patrick 
et al (1988) suggest a wide range, such as work life, 
recreation, household management, family life and social 
life. In fact, the aim of the measurement principally governs 
the selection of the well-being components. As a result, a 
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major distinction of all the measures is their descriptors 
and contents of the health dimensions. In addition, in most 
cases, the number of degrees in each dimension reflects the 
refinement of the well-beings. 
Secondly, what approach and which strategy appropriately 
capture the levels of the well-being satisfaction? As there 
exists no standard with which to compare it, the best scaling 
method is still controversial. They remain to be tested. Two 
competing strategies of devising the measurement of the well- 
being preference are the assessment of each separate health 
dimension at a time and that of a health state comprising all 
the relevant health components. In the f irst instance, an 
arbitrary rule of combining all dimensions is dictated (e. g. 
the Quality of Well-Being Scale and McMaster Index). The 
extreme case completely rules out the aggregation of all 
dimensions (e. g. the Nottingham Health Profile). In the 
second, including the Rosser index and EuroQol instrument, a 
respondent has a chance to compare all the health states 
being considered. Not only is the valuation of the health 
states made simultaneously but also the trade-off between 
dimensions within any health state. 
Thirdly, how diseases, accidents or treatments affect a 
change in people's well-beings and satisfaction. This is an 
issue that is gaining attention increasingly and becoming 
important to most health agents such as clinicians, health 
planners, health decision-makers, doctors and health 
economists alike. At a wide range of levels, most of the 
health status measures are designed to be applied (e. g. 
specific treatments as well as national resource allocation) . 
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A measure that does very well at one level might not equally 
do so at others since the details required by each level 
usually differ. 
2.2. Health-related quality of life measurement. 
Basically, the measurement can be split into two main 
categories on the basis of the scope of applicability. 
Disease-specific measurements have been created for routine 
patient monitoring in terms of signs and symptoms relevant to 
a particular disease. The measures such as the Arthritis 
Impact Measuring Scale (AIMS) , the Functional Living Index 
Cancer (FLIC) , the QL-Index and Barthel Index are reviewed in 
Kind (1988a). The incomparability between health 
interventions based on distinctive measurements makes them 
inappropriate for a general economic evaluation study. 
By contrast, generic measurements are designed to be 
capable of measuring health impacts in the widest possible 
range of health settings. In addition, the cardinal scale 
achieved is crucial for the comparison of health impacts. The 
economic appraisal usually employs the results of these 
measurements. Recently a new measurement developed 
specifically for the resource allocation assessment has been 
launched. It is based on the crucial structures of the 
existing measures (The EuroQol Group, 1990). Extensive 
discussions of most of these measures are made in Kind 
(1988a), Kind (1988b) and Rosser (1983). 
Key generic measures and their scaling methods are 
summarised in Tables 3 and 4. Table 3 compares the 
descriptors of six instruments in their number and types of 
health dimensions, levels of the dimensions, number of the 
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Table 3: Different characteristics of descriptors of 
key health-related quality of life measures. 
QWB 
I 
SIP 
I 
NHP MHIQ 
I 
Rosser 
I 
EuroQol 
- 
1. Number and types of health dimensions 
4 12 6 for the 4 2 5 
-mobility -ambulation first part -physical -disabi- -mobility 
-physical -mobility -physical function lity -selfcare 
activity -body care mobility -role -dis- -usual 
-social -social -pain function tress activity 
activity interact- -sleep -socio- -pain/ 
-symptoms ions -energy emotion- discom- 
and -communica- -social al fort 
problems tion isolation function -anxiety/ 
-emotional -emotional -health depress- 
behaviour and 7 for problem ion 
-alertness the second 
behaviour part 
-home -paid 
management employment 
-recreation -job around 
and part- the home 
times -social life 
-eating -family 
-sleep and relations 
rest -sex life 
-work -hobbies/ 
interests 
, -holidays 
2. levels of the dimensions 
4-5 affirmative 3 in the 6,5,4 8 and 4 3 
for the and first part and 8 
first negative and yes/no 
three and in the 
23 of second part 
symptoms 
and 
problems 
3. Number of the statements to be answered 
43 for 136 38 and 7 42 29 18 
the first 
three and 
63 for 
the last 
4. Form of administering questionnaire 
specially both interview inter- inter- self- 
trained self-com- view view complet- 
interview pletion ion 
er and inter- 
view 
Notes : QWB = The 
SIP = The 
NHP = The 
MHIQ = The 
Rosser = The 
EuroQol = The 
Quality of Well-Being Scale 
Sickness Impact Profile 
Nottingham Health Profile 
McMaster Health Index Questionnaire 
Rosser Index 
EuroQol Instrument 
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Table 4: Different characteristics of the valuation methods of 
key health-related quality of life measures. 
QWB 
I 
SIP NHP MHIQ Rosser EuroQol 
1. Scaling method 
categori- rating the pair compa- categori- magni- visual 
cal relative risons cal scal- tude analogue 
scaling severity of ing and estima- scaling 
dysfunction time tion 
of each trade-off 
statement 
2. Scale unit 
0-1 0-100 % 0 (no 0 (extre negative 0 (worst 
(the (the higher problem) mely poor to I imagin- 
higher score, the to 100 (all function) (perfect able con- 
the score more dysfun problems) to 1 health) dition) 
the less ctional) (extreme- to 100 
dysfunct- ly good (best im- 
ional) function) aginable 
I Ione) 
3. The final form of the weightings 
weights weights weights weights weights weights 
for both for both for only for both for only for only 
each cate each cate- each category each cate health health 
gory and gory and gory and states states 
heath health health 
Istate* Istate* I Istate* 
Notes : See notes at Table 3 for the abbreviations. 
The aggregation of the categories towards the values for 
the health states is fundamentally based on mathematical 
and statistical methods. 
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statements used, and forms of administering the 
questionnaires. The scaling methods, scale units and f inal 
form of the weightings are presented in Table 4. 
2.3. The measurement approaches to the health-related 
quality of life preferences. 
2.3.1. The development and classification of the 
measurement methods. 
Following the Bernoulli's solution to the St. Petersberg 
paradox that people are interested in maximising expected 
utility more than expected amount of money, the importance of 
subjective preference over consequences is gaining more 
attention. Also, the psychologists have demonstrated that it 
is possible to measure, among many qualitative aspects, 
preference on a psychological scale for physical objects 
(Torgerson, 1958). As a result, attempts to measure 
preference have been evident in many disciplines. A variety 
of the measurement methods have been developed in order to 
serve one's own objective. Though diversified in theoretical 
framework and procedure, they share some basic rules of 
measurement and encounter similar problems. In some cases, 
their outcomes are found to be related. 
It is commonly agreed that ordinal or rank-order 
preference can be estimated. The quantification of cardinal 
preference is not accepted by all. Lee (1971) points out that 
economists have no consensus on the measurability of 
consumer's cardinal utility of commodities. 
According to Schoemaker (1982), cardinal utility has at 
least three levels. At the top level, it is defined as 
strength of preferences (i. e. showing degree and direction of 
preference). At the middle, it requires that utility should 
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be able to follow a transformation rule. The linear 
transformation is the basic and simple requirement. At the 
bottom is preference with interval property (i. e. preference 
on an equal-interval scale). Most scaling methods at present 
pursue only the simplest form of cardinal preference. Though 
some methods are claimed to estimate the middle level 
preference (e. g. preference on a ratio scale by the ratio 
magnitude estimation technique (Stevens, 1971)), their 
empirical evidence is inconclusive and limited. 
A basic theoretical framework underlying the preference 
measurement is the view that utility is related to a set of 
stimuli of the object in consideration (i. e. different levels 
of an attribute) in a definite pattern (or in functional 
form). Such an association is known as the utility function. 
For example, Lee (1971) shows that the Bernoulli utility 
theory assumes utility gained to depend on amount of 
commodity consumed in a logarithmic pattern. However, this 
has three main limitations (Lee, 1971). First, actual utility 
may be different from expected ones. This would result in a 
discrepancy in predicting rational behaviour. Secondly, to 
the psychologist, it cannot render the exposition of the 
human preference structure. Thirdly, since utility function 
varies between people and within individuals, it is extremely 
difficult for an estimated utility function to generalise. 
It is believed that the size of preference can be 
influenced by such factors as intensity, duration, certainty 
and propinquity (Lee, 1971). Therefore, it is no surprising 
that they are employed in the preference measurement methods. 
116 
Schoemaker (1982) distinguishes two types of utility 
measurement with respect to the certainty and risky 
conditions underlying the procedure. The distinction often 
fails to be recognised and therefore frequently causes some 
confusion. The implication is that the model involving the 
expected utility measured under certainty conditions has no 
normative justification whereas the model based on that 
measured under risky conditions does. Though the outcomes of 
the two differ, it is possible to compute an equivalent of 
one to the other (Schoemaker, 1982). 
The utility measurement under certainty conditions and 
that under risky conditions are correspondent to direct and 
indirect utility measurement methods defined by Lee (1971), 
respectively. Jones (1974) explains such a classification. In 
the former the judgements made are with real numbers or on 
the basis of some pre-set ratio whereas the responses in the 
latter require a manipulation before utilities are obtained. 
Pair comparisons, magnitude estimation and categorical 
rating are the most fundamental and important direct utility 
measurement methods. Some modifications of the last technique 
are distinctively labelled as the graphical rating scale or 
visual analogue scale method. The indirect utility estimation 
methods mainly consist of standard gamble and time trade-off 
techniques. 
Streiner et al (1989) points out that the advantage of 
the direct method is in its simplicity to design, little pre- 
testing requirement and understandability by subjects. 
However, bias in responses can occur as a result of the 
insufficient attention of subjects to obvious questions in 
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the elicitation (Lee, 1971; Streiner et al, 1989). In 
addition, the precision of the estimation is usually 
suboptimal because of the subjects, reluctance to assign an 
extreme category to near the top or the bottom of any scale. 
A different classification is offered by Streiner et al 
(1989) in the context of the health state utility valuation. 
Their three categories are direct estimation techniques, 
comparative methods and econometric methods. Whatever the 
classification, the utility measurement approaches are the 
same. 
2.3.2. Vital characteristics of the key measurement methods. 
Theoretical background, procedure, variation and 
application to the health state context are discussed for 
each key utility measurement method. 
a) Pair comparisons method. 
Underlying the pair comparisons methods is the law of 
comparative judgement, which states that the comparisons of 
two stimuli at a time and the identification of the preferred 
member in every pair can generate a psychological continuum 
scale. Two important axioms are that each stimulus has a 
correspondent value on the scale and that the mean of the 
value distribution of a stimulus derived from a group of 
subjects is taken as its scale value. 
The first step of the procedure is to specify a set of 
stimuli so that they can be placed on the same interval 
scale. A subject is asked to indicate in every pair presented 
the more preferable stimulus with regard to the attribute in 
consideration. No equality is permitted. The size of n 
stimuli requires the judgements of n(n-l)/2 pairs. 
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This method is subject to time and space errors as well 
as fatigue and practice effects (Torgerson, 1958). However, 
these could be brought under control by arranging the 
appropriate positions of the members of each pair and 
ordering the proper pair presentation. The arrangements may 
be at random or manipulated to obtain the maximum desirable 
effect. 
This method is unpopular for the health state utility 
measurement. 
b) Magnitude estimation method. 
The magnitude estimation method assumes that subjects can 
represent the magnitudes of the attribute under study by 
numbers given to a series of stimuli. 
The common procedure is initially to show a subject a 
standard stimulus with a pre-set number. He is then asked to 
provide numbers of the rest of the stimuli with respect to 
the number of the standard. One of its variations is to 
present a subject with numbers (e. g. twice the standard 
number or one-fifth) and ask him to provide the magnitude of 
the stimuli. 
Stevens (1971) claims that the application that sets out 
to elicit one judgement for a stimulus could reduce biases 
from range and spacing of the stimuli to a minimum. Also, he 
suggests some improvements. A standard should be chosen by 
the subject himself. The ordering of the stimulus 
presentation should be kept irregular. The first of the 
stimuli to be compared should be in the middle of the range. 
An elicitation session should contain between 10 and 20 
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stimuli. A practice session with an elementary attribute like 
apparent length of lines could be advantageous. 
Kaplan et al (1979) apply the classical magnitude 
estimation method to the health status valuation. The 
following are the instructions of the method in their work as 
quoted. 
"Each of these cards described the health 
situation of some person on a given day. We 
would like you to tell how desirable you 
believe a day in the lif e of the described 
person seems by giving a number to it. Let's 
give the f irst case the number 10. Now assign 
numbers to the other cases. Using the number 
10 as your guide. For example, if a case 
seems 10 times as desirable as the first case 
you would use a number 10 times as large as 
100. If seems one-fifth as desirable, you 
would use the number 2 and so forth. Use 
fractions, whole numbers or decimals, but 
make each assignment in relation to the 
desirability of the first case, as you see 
fit. " (Kaplan et al, 1979). 
Rosser et al (1978) employ the magnitude estimation 
method without a pre-determined standard to rate the health 
state valuation. They asked the respondents this sort of the 
question : "How many times more ill is a person described as 
being in state 2 as compared with state 1? 11 
Sintonen (1981) uses the method to value the multi- 
dimensional health states. The model postulates that the 
utility of a health state is the integration of the utilities 
of all the dimensions with certain levels. The utility of 
each dimension at a particular level in turn is the 
multiplication of the value of that level in that dimension 
and the value of the relative importance of the dimension. 
Both the relative important weights and the values of. the 
levels are derived by the magnitude estimation method. This 
two-stage valuation procedure assumes the independence of the 
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value of the elicited level of any one dimension from the 
values of the levels of all other dimensions kept constant. 
Though this assumption is less likely to hold in real 
conditions, the model is recommended and the results are 
considered an approximation. 
A slight inconsistency in the magnitude estimation 
results arises from the inclusion of dead and unconscious 
states as stimuli in the work by Sintonen (1981). 
c) Categorical rating method. 
The categorical rating method is derived from the law of 
categorical judgement (Torgerson, 1958). The law postulates 
that ordering a set of stimuli into categories provided can 
give rise to a psychological scale. Two basic assumptions are 
required. First, subject's psychological scale can be 
partitioned into a given number of ranked categories. 
Secondly, he can match stimuli with the corresponding 
categories. 
The simplest procedure of this method is to ask the 
subject to assign each stimulus to a set of categories. The 
stimuli, the number of which is set by the analyst, are 
presented once at a time. A slightly complicated modified 
technique is to ask the subject to mark off his response on 
a continuous line. The distance becomes the value of 
stimulus. 
Streiner et al (1989) describe the visual analogue scale 
method in the context of the health state valuation. A line 
with a given length (e. g. 100 mm. ) is labelled at both ends 
(e. g. no pain and pain as bad as it could be). To measure a 
subject's own health state, he is requested to mark on the 
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line, representing his perceived health state. One of its 
variants, which is in the form of a vertical line (or band) 
with a numerical scale like a thermometer, stems from an 
attempt to make it easier for older people to complete 
(Streiner et al, 1989). 
Kaplan et al (1979) use the following instructions of 
their category rating method to estimate the health status 
values. It should be noted that the equal interval judgements 
by the subject are required in this measurement. It is an 
unusual practice (Siegrist et al, 1989). 
"Think about the day described on each page 
and rate it by choosing a step on the ladder 
from zero (0) to ten (10). All health 
situations can be placed on one of the steps * If the page described someone who is 
completely well, then choose the top step, 
ten. If you think the situation described is 
about as bad as dying, then choose the bottom 
step, zero (0) . If you think the person Is 
situation was about half-way between being 
dead and being completely well, then choose 
step 5. six is one step better than 5,5 is 
one step better than 4 and so on. You can 
choose any of the steps from zero (0) to ten 
(10) depending on how bad or good you think 
that day was. " (Kaplan et al, 1979) 
The application of the category rating method to the 
multi-dimensional health status valuation can be found in 
Sintonen (1981). His model was previously described. 
Recently, the visual analogue scale has been increasingly 
applied to value health states (Essink-Bot et al, 1990; The 
EuroQol Group, 1990). Details of this method, employed in the 
EuroQol instrument, will be elaborated later on. 
d) Standard gamble method. 
Historically, the development of the standard gamble 
method followed the expected utility theory. The expected 
utility theory focuses on decisions over choices with 
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different levels of risky consequences, which may be either 
simple- or multi -dimensional (Schoemaker, 1982) .A basic 
expected utility model may be generally specified as the 
maximisation of the following equation. 
F (P j) U (Xi) 
n 
and P, i 
i=1 
where F probability transformation 
U utility of consequence 
xj a consequence 
Schoemaker (1982) points out that the model can be 
modified by taking into account one or more of the following 
things. 
1) How utility is measured. 
2) What types of probability transformation F( are 
allowed. 
3) How consequences are measured. 
There are four main purposes of the expected utility 
model (Schoemaker, 1982). 
1. It may be used to describe the decision-making process 
involving risky choice. 
2. It could of f er predictions f or some decision-making 
processes. 
3. A rightly specified model could show the optimality in 
human behaviour that is observable. 
4. Its prescriptive or normative function could recommend 
appropriate options among various possible alternatives 
compatible with the decision-makers, preferences. 
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Von Neumann et al (1953) demonstrate that with a set of 
axioms that govern preferences between gambles, the interval 
scale utilities of consequences and gambles can be derived. 
The basic six axioms are described as follows. The meanings 
of the symbols that are found are given below. 
P, PI , P", P,, and Pb probabilities 
Oi, Oj, and Ok three consequences 
> is more desirable than 
< is less desirable than 
= is indifferent to 
Axiom 1: An individual has to decisively determine between 
two consequences, either that which is more desirable or that 
they are indifferent. In a symbolic expression, only one of 
the following three conditions can be true within an 
individual. 
Oj > Oj , Oj > 01 , Oj - Oj 
Axiom 2: The preferences must be transitive. That is, 
if Oi>Ojandif 0i >Ok I then Oi>Ok * 
Axiom 3: For probability between zero and one, if an 
individual prefers one consequence to the other, he will 
prefer the former with certainty to a risky option combining 
the two consequences, and vice versa. This means 
if Oi > Oj , then 0i > [Poi , (1-P)Oj1 or 
if Oi < Oj , then 0i < [POj , (1-P)Ojl . 
Axiom 4: Given an option with a certainty consequence and a 
risky one combining more and less desirable consequences than 
the certainty consequence, there exist a probability that the 
certainty option will be preferred and a probability that the 
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risky option will be preferred. In other words, if 01 > Oj 
> OkI then there exist Pa in that [PaOi I (1-Pa)Okl < OJ 
and Pb in that [PbOi J, (3--Pb)Okl > OJ * 
Axiom 5: The preferences must not be affected by the order 
of the consequences presented in a gamble. Or 
[POi , (1-P)Oj] -[ (I-P)Oj, Poi) . 
Axiom 6: Whether a gamble is normal or compound should not 
affects preferences. If the probabilities in a compound 
gamble are assumed to be independent, the gamble can be 
reduced to a normal gamble in which the probability of the 
joint occurrence of two consequences is equal to the 
multiplication of the two probabilities of the two 
consequences. That is, 
[P[Ploi, (l-P')Oj]' (I-P)Ojl - [P110i, (I-P1')OJ1 
where P" p-P/ 
The utilities obtained from an experiment are not unique. 
Their equivalents can be derived in accordance with a 
positive linear transformation. That is, 
U'(0i) aU (0i) +b. 
where UI(Oi) and U(Oi) new and old utilities 
aa positive constant real number 
ba constant real number 
The standard gamble method is devised to measure utility 
under these axioms. Its basic procedure is initially to 
create two choices. One has a certainty consequence, the 
other is a risky alternative. It is composed of two 
consequences which are more and less desirable than the 
previous consequence. The probability in the risky option is 
varied until the equalising of the two options is achieved. 
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The utility of the certainty consequence can be computed by 
the following equation. 
U (0i) P U(00 + (1-P) U(Ok) 
By letting U(Oi) and U(Ok) be one and zero (or using a 
unit scale) , the probability at the indif f erence point 
is the 
utility value. That is, 
U (0i) =p- 
Kneppreth et al (1973) suggest that in order to get 
subjects to become more familiar with or to better comprehend 
probabilities, two-colour wheels or bars with variable sizes 
of coloured areas should be used to illustrate the 
probabilities. 
Torrance et al (1972) 
to value health states. 
state n-l is supposed to 
is the certainty of good 
state n-l f or time t and , 
exemplify the use of this technique 
The utility of a given morbidity 
be elicited. The first alternative 
health for time t, then the health 
leath afterward. The second consists 
of certainty and risky consequences. A certainty good health 
will last for time t. In a risky part there are a probability 
P of a good health, as a result of a hypothetical drug 
effect, for time t, followed by death and a probability 1-P 
of immediate death. The subject is requested to choose 
between them. The probability P is altered so as to arrive at 
the equalising of the two options. At the indifference point, 
the utility of the health state n-l can be determined by the 
following equation. 
h1t + h,, -It 
h1t + h1tP + h,, t (1-P) 
where h1t represents the utility of a good health and 
is set to be 1. 
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h, 
-, represents the utility of the 
health state n-1. 
hn represents the utility of dead state and 
is set to be 0. 
So hn-1 P. 
The reason for incorporating a certainty of good health 
in both options in this application is to demonstrate to 
subjects that both the unhealthy and death are future events. 
Torrance et al (1972) claim that by doing so, the reliability 
of the results is enhanced. The scenarios are compatible with 
the fact that the study outcome is applied to the assessment 
of future health programmes. 
Inconsistency in the subject's responses is one of the 
major problems of this method. It could arise from the 
grounds that subject would be indifferent to options on a 
range of the probabilities and he may respond 
probabilistically to different presentations of the same set 
of options (Lee, 1971) . The elicitation outcome best reflects 
a subject's present preferences but only a slight tendency of 
his future ones (Kreppreth et al, 1973). 
Even in a study carefully designed to obtain a high level 
of the response consistency, the incompatible responses are 
still commonplace (Farquhar, 1984). Farquhar (1984) advises 
that the inconsistent responses could be allowed for either 
by separating consistent ones from inconsistent ones and 
adjusting the latter appropriately, by finding a utility 
function reconcilable with the responses or by adopting an 
expected utility model that accepts the anomalous responses. 
If they cannot generate a satisfactory outcome, alternative 
utility measurement methods should be explored and developed 
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to keep inconsistent responses to a minimum or get rid of 
them. For instance, stochastic utility theories were created 
to take into account probabilistical preferences. However, 
its normative appeal is comparatively weakened (Lee, 1971). 
e) Time trade-off method. 
The rationale of the development of the time trade-off 
method is to avert the difficulty arising from the 
probability component in the standard gamble technique 
(Streiner et al, 1989). Instead, this method uses a person's 
life years left as an adjustor. 
Torrance et al (1972), who developed this technique, 
demonstrate how to use it. Subjects are presented with two 
certainty options and asked to select between them. The first 
is an unhealthy state n-1 lasting for time t, followed by 
death. The second is a good health spanning for time x which 
is shorter than t, followed by death. The time x is changed 
until he is indifferent between the two options. His utility 
for this health state n-1 can be computed by the following 
equation. 
hn-lt hlx + hn (t -X) 
where h, denotes the utility of a good health in time t 
and is set to be 1. 
hn-, denotes the utility of the health state n-1 
in time t. 
h. denotes the utility of death after time x 
and is set to be 0. 
Hence, hn-1 2i 
t 
The article also demonstrates how to apply the method in 
conditions that do not involve death. The scenarios of the 
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two options are changed. The requirement is that the two 
health states in the composite option must be more and less 
preferable to the health state in the other. The first option 
is an unhealthy state i lasting for time t, followed by good 
health. The second is another unhealthy state i+1 lasting for 
time x<t, followed by good health. Again, the time x is 
varied until the indifference point between the two options 
is acquired. Given that the utility of the health state i+l 
is assumed or known, the utility of the health state i can be 
derived from the following equation. 
hit hilx + h, (t-x) 
hi 1-x (1 - hi+, ) 
t 
2.3.3. Comparisons of the measurement methods. 
Each method is discussed in terms of advantages, 
disadvantages and relationships with other methods found in 
various studies. 
a) Pair comparisons method. 
This method is most appropriate for attributes that are 
difficult to arrange in a logical or objective pattern 
(Jones, 1974). It could control bias due to an apparent 
ranked order of responses by hiding the ordering (Streiner et 
al, 1989) . It can guarantee interval-scale responses in cases 
with relatively few stimuli. 
A major setback for this method is that it cannot be 
applied for an individual person (Anderson, 1976). The result 
of the method based on a group cannot be interpolated to 
particular individuals because the individual responses would 
be sharply diversified. Apparently, it is unsuitable for the 
elicitation of a large number of stimuli. Though there is a 
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short-cut method, a task may in most cases still be huge 
(Jones, 1974). The last disadvantage might explain why there 
are few pair comparisons studies, particularly in the health 
status context. Also, its associations with other methods are 
rarely of interest. 
b) Magnitude estimation method. 
The simplicity of the method is indicated by Stevens 
(1971). He found that the performance of the untrained, 
inexperienced college participants is as satisfactory as that 
of those with more skill. 
The magnitude estimation result in the analysis by Kaplan 
et al (1979) is in contrast to those in the earlier analyses. 
They dismiss the method as inappropriate for the health 
status utility measurement. 
Sintonen (1981) claims that a magnitude estimation method 
with bounded ends is equivalent to a category rating one. 
Anderson (1976) pointed out some procedural and empirical 
differences between the magnitude estimation and the 
categorical rating methods. The former does not limit the 
size of responses (i. e. the numbers) which could result on a 
large scale. On the contrary, in the latter, a workable 
number of categories has to be devised. 
Most studies indicate that for most psychophysical 
attributes and social dimensions, their initial results are 
unrelated but their association could be non-linear. Stevens 
(1971) suggests that their relationship could be represented 
by a concave downward curve. Kaplan et al (1979) finds that 
in most cases, the mean values derived from the category 
rating method are linearly related to the logarithms Of the 
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arithmetic or geometric mean values based on the magnitude 
estimation method. 
In the work by Sintonen (1981), the mean values based on 
the magnitude estimation method were higher and the standard 
deviations lower than those elicited by the category rating 
method at some levels of the health dimensions. Moreover, the 
apparent difference of the two techniques can be seen in the 
values for dead and unconscious states. In the magnitude 
estimation method, death was rated lower than unconsciousness 
whereas this was reversed in the other method. However, this 
study suffered from unrepresentative sampling and too small 
a number of samples. The generalisation of the result should 
be made with care. 
Anderson (1976) concludes that the magnitude estimation 
method is biased and invalid whereas the categorical rating 
method produces true interval scores. Also, Jones (1974) 
finds that the averaging of the values for two stimuli shows 
the distortion in the responses based on the magnitude 
estimation method but does not in those derived from the 
category rating method. 
c) Category rating method. 
This method, in various forms, is the most popular in 
empirical studies. It is simple to understand for subjects 
and could provide sufficient information in a limited 
duration of the measurement. Its theoretical and practical 
applications are regarded as successful (Jones, 1974). 
However, Stevens (1971) remarks this method as "the least 
satisfactory form of partition scale". Kaplan et al (1979) 
refer to the argument made by others that the category rating 
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method is subject to bias. The reason behind this is that 
subjects try to separate the stimuli that are close together 
and thereby the responses overstate their real distances. 
Moreover, the drawing together of those that are actually 
distant apart underestimates the real differences. 
There is controversy over the interval level scale 
achieved by the categorical rating method, visual analogue 
scale method and other related methods. Streiner et al (1989) 
believe that it is possible for interval scores to be 
produced. Conversely, Sintonen (1981) finds that the health 
state values from a category rating method in his analysis 
has no equal-interval property and the visual analogue scores 
in the study by Essink-Bot et al (1990) show a sign of a 
dichotomous pattern : most scores clustering around the top 
and bottom ends of the scale. 
Streiner et al (1989) state that there is evidence to 
establish an association between the outcomes of the category 
rating method with continuous categories and those of the 
visual analogue scale. 
Some advocate that the scores derived from the visual 
analogue scale could be made equivalent to those based on the 
time trade-off technique by a power function transformation 
(Nord, 1991b). Similarly, the empirical study by Torrance et 
al (1982) indicates a power function relationship between the 
standard gamble scores and the category rating scores. 
Regarding the more accurate measurement and the higher 
approval from participants, Streiner et al (1989) favour some 
other methods (e. g. the graphical rating scale technique) at 
the expense of the visual analogue scale method. 
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d) Standard gamble method. 
It is widely accepted that the value of the standard 
gamble method lies in its satisfaction of theoretical and 
normative perspectives (Lee, 1971; Kneppreth et al, 1973). 
Schoemaker (1982) points out that since its axioms are 
appealing, it could be regarded as a rational decision 
criterion. 
Nevertheless, there are a great deal of criticisms of 
these methods, some of the most important are summed up here. 
Streiner et al (1989) state that some of these problems occur 
in the context of the health state valuation based on this 
technique. 
1) Due to the difficulty of the procedure, it is 
necessary to have a trained interviewer to guide subjects. 
Therefore, it becomes time-consuming and complicated. 
2) Inaccurate or inconsistent responses could occur as a 
result of a misunderstanding of the concept of probability. 
3) Utility of consequence could be confounded by the 
utility of gambling. Lee (1971) argues that the existence of 
the latter violates the axioms 3,4 and 6 described earlier. 
4) Schoemaker (1982) provides various empirical evidence 
against the axioms. Also, Lee (1971) addresses extensively 
the inconsistent and intransitive response problems. In a 
compound gamble, the probabilities are not usually viewed 
independently. People tend to overestimate the probabilities 
in joint consequences and underestimate the probabilities in 
separate consequences (Schoemaker, 1982). Lee (1971) also 
questions the validity of the relation between component 
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utility and composite utility in the context of multi- 
dimensional consequences. 
5) The limitation in processing information available to 
people could play a significant role in their decision- 
making. People may simplify the process by focusing on some 
of the aspects encountered. For instance, people sometimes 
disregard consequences with low probability or underscore the 
loss prospect (Schoemaker, 1982). This could affect the 
format of the technique and the outcome obtained accordingly. 
These problems damage the descriptive function of the 
standard gamble method for practical decision-making 
behaviour. In addition, due to these criticisms, its validity 
of the normative function is questionable (Schoemaker, 1982). 
In the view of Kneppreth et al (1973), the method is 
inappropriate for the health care issues. 
With reference to the similarity and reliability of their 
empirical results, Torrance et al (1972) claim that the 
standard gamble method is similar to the time trade-off 
method. 
e) Time trade-off method. 
The advantages of the method are based on the concept of 
trade-off and the avoidance of the probability application. 
However, as mentioned before, it is found to be related to 
the standard gamble method and the scepticism for the 
standard gamble technique could lead to suspecting the 
validity of the time trade-off counterpart. 
2.3.4. Assessment of the measurement methods. 
From what has been discussed, it is obvious that there is 
no perfect utility estimation method. Further to their 
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disadvantages, the responses obtained are subject to bias 
arising from the procedure. 
Lee (1971) argues that the utility of a consequence is 
influenced by the time dimension and contextual presentation 
of various choices involved. The bias sources, as Farquhar 
(1984) summarises, include subtle scenario outline, question 
format, response mode and personal perspectives. Kaplan et al 
(1979) add to the list differences in wealth or income, 
aversions to gambling, prognostic prospects and discounting 
factors. 
The use of real scenarios in the utility measurement 
procedure could cause the responses acquired to be partial 
towards subjects' own benefits. Sintonen (1981) finds that a 
slight inconsistency in the responses elicited was connected 
to the different causes of death hypothetically encountered 
by subjects. Although no impacts of the subjects, background 
variables on the visual analogue scores were f ound in the 
analysis by Essink-Bot et al (1990), the logical inconsistent 
responses occurred at an individual level. 
In addition, Schoemaker (1982) points out that the 
overestimation of one's subjective probability is another 
important bias source. A serious implication of any bias in 
the utility measurement outcome is that the analysis could 
not be generalised beyond conditions specified and the 
subjects participating in the procedure. 
Here are a selection of the suggested solutions to tackle 
some of the biases mentioned. 
1) In order to lessen the temporal impact, the 
elicitation procedure can be devised in a way that 
135 
consequences with different periods can be regarded as 
different consequences (Lee, 1971). As a simple case, one 
time unit is used as a segmentation criterion. The utility 
differential observed from valuing an identical consequence 
in different moments of time would suggest the existence of 
the temporal effect. 
As in the real world, most subjects could feel 
uncertainty about the unknown duration of health status. 
Change in duration assumed in the elicitation procedure could 
affect the values for health states. Sintonen (1981) argues 
for his analysis without the duration specification because 
this would challenge subjects with uncertainty. As a result, 
their decision would incorporate this aspect, which is 
implicitly included in the study outcome. 
2) It is suggested that for the applications not familiar 
to the subjects to matter, more than one utility measurement 
method should be attempted (Farquhar, 1984). They may be 
distinguishable methods or variants of a fundamental one. The 
result comparison could identify the bias effects. The 
appropriate method and elicitation outcome would be 
highlighted accordingly. There may be a variety of the 
outcome definitions that can be used in the assessment. For 
instance, Essink-Bot et al (1990) use, in their analysis, the 
response consensus, which is defined by the degree of 
agreement between individual scores and group means in the 
case of the cardinal scale assumption. (Also for an ordinal 
scale, individual rankings and group rankings. ) 
3) According to Schoemaker (1982), the modifications of 
the expected utility theory have been done initially in a way 
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that some alternative utility measurement methods could 
disregard the axioms that are not met in practice and 
incorporate the subject Is cognitive impact on decision-making 
behaviour. Farquhar (1984) speculates that they would play a 
significant role in the Utility measurement. 
A suitable scaling technique for a particular health 
state valuation could be realised as a result of assessing 
the conformity of the objectives and constraints of the task 
to the procedures of various techniques and weighting between 
advantages and disadvantages of all feasible methods. For 
example, for an experiment with postal survey, the visual 
analogue scale method might be the first choice. On the other 
hand, a study focusing on firm theoretical or normative 
support could profit most from the standard gamble technique. 
After selecting an appropriate method, the design of the 
technique would be flexible so as to include into the scaling 
task more good characters, such as the bias control 
arrangements, which may be evident in other studies (Streiner 
et al, 1989). 
Validity and reliability of the scaling method can in 
some cases be employed to justify its use. The doubt over the 
content validity of the visual analogue scale approach to the 
health state valuation is raised, following the argument that 
it is less likely for people to apply numbers commonly used 
in their basic routine computation to the quantification of 
their quality of life (Nord, 1991b). 
However, the criteria for the validation is 
controversial. Sintonen (1981) suggests that the valuation of 
health states obtained by the category rating and magnitude 
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estimation methods in his analysis could be validated by the 
valuation based on a direct valuation of the health states. 
Conversely, Kneppreth et al (1973) argue that a direct 
validation of the valuation responses is impossible. They 
suggest that the validity test of the valuation result should 
take account of expert opinion, internal consistency and 
prediction precision. Lee (1971) believes that the accuracy 
of the predictions, as a vital validity criterion, of the 
magnitude estimation method makes it acceptable to most 
psychologists. 
A scaling technique based on a combination of various 
good components should be pilot tested for feasibility, 
assumption validation, the assessment of the bias impacts and 
so on before it is launched. 
2.4. The health state valuation instrument and scaling 
methods used in this study. 
a) Health state measurement and its descriptors. 
Almost all the health status measures discussed before 
are, more or less, eligible to be used. Through comparing 
their performance outcomes, the best measurement could be 
chosen and applied to the ensuing cost utility analysis. But, 
due to a constraint in resources and a difficulty of 
employing more than one instrument in a pioneer study like 
this, in Thailand only a single instrument is used. Regarding 
the prime purpose of the application to the resource 
allocation in this study, potentiality of benefiting the 
international community of the valuation users and other 
relevant considerations, the EuroQol instrument is selected 
for this study. 
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The design of the EuroQol instrument can overcome 
problems of a costly large-scale survey, and a great deal of 
respondents' effort and burden. Also, the sole purpose of 
its application to the economic appraisal is in line with the 
ultimate use of the study valuation result. Its broad 
objectives of the creation and development of a universally 
standard valuation measure increase the opportunity for the 
utilisation and the usefulness of the results. As quoted, 
"the principal aim of the EuroQol instrument is to test the 
feasibility of jointly developing a standard non-disease 
specific instrument of describing and valuing health-related 
quality of life. As a result, with the capacity to generate 
cross-national comparisons of the health state valuations, it 
could facilitate the exchange of the data on methods, and 
lead to standardisation in the collection and reporting 
quality of life data. " (The EuroQol Group, 1990). 
The applications of the existing health status 
measurement methods to developing countries like Thailand 
could save the country resources, time and effort. As the 
health-related quality of life measurement is new to Thai 
researchers at the present time, side benefit would accrue to 
other relevant analyses in Thailand in the future. 
In its latest version, which is used in this study, it 
employs five distinct health dimensions (or domains) with 
three levels in each. They consist of mobility, self-care, 
usual activities, pain/discomfort and anxiety/depression. 
These dimensions were chosen by the EuroQol Group through a 
detailed investigation of the descriptors of the key health 
status measures. There are in fact 243 possible combined 
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health state descriptors. But fourteen vital descriptors were 
selected and used in this version. Their selection criteria 
also involved their frequent use in most studies and the 
coverage of a wide range of severity levels within each 
health dimension. This, it is claimed, widens the chance to 
utilise this instrument in many different populations, 
varying from healthy people to the severely ill. 
The statements correspond to each dimension with three 
severity levels. These are shown in Table 5. The sixteen 
descriptors are put on two successive pages in the 
questionnaire. Two health states, no problems in all the 
dimensions and extreme problems in all, are repeated. 
Subjects are then asked to locate the dead state in both 
pages after all the other states are completed. These 
repetitive states could be used in the reliability test of 
the valuation. The full questionnaire is presented in 
Appendix I. 
b) Health state scaling method. 
One of the biggest concerns in applying any complicated 
valuation scaling technique to a population with no previous 
experience of it before, as in this study, is whether or not 
people would understand it. The findings are that the time 
trade-off method is regarded as the simplest one, followed by 
visual analogue method with standard gamble method the most 
difficult one (Torrance, 1986). This could therefore guide 
appropriate scaling methods to this study. 
As the EuroQol instrument is intended to be self- 
administered, a visual analogue scale in the shape of a 
thermometer is a built-in scaling method in the 
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Table 5: The statements of the health dimensions of 
the EuroQol instrument. 
I. Mobility. 
1.1 have no problems in walking about. 
2.1 have some problems in walking about. 
3.1 am confined to bed. 
II. Self-cars. 
1.1 have no problems with self-care. 
2.1 have some problems washing or dressing myself. 
3.1 am unable to wash or dress myself. 
III. Usual activities. 
1.1 have no problems in performing my usual activities 
(e. g. work, study, housework, family or leisure activities). 
2.1 have some problems in performing my usual activities. 
3.1 am unable to perform my usual activities. 
IV. Pain/Discomfort. 
1.1 have no pain or discomfort. 
2.1 have moderate pain or discomfort. 
3.1 have extreme pain or discomfort. 
V. Anxiety/Depression. 
1.1 am not anxious or depressed. 
2.1 am moderately anxious or depressed. 
3.1 am extremely anxious or depressed. 
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questionnaire. (It is called "the feeling thermometer" 
hereafter. ) This technique is chosen for a low-cost postal 
survey. A supplementary interview survey assists the analysis 
to satisfy the survey both qualitatively and quantitatively. 
Its rationale and procedure will be discussed later. 
Moreover, benefit would arise by adding time trade-off method 
to the interview survey. The valuation outcome of both 
methods can be compared. 
The features of the two scaling techniques and their 
specific modifications in this study are described as 
follows. The feeling thermometer uses a band with a certain 
length on which the health states in consideration are 
scaled. It has two reference points : the best imaginable 
health state with a maximum score of 100 at the top end and 
the worst imaginable health state with a minimum score of 0 
at the bottom. A subject has to draw a line from a box 
containing a health state descriptor to a point on the scale. 
The distance between zero and the score for that health 
state, which can be read from the number accompanied, is its 
value. 
In practice, time trade-off method has a difficulty in 
selecting the number of the extra life years. It creates a 
dilemma. The longer the life chosen, the more refined values 
the method produces but the more time and burden in the 
elicitation process. Therefore, the determination of the 
appropriate number of the years depends on the balance 
between these two opposites. This analysis uses a ten-year 
extra life in the time trade-off scaling and hope that the 
evaluators are not discouraged in answering the questions of 
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the valuation and that the values obtained could be 
sufficiently sensitive to distinctive health states. Although 
this method can be adjusted for worse-than-death cases, the 
arrangement for replacing the dead state by the worst health 
state takes a considerable time and is most likely to confuse 
the respondents. Hence, it is expected that the obtained 
values of any health states equivalent to dead state (zero 
score) cannot be indicative of the distinction not only 
between them and dead state but also among themselves. 
In order to avoid the framing effect problem and other 
potential bias problems in the scaling procedure, it is 
suggested that the time trade-off scaling should use a 
balance approach between gain and loss of the extra lif e 
years. The "ping-pong" pattern of asking the questions, which 
is one of the popular methods, is used here. Also, the 
evaluators are presented with a time trade-off board in the 
session of the time trade-off scaling. This board showing all 
the information given to the evaluators is supposed to help 
reduce the information load. 
2.5. A commentary of the EuroQol instrument. 
a) Critiques of the EuroQol instrument. 
One of the major prerequisites for a new health status 
measure to be accepted is the proof of its validity. The lack 
of this respect in the early development stage of the EuroQol 
instrument becomes its common criticism. Carr-Hill (1991) 
anticipated piloting, testing and validation of the EuroQol 
instrument. In addition, it is necessary to substantiate the 
validity of the multi-dimensional health states employed 
(Carr-Hill, 1992). 
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The validity assessment could be difficult as Carr-Hill 
(1992) points out that even a basic test like the face (or 
content) validity --the use and presentation of the health 
dimensions are considered as appropriate and reasonable 
(Selby, 1988)-- must match genuine health conditions. 
Moreover, Selby (1988) adds that such a test is subject to 
many possible sources of bias. 
Carr-Hill (1991) compares the scaling technique used in 
the EuroQol instrument (i. e. the feeling thermometer) to the 
ordinary thermometer (i. e. for measuring heat) . The former 
is 
expected to work like the latter in the sense that its 
applications to any person should result in the same score 
for a health state. The fact that most people can feel their 
health conditions but few can quantify them lead to the 
belief that the feeling thermometer does not achieve the task 
set out by the EuroQol instrument developers. 
The usable response rates of the early postal self- 
administering surveys--21 to 37%--are regarded 
"extraordinarily low" by Carr-Hill (1991). It is the 
incorporation of being dead and other health states in a 
common scale that could be responsible for the low completion 
rate (Carr-Hill, 1992). The denial of people to rate in such 
a way is supported by a study that improved a considerable 
proportion of the usable responses as a result of omitting 
the dead state in the scaling exercise (Nord, 1991a). 
Some aspects of the EuroQol instrument are obscure. It is 
inappropriate to combine and compare the scores offered by 
different people who are most likely to possess different 
ways of the valuation (Carr-Hill, 1991). Moreover, the same 
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critic accuses the developers of neglecting the respondents I 
patterns of weighting component dimensions to arrive at the 
value for a health state. 
It can be denied that the scores obtained would maintain 
the equal interval property as assumed in the feeling 
thermometer. Carr-Hill (1991) believes that most respondents 
do not understand the meaning of a change in the scores. 
Some scores obtained were in contrast to the logical 
expectation. Carr-Hill (1991) observes the inconsistency. A 
change in the selfcare dimension alone caused the smallest 
inconsistency level--5% of the total samples. The largest 
inconsistency rate was found from the alteration in the pain 
dimension--32%. Also, the reliability of the score for any 
health state may be undermined when a study (Brook et al, 
1991) produced an average difference of 10 points for a 
health state which was asked to score twice in two successive 
pages of the EuroQol questionnaire (Carr-Hill, 1992). 
One of the important aspects of the valuation result, as 
Carr-Hill (1989) argues, is the difference between pairs of 
health state values since the actual use of the valuation 
findings rests on changes in health states. Nevertheless, all 
his criticisms are devoted to the changes in the severity 
level in any single dimension. A rise in the severity level 
from no problems to the moderate problems in the mobility and 
selfcare dimensions did not produce the same additional 
scores as that from the moderate problems to the extreme 
ones. In addition, the same shifts in the severity level in 
the selfcare dimension, in pain and in mood generated 
significantly different score changes. 
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b) Responses to the critiques of the EuroQol instrument. 
The EuroQol Group (1991) iterates the position of the 
EuroQol instrument that it is by no means a final version and 
its survival depends on tests on populations with different 
cultural backgrounds. Therefore, the key tests for ensuring 
the standard of the EuroQol instrument as applied to most 
health status indices in the past have yet to come. It needs 
further development to remove various setbacks. These would 
in turn shape the EuroQol instrument to be a more acceptable 
index. 
Despite this progress, however it certainly has two 
limitations (The EuroQol Group, 1992). First, it cannot 
incorporate all forms of change in health status. Secondly, 
its sensitivity to the changes cannot possibly be satisfied 
in all purposes of its use (e. g. clinical intervention 
studies). 
It is inappropriate to compare the f eeling thermometer to 
a normal thermometer. The fallacy is based on the belief that 
the former should make everyone presented with the same 
health states, rate the same scores, in the same way that the 
latter can indicate the same temperatures of the identical 
quantities of heat in various objects. But it is forgotten 
that in the former the individual's scores for health states 
are based on his preferences, which are subjective and differ 
between people. Their mechanisms and functions are utterly 
dissimilar. 
It is the variation in the valuation scores between 
people that it is important to understand. The EuroQo1 Group 
(1991) stresses that the associations between the scores and 
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respondent's attributes should be systematically 
investigated. 
The criterion to justify the outcome of a data survey 
depends partly on opinion. According to the Euroqol Group 
(1991), their response rates should not have been regarded as 
extremely low unless it was compared with a similar survey. 
In fact, they claim that there are no other publications of 
the postal survey of the health state valuation with 
psychometric scaling method. 
It is likely that many factors are responsible for the 
low return rates (e. g. relocation of the samples, lack of 
incentives to administer the questionnaire, etc. ). It is 
essential to identify the sources accounting for the major 
proportions of the non-returns and find the means to increase 
the rate accordingly. 
The EuroQol Group (1991) accepts that the improper 
arrangement for the valuation for dead state together with 
those f or other health states in the same questionnaire. 
However, they have not come up with a satisfactory solution 
for this issue after some studies. 
Due to its developmental status, the conditions 
underlying the valuation result have yet to be assessed. 
Following one of its studies (Nord, 1991a) , the Euroqol Group 
(1992) conceded that the valuation scores may not maintain 
the interval scale property. However, it is made clear in 
that article that the EuroQol instrument does not assume the 
existence of an interval scale. 
The difference in the scores due to a change in the 
severity level, in a dimension observed in the findings based 
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on the EuroQol instrument, should not be overrated. It should 
be remembered that its principal objective is the multi- 
dimensional health state valuation. The scores for the single 
dimensions derived from the scores for the multi -dimensional 
health states, if valid, are an indirect valuation which 
could not represent the respondents' genuine valuation. The 
EuroQol Group (1991) points out that the score differential 
should be measured on the basis of a health state, not the 
component dimensions. At the multi-dimensional level, an 
individual has an opportunity to weight various single 
dimensions so as to achieve a score for a health state. The 
trade-off pattern and preferences for single dimensions are 
not homogenous across subjects. These facts not only lend 
support to the multi-dimensional health state valuation for 
its reflection on individual's own preference trade-off 
principle but also suggest nothing wrong with the different 
scores within any single dimension. Applying the multi- 
dimensional health state valuation can help avoid making 
assumptions about the unknown trade-off (The EuroQol Group, 
1992). In addition, they suggest that it is possible to 
examine the weighting pattern between various single 
dimensions by using the values for composite health states. 
Similarly, there is no prior assumption that valuing the 
change from the condition of no problems to that of moderate 
problems in any dimension should be the same as that from the 
condition of moderate problems to that of extreme problems. 
The model for such a valuation change pattern is still to be 
explored. 
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c) Assessment of the problems in the EuroQol instrument. 
Of all the criticisms made of the EuroQol instrument, 
only the basic properties --validity and reliability--and the 
unmet properties of the interval scores appear to prevail. 
They do not downgrade however the usefulness of the result in 
general. This is because the chief objective of the 
instrument (i. e. the quantification of health) can be 
sustained. The disadvantages of these two issues may be 
viewed as the causes of inaccuracies in the result, which may 
be allowed for, to some extent, by the user's judgement. In 
addition, both of them can be empirically tested. This could 
determine the extent of the problem. 
The importance of the interval score property depends 
upon the health programmes to which the analysis outcome is 
supposed to be applied. If the quality of life aspect is 
crucial, then the interval scores should be reliable and 
accurate. In other cases, the issue may be more relaxed. The 
basic property issue is, relatively speaking, little 
significance. This is because no standard definitions of 
these properties are available. Very few health status 
indices could meet all the definitions created for these 
basic requirements. Moreover, more tests based on the EuroQol 
instrument are on the way. 
2.6. Whose values should count in the Thai health sector. 
The classification of the subjects for the quality of 
life valuation is a matter of opinion. Each type of the 
subject has their own supporting reasons for their 
entitlement to incorporating their quality of life view into 
a cost-utility analysis and ultimately the health resource 
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allocation. They are not right or wrong but rather 
appropriate or not. 
The arguments for using the patient's perspective are 
that their suffering could be expressed more realistically 
than any others. Doctor's and health professional's large 
stock of the experience in a wide range of illnesses with 
different severity makes them a desirable option. This choice 
gets strengthened by the fact that they also deliver health 
services and closely communicate with patients. Their views 
might as well represent their patients'. Healthy people in 
the community are selected on the grounds that they would 
make a fair judgement due to independence from being 
influenced by the morbid suffering and medical training. 
Politicians I and health officials I perspective is regarded as 
appropriate as they are in charge of the health programme 
planning and implementation as well as setting the health 
resource priority and distributing the resources. The general 
public are eligible because they pay for health programmes 
and are the beneficiaries of the services. They also include 
the members of the groups above but in a small proportion for 
each. 
The categorisation of the groups and their selection 
should be compatible with the analysis viewpoint or the 
purpose of the work. For example, Drummond et al (1987) 
suggest using the general public's quality of life weightings 
for the analysis with the societal viewpoint because the 
findings are supposed to guide the policies of health 
programmes which are of direct relevance to them. By 
contrast, in the cost-benefit context of public Policy, 
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Feldstein (1970) favours health officials' weightings. Using 
the quality of life values of the general public, according 
to Green et al (1988), means their participation in the value 
judgement formation of economic assessment. Nevertheless, 
alternative subject groups' quality of life valuation may be 
used to obtain a wider scope of the analysis unless the 
constraints in the analysis allow to do so. 
Since the cost-utility analysis result is supposed to be 
applied to the health service allocation and utilisation, 
Kind (1990b) believes that the quality of life weightings 
should rest on politicians and the government, whose 
responsibility is to influence health programmes to ensure 
that they operate in a right direction, but he does not rule 
out other groups' valuations, the availability of which is 
useful for checking the possible differences between the 
distinctive sources of the valuation. 
Such an argument is true with regard to the structure of 
the decision-making about the health policy and 
implementation in the Thai health sector because the 
government's role in the sector has been expanded in recent 
years. According to the utilisation pattern of health 
services by the Thai population, the proportion of the health 
centre and public hospital services use was up from 26.8% in 
1979 to 47.2% in 1985 (Health Planning Division, 1990). The 
greater share arose as a result of some people switching from 
self-treatment (i. e. buy drugs from drugstores without 
medical consultation) to seeking standard care in public 
health institutions. Therefore, the rise in the utilisation 
means that for those turning to the public services, their 
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private views about the quality of life previously taken into 
account exclusively for their own decision about the health 
resource allocation (i. e. buying which drugs and how many) 
have been affected by the health officials' valuation or 
combined with the professionals, one in determining the 
health service use and allocation. 
However, there is an exception for not applying their 
valuation. The use of the quality of lif e weightings of a 
certain group in particular would be acceptable in some 
specific context or condition. For instance, in a clinical 
trial of an intervention against a disease, only the quality 
of life valuation of the participants in the trial is of 
relevance (Capewell, 1988). 
Taking into account the above issues, this study includes 
as many groups of respondents as is feasible and classifies 
them so as that the result could be of most benefit to the 
health resource allocation and health programme 
implementation. 
2.7. The valuation survey in Thailand and the results. 
This section describes the valuation survey in Thailand 
and reports its results. Its planning, implementation and 
outcome presentation mainly fall into the following eight 
steps. Each is elaborated below. 
1) Data collection method. 
A postal survey and an interview survey incorporating 
time trade-off method were planned to be implemented in 
Thailand. Since the postal survey was expected to produce a 
relatively low rate of questionnaire return, a high 
possibility of incomplete questionnaires, a delay in getting 
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the questionnaire back and the damage of the questionnaires 
from the postal services, the interview survey could 
guarantee the sufficient number of the samples in the 
analyses that would follow. The comparison of the two options 
of the valuation survey could indicate which alternative is 
most cost-effective. It would suggest the appropriate data 
collection method for the future surveys in Thailand. 
2) Respondent selection. 
The fact that the ratio of a doctor to the Bangkok 
population was about 1: 1200 (Division of Health statistics, 
1988) suggests that if a simple random sampling is conducted 
in Bangkok, there would be one doctor in a sample size of 
1200 subjects. To ensure that the study has a reasonable 
proportion of people with different health experience 
backgrounds in a manageable sample size so that statistical 
tests can be performed with regard to this personal variable, 
the health experience grouping was used as a basis of the 
sampling. 
The three main categories of a person's health experience 
used in this study are health professions, patients and 
healthy people. As doctors and health administrators take a 
higher proportion of authority than other health 
professionals in the Thai health care system, their valuation 
may be more useful for the implications of the economic 
evaluation study. Therefore, the two health professions are 
combined as a group. Since the severity of illness has often 
been found to affect the valuation, patients with a temporary 
illness and those with a terminal illness are treated as two 
groups. As the less ambiguous notification of the illness in 
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practice and the large proportions treated in the study 
hospital at the time of the survey are the selection criteria 
for the two kinds of patients, bronchitis patients were used 
to represent the former and cancer patients to the latter. 
Healthy people are simply defined as people who feel that 
they are in good health and do not obtain any medication at 
the moment of the survey. As a result, the four groups to be 
sampled in this survey were doctors and administrators, 
bronchitis patients, cancer patients and healthy people. 
3) Sample size, samples' location and sampling method. 
Theoretically, an appropriate sample size could be 
determined by the precision of the estimation. Without prior 
information of population characteristics (i. e. of doctors, 
health administrators, bronchitis patients, cancer patients 
and healthy people), the appropriate number of the 
observations is difficult to specify. However, as a rule of 
thumb, a large sample leads to a higher degree of 
significance level, all other things constant, and this makes 
a better precision of the samples towards the population. 
Because of the anticipated low rate of completed 
questionnaires returned, the sample size in the postal survey 
were set so large that there would be the sufficient data 
left to be analysed. A 1000 sample size was chosen for the 
postal survey and a 400 sample size for the interview 
counterpart. 
The samples in the four groups were equiproportionally 
divided in both surveys. That is, there were 250 equal 
doctors and health administrators, 250 cancer patients, 250 
bronchitis patients and 250 healthy persons in the postal 
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survey. Similarly, the interview survey had 100 subjects in 
each group. 
To make a choice of sample location simple and to 
minimise costs under the time constraint, Siriraj hospital, 
from where the two groups of patient samples and doctor 
samples were drawn, was selected as a sampling site. It is a 
University medical school Is hospital and the largest hospital 
in Thailand, with more than 2500 beds. It is situated in 
Bangkok. Most medical research has been carried out there and 
most of the modern medical technology and techniques are 
tried and studied under experts' supervision. The large 
annual intake of patients, who come from all parts of the 
country either by a referral system or by their own 
willingness, were anticipated to make the study achieve the 
targets of 500 samples of the two patient groups in the 
postal survey and of 200 samples in the interview survey. 
The healthy subjects were sampled f rom Siriraj 
subdistrict, the location of the hospital. The health 
administrator samples were obtained from the Ministry of 
Public Health. The random sampling method was applied to all 
groups. A random number table was employed. 
The sampling of the two groups of patients was based on 
their medical record numbers. This method caused a great deal 
of trouble for the interview survey because of the costly 
follow-up of the patients and time limitation. As a result, 
unlike the postal samples who were selected from patients' 
visits to the outpatient department durina 1990, the 
interview samples were only taken from the current patients 
visiting the hospital during the survey period. 
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The names and addresses of the doctor and health 
administrator populations were obtained f rom the hospital 
directory provided by the medical school's personal 
management unit and from the directory of the ministry of 
Public Health supplied by its Division of Health Planning. As 
the majority of health administrators are in Bangkok, the 
rest are distributed to all over the country. Since the 
survey could not afford to interview those outside Bangkok, 
it recruited only those working in the capital. Nevertheless, 
the postal survey covered all of them. 
The electorate of Siriraj subdistrict was used as the 
population of the healthy people. The district hall supplied 
the list of the electorate, both names and addresses, in that 
area. 
The population information available of the study groups 
indicated that there were 492 physicians, working in 21 
departments in the hospital in February, 1991. They not only 
treated, patients but also taught and conducted medical 
research. The health administrators, including Permanent 
Secretary, directors-general, directors and heads of 
hospitals, amounted to 427 persons at the same time. Because 
of the huge number of the patients in the hospital, no 
computation of the precise number of the patients in each 
type of illness was processed. In other words, the accurate 
populations of the two patient groups were not known. The 
number of eligible electorate of the subdistrict was 11251 
persons at that time. 
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4) The Thai version Euroool questionnaire. 
The survey procedure in Thailand took 5 months, from 7 th 
January 1991 to 6t' June 1991. A translation of the EuroQol 
descriptors into Thai was the initial step. Since there is no 
one-to-one relationship between Thai and English, a number of 
words create potential problems in the selection of the 
perfect ones. The most effective means used in this study was 
to let many people such as English-teaching Thais, doctors, 
ordinary people make judgements by comparing the contents of 
both English and Thai (in a draft form) descriptors. The 
criterion of selecting the best words was that they could 
make the readers envisage the health states using such 
descriptors. 
Those who agreed to help check the descriptors agreed 
that the translation, in general, was correct. However, some 
suggested a number of alternatives for a few of the words. 
Here are the disagreements. It was argued that some lay 
persons may not understand certain formal and technical 
medical terms like "anxiety" and "depression". According to 
one of the panel, patients get used to their common and 
colloquial terminology. These words, common substitutes 
supplied by that judge were put in parentheses attached to 
the standard ones in the Thai version. Another problem, to a 
lesser extent, is a translation of "discomfort". No better 
substitute was offered however. 
In addition to maintaining all the key aspects of the 
English EuroQol questionnaire, the Thai counterpart contains 
all the variables required for in this study. it is presented 
in Appendix I. In order to make the interview and postal 
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surveys comparable, they follow a similar format and are 
mainly self-administered despite the fact that the interview 
samples had a chance to be supplied with explanations for 
some dubious points. The interviewers read the questionnaire 
to illiterate respondents and those with reading problems and 
recorded their answers. The postal counterparts were 
instructed to seek their own available readers. The series of 
the health states elicited in the time trade-off session is 
the left-downward direction of the health states displayed in 
the principal layout. 
The time period for sending out 1000 postal 
questionnaires was between 1" March and 14 Ih March 1991 and 
the interview was carried out between 11th March and 3 lr*t May 
1991. 
5) The survey problems. 
The problems encountered by postal survey were relocation 
and death of some patients, especially the cancer patients. 
As a result, a number of questionnaires were not delivered to 
some samples. For the interview survey, though it is 
relatively a smaller problem a low cooperation rate among 
doctors and health administrators resulted in a falling short 
of the target number for this group. 
By examining the questionnaires returned, it is found 
that the number of postal subjects incapable of administering 
the questionnaire far exceeded that of the interview 
counterparts. The postal subjects, major problem was failing 
to do the feeling thermometer scaling. Various reasons for 
this were given in the returned questionnaires. These 
included being unable to understand the method, difficulty in 
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imagining the health states and lack of adequate knowledge 
(and a preference following doctors, advice and values). Few 
interview subjects were excluded, the main reason being 
inability to understand the contents of the health states. 
The real factors underlying this for the groups of the 
patients and the healthy people in the community might be 
ageing, illiteracy and having extremely serious illness. 
Missing information was another problem and 
uncontrollable in the postal survey due to negligence and the 
like. However, in the interview survey, it was minimised due 
to the questionnaire check before the respondents left. 1, 
6) The survey results and the sample characteristics in the 
surveys. 
The interview survey acquired 359 samples (89.75 % of the 
400 sample target). Five samples (1.4 %) were incomplete and 
unusable. So the remaining 354 samples were left in the 
analysis. Sixty-nine health profession samples (69 % of the 
target) were interviewed but two were defective. Ninety 
cancer patients (90 %) participated in the interview. Again, 
two were imperfect. The interview of one hundred bronchitis 
patients met the target. Nevertheless, one sample was 
incomplete. Fortunately, one hundred samples of the healthy 
people group were obtained without any information 
incompleteness. 
For the postal survey, there were 233 completed 
questionnaires returned (23.3 % of the total sending-out 
samples). Of these, 69.5 % (162 samples) were usable. The 
incomplete questionnaires (71 samples or 30.5 %) answered only 
the socio-economic part. Figure 1 summarises the survey 
outcome. 
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Figure 1: The outcome of the Thai valuation survey. 
Survey 
post interview 
(n=233) (n=359) 
r- 
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use no use complete incomplete 
(n=162) (n=71) (n=354) (n=5) 
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The samples I key characteristics in the interview and 
postal surveys, the statistics of which are presented in 
Tables 6 and 7, are summed up as follows. 
a) The interview samples. 
Regarding the current problems of health, pain/discomfort 
was comparatively the major problem. Its extreme condition 
was found in 10% of the total samples and its moderate 
condition in 52%. The next serious problem was 
anxiety/depression, the extreme level of which occurred in 7% 
of the total. Usual activities problems were ranked in the 
middle of the five dimensions. Minor problems included their 
mobility and self -care, moderate conditions of which were 30% 
and 2%, respectively. Responses to the change in health 
condition between the current and last whole year indicate 
that the percentage of samples with a deterioration in health 
conditions is slightly greater than that with the sustained 
health. Only one fourth claimed that their health had 
improved. 
The percentage of subjects that indicated that the 
questionnaire completion was (particularly the feeling 
thermometer valuation) fairly difficult and that was fairly 
easy are virtually the same. On the contrary, most subjects 
found the time trade-off questions fairly easy. The finding 
is consistent with other studies mentioned before in this 
chapter. 
Since the sample distribution is non-normal, the median 
values of the numerical variables are presented. The samples 
had five years of schooling. Their average age was about 46 
IF 
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Table 6: Some statistics of the interview samples' 
key characteristics. 
Characteristic number percent 25th median 75th 
percen percen 
tile tile 
1. Mobility condition 
1.1 no problem 235 66.4 
1.2 moderate problem 119 33.6 
1.3 extreme problem 0 0 
2. Self-care condition 
2.1 no problem 347 98.0 
2.2 moderate problem 7 2.0 
2.3 extreme problem 0 0 
3. Usual activity condition 
3.1 no problem 260 73.7 
3.2 moderate problem 80 22.7 
3.3 extreme problem 13 3.7 
4. Pain/discomfort condition 
4.1 no problem 132 37.5 
4.2 moderate problem 184 52.3 
4.3 extreme problem 36 10.2 
5. Anxiety/depression condition 
5.1 no problem 202 57.1 
5.2 moderate problem 128 36.2 
5.3 extreme problem 24 6.8 
6. Change in health condition 
6.1 better than previous 91 25.9 
year 
6.2 same as previous 128 36.4 
year 
6.3 worse than previous 133 37.8 
year 
7. Difficulty of the feeling 
thermometer scaling 
7.1 very difficult 26 7.4 
7.2 fairly difficult 163 46.3 
7.3 fairly easy 155 44.0 
7.4 very easy 8 2.3 
8. Difficulty of the time 
trade-off scaling 
8.1 very difficult, 15 4.3 
8.2 fairly difficult 147 42.1 
8.3 fairly easy 175 50.1 
8.4 very easy 12 3.4 
9. Education (year) 45 14 
10 . Age (year) 34 46 57 
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Table 6: Some statistics of the interview samples' 
key characteristics. (continued) 
Characteristic number percent 25th median 75th 
percen percen 
tile tile 
11. Individual income (baht) 0 24000 72000 
(US$) (0) (923) (2769) 
12. Household income (baht) 42000 89630 240000 
(US$) (1615) (3447) (9230) 
13. Current occupation 
13.1 government employee 89 25.9 
13.2 private businessmen 49 14.3 
13.3 private employees 91 26.5 
13.4 retired persons 19 5.5 
13.5 housewives 57 16.6 
13.6 students 13 3.8 
13.7 unemployed persons 24 7.0 
13.8 monk 1 0.3 
14. Exercise time (minute) 0 0 300 
15. Cigarette smoking 0 00 
16. Smoking status 
16.1 current smokers 47 13.4 
16.2 given-up smokers 89 25.4 
16.3 non-smokers 215 61.3 
17. Alcohol drinking 0 00 
18. Current health status score so 70 80 
19. Family size 4 57 
20. Residential area 
20.1 urban residents 293 82.8 
20.2 rural residents 61 17.2 
21. Health service use 2 6 12 
22. Health experience group 
22.1 doctors and health 67 18.9 
administrators 
22.2 bronchitis patients 99 28.0 
22.3 cancer patients 88 24.9 
22.4 healthy people 100 28.2 
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Table 7: Some statistics of the postal samples' 
key characteristics. 
characteristic nUmber percent 25th median 75th 
percen percen 
tile tile 
1. Mobility condition 
1.1 no problem 132 82.5 
1.2 moderate problem 27 16.9 
1.3 extreme problem 1 0.6 
2. Self-care condition 
2.1 no problem 159 98.8 
2.2 moderate problem 1 0.6 
2.3 extreme problem 1 0.6 
3. Usual activity condition 
3.1 no problem 138 86.3 
3.2 moderate problem 22 13.8 
3.3 extreme problem 0 0 
4. Pain/discomfort condition 
4.1 no problem 74 46.0 
4.2 moderate problem 84 52.2 
4.3 extreme problem 3 1.9 
5. Anxiety/depression condition 
5.1 no problem 78 48.4 
5.2 moderate problem 77 47.8 
5.3 extreme problem 6 3.7 
6. Change in health condition 
6.1 better than previous 43 26.7 
year 
6.2 same as previous 103 64.0 
year 
6.3 worse than previous 15 9.3 
year 
7. Difficulty of the feeling 
thermometer scaling 
7.1 very difficult 21 13.3 
7.2 fairly difficult 106 67.1 
7.3 fairly easy 26 16.5 
7.4 very easy 5 3.2 
8. Education (year) 10 16 20 
9. Age (year) 34 43 54 
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Table 7: Some statistics of the postal samples' 
key characteristics. (continued) 
Characteristic number percent 25th median 75th 
percen percen 
tile tile 
10. Individual income(baht) 33050 119970 200000 
(US$) (1271) (4614) (7692) 
11. Household income (baht) 100000 194970 300000 
(US$) (3846) (7499) (11538) 
12. Current occupation 
12.1 government employees 100 61.7 
12.2 private businessmen 16 9.9 
12.3 private employees 28 17.3 
12.4 retired persons 2 1.2 
12.5 housewives 6 3.7 
12.6 students 6 3.7 
12.7 unemployed persons 3 1.9 
12.8 monk 1 0.6 
13. Exercise time (minute) 7 200 Soo 
14. Cigarette smoking 000 
15. Smoking status 
15.1 current smokers 29 18.2 
15.2 given-up smokers 30 18.9 
15.3 non-smokers 99 62.3 
16. Alcohol drinking 000.2 
17. Current health status score 70 80 90 
18. Family size 456 
19. Residential area 
19.1 urban residents 143 88.3 
19.2 rural residents 19 11.7 
20. Health service use 136 
21. Health experience group 
21.1 doctors and health 82 50.6 
administrators 
21.2 bronchitis patients 33 20.4 
21.3 cancer patients 15 9.3 
21.4 healthy people 32 19.8 
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years. The annual individual earning was 24000 baht (US$ 923) 
and the household income was about three and half times the 
individual income. Private employee and government employee 
are the two main occupations, covering more than fifty 
percent of the total sample. 
In the year before, they did not exercise monthly. Also, 
they smoked no cigarettes. Sixty-one percent of the sample 
never smoked and they did not drink alcohol. Their current 
health status was scored at 70 on the feeling thermometer 
scale. 
Their family had 5 members. The majority of the sample 
live in urban areas. This may result from the fact that the 
community selected is in an urban area and that most of the 
doctors and health administrators lived in Bangkok. They made 
6 visits to obtain their health services in the year before. 
The number of the doctors and health administrators are 
relatively smaller than the other groups, which almost 
achieved the target, owing to their reluctance to 
participate. 
b) The Postal samiDles. 
Their most serious current problem of health was 
anxiety/depression, followed by pain/discomf ort. The problems 
of mobility and usual activities could be considered in the 
same order. The least serious problem was, like the interview 
samples, self-care. Two thirds of the samples found the 
questionnaire fairly difficult. This is attributable to the 
lack of assistance available to them in interpreting some 
points in the questionnaire, compared with the interview 
counterparts. 
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The samples I schooling years were extraordinarily high 
(16 years). This is explained by the fact that the result 
contains the doctors and health administrators, who usually 
have a large number of studying years, as a majority. Their 
average age was 43 years old. The large proportion of the 
doctors and health administrators, who normally get high 
payments, in the survey make both annual income and household 
income considerably high. Government employee was the major 
occupation, followed by private employee. 
They spent 200 minutes on monthly exercise. Like their 
interview counterparts, they smoked no cigarettes. More than 
60 % of the samples never smoked but 18 % still kept smoking. 
They did not drink alcohol. The current health status was 
scored at 80. 
Like the interview survey, the family size was 5 members. 
Again, a large proportion of the sample were urban residents. 
In the previous year, they had used health services, on 
average, 3 times. The survey was dominated by the doctors and 
health administrators (50.6 %). 
If only the cost of mail delivery and the payment to the 
interviewers are considered (other items seemed to be 
similar) , then the postal and interview surveys spent 37 baht 
(US$ 1.42) and 40 baht (US$ 1.54) for a completed 
questionnaire. (Using the exchange rate of 26 baht a US 
dollar. ) However, this does not include in the interview the 
valuation result of the time trade-off scaling and the gain 
of the reduction in the sample concentrating on a certain 
group. It seems that the interview survey is more cost 
effective and more appropriate than the postal survey in the 
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study and for these sample sizes. Nevertheless, it is unclear 
whether in the larger size the interview survey would 
maintain the cost-effectiveness. Also, the postal survey 
might have a different trend. 
7) The valuation results in the surveys. 
For the interview survey, the health state valuation by 
the feeling thermometer and time trade-off methods are shown 
in Tables 8 and 9. According to the feeling thermometer 
scores, two health states are considered as "worse than 
death" the all-extremely severe state (33333) and 
unconscious state. Without converting the feeling thermometer 
scores onto the same basis as the time trade-off scores, both 
sets of the values cannot be meaningfully compared due to the 
difference in the references of the scales. 
Table 10 compares the ranks of the pre f erred- to -death 
states (with respect to the mean values) of the two scaling 
techniques. Some health states have different ranks between 
the two methods. This is not serious however since it occurs 
in the adjacent health states. Hence, the overall structure 
of the valuation results of the two scaling methods is 
similar with respect to their ordinal values. 
One apparent factor responsible for smaller 
discriminations using the time trade-off scores than the 
feeling thermometer scores is that the time trade-off method 
allowed a respondent to compare the single health state in 
consideration with respect only to the perfect health state 
and the dead state whereas in the other he/she compares and 
contrasts 8 health states simultaneously. In the latter, the 
decision to value any health state takes account of the 
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Table 8: The feeling thermometer scores of the interview samples. 
health 
state 
mean 25th percen 
tile 
median 75th percen 
tile 
standard 
deviation 
11111 94.2 90 100 100 9.0 
11111R 94.8 90 100 100 9.0 
11112 73.1 60 80 90 16.4 
11121 73.2 60 80 85 16.4 
11211 66.7 50 70 80 17.1 
12111 59.3 50 60 70 18.3 
21111 74.2 65 80 90 15.1 
11122 59.0 50 60 70 17.8 
21232 41.0 30 40 50 16.3 
22233 29.6 20 30 40 17.3 
22323 26.6 13 25 40 16.5 
32211 38.4 30 40 50 18.7 
33321 23.1 10 20 30 16.0 
33333 10.6 0 10 20 13.8 
33333R 9.9 0 5 18 12.7 
Uncon 5.0 0 0 10 10.4 
scious 
Deathl 20.9 3 20 35 18.7 
eath2 20.6 0 20 35 19.3 
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Table 9: The time trade-off scores of the interview samples. 
health 
state 
mean 25th percen 
tile 
median 75th percen 
tile 
standard 
deviation 
11112 70.7 55 85 95 32.6 
11121 72.2 55 85 95 31.9 
11211 69.3 55 85 95 34.1 
12111 62.3 35 75 95 36.0 
21111 70.7 55 85 95 31.9 
11122 70.4 55 85 95 32.0 
21232 31.2 0 5 65 37.6 
22233 13.0 0 0 5 27.6 
22323 17.9 0 0 25 30.2 
32211 17.9 0 0 25 31.2 
33321 9.2 0 0 0 23.7 
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Table 10 : The rank comparison of the feeling thermometer scores 
and time trade-off scores of the interview samples. 
health states ranks for the 
feeling thermometer 
score 
ranks for the 
time trade-off 
score 
remark 
21111 1 2 
11121 2 1 
11112 3 3 
11211 4 5 
12111 5 6 
11122 6 4 
21232 7 7 
32211 8 8 
22233 9 10 
22323 10 9 
33321 11 11 
Note denotes the rank for the health state 
from the two scaling methods differs. 
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values of the others. This would make the decision for the 
valuation become delicate. The ten-year extra life may be 
another factor accounting for the indiscriminate time trade- 
off scores of some health states. As shown in Appendix II, 
the scale has a 10-point interval. Hence, the health states 
that have a value differential of less than 10 points may 
fall into the same category. 
Table 11 shows the feeling thermometer values in the 
postal survey. Unlike the interview counterpart, four health 
states are regarded as "worse than death" 22323,33321, 
33333 and unconscious states. 
The comparison of the health state ranks according to the 
descending values with the feeling thermometer scale from the 
two surveys is presented in Table 12. Nine pairs of health 
states have different ranks. Most of these involve the 
multiple-severity health states. 
8) A check for the quality of the obtained data. 
The data quality is regarded as a prime importance of the 
subjective elicitation study. Similarly, the crux of a 
pragmatic analysis like this one depends on the quality of 
the acquired responses. The fact that the qualitative data of 
the surveys cannot be tested with reference to any similar 
sorts of the information leads to the investigation of 
compatibility among variables. Reasonable and reliable 
responses of these variables, indicated by such an 
investigation, could lead to the acceptance of the valuation 
findings in the study. 
An underlying principle of this investigation is that 
there is a natural relevance between some variables. The 
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Table 11 : The feeling thermometer scores of the postal samples. 
health 
state 
mean 25th percen 
tile 
median 75th percen 
tile 
standard 
deviation 
11111 86.3 80 90 100 16.2 
11111R 88.0 80 91 100 15.3 
11112 72.7 60 74 90 19.2 
11121 73.9 60 80 90 21.2 
11211 79.1 70 85 90 17.5 
12111 57.2 40 69 80 27.9 
21111 71.5 60 80 90 23.7 
11122 54.4 40 58 70 23.4 
21232 37.5 20 33 50 24.4 
22233 24.8 6 20 39 23.6 
22323 19.7 1 10 30 21.6 
32211 31.0 10 30 50 25.1 
33321 17.9 0 10 30 20.3 
33333 10.4 0 0 10 18.8 
33333R 10.9 0 2 10 17.3 
Uncon 10.5 0 0 10 20.3 
scious 
Deathl 23.0 0 10 50 25.6 
ath2 23.5 0 12 47 26.0 
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Table 12 : The rank comparison of the feeling thermometer scores 
between the interview survey and postal survey. 
health states ranks in the 
interview survey 
ranks in the 
postal survey 
remark 
11111R 1 1 
11111 2 2 
21111 3 6 
11121 4 4 
11112 5 5 
11211 6 3 
12111 7 7 
11122 8 8 
21232 9 9 
32211 10 10 
22233 11 11 
22323 12 14 
33321 13 15 
Deathl 14 13 
Death2 15 12 
33333 16 18 
33333R 17 16 
Unconscious 18 17 
Note denotes the rank for the health state 
from the two surveys differs. 
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check is built on the comparisons of pairs of tested 
variables. Three types of check are applied to the data from 
both surveys. First, the relevance of the two nominal 
variables is analysed by crosstabulation. Secondly, an 
association between nominal and ratio scale variables is 
highlighted by comparing the values of the latter. Finally, 
a correlation analysis indicates the degree and direction of 
relationship between two ratio scale variables. 
a) The interview survey. 
The relationship between the health experience and 
occupation variables shows that the unemployed, the retired 
and housewives became patients more often than any other 
occupations. Both the bronchitis and cancer patients had 
higher percentages of current and former smokers than the 
health profession group and the healthy people group. They 
also reported more serious problems in all five dimensions 
than did the other two groups. Moreover, they felt their 
current health condition to be worse than that of the year 
before. They had lower education levels, lower earning 
income, higher health service uses and less exercise time. 
However, advice on their current health problems might make 
them abstain from consuming alcohol and smoking. 
The retired group reported more years of age than the 
others. The unemployed who reported their inability to earn 
had the lowest household income. Housewives, the retired and 
the unemployed used more health services than any others. 
Private employees also used many health services since they 
usually had a welfare scheme to cover the sick expenses. 
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The correlation analysis implies that the better educated 
person earned a higher income and drank a good deal of 
alcohol. It also indicates that the younger person obtained 
fewer health services and did more exercise. The close 
association of the two kinds of incomes is evident. The 
behaviours of smoking and drinking were frequently found 
together. 
According to these findings, the reliability of the 
valuation scores in the interview survey is hard to reject. 
Therefore, we can be confident in using this set of the 
variables and the valuation data. 
b) The postal survey. 
Though the number of unemployed, the retired and 
housewives are small, they make up a high percentage in both 
types of illness. There is no significant difference in the 
health problems and in health condition change from the year 
before across all the health experience groups. One possible 
reason for this is that most of the two patient groups, who 
were the patients at the year before (1990), had returned to 
normal when replying the questionnaires. The cancer patients 
used a large number of health services and had less exercise 
time. They also did not smoke and drink as much as the other 
groups. 
The correlation analysis indicates that the older samples 
tended to earn more. The better educated subjects earned the 
higher incomes. Like the interview samples, the postal 
samples' individual income was closely related to their 
family income, and the smoking and drinking activities 
corresponded accordingly. 
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The relationship between the variables in the postal 
survey are less obvious than those in the interview survey. 
This is partly due to the samples concentrating on the doctor 
and health administrator group. Nevertheless, despite this 
issue, the postal responses do not suggest any indications of 
false reactions. 
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Chapter 3 
The analysis of some suspect sources of 
the effects on the Thai valuation 
As the quality of life valuation is a new issue in the 
economic evaluation of health programmes, this chapter 
performs some tests to ensure some data reliability and 
illustrates some means of processing the data obtained in the 
decision-making process. The f irst five sections involve the 
analyses of some possible impacts on the Thai valuation, 
comprising a literature review of the impact investigation; 
an exposition of the effect; the definition and measurement 
of some suspect sources of the effect; data form, unit of 
observation and statistical method of the analysis; and the 
presentation of the analysis results. The sixth and seventh 
sections discuss the analysis implications for the issues of 
whose values should count and of the value aggregation 
process. It concludes by discussing some implications for the 
health state measurement. 
3.1. A literature review of the impact investigation. 
Since the impact of respondents, background upon the 
health state valuation is an emerging issue, a limited number 
of the studies have been undertaken. Two apparent advantages 
could be learnt from these studies. First, it helps recruit 
the likely factors. The magnitudes of the impacts are also 
made known. Secondly, the direction (i. e. which group 
produces greater values than which) and the location (i. e. 
which health states have the contradictory valuations) of the 
impacts could be anticipated. 
The study of the health state valuation impact by Wright 
(1986) can be regarded as a start of the inquiry. He 
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investigates the influences of age and sex on some types of 
health ratings across a wide range of age groups. His health 
ratings are current health, previous health, best health, 
best possible health and health satisfaction self-ratings, 
estimated population average health ratings and estimated 
age/sex average health ratings. The scoring method used was 
marking a cross, representing a subject's health status on an 
undivided bipolar line. As a result, the responses obtained 
were claimed to be the absolute values. The study enroled 377 
subjects who were sampled from the electoral list in three 
wards of the City of York. They either gave interviews or 
completed questionnaires. 
The main findings are as follows. The mean values of the 
current health rating exceed those of the population average 
and those of age/sex average health ratings. The scores for 
the previous best health and those for the best possible 
health are higher than those for the current health. Non- 
parametric analysis indicates age and sex have significant 
influences on most types of the health ratings. It is argued 
that the older subjects who experience more medical 
conditions and suffer greater functional limitations are more 
likely to be chronically ill than the young ones. According 
to the previous best health self-rating scores, it is found 
that there is a "ceiling" health score for women, which is 
lower than that for men. It is interpreted that a real and 
persistent sex difference in perceived health status exists. 
Moreover, the female subjects reported more medical problems 
than the male counterparts and the former were more likely to 
be chronically ill than the latter. 
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Another vital result shows that sex differences influence 
the importance of well being at each life stage. The women 
gave the high priority to bringing up children, looking af ter 
elderly relatives and coping with the death of a spouse. By 
contrast, the men emphasised on starting school, setting up 
home for the first time and being at the peak of their 
earning power. 
In investigating what accounts for the health state value 
difference in various life stages, Loomes et al (1989) offer 
two explanations. First, the factors like domestic 
circumstances, level of income and career development 
compatible with one age group are of relatively more 
importance than other groups. secondly, the presence of risk 
and discount rate for the future life makes a middle age 
group preferable to an old one. 
Kind et al (1987) analyse the impact of the subjects, 
health experience on the valuation with the Rosser index. It 
is found that scores from different types of the subjects 
(medical patients, psychiatric patients, medical nurses, 
psychiatric nurses, healthy volunteers and doctors) 
substantially vary. This indicates that the health experience 
is a source of the valuation division. 
The finding about this background impact was not well 
received and attracted much attention as a result of two key 
criticisms. First, the study used a small number of samples. 
Secondly, magnitude estimation method, a scaling method in 
the study, is undermined by the evidence in Kaplan et al's 
study (1979), which shows that the values obtained from the 
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method in the 0-1 standard scale are compressed at the lower 
end of the scale near the dead state. 
As an inquiry method for detecting a sign of the 
selection bias from the participated respondents, the EuroQol 
Group (1990) claims that the valuations with the EuroQol 
instrument from the UK, Sweden and the Netherlands vary 
little with a number of background variables and are 
insignificantly affected. Since the objectives of that paper 
do not focus on the valuation impact, the issue may not be 
thoroughly investigated nor extensively tested. 
However, later on, the British data set is reexamined on 
this issue by Kind (1990a). He analyses the effects of some 
of the evaluators, personal backgrounds. The data was 
collected from a sample of 292 patients and 35 general 
practitioners in Frome. Subjects are categorised into two 
groups for each personal attribute : age 60 or under versus 
over 60, male versus female, own health rating less than 85 
versus 85 or over, current or ex-smokers versus non-smokers, 
minimum education versus intermediate or high level 
education, and never worked in health and services sectors 
versus worked in them. The t-test is the only statistical 
test. The major impact is the education factor. Its degree of 
influence can be judged from thirteen significant health 
states out of the total sixteen states. Virtually all the 
significant states are the multiple-severe states. Subjects 
with minimum education scored higher than those with higher 
education in all the states except for the perfect health and 
dead states. The self-rating scores of current health 
produces a moderate effect, having the statistical 
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significance in half the total health states. The healthier 
subjects valued higher scores than the others in all the 
states except for the dead state. Other background factors 
create statistical significance in no or few health states. 
Brooks et al (1991) report their Swedish valuation with 
the original version of the EuroQol instrument. Despite a 
likely unreliability of the result arising from the sample 
responses or the valuation method, the comparison of the 
valuation between the respondents, own health status less 
than 75 and those 75 or over is significant in 9 out of the 
total 16 health states. Like Kind's study (1990a), t-test is 
solely performed. Education (minimum education versus 
intermediate or higher level education) becomes the second 
most influential factor. It shows a significant disparity of 
the values in 7 out of the 16 states. Moreover, they find a 
high valuation could be a result of the age impact but there 
are a few significant health states. Sex, smoking status 
(current or ex-smoker versus never smoked) and health sector 
job (never worked in health and social services versus worked 
in the sectors) indicate no impacts on the valuation. 
The influence of the health service utilisation on the 
values of the health states is investigated by Kaplan et al 
(1976). Their hypothesis is that people in low levels of 
well-being (defined by the Quality of Well-Being Index) would 
use medical services (represented by the total number of 
physician contacts, comprising visits plus phone calls) more 
than would people in higher levels. The weighted correlation 
for this relationship is -0.55. On the top of that, they 
employ this finding to predict that the values would decrease 
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with older people since most old people usually use more 
services than the young do. 
Above are the studies of the valuation of general health 
status measures. The value split in a specific-disease 
valuation is tested by Pliskin et al (1980) in the context of 
CABG surgery. They expect the utility function of the 
patients, health status depends on their characteristics like 
age, family status, employment, financial background and 
anticipated level of activity. However, the empirical study 
does not show the association between the health state 
utility (measured by three degrees of chest pain none, mild 
and severe) age, number of children and subjects profession. 
The small number of subjects and inappropriate design 
experiment could possibly be major setbacks for the analysis. 
moreover, it is observed that the respondents are likely to 
have the unequal values of years presented in the elicitation 
process. The subjects, characteristics were found to have an 
association with the expected life years left. 
From these studies, it could be learnt that all the 
analyses expect the existence of some personal characteristic 
impacts upon the valuations but, not all of them can detect 
such impacts. In addition, in those where the impacts exist, 
identical influential variables do not show similar degrees 
of the impacts. These facts not only encourage unravelling 
the impacts of some personal attributes (which are not 
included in these studies) but also suggest a possibility of 
a small number of the influences uncovered. Moreover, the 
degrees of the impacts are unclear. 
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3.2. An exposition of the effect from some sources upon 
the valuation. 
The current concepts and measurements of all the health- 
related quality of life measures inevitably relate to the 
social, familial, personal factors and individual environment 
that may influence it. Conceptually, Megone (1990) 
categorises the quality of life into the private and public 
parts. The former, which is a focus of all the health status 
measures discussed before, regards an individual's own 
perception of their well-beings. on the other hand, the 
latter takes account of the quality of the living conditions 
around an individual and is also indicative of one's well- 
being. Environment and culture are apparently two main 
factors of the living situations. 
The two types of the quality of life intertwine in the 
way that an individual's quality of life is affected by the 
quality of his/her living conditions and consequently the two 
constitute the whole view of the well-beings. Although 
distinguished at theoretical level, these two aspects of the 
quality of life cannot be decisively separated in practice at 
the present time. 
Patrick et al (1988) suggest that the determinants of the 
health-related quality of life at the individual level 
include health care, health habits, health knowledge and 
attitudes, uses of services; social networks and coping 
skills; economic, educational and psychological resources. 
They support the argument by giving an example that in 
measuring the rheumatoid arthritis patients, well-being and 
health-related disadvantages, their social lives are not 
under their own control but their living society. 
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This line of the concept, in a way, stems from an 
observation of the interactions of trios : health, people and 
environment. As the health status measurement relates to the 
first two, the third variable's influence could be detected 
in the health status measurement result. Two vital points are 
drawn from the arguments above. First, they provide a basic 
ground for expecting the existence of the impacts on the 
health state valuation. Secondly, the investigation of the 
impacts should be extended especially to cover people's 
environment. 
Guided by these contentions and the study findings 
reviewed, this study chooses people's characteristics as 
analytical variables in the following criteria. First, since 
the analysis is empirically pragmatic and intended to be 
useful for the decision-makers, the variables should involve 
the parameters commonly used in the Thai officially routine 
surveys of data. Key common parameters are education 
achievement, age and income level. Secondly, although some 
subjective influences, like attitude, link people with their 
health perception (and consequently affect the health state 
valuation) it is difficult to measure such influences 
directly. However, the approximation of the attitude towards 
health such as smoking, drinking and doing exercise is 
possible to make. Moreover, some studies have found the 
impact of people's current health status upon the valuation 
without any convincing explanations responsible for this. It 
could be regarded as a psychological factor in the valuation. 
Thirdly, the environment concept can be taken as narrow as 
within a family (e. g. the impact of family size) or as broad 
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as the living location, an example of which is residential 
condition. In addition, it should include health facilities 
and infrastructures, the impacts of which are definitely 
relevant to people's health. Health service utilisation and 
health experience, associating with the health care settings, 
are two simple variables for the effect of health 
institutions. It needs to be stressed that this is not the 
only way to classify the variables. 
3.3. The definition and measurement of some suspect sources 
of the effect on the Thai valuation. 
Two major sources of the impact analysis in this study 
are the respondents I personal backgrounds and the measurement 
process. The former contains eleven variables and the latter 
comprises the survey method and scaling technique. The 
following are the discussions of the definitions and 
practical measurements of the variables. Some variables with 
a wide range of alternative measures and those employing 
specific estimates to the Thai situation are intensively 
elaborated. The time reference mentioned is the current 
period. For convenience, a calendar year is used as a unit of 
the period. 
a) The personal background effect. 
1) Education variable 
in this analysis, the number of schooling years 
represents the education variable. The number of schooling 
years can be varied from zero (unattending a school) to some 
16 years or more (a Bachelor's degree or higher). Although 
there is the compulsory number of the years in a school in 
Thailand, in practice the measure has not been as successful 
in keeping people in schools as the government would wish. It 
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is possible to see school leavers in any years of schooling. 
Education groups are primary school, secondary school, high 
school, college and university, and postgraduate. These 
groups are correspondent to the following range of the study 
years : 1-4,5-7,8-12,13-16 and over 16 years; 
respectively. Though a new national curriculum may have a 
slightly different number of the years between the secondary 
and high schools, the grouping system is hardly affected. 
2) Age variable. 
Simply, age is measured by the number of years old. Most 
studies of the health state valuations try to avoid eliciting 
children's utility of health status because of their 
inability to understand the process. Instead, some use 
parents' preferences. But it may cause some problems. 
This study, therefore, is confined to adults. According 
to the Thai law, a person aged 18 or over, considered as an 
adult, can make a legal decision without his/her parents' 
consent. Hence, based on this definition, this study 
recruited people aged 18 and over. 
3) Income variable. 
With reference to a standard definition, income is 
regarded as the amount of funds, goods and services received 
by an individual, cooperation or economy in a given time 
period. A difficulty in using this concept arises when there 
are non-earning people. The retired, housewives, children and 
the unemployed may not have a significant and explicit income 
(even zero income). They are of course excluded from the 
analysis if this definition is applied. Such an unwanted 
condition absolutely biases the analysis. 
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To rectify the setback of using an individual's income, 
which has a direct effect on oneself, two more variations are 
employed. First, occupation could reflect people's financial 
and economic status, both earners and non-earners. The 
following seven occupation groups are used here. 
a) Government employee 
b) Private businessman 
C) Private employee 
d) Retired person 
e) Housewife 
f) Student 
g) Unemployed person 
Secondly, an annual income of a household can reflect 
financial or wealth condition of most people in the sense 
that household members usually share or spend the total 
resources the family possesses, regardless of family members I 
earning or non-earning status and of how much or how little 
they earn. 
In some cases, a difficulty in estimating an amount of 
income can occur due to earning on non-market goods and 
services. For instance, a large proportion of Thai people 
live on farm produce. As a result, some forms of the income 
such as the stored produce and the produce for self- 
consumption are difficult to accurately approximate. 
Nevertheless, it is reasonable to let a subject estimate 
his/her own income as well as household income by taking into 
account all the implicit and explicit incomes. 
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4) Exercise variable. 1, 
The variable takes into account exercise, physical 
fitness or sports activities performed regularly. The 
performance time, denoting the extent of the attitude to 
having good health, is measured in terms of the duration 
(minutes) of doing the activities monthly. 
5) CicTarette smokinq variable. 
This variable is regarded to fathom the attitude towards 
bad health. The degree of the attitude may be estimated by 
the number of cigarettes smoked in a given period. moreover, 
it can measure the opposite attitude for given-up and non- 
smokers. As a result, the first measure for this variable is 
an average number of the cigarettes smoked daily. The second 
has three categories of the smoking status : current, given- 
up and non-smokers. 
6) Alcohol drinking variable. 
Like the smoking variable, excessive drinking is 
compatible with a bad health attitude. An average amount of 
the alcohol drinking in terms of (big) bottles in a week 
denotes the variable measure. Since various kinds of alcohol 
have more or less a similar quantity (e. g. a small bottle 
contains about one third of a litre and a big one three 
quarters) and since bottle counting could be easier for 
drinkers than other means, this unit is reliable. However, 
the fact that various kinds of alcohol have different 
damaging effects on health may be raised to refute the bad 
health attitude of the drinking. It, therefore, assumes the 
homogenous impact on health of all sorts of alcohol. 
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7) Current health status variable. 
In order to ease the analysis and avoid confusion in a 
subject, the current health status is objectively measured by 
the same scaling method as is the main valuation procedure. 
The current health status variable is self-determined and 
independent of any guided framework of health, unlike the 
principal valuation. 
8) Familv size variable. 
Traditionally, the nature of a Thai family is an extended 
family, where many relatives stay together as members of a 
family. Such a common, large family may create a good 
environment for members' quality of life in supplying 
abundant care. On the other hand, it may be a source of 
hazard environment if the risk of contracting infectious 
diseases is high. 
A common feature of the family is a frequent relocation 
of its members. That is, it is often found that the number of 
people actually living in a house keeps changing. Hence, this 
analysis counts the number of family members permanently 
staying regarded by respondents. 
9) Residential area variable. 
Two types of residential area according to a geographical 
criterion are sharply separated in Thailand. The distinction 
is mainly a result of the living standard. An urban area has 
almost all kinds of public utility available such as nearby 
hospitals and clinics, electricity supply, water supply, 
refuse collection and sewage treatment. On the contrary, a 
rural area lacks most of what its counterpart has. In 
general, the living conditions in a rural area are quite 
190 
lower than the standard. It is simple for subjects to 
identify their residential areas. Their address can be used 
to cross-check the response to this variable. 
10) Health care use variable. 
Without a standard concept of health care, it can be 
considered from the narrowest to broadest senses. Most 
developed countries have an intuitive concept of the health 
care, referring to that provided by qualified and licensed 
practitioners. Due to a difficulty in getting access to 
health care providers, an insufficiency of doctors and the 
lack of minimum health care for all people's need, some 
people in Thailand have to rely on, for example, the 
traditional medicine, local healers and herbs in addition to 
the limited supply of health services. To use the developed 
countries, health care definition would considerably 
underestimate the real number of the uses needed in Thailand. 
The application of the health care definition omits the real 
view of a whole population. Moreover, a substantial 
proportion of minor-ill people, having their own self- 
treatment, never appears in any records of the public and 
private health sectors. All of these make it difficult to 
appropriately define and measure health care in Thailand. 
This fact is also true for many other developing countries. 
This analysis uses the broadest concept of health care, 
which apparently corresponds to the genuine situation in 
Thailand. The variable is defined as care and services in any 
forms the sick acceptably obtain for reducing their illness, 
pain, discomfort, etc. Therefore, the magnitude and form of 
health care include the number of visits to a hospital, a 
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physician, a drug store, a traditional practitioner, a local 
healer and other relevant health facilities in a year; the 
number of days spent in a hospital and other health care 
institutions in a year; the number of prescriptions and 
treatments obtained in a year; and the like. 
A person may use many forms of health care in a year. 
This causes a problem in aggregating them. A composition of 
all the forms is not available for the time being. Thus, the 
number of the visits to various health care sources, which is 
the most common form and could cover a large proportion of 
health care uses, is used to measure health care utilisation. 
It should be emphasised that this measure could 
underestimate actual health care received. Also, it is 
necessary to interpret it with care. For example, the fact 
that two people have the same number of visits does not imply 
that they obtain equivalent amounts of health care. 
11) Health experience variable. 
Health experience can be defined in numerous ways. Past 
studies argue that the health state valuation is affected by 
medical profession's knowledge and expertise, patients, 
experience of illness and people's health state. The group 
classification according to this variable can be found in the 
respondent selection section of Chapter 2. 
b) The measurement process effect. 
1) The survev method. 
The interview and postal methods are two data collection 
forms in this study. The conduct of the two means in the 
survey has been discussed in Chapter 2. It is important to 
know if respondents, valuation behaviour, in an actively 
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participated valuation like an interview, is different from 
that in a passively participated one like a mail. 
2) The scaling techniaue. 
The two scaling methods employed in this study have been 
described in the previous chapter. Since there is no standard 
scaling technique, it is essential to test whether the 
different valuations could be produced by different scaling 
methods. The best valuation result may be used in the cost- 
utility analysis later on. 
3.4. Data form, unit of observation and statistical method of 
the analysis. 
3.4.1. Data preparation. 
Different scales can be derived from the valuation data 
obtained. A scale of 0-1 (death and perfect health) is 
commonly employed in the economic assessment. The analysis 
could examine the impact on the standardised values (i. e. the 
transformation of the original cardinal scores into the 
scores with a0 (death) to 1 (perfect health) scale). When 
the cardinal property of a valuation is dubious (yet to be 
proved), the impacts upon the valuation can still be tested 
by the ordinal version of the valuation and the result is 
reliable. The analysis may also find out if there are any 
sustained impacts on the valuation as the values are changed 
from one scale to another. Hence, three data sets stemming 
from the valuation in each survey are investigated for the 
effect. They are discussed in detail below. 
1. Health state values with two references of the best 
and worst imaginable health states are original from the 
surveys. Despite its criticism of dependence among the health 
states, which requires all the health states under study to 
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be assessed simultaneously, the findings of individual health 
states are useful for not only the improvement in the health 
state measure construction but also other studies based on a 
similar kind of the health state descriptors, like clinical 
assessment of some health interventions. 
2. Rank order values of health states approximate the 
ordinal property of the valuation, ranking a subject's all 
health states. They are compared with one's own reference 
(s) , which may be or may not be dif f erent f rom the two health 
state references provided. The procedure is done by ranking 
the original values in descending order (ie. high scores get 
low ranks). A tie rank is represented by a mean rank. 
It is believed that the ordinal values could have a 
higher capacity of the interpersonal comparisons than the 
original interval scores if, there is a wide range of 
perceptual references used by the subjects. It is possible, 
for instance, that respondents may give the cardinal values 
differently but the ranking order identically. In spite of 
the two references of the best and worst imaginable health 
states at the top and bottom ends of the feeling thermometer 
scale, it is appropriate if there is a doubt that the 
subjects used them literally. It may sensibly replace the 
interval scores if there is a violation of the equal interval 
property. In addition, it takes into account the dependence 
among the health states in terms of the relative ranks. 
3. Standardising health state values in 0-1 scale 
(O=death and l=healthy) makes a more definitive interpersonal 
comparisons than the previous two types. (The scale may be in 
a unit of 0-100 and the healthy state becomes 100. Using a 0- 
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1 unit scale is preferable since eventually the QALY 
computation depends on a 0-1 unit of the quality of life 
weighting. ) Arbitrarily, the health state 11111 (no problems 
in the five domains) is employed as an anchor point for the 
healthy state. The dead state is also straightforward. 
These two references attach some criticisms. Loomes et al 
(1990) claim that the standardisation by using healthy and 
death references imposes an implicit assumption that this 
unit of health for all individuals is the same. Nevertheless, 
this kind of the transformation has widely been used in 
operational assessments of health status. Kaplan et al (1979) 
support that it makes the arbitrary numbers of the scaling 
procedures to be a meaningful comparable unit. Bush (1984a) 
points out that the transformation makes the values obtained 
more reliable for scientific outcome measurement than non- 
standardised counterparts and more comparable for different 
diseases and people's backgrounds. 
Since the time trade-off method in this study inherently 
has healthy state (the health state 11111) and dead state as 
the references, its cardinal and standardised forms are the 
same. Therefore, to avoid the repetition, the time trade-off 
scores are not analysed in the cardinal form section. 
Before proceeding further, it is the right time to take 
a look at the reliability of each data form of the valuation 
obtained. Reliability of the valuation result generally means 
the extent of the reproducibility of the result. It also 
allows for some random error within an individual respondent. 
There are several methods to measure the reliability. As far 
as this survey is concerned, the repetitive valuation of 
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three health states : 11111,33333 and dead state could be 
used as an internal consistency reliability test. 
The test is measured by the Pearson product-moment 
correlation analysis. (The Spearman rank correlation analysis 
produces similar outcomes. ) For the cardinal form, the 
correlation coefficients of the health states 11111,33333 
and dead state in the interview survey are 0.75,0.68 and 
0.84, respectively. The postal survey has a higher degree of 
the reliability. The coefficients of its three health states 
are 0.75,0.84 and 0.98, respectively. 
The coefficient of the standardised form of the health 
state 33333 in the interview and postal surveys goes up 
substantially to 0.99 and 0.97, respectively (or 0.89 equally 
if measured by the Spearman method) . The high internal 
consistency of the standardised values may be due to a scale 
with two reference points of the health state 11111 and dead 
state used by most respondents in their decision about the 
valuation, though only one health state is available for the 
test. The high degree of the reliability of the standardised 
form could support the 0-1 scale transformation and the use 
of the standardised data in the analyses following. 
The coefficients of the ordinal form of the three health 
states in the interview survey are 0.45,0.28 and 0.75, 
respectively. Those in the postal survey are 0.52,0.51 and 
0.93. Again, the reliability of the postal survey outperforms 
that of the interview survey. It should be noted that the 
values for the dead state in both cardinal and ordinal forms 
in the two surveys possess the highest degree of reliability. 
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This means that most respondents in both surveys ascertain 
not only the value given to the dead state but also the rank. 
3.4.2. Procedures of the statistical tests. 
There are two issues to be considered in selecting 
appropriate methods of the statistical analysis. A 
distinction in these issues could possibly change the 
conclusions obtained and the implications. First, the 
distribution of the variables involved, particularly the 
health state values, divides the tests into parametric and 
non-parametric analyses. The former, based on the normal 
distribution assumption has powerful and robust tests. On the 
contrary, the latter, possessing the assumption of a non- 
specific distribution produces less powerful counterparts. 
However, it is suggested that this drawback could be 
rectified by increasing the sample size (Siegel, 1959). 
The distribution of the health state values is assessed 
by the Kolmogorov-Smirnov test. The results in Tables 13 and 
14 reject the normal distribution for the cardinal and 
standardised values at the significant level of less than 
0.001 in virtually all the health states in both surveys. The 
non-normal distribution is also found in many studies of this 
kind (Rosser et al, 1978). Therefore, the non-parametric 
tests for this analysis are appropriately employed. 
Univariate analysis is regraded as the main test. One should 
not overlook the impacts of the multiple factors or their 
interactions. Although the findings of the multiple factors 
might be found to be more compelling than those of the single 
variable, multivariate non-parametric analyses are available 
in a very limited number (e. g. two-way analysis of variance) . 
197 
Table 13 : The Kolmogorov-Smirnov normality distribution test 
for the cardinal data. 
K-S statistics 
the feeling the feeling 
Health state thermometer thermometer 
scores in scores in 
the interview the postal 
survey survey 
11111 6.188* 2.808* 
11111r 6.543* 3.029* 
11112 3.260* 1.624** 
11121 3.161* 2.297* 
11211 2.222* 2.455* 
12111 2.692* 2.139* 
21111 2.906* 2.652* 
11122 2.143* 1.210 
21232 2.158* 1.546** 
22233 2.532* 2.163* 
22323 2.697* 2.396* 
32211 2.209* 1.622** 
33321 2.657* 2.542* 
33333 4.142* 3.783* 
33333r 4.377* 3.481* 
uncon 6.875* 4.082* 
deathl 2.460* 2.082* 
death2 2.699* 1.978* 
Notes probability less than 0.001. 
probability less than 0.05. 
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Table 14 : The Kolmogorov-Smirnov normality distribution test 
for the standardised data. 
S statistics 
Health state 
11112 
11121 
11211 
12111 
21111 
11122 
21232 
22233 
22323 
32211 
33321 
33333 
33333r 
uncon 
the feeling 
thermometer 
scores in 
the interview 
survey 
4.824* 
5.430* 
5.168* 
5.785* 
4.374* 
5.766* 
5.139* 
4.935* 
4.090* 
5.128* 
5.925* 
5.803* 
5.852* 
6.852* 
the time 
trade-off 
scores in 
the interview 
survey 
5.002: 
5.205 
5.099: 
4.071 
5 . 008* 4.395* 
5.63 0: 
7.629 
6.833: 
7.107 
7.993* 
the feeling 
thermometer 
scores in 
the postal 
survey 
2.606* 
1.938* 
1.854** 
3 . 290* 2 . 513* 2 . 992* 2 . 897* 3.603* 
2 . 933* 2.718* 
3 . 296* 3 . 774* 3 . 553* 3 . 391* 
Notes probability less than 0.001. 
probability less than 0.05. 
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Some two-way analysis of variance methods were attempted but 
contributed insignificantly to the result of the main method. 
Therefore, their results will not be presented. 
The Kruskal-Wallis one -way-analys is -of -variance by ranks 
(K-W) , dealing with non-parametric 
distribution of single 
variable, is used as a principal method. The null hypothesis 
is that there are indifferent distributions of ranks among 
all groups according to a variable. Chi-square statistics is 
used in the significance test. Other methods like the Chi- 
square test, comparing the difference between the expected 
and observed number of cases in each category of a variable, 
were also attempted but they became inappropriate in many 
respects since huge tables with repeated results and a large 
number of empty cells were inevitably produced. In general, 
they gave the similar conclusions to the Kruskal-Wallis test. 
The Mann-Whitney U test, an equivalent of the K-W test for 
two independent samples, is employed for the impact test for 
the survey method and scaling technique. 
Some characteristic variables are categorised into groups 
so that the analysis can be handled. The basis of the 
grouping is in accordance with some natural settings such as 
the education level and the official classifications such as 
the income level. This could correspond with the group 
identifications usually used in the decision-making process 
for the Thai public policy. 
When there are too small a number of cases in a category 
to make the test possible, that category may be either merged 
to the next one or dropped out of the analysis. A few 
regroupings and discarded categories are performed in the 
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postal data set. The statistics of the groups of all the 
variables in the two surveys used in the analysis are 
summarised in Tables 15 and 16. 
Secondly, since the ultimate use of the health state 
values in this study involves the economic appraisal, one 
assumption of the Pareto efficiency criteria regarding an 
individual as his own judge of the welfare, makes it sensible 
to employ an individual subject as a unit of the observation. 
This opposes many studies in both the quality of life 
assessment and clinical trial. Rosser et al (1978) use the 
median values of each health state for each health experience 
group as a unit of the observation to show the differentials 
in the values between pairs of the groups by the Kruskal- 
Wallis test. Similarly, Kind (1990a) employs the mean 
category score for each state, which was computed from the 
pooled experimented data. Bush (1984a) advocates the average 
values in clinical trials' standpoint by stating that the 
health-related quality of life is the average level of 
satisfaction or that response to illness experienced by a 
large number of patients in the same state. 
The importance of selecting between the individuals and 
averages as a unit of the analysis gains more consideration. 
Bush (1984b) accepts the distinctively suitable unit of the 
analysis for resource allocation studies and clinical trials. 
He explains that "individual responses are paramount for 
individual patients (especially if the response itself is 
subject to direct intervention) but the scientific problem in 
clinical trials is to find the systematic or average outcome 
differences between the treatment groups". 
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Table 15 : Basic information of regrouped variables with at least interval score for the interview survey. 
Variable mean median s. d. n % 
1. education (year) 
(illiteracy) 0.0 0 0.0 32 9.1 
(primary school) 3.7 4 0.8 140 39.8 
(secondary school) 6.0 6 0.7 24 6.8 
(high school) 10.4 10 1.2 45 12.8 
(college and university) 14.2 13 1.3 45 12.8 
(postgraduate) 21.6 20 4.9 66 18.8 
2. age (year) 
(18-30) 25.3 26 3.8 70 19.8 (31-40) 36.2 37 2.8 72 20.3 (41-50) 45.7 45 2.9 63 17.8 
(51-60) 55.7 56 2.8 96 27.2 
(>60) 67.0 66 5.3 53 15.0 
3. individual income (baht) 
(0) 0 0 0 109 33.3 
(0-9000) 4884 5000 2304 21 6.4 
(9001-18000) 13509 12480 3063 21 6.4 
(18001-30000) 24457 24000 3150 32 9.8 
(30001-60000) 42027 36300 8149 50 15.3 
(60001-120000) 83561 72000 17791 29 8.9 
(120001-240000) 210706 222600 32411 36 11.0 
(>240000) 432445 300000 344853 29 8.9 
4. household income (baht) 
(0-18000) 9228 10000 5009 19 6.5 
(18001-30000) 25117 24000 3797 24 8.2 
(30001-60000) 46542 48000 9545 72 24.6 
(60001-120000) 90975 96000 18579 65 22.3 
(120001-240000) 187978 180000 36804 45 15.4 
(>240000) 583645 420000 497765 67 22.9 
5. exercise (minute) 
(no exercise) 0.0 0 0 188 53.4 
(exercise) 652.5 300 959 164 46.6 
6. cigarette smoking (cigarette) 
(non smoker) 0.0 0 0.0 309 88.3 
(smoker) 11.7 10 6.9 41 11.7 
Notes s. d. is standard deviation. 
n is number of cases. 
% is percent of cases with respect to the total. 
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Table 15 : Basic information of regrouped variables with at 
least interval score for the interview survey 
(continued). 
Variable mean median s. d. n% 
7. drinking (bottle) 
(non drinker) 0.0 0 0.0 309 87.3 
(drinker) 1.8 1 2.2 45 12.7 
8. today's health score 
(1-40) 31.4 40 12.6 20 5.7 
(41-50) 49.9 50 0.8 74 21.0 
(51-60) 59.4 60 1.6 48 13.6 
(61-70) 69.5 70 1.5 73 20.7 
(71-80) 79.4 80 1.5 73 20.7 
(81-90) 88.4 90 2.6 50 14.2 
(91-100) 96.7 95 2.5 15 4.2 
9. family size (person) 
(1) 1.0 1 0.0 13 3.7 
(2) 2.0 2 0.0 29 8.2 
(3-4) 3.6 4 0.5 110 31.2 
(5-10) 6.6 6 17.0 176 49.9 
(>10) 14.8 13 5.0 25 7.1 
10. health service use (time) 
(0) 0.0 0 0.0 40 11.4 
(1-5) 2.7 3 1.4 130 37.0 
(6-10) 8.4 9 1.7 70 19.9 
(11-15) 12.8 12 1.3 53 15.1 
(16-20) 19.1 20 1.4 15 4.3 
(>20) 51.0 36 27.6 43 12.3 
Notes s. d. is standard deviation. 
n is number of cases. 
% is percent of cases with respect to the total. 
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Table 16 : Basic information of regrouped variables with at 
least interval score for the postal survey. 
Variable mean median s. d. n% 
1. education (year) 
(primary school) 3.8 4 0.5 18 12.6 
(secondary school) 6.4 6 0.7 11 7.7 
(high school) 10.2 10 1.2 14 9.8 
(college and university) 15.2 16 1.1 29 20.3 
(postgraduate) 21.8 20 6.0 71 49.6 
2. age (year) 
(18-30) 24.6 24 3.4 35 21.9 
(31-40) 38.9 37 2.3 35 21.9 
(41-50) 45.3 45 2.9 36 22.5 
(51-60) 55.4 56 2.2 49 30.6 
(>60) 70.8 70 8.4 5 3.1 
3. individual income (baht) 
(0-18000) 5191 0 6266 22 14.1 
(18001-30000) 24040 24000 4391 15 9.6 
(30001-60000) 47259 50000 9062 18 11.5 
(60001-120000) 98500 100000 18303 30 19.2 
(120001-240000) 190503 200000 35073 52 33.3 
(>240000) 382472 300000 178541 19 12.2 
4. household income (baht) 
(0-18000) 7857 80000 4706 7 4.9 
(18001-30000) 26000 30000 5477 5 3.5 
(30001-60000) 46969 42000 9466 13 9.1 
(60001-120000) 97592 100000 15498 25 17.5 
(120001-240000) 185961 187485 35801 42 29.4 
(>240000) 478582 400000 251021 51 35.7 
5. exercise (minute) 
(no exercise) 0.0 0 0 37 23.6 
(exercise) 649.2 300 1180 120 76.4 
6. cigarette smoking (cigarette) 
(non smoker) 0.0 0 0.0 129 80.6 
(smoker) 14.4 15 5.7 31 19.4 
7. drinking (bottle) 
(non drinker) 0.0 0 0.0 118 72.8 
(drinker) 1.5 1 1.7 44 27.2 
Notes s. d. is standard deviation. 
n is number of cases. 
% is percent of cases with respect to the total. 
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Table 16 : Basic information of regrouped variables with at 
least interval score for the postal survey 
(continued). 
Variable mean median s. d. n % 
8. today's health score 
(1-60) 50.3 50 12.8 23 15.2 
(61-70) 68.7 70 2.2 29 19.2 
(71-80) 78.8 80 2.3 43 28.5 
(81-90) 88.2 90 2.4 37 24.5 
(91-100) 96.6 95 2.9 19 12.6 
9. family size (person) 
(1-4) 3.1 3 1.4 66 41.5 
(>4) 6.9 6 2.4 93 58.5 
10. health service use (time) 
(0) 0.0 0 0.0 31 19.6 
(1-5) 3.0 3 1.4 79 50.0 
(6-10) 8.1 8 1.9 27 17.1 
(>11) 26.7 15 23.4 21 13.3 
Notes s. d. is standard deviation. 
n is number of cases. 
% is percent of cases with respect to the total. 
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Loomes et al (1990) point out two shortcomings by using 
aggregate data. First, the aggregates cannot include the 
different discount rates for the health-related quality of 
life between individuals. Secondly, the averages cause 
welfare loss by ignoring the valuations at the margin. 
Aggregate values implicitly weigh one's benefits against 
another's (Williams, 1988) . It 
is essential to determine 
whether or not the assumption underlying the aggregation of 
the values are justified according to constraint and settings 
in the decision-making process. Carr-Hill (1992) accuses the 
use of aggregate valuation of overlooking the individual and 
inter-temporal variation. Hence, the analysis based on the 
individual unit of the observation could take into account 
the individual variation and maintain the individual 
weighting pattern. 
Despite the wide acceptance of using aggregate unit in 
clinical trials, Schipper et al (1988) claim that there is a 
continuing debate over the two kinds of the unit. The 
contemporary medical specialists focus on individual patients 
whereas the community-based traditional (public health) 
approach is concerned with the collective effect. Due to the 
different unit of the observation used in various studies, 
care must be taken in comparing the results. 
To make the analysis comprehensive, it analyses with both 
individual and aggregate values as the unit of the 
observation. In the individual observation unit analysis, a 
source variable is denoted by an individual respondent's data 
and the correspondent valuation by his/her own value of the 
health state concerned. In the aggregate counterpart, a 
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source variable is represented by the respondents I median 
value for a certain grouping and the valuation by their 
median score for a health state. 
3.5. The result of the analysis. 
3.5.1. The findings of the individual data analysis. 
1) The personal background effect. 
a) The findings of the original interval score data. 
The Kruskal-Wallis statistics indicate that both surveys 
commonly have subject's health experience, income level and 
education level as major influences. In Tables 17 and 18, 
they are statistically significant at 0.05 in at least half 
of the health states. 
Median values, which are usually used in the non- 
parametric analysis, of all groups in each major factor are 
reported in Tables 19-24. In most health states, the 
bronchitis patients, cancer patients and healthy people 
groups show higher median values than the health profession 
group. Groups of illiteracy, primary school and high school 
subjects possess higher median values in slightly more 
health states than the others. The middle income (between 
18001-60000 baht) groups, median values are the highest in 
most of the health states whereas the highest income (>240000 
baht) group's the lowest. 
In their absolute terms, the highest difference of the 
median values between the groups f rom the three variables 
ranges about 10-30 for almost all the health states. But in 
some of them the variations are substantial when they are 
measured relative to their median values. For example, the 
value ranges of the health state 11111 and others with one- 
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Table 17 The Kruskal-Wallis test for the feeling thermometer 
scores in the interview survey. 
health 
state 
iiiii 
11111R 
11112 
11121 
11211 
12111 
21111 
11122 
21232 
22233 
22323 
32211 
33321 
33333 
33333R 
uncon 
deathl 
death2 
age educat income hhincome 
6.112 21.019* 
4.455 22.632* 
4.523 19.036* 
9.775* 20.303* 
12.909* 62.499* 
7.042 16.511* 
9.971* 3.982 
9.132 14.143* 
2.850 10.592 
3.508 15.703* 
18.205* 13.659* 
1.425 18.774* 
0.538 12.878* 
3.899 3.049 
3.036 6.963 
6.536 12.080* 
6.438 5.130 
3.455 4.694 
21.976* 19.423* 
27.677* 22.692* 
21.161* 12.005* 
25.161* 22.357* 
29.711* 10.106 
12.528 9.223 
15.617* 6.555 
23.112* 25.716* 
8.294 2.521 
9.008 3.805 
8.273 7.327 
11.067 3.324 
4.439 5.291 
5.465 5.575 
14.155* 10.344 
14.559* 3.197 
7.226 7.117 
6.226 5.055 
fs 
3.946 
1.565 
2.130 
2.562 
3.849 
9.343 
2.607 
4.451 
9.066 
6.870 
1.026 
3.460 
2.927 
2.329 
0.206 
2.985 
3.100 
1.243 
hs 
15.513* 
12.597* 
8.359 
5.796 
14.410 
5.035 
9.235 
4.896 
3.279 
3.091 
2.455 
3.920 
3.584 
8.574 
7.153 
11 . 869* 6.072 
6.307 
thv 
4.129 
5.577 
7.503 
15.012* 
67.108* 
11.410 
5.621 
17.697* 
13 . 760* 3.836 
2.735 
7.848 
6.983 
2.683 
3.998 
14.188* 
1.871 
0.856 
Notes 
age 
educat 
income 
hhicome 
fs 
hs 
thv 
probability less than 0.05. 
age variable (5 groups). 
education variable (6 groups). 
individual income variable (8 groups). 
household income variable (6 groups). 
family size variable (5 groups). 
health service use variable (6 groups). 
current (today's) health values (7 groups). 
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Table 17 : The Kruskal-Wallis test for the feeling thermometer 
scores in the interview survey (continued). 
health 
state 
type occ smoking drinking cigar resident exercise 
11111 7.032 15.476* 3.752 0.576 0.637 3.326 1.038 
11111R 12.977* 13.669* 3.212 1.342 0.713 8.456* 3.017 
11112 20.417* 21.171* 2.908 0.539 0.285 0.595 3.110 
11121 24.190* 8.943 1.481 2.732 1.287 0.036 2.871 
11211 60.368* 62.806* 1.912 7.553* 1.824 0.564 8.725* 
12111 9.393* 6.176 0.343 2.829 1.623 3.378 2.123 
21111 4.848 9.035 2.472 0.933 1.336 3.340 1.271 
11122 31.635* 7.612 2.142 3.393 0.151 0.230 1.295 
21232 9.305* 6.307 0.364 0.071 0.038 0.342 5.632* 
22233 13.277* 10.963 1.862 0.000 0.461 0.135 6.497* 
22323 3.980 10.948 0.140 0.250 0.033 0.604 3.010 
32211 12.527* 11.675 0.906 0.016 0.193 0.070 0.151 
33321 10.908* 7.836 0.052 1.868 0.014 2.192 4.919* 
33333 11.995* 2.539 8.130* 1.052 0.080 1.649 1.151 
33333R 5.067 6.425 2.558 0.318 0.018 0.383 0.427 
uncon 5.052 7.363 2.632 5.932* 0.139 0.002 0.633 
deathl 22.531* 5.579 1.526 0.256 0.081 1.420 3.276 
death2 9.641* 5.280 0.951 0.123 0.411 0.494 0.825 
Notes 
type 
occ 
smoking 
drinking 
cigar 
resident 
exercise 
probability less than 0.05. 
health experience variable (4 groups). 
occupation variable (7 groups). 
smoking status variable (3 groups). 
alcohol drinking variable (2 groups). 
cigarette smoking variable (2 groups). 
residential area variable (2 groups). 
exercise variable (2 groups). 
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Table 18 The Kruskal-Wallis test for the feeling thermometer 
scores in the postal survey. 
health 
state 
age educat income hhincome fS hs thv 
11111 7.677 17.462* 15.290* 9.003 1.403 5.734 8.337 
11111R 7.015 19.003* 15.569* 9.480 1.512 4.646 6.236 
11112 2.426 6.614 2.035 7.666 0.293 1.417 7.599 
11121 9.674* 4.828 3.448 4.043 3.358 8.091* 9.765* 
11211 3.980 6.484 4.724 3.088 1.610 5.085 20.433* 
12111 2.722 2.550 6.239 4.533 0.600 1.494 8.104 
21111 4.690 9.332 1.917 5.756 0.334 7.969* 1.671 
11122 7.406 3.096 12.536* 22.249* 0.550 2.700 3.840 
21232 2.845 5.894 6.339 9.588 1.191 1.684 6.089 
22233 2.722 12.296* 8.296 18.710* 0.499 0.318 1.868 
22323 2.178 11.248* 9.666 9.577 0.029 1.988 4.412 
32211 2.693 2.583 13.662* 8.419 0.836 2.065 8.995 
33321 2.591 2.563 11.204* 10.348 1.217 9.616 3.452 
33333 4.637 9.597* 16.182* 10.972 1.840 2.586 3.817 
33333R 4.084 14.277* 21.464* 15.393* 0.248 3.180 4.905 
uncon 6.249 1.689 5.405 11.751* 1.186 4.078 1.716 
deathl 0.610 11.253* 7.555 5.773 0.233 3.790 2.094 
death2 0.588 13.589* 8.670 5.795 0.677 2.756 2.186 
Notes 
age 
educat 
income 
hhicome 
fs 
hs 
thv 
probability less than 0.05. 
age variable (5 groups). 
education variable (5 groups). 
individual income variable (6 groups). 
household income variable (6 groups). 
family size variable (2 groups). 
health service use variable (4 groups). 
current (today's) health values (5 groups). 
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Table 18 : The Kruskal-Wallis test for the feeling thermometer 
scores in the postal survey (continued). 
health 
state 
type occ smoking drinking cigar resident exercise 
111111 17.600* 16.792* 1.649 0.497 0.065 9.410* 4.371* 
11111R 18.219* 15.016* 1.923 3.592 0.652 4.597* 0.776 
11112 1.702 1.665 2.617 1.670 1.773 0.667 1.330 
11121 2.856 2.905 0.132 0.461 0.167 0.454 0.923 
11211 11.538* 6.108 1.166 2.314 0.212 3.897* 0.975 
12111 0.868 6.581 0.488 3.075 0.229 0.635 2.548 
21111 3.972 4.143 0.997 2.010 0.640 0.146 0.018 
11122 3.376 11.045 2.771 0.009 0.455 0.182 0.692 
21232 7.205 6.306 1.430 0.020 1.690 0.236 0.005 
22233 5.599 5.205 7.770* 4.876* 7.206* 3.874* 0.167 
22323 16.585* 8.804 2.991 4.404* 4.259* 2.129 0.558 
32211 4.192 4.884 7.462* 0.166 3.782 0.121 0.021 
33321 2.479 4.983 8.532* 0.441 7.404* 0.538 0.067 
33333 8.922* 16.402* 0.863 3.154 1.756 4.278* 0.201 
33333R 17.675* 16.982* 1.489 2.259 1.506 5.487* 0.305 
uncon 9.103* 20.061* 1.717 0.300 1.183 5.142* 0.252 
deathl 7.778 10.004 0.151 0.006 0.104 1.019 4.395* 
death2 8.489* 12.080 0.007 0.007 0.189 0.555 3.809 
Notes 
type 
occ 
smoking 
drinking 
cigar 
resident 
exercise 
probability less than 0.05. 
health experience variable (4 groups). 
occupation variable (7 groups). 
smoking status variable (3 groups). 
alcohol drinking variable (2 groups). 
cigarette smoking variable (2 groups). 
residential area variable (2 groups). 
exercise variable (2 groups). 
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Table 19 Median feeling thermometer scores in the interview 
survey according to the subject's health experience. 
health 
state 
health 
profession 
bronchitis 
patients 
cancer 
patients 
healthy 
people 
range 
11111 95 100 100 100 5 
11111R 95 100 100 100 5 
11112 60 80 80 so 20 
11121 70 80 70 80 10 
11211 80 70 60 60 20 
12111 70 60 50 60 20 
21111 80 80 70 70 10 
11122 60 60 60 70 10 
21232 40 45 40 40 5 
22233 20 30 30 30 10 
22323 20 25 30 30 10 
32211 30 40 40 40 10 
33321 19 20 25 20 6 
33333 5 10 10 0 10 
33333R 5 10 10 0 10 
uncon 0 0 0 0 0 
deathl 15 10 20 25 10 
death2 10 13 20 25 15 
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Table 20 : Median feeling thermometer scores in the interview 
survey according to the subject's income groups. 
health 
state 
0 0- 
9000 
9000- 
18000 
18001- 
30000 
30001- 
60000 
60001- 
120000 
120001- 
2400000 
240000+ range 
11111 100 95 100 100 100 100 91 98 9 
11111R 100 100 100 100 100 100 91 98 9 
11112 80 70 80 80 80 70 73 68 12 
11121 80 70 80 80 80 75 70 70 10 
11211 60 70 70 60 70 70 75 80 20 
12111 60 50 60 60 60 70 70 69 20 
21111 80 60 90 70 80 75 80 75 30 
11122 60 60 65 60 70 60 60 50 20 
21232 40 40 40 50 50 40 40 38 12 
22233 30 30 30 30 30 30 24 20 10 
22323 30 30 20 28 30 20 20 20 10 
32211 40 50 40 40 40 40 30 40 20 
33321 20 20 20 23 28 20 20 20 8 
33333 10 10 0 3 10 10 8 8 10 
33333R 0 2 0 10 10 10 8 10 10 
deathl 20 4 15 20 25 20 20 20 21 
death2 20 5 20 20 25 10 15 10 15 
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Table 21 Median feeling thermometer scores in the interview 
survey according to the subject's education level 
groups. 
health 
state 
illiteracy primary 
school 
secondary 
school 
high 
school 
university 
& college 
post- 
graduate 
range 
11111 100 100 100 98 95 98 5 
11111R 100 100 100 100 100 95 5 
11112 70 80 70 70 75 70 10 
11121 80 80 70 70 70 70 10 
11211 60 60 65 60 65 80 20 
12111 50 60 60 60 60 70 20 
21111 70 80 70 70 80 80 10 
11122 60 68 so 60 60 60 18 
21232 48 40 30 40 40 40 18 
22233 30 30 20 30 27 20 10 
22323 30 30 20 30 20 20 10 
32211 40 40 so 40 40 30 20 
33321 20 20 30 25 20 19 11 
33333 '10 5 10 10 10 5 5 
33333R 0 5 10 10 10 5 10 
uncon 0 0 5 0 0 0 5 
deathl 13 20 10 25 20 10 15 
death2 10 20 10 20 20 10 10 
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Table 22 : Median feeling thermometer scores in the postal survey 
according to the subject's health experience. 
health 
state 
health 
profession 
bronchitis 
patients 
cancer 
patients 
healthy 
people 
range 
11111 95 90 80 88 15 
11111R 95 95 80 90 15 
11112 70 80 70 80 10 
11121 80 80 74 80 6 
11211 90 80 70 80 20 
12111 70 70 so 60 20 
21111 80 80 80 80 0 
11122 52 60 66 50 16 
21232 30 45 40 35 15 
22233 13 20 30 20 17 
22323 10 25 22 8 17 
32211 30 40 35 25 15 
33321 10 20 10 8 12 
33333 0 0 10 2 10 
33333R 0 10 10 2 10 
uncon 0 5 1 0 5 
deathl 10 35 15 36 26 
death2 
L 
8 39 20 36 31 
11 
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Table 23 : Median feeling thermometer scores in the postal survey 
according to the subject's education level groups. 
health 
state 
primary 
school 
secondary 
school 
high 
school 
university 
& college 
post- 
graduate 
range 
11111 80 80 93 90 95 15 
11111R 83 70 90 95 95 25 
11112 70 80 80 80 70 10 
11121 70 80 90 80 80 20 
11211 70 80 90 85 85 20 
12111 55 50 60 60 70 20 
21111 80 60 90 80 80 30 
11122 50 60 65 50 55 is 
21232 45 30 50 30 30 20 
22233 50 10 28 10 15 35 
22323 20 9 20 10 10 11 
32211 39 13 38 30 30 26 
33321 15 10 10 10 10 5 
33333 10 1 10 2 0 10 
33333R 10 4 10 0 0 10 
uncon 0 0 3 0 0 3 
deathl 10 50 13 15 10 40 
death2 23 70 13 20 10 60 
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Table 24 : Median feeling thermometer scores in the postal survey 
according to the subject's income groups. 
health 
state 
0- 
18000 
18001- 
30000 
30001- 
60000 
60001- 
120000 
120001- 
2400000 
240000+ range 
11111 83 80 90 95 95 90 15 
11111R 85 90 90 97 95 95 12 
11112 70 85 80 75 73 70 15 
11121 75 80 80 80 80 80 5 
11211 80 80 81 90 85 90 10 
12111 53 60 65 70 70 55 17 
21111 75 80 80 80 80 73 7 
11122 50 60 70 60 52 40 30 
21232 30 50 48 30 35 30 20 
22233 25 40 20 15 20 15 25 
22323 10 40 10 10 12 10 30 
32211 33 41 11 38 28 25 30 
33321 10 30 5 10 15 9 25 
33333 5 20 0 0 0 0 20 
33333R 8 20 0 0 1 0 20 
uncon 1 5 0 0 0 0 5 
deathl 15 50 9 10 9 11 41 
death2 28 50 8 14 9 10 42 
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moderate health problem on the average equal 10-20%. On the 
contrary, those of the worse health states could become 100- 
200%. This highlights the marked variation between the 
single-moderate and multiple-severe health states. In 
addition, an observation about the valuation behaviour 
between the two types of the health states is made by Kind 
(1990a) when his analysis finds significant differences in 
the valuation of the more severe health states. 
Although the study by Rosser et al (1978) employs median 
values and magnitude estimation scaling method, subject's 
health experience is reported to be the only significant 
background as it is the most inf luential of the three factors 
in this study, due to its highest number of the significant 
health states. 
One common point between this study and Rosser et al's 
study is that the health professions (mainly doctors) place 
less emphasis (lower score) than other groups on the 
importance of death. However, one obvious difference between 
them is that the volunteer group in Rosser et al Is study 
regards death as the worst health state whereas all groups in 
this study have a couple of health states worse than death. 
The influence of education on the valuation is also 
supported by Kind (1990a) . In his study a large proportion of 
significant health states (13 out of 16) in relation to this 
variable are indicated and make it the most important 
determinant responsible for the valuation division. On the 
other hand, this study obtains 8 significant states from a 
total of 16 states for this factor, which is placed in the 
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second major influential determinant, next to the health 
experience variable. 
There are four possible explanations for the impacts of 
the three characteristic variables. First, the effects 
genuinely arise from the difference in the personal health 
experience, education level and income level. Secondly, the 
health-related quality of life concept, instrument and 
measurement in the current f orms could not separate the value 
of the quality of life from its determinants such as personal 
and social factors (Patrick et al, 1988). Take the degree of 
a dysfunction (say, daily activities) which is one of the 
domains commonly appearing in most health status and health 
state measurements, for an example. The activity limitations 
are supposed to be reflected in the values offered. Financial 
status (e. g. income earning) could interfere in one's 
judgement of the undesirability of such limitations happening 
to oneself. For instance, subsistent workers, absence from 
their job could produce distinct levels of undesirability 
from wealthy people's, given the same degree of the 
limitations, objectively measured by physical examinations. 
Ware (1984) suspects that the measurement of 
dysfunctional health status is confounded by socio-economic 
variables. The fact that more people will be behaviourally 
dysfunctional if they have low income, than if they have high 
income, justifies that part of behavioral functioning is the 
measure of income. 
Thirdly, since almost all the health states presented to 
subjects are artificially potential, the values elicited 
partially reveal their capacity to cope with each health 
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state from the present standpoint (Loomes et al, 1990). 
Income and education level are among the crucial factors 
assisting an individual to adjust towards new environs, if 
those health states become true. Therefore, subjects with 
differing levels of these factors incline to offer distinct 
values. 
Finally, it could be argued that the impacts are likely 
to exist in any kinds of the measurement involving people's 
backgrounds, not specific to valuation of illness (Rosser et 
al, 1978). They also hope that the discrepancy could be 
estimated and allowed for by some appropriate means. 
b) The findings of the rank order data. 
Tables 25-27 give some key statistics of rank order 
values of the three data sets. Tables 28-30 show the results 
of the Kruskal-Wallis test of the ranks. The interview survey 
with feeling thermometer scores produces the greater effects 
than the other two. The subject's health experience, 
household income level and education level are statistically 
significant at 0.05 in half of all the health states. 
In a comparison of the results between the original 
interval scores and the rankings, the former is expected to 
encompass the latter (because of the interval properties 
covering the ordinal ones). one expects that the former's 
statistically significant health states become a subset of 
the latter's. However, it appears that major influential 
variables have some health states significant in the ranking 
analysis but insignificant in the other. For example, based 
on the subject's health experience variable, the significance 
in the health states 21111 and 33333r differs in the two 
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Table 25 : 25th percentile, median, 75th percentile and mode of 
ranks of the feeling thermometer scores in the 
interview survey and the sample percentage of mode. 
health 
state 
25th per 
centile 
median 75th per 
centile 
mode sample percentage 
of mode 
11111 1.5 1.5 2.0 1.5 65.5 
11111R 1.5 1.5 1.5 1.5 64.4 
11112 3.5 4.5 6.3 3.0 15.0 
11121 3.5 4.5 6.0 4.0 15.8 
21111 3.5 4.5 6.0 4.0 15.3 
11211 4.0 6.0 7.5 3.0 11.6 
12111 5.5 7.0 8.5 7.0 11.6 
11122 5.5 7.0 8.5 7.0 13.3 
21232 9.0 10.0 11.0 9.0 13.6 
32211 9.0 10.5 12.0 10.5 9.9 
22233 10.5 12.0 13.5 12.5 10.7 
22323 10.5 12.5 14.0 12.5 9.3 
33321 11.5 13.0 14.5 13.0 11.9 
deathl 11.0 14.0 16.0 16.0 10.7 
death2 11.0 14.0 16.0 16.0 9.6 
33333 15.0 16.0 17.0 17.0 20.3 
33333R 15.0 16.0 17.0 17.0 20.1 
uncon 16.0 17.0 17.5 17.0 23.4 
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Table 26 : 25th percentile, median, 75th percentile and mode of 
ranks of the time trade-off scores in the 
interview survey and the sample percentage of mode. 
health 
state 
25th per 
centile 
median 75th per 
centile 
mode sample percentage 
of mode 
11112 2.5 3.5 5.0 3.5 13.3 
11121 2.5 3.5 5.0 3.5 14.7 
11211 2.5 3.5 5.5 3.5 14.1 
11122 2.5 3.5 5.5 3.5 16.1 
21111 3.0 3.8 5.0 3.5 15.5 
12111 3.5 4.5 6.0 3.5 14.1 
21232 6.0 8.0 9.0 9.0 19.2 
32211 7.5 9.0 9.5 9.0 20.9 
33321 8.5 9.0 10.0 9.0 22.0 
22323 7.0 9.0 9.5 9.0 22.0 
22233 8.0 9.0 9.5 9.5 20.6 
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Table 27 : 25th percentile, median, 75th percentile and mode of 
ranks of the feeling thermometer scores in the 
postal survey and the sample percentage of mode. 
health 
state 
25th per 
centile 
median 75th per 
centile 
mode sample percentage 
of mode 
11111 1.5 2.0 4.0 1.5 35.8 
11111R 1.5 2.0 3.5 1.5 38.9 
11211 3.0 3.5 5.0 3.0 19.1 
11121 3.0 4.5 6.5 4.0 9.9 
21111 3.5 4.5 6.4 4.0 11.7 
11112 3.5 5.0 7.0 4.5 11.7 
12111 5.4 7.0 9.5 8.0 9.3 
11122 6.5 8.0 10.0 8.0 16.0 
21232 8.5 10.0 11.0 9.0 16.7 
32211 9.0 11.0 12.5 10.0 10.5 
22233 10.0 11.5 13.5 11.0 10.5 
deathl 10.0 12.5 16.0 16.0 5.6 
33321 11.5 13.0 14.9 12.5 12.3 
22323 11.5 13.0 14.5 13.0 11.7 
death2 10.0 13.0 16.0 13.0 5.6 
33333R 13.0 14.5 16.0 16.0 9.9 
33333 13.0 15.0 16.0 15.5 10.5 
uncon 13.25 15.5 16.5 16.0 16.0 
223 
Table 28 : The Kruskal-Wallis test of rank for the feeling 
thermometer scores in the interview survey. 
health age 
state 
11111 2.222 
1111IR 5.884 
11112 0.214 
11121 5.309 
11211 10.408* 
12111 3.022 
21111 4.717 
11122 6.785 
21232 1.616 
22233 3.394 
22323 9.816* 
32211 3.939 
33321 2.548 
33333 6.237 
33333R 5.623 
uncon 4.932 
deathl 5.243 
death2 2.274 
educat income hhincome 
8.411 8.197 3.116 
17.843* 9.053 17.986* 
26.033* 23.443* 10.636 
27.734* 26.948* 26.930* 
84.699* 34.512* 16.203* 
14.448* 16.191* 16.951* 
6.155 14.351* 9.047 
26.239* 29.320* 36.133* 
5.006 5.032 1.633 
3.609 4.474 3.368 
9.532 5.421 5.587 
13.485* 7.090 5.351 
5.179 2.046 8.735 
4.077 13.337 16.864* 
8.718 10.197 7.178 
2.885 6.821 2.748 
2.040 3.800 11.305* 
6.662 5.285 6.495 
fs hs thv 
7.300 4.753 5.940 
3.451 4.314 7.041 
4.247 5.145 11.485 
2.796 3.912 6.399 
7.044 18.699* 39.126* 
6.762 3.328 4.302 
5.082 4.625 4.077 
2.747 3.048 8.607 
4.639 8.766 11.139 
5.573 0.953 5.389 
1.215 3.421 3.242 
2.390 3.333 7.232 
0.724 4.619 8.975 
4.171 2.424 7.490 
2.398 9.165 7.986 
0.435 4.385 4.396 
4.417 6.047 1.877 
1.015 6.849 1.348 
Note : See notes at Table 17. 
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Table 28 : The Kruskal-Wallis test of rank for the feeling 
thermometer scores in the interview survey 
(continued). 
health 
state 
type occ smoking drinking cigar resident exercise 
11111 2.198 6.654 2.233 0.542 0.048 0.289 0.135 
11111R 6.164 4.517 1.735 1.025 1.012 2.177 1.945 
11112 27.867* 31.042* 0.796 0.400 0.017 0.475 6.422* 
11121 35.362* 18.983* 0.478 8.222* 0.025 0.030 3.023 
11211 81.123* 73.770* 2.010 6.966* 1.583 0.425 16.820* 
12111 15.632* 8.147 2.473 1.856 4.631* 2.870 4.024* 
21111 14.600* 17.314* 0.860 0.057 0.398 0.843 0.945 
11122 46.545* 14.450* 3.424 4.398* 0.275 0.169 2.216 
21232 10.139 10.224 0.904 0.625 0.017 1.938 2.387 
22233 6.909 8.662 4.637 1.023 0.911 0.706 0.876 
22323 2.633 15.551* 0.439 0.175 1.213 1.562 0.017 
32211 5.698 5.286 1.511 0.067 0.639 0.264 0.628 
33321 6.600 1.851 0.478 2.007 0.384 6.279* 0.670 
33333 17.498* 3.420 12.361* 1.511 0.727 2.801 0.118 
33333R 20.050* 5.559 2.662 0.521 0.050 0.397 0.245 
uncon 5.140 3.092 2.068 1.763 0.108 1.423 0.671 
deathl 20.676* 3.584 2.552 0.711 0.156 3.842* 1.089 
death2 4.966 3.128 0.559 2.172 0.048 1.410 0.061 
Note : See notes at Table 17. 
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Table 29 : The Kruskal-Wallis test of rank for the time trade-off 
scores in the interview survey. 
health age educat income hhincome fs hs thv 
state 
11112 4.774 13 . 537* 16.727* 19.348* 1.604 2.176 8.900 
11121 6.681 6.662 13.079 7.859 5.682 2.964 7.541 
11211 2.458 5.352 2.396 4.010 1.472 7.919 4.343 
12111 7.009 9.564 6.666 7.639 2.586 1.925 2.126 
21111 0.957 6.696 6.383 2.970 5.042 4.366 5.265 
11122 10.409* 12.092* 14.899* 16.395* 4.293 5.613 2.792 
21232 8.018 5.247 10.424 6.664 5.730 5.530 7.538 
22233 9.191 9.256 13.762 19.904* 4.631 2.000 2.574 
22323 16.986* 4.390 6.359 3.698 1.444 4.722 11.435 
32211 5.217 4.274 3.720 1.799 4.100 4.636 5.968 
133321 3.124 5.394 1.740 0.657 3.528 8.014 5.531 
Note : See notes at Table 17. 
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Table 29 : The Kruskal-Wallis test of rank for the time trade-off 
scores in the interview survey (continued). 
health 
state 
type occ smoking drinking cigar resident exercise 
11112 21.399* 22.127* 9.881* 2.323 0.051 0.057 0.824 
11121 6.715 15.315* 5.051 1.308 0.087 0.299 0.004 
11211 2.171 5.177 2.040 1.882 0.687 0.619 1.300 
12111 8.870* 4.640 2.364 0.008 0.796 4.990* 0.411 
21111 7.139 10.678 4.402 0.128 0.054 2.464 2.516 
11122 11.933* 8.645 0.018 0.428 0.678 0.428 2.001 
21232 8.856* 4.362 3.232 0.170 0.129 1.187 0.776 
22233 1.431 2.070 0.736 1.151 0.139 1.050 3.846* 
223 3 4.719 13.456* 3.949 0.089 1.155 10.126* 0.300 
32211 2.970 4.012 2.715 8.154* 2.667 0.000 2.340 
33321 0.869 0.505 2.041 0.285 0.659 2.007 1.134 
Note : See notes at Table 17. 
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Table 30 : The Kruskal-Wallis test of rank for the feeling 
thermometer scores in the postal survey. 
health 
state 
age educat income hhincome fS hs thv 
11111 5.732 18.970* 20.506* 18.647* 0.501 5.592 2.685 
11111R 1.165 24.701* 10.569 10.478 1.800 4.948 1.400 
11112 0.886 3.474 1.291 5.505 0.082 1.707 1.848 
11121 3.753 4.280 2.046 1.217 0.979 2.495 3.306 
11211 4.723 1.036 3.550 4.775 1.126 4.955 12.474* 
12111 2.542 4.373 10.355 6.453 0.215 2.604 6.566 
21111 0.672 14.876* 2.173 0.948 0.385 2.075 1.879 
11122 4.072 3.648 11.287* 9.433 0.094 2.498 1.889 
21232 3.390 1.725 7.543 10.785 5.004 2.714 4.779 
22233 10.992* 13.486* 5.786 18.645* 2.473 1.436 1.058 
22323 4.087 6.723 7.468 7.280 0.089 1.785 9.236 
32211 1.640 2.505 4.830 5.629 1.384 0.384 6.676 
33321 5.034 5.249 1.218 0.364 3.662 8-287* 0.889 
33333 8.556 5.065 9.819 12.449* 0.602 1.310 4.372 
33333R 3.055 6.668 12.847* 5.319 0.187 1.251 0.983 
uncon 5.056 1.023 8.026 5.177 0.083 4.795 2.686 
deathl 2.465 12.740* 6.641 2.371 0.506 0.736 1.773 
death2 2.911 16.437* 8.581 3.528 1.301 2.407 1.727 
Note : See notes at Table 18. 
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Table 30 : The Kruskal-Wallis test of rank for the feeling 
thermometer scores in the postal survey (continued). 
health 
state 
type occ smoking drinking cigar resident exercise 
11111 21.960* 17.434* 2.639 0.088 0.876 5.935* 4.174* 
11111R 5.545 5.865 0.811 0.390 1.191 2.195 2.725 
11112 3.158 0.997 7.698* 1.376 6.388* 0.190 0.917 
11121 1.413 0.314 0.757 0.405 0.341 0.015 0.001 
11211 6.422 4.879 0.529 0.025 0.168 1.686 0.159 
12111 7.748 4.274 0.382 2.245 0.075 0.307 2.475 
21111 2.812 3.701 1.686 0.000 0.345 3.050 0.004 
11122 2.744 0.529 3.079 1.222 0.016 3.193 0.901 
21232 1.757 0.637 0.106 0.748 0.161 0.239 0.072 
22233 2.610 0.429 2.327 1.666 2.399 2.737 1.494 
22323 11.196* 0.941 0.849 2.652 1.424 2.468 0.023 
32211 1.718 0.951 10.220* 0.304 0.675 0.702 0.520 
33321 2.048 4.397 1.719 0.294 0.348 0.317 1.293 
33333 2.849 3.797 0.852 0.456 0.688 1.845 2.616 
33333R 5.021 1.756 2.321 0.322 0.681 3.071 3.449 
uncon 4.446 5.869 0.115 0.113 0.056 1.452 0.936 
deathl 3.313 4.193 2.906 1.573 1.669 2.120 1.982 
death2 6.184 5.503 2.198 1.027 1.173 1.601 1.722 
Note : See notes at Table 18. 
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results. The differences are also found in the health state 
12111 according to the income level variable and in the 
health states 11211,12111,33333 and deathl with respect to 
the household income level variable. 
This casts doubt about whether or not the properties of 
the interval scores are viable. Some unexpectations between 
the two types of the scores could make a caution about the 
applications of the interval scores in the economic 
evaluation and decision-making. Some studies using the 
EuroQol instrument have found the invalidity of the interval 
property of the feeling thermometer scores (The EuroQol 
group, 1992). 
According to Table 31, as the previous results are 
confirmed, the two types of the patients' rankings based on 
the feeling thermometer scores in the interview survey are 
very close. The ef f ects of the health experience upon the 
disparity in rankings occur in the health states with single- 
moderate problem more often than in those with multiple 
problems. All the single-moderate health states have the 
highest rank difference greater than one, while most of the 
multiple-severe health states less than or equal to one. In 
addition, the health professions gave higher ranks (less 
preference) for single-moderate health problems in anxiety 
and pain than the healthy people did. on the other hand, the 
former offered lower ranks (more preference) for those in 
usual activities, selfcare and mobility. 
Table 32 indicates that the lowest household income group 
scored the lowest ranks (most preference) in half of all the 
health states. On the other hand, most health states with the 
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Table 31 : Median ranks of the feeling thermometer scores in the 
interview survey according to the subject's health 
experience. 
health 
state 
health 
profession 
bronchitis 
patients 
cancer 
patients 
healthy 
people 
range 
11111 1.5 1.5 1.5 1.5 0.0 
1111IR 1.5 1.5 1.5 1.5 0.0 
11211 3.5 6.5 6.5 7.0 3.5 
21111 4.0 4.5 4.0 5.3 1.3 
11121 5.5 4.5 4.5 4.0 1.5 
11112 6.0 4.5 4.5 4.0 2.0 
12111 6.0 7.0 7.5 7.0 1.5 
11122 8.0 7.0 7.5 6.0 2.0 
21232 10.0 9.5 10.0 10.3 0.8 
32211 10.5 10.5 10.0 10.5 0.5 
22233 12.0 11.5 11.5 12.5 1.0 
22323 12.5 12.5 12.0 13.0 1.0 
33321 13.5 13.0 13.0 13.5 0.5 
deathl 14.3 15.0 14.0 12.3 2.7 
death2 14.5 14.5 14.5 13.0 1.5 
33333 16.0 16.0 15.5 16.5 1.0 
33333R 15.5 16.0 16.0 16.5 1.0 
uncon 17.0 16.5 17.0 17.0 1.5 
--JI 
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Table 32 : Median ranks of the feeling thermometer scores in the 
interview survey according to the subject's household 
income level groups. 
health 
state 
0- 
18000 
18001- 
30000 
30001- 
60000 
60000- 
120000 
120000- 
240000 
240000+ range 
11111 1.5 1.5 1.5 1.5 1.5 1.5 0.0 
11111R 1.5 1.5 1.5 1.5 1.5 1.5 0.0 
11112 4.5 5.5 4.5 4.0 4.5 5.0 1.0 
11121 4.5 4.8 4.0 4.0 4.5 5.5 1.5 
21111 5.5 4.0 4.5 5.0 4.5 4.0 1.5 
12111 5.5 7.3 7.5 7.5 7.0 6.6 2.0 
11211 7.0 5.5 6.5 6.0 6.0 5.0 2.0 
11122 7.0 6.0 6.0 7.0 6.5 8.0 2.0 
32211 9.5 10.8 10.5 10.5 9.5 10.5 1.3 
21232 10.0 9.3 10.0 10.0 10.0 10.0 0.7 
22233 11.5 11.5 12.0 12.0 12.0 12.0 0.5 
22323 11.5 12.5 12.0 12.5 12.0 13.0 1.5 
33321 12.5 12.8 13.0 14.0 13.5 13.0 1.5 
33333 15.0 15.8 16.5 16.5 16.5 15.5 1.5 
deathl 16.0 14.8 14.0 13.5 14.0 13.5 2.0 
death2 16.0 14.5 13.8 14.0 13.8 14.0 2.2 
33333R 16.0 15.5 16.5 16.5 16.0 16.0 1.0 
uncon 17.0 17.0 17.0 17.0 17.0 17.0 0.0 
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highest ranks (least preference) were offered by the highest 
income class. The rank patterns among the middle household 
income groups (30001-240000 baht) are similar in most health 
states. The household income factor also supports the 
argument that the wider highest rank dif f erences are with the 
states with one-moderate problem. 
No one group decisively offered either the highest or 
lowest ranks to more health states than any group did, 
according to the median rank values of the education level 
categorisation in Table 33. Moreover, the highest rank 
differences between the health states with one-moderate 
problem and those with many problems are similar. 
One argument, possibly accountable for distinguished 
highest rank differences between the two types of the health 
states, is that the subjects tended to differentiate a 
variation in single health dimension problems apparently. As 
the number of ill-health dimensions varies, the ability to 
weight them in a clear-cut pattern declines. Kaplan et al 
(1988) find that their Quality of Well-Being Index become 
very sensitive to the top-end variation. At this end are 
minor health problems. It is noted that the health state 
11211 has the widest highest rank difference in almost three 
influential variables. This could imply that in this health 
state the subjects, opinion sharply divides. However, such a 
case does not emerge in the analysis of the original interval 
scores. This is also raised to reinforce the conflict of the 
ordinal versus cardinal properties of the valuation. It is 
possible that the content for the usual and daily activities 
causes a variety of interpretations and imaginations. As a 
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Table 33 Median ranks of the feeling thermometer scores in the 
interview survey according to the subject's education 
level groups. 
health 
state 
illiteracy primary 
school 
secondary 
school 
high 
school 
university 
& college 
post- range 
graduate 
11111 1.5 1.5 1.5 1.5 1.5 1.5 0.0 
11111R 1.5 1.5 1.5 1.5 1.5 1.5 0.0 
11112 4.0 4.0 4.8 4.5 4.5 6.0 2.0 
11211 4.0 4.0 4.3 4.0 5.0 5.0 1.0 
21111 5.0 4.5 4.5 4.5 4.0 4.0 1.0 
11211 6.0 7.0 7.0 6.0 6.0 3.5 3.5 
11122 6.3 7.0 7.3 7.0 7.0 8.0 1.7 
12111 8.0 7.0 7.3 7.0 7.0 6.0 2.0 
21232 9.5 9.5 10.5 10.0 9.5 10.0 1.0 
32211 10.5 10.5 8.5 10.0 10.0 10.5 2.0 
22233 11.5 12.0 12.8 12.0 11.5 12.0 1.3 
22323 12.5 12.0 13.5 13.0 12.5 12.5 1.5 
33321 13.0 13.0 12.0 13.0 13.5 13.3 1.5 
deathl 14.0 14.0 14.5 14.0 13.3 14.5 1.2 
death2 14.5 13.75 15.5 15.0 13.0 14.5 2.5 
33333 16.0 16.5 15.5 16.0 16.0 16.0 1.0 
33333R 16.5 16.5 15.5 16.0 16.0 15.5 1.0 
uncon 17.0 17.0 16.5 17.0 17.0 17.0 0.5 
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result, the scores may reflect different matters and divert 
from the intent of the question. For example, Bush (1984a) 
finds that the "performance" of the activities is usually 
confused with the "capacity". Kind et al (1991) make a 
commentary of their valuation result that the questions in 
their valuation procedure are possibly interpreted 
differently from the intended meanings by the respondents. 
c)The findings of the standardised data. 
Tables 34-36 report the mean, 25 th percentile, median, 75 th 
percentile and standard deviation of the transformed health 
state values in all sets of the data. As an evidence to 
support the justification of the standardisation, a scale of 
100 between the perfect health (11111) and dead state is a 
majority in both surveys. There are about 10-11 % of the 
subjects selecting such a range. The standardisation could 
make the interpersonal comparisons clearer and more 
meaningful for all the subjects. 
The results of the Kruskal-Wallis test in Tables 37-39 
indicate that the subject's health experience remains the 
single influential factor in the interview survey with the 
feeling thermometer and the time trade-off scores whereas the 
impacts of all the variables in the other survey virtually 
vanish. 
The median values of the feeling thermometer and time 
trade-off scores, in accordance with the health experience 
variable, are shown in Tables 40-41. Like all previous 
results, the two types of the patients possess the similar 
median values in most health states. The groups can be 
arranged in the following order of high to low median feeling 
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Table 34 : Mean, 25th percentile, median, 75th percentile and 
standard deviation of the tranformed scores (0-1 scale) 
of the feeling thermometer scores in the interview 
survey. 
health 
state 
mean 25th per 
centile 
median 75th per 
centile 
standard 
deviation 
average 11111 1.00 1.00 
11112 0.67 0.56 0.74 0.88 0.57 
11121 0.69 0.60 0.75 0.86 0.63 
11211 0.62 0.45 0.63 0.80 0.70 
12111 0.55 0.33 0.55 0.73 0.93 
21111 0.68 0.58 0.76 0.89 0.52 
11122 0.55 0.37 0.55 0.68 0.86 
21232 0.30 0.10 0.28 0.44 0.91 
22233 0.11 -0.07 0.11 0.30 0.87 
22323 0.07 -0.11 0.07 0.28 0.71 
32211 0.25 0.00 0.25 0.45 0.98 
33321 0.07 -0.18 0.05 0.20 1.15 
33333 -0.12 -0.34 -0.11 0.00 1.14 
33333R -0.13 -0.37 -0.11 0.00 1.16 
uncon -0.18 -0.43 -0.17 0.00 1.21 
average death 0.00 0.00 
Note : The number of the valid cases is 354. 
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Table 35 : Mean, 25th percentile, median, 75th percentile and 
standard deviation of the time trade-off scores 
in the interview samples. 
health 
state 
mean 25th per 
centile 
median 75th per 
centile 
standard 
deviation 
11121 0.72 0.55 0.85 0.95 31.9 
21111 0.71 0.55 0.85 0.95 31.9 
11112 0.71 0.55 0.85 0.95 32.6 
11122 0.70 0.55 0.85 0.95 32.0 
11211 0.69 0.55 0.85 0.95 34.1 
12111 0.62 0.35 0.75 0.95 36.0 
21232 0.31 0.00 0.05 0.65 37.6 
32211 0.18 0.00 0.00 0.25 31.2 
22323 0.18 0.00 0.00 0.25 30.2 
22233 0.13 0.00 0.00 0.05 27.6 
33321 0.09 0.00 0.00 0.00 23.7 
Note : The number of the valid cases is 354. 
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Table 36 : Mean, 25th percentile, median, 75th percentile and 
standard deviation of the tranformed scores (0-1 scale) 
of the feeling thermometer scores in the postal 
survey. 
health 
state 
mean 25th per 
centile 
median 75th per 
centile 
standard 
deviation 
average 11111 1.00 1.00 
11112 0.71 0.58 0.77 0.95 0.76 
11121 0.73 0.58 0.82 0.97 0.58 
11211 0.85 0.75 0.90 1.00 0.41 
12111 0.27 0.34 0.60 0.82 2.01 
21111 0.77 0.57 0.81 0.95 0.78 
11122 0.21 0.24 0.50 0.76 1.51 
21232 -0.12 -0.07 0.22 0.52 1.89 
22233 -0.72 -0.30 0.06 0.27 4.20 
22323 -0.57 -0.49 0.00 0.20 2.18 
32211 -0.13 -0.11 0.16 0.38 1.57 
33321 -1.20 -0.49 0.00 0.20 6.87 
33333 -1.09 -0.60 -0.06 0.01 4.98 
33333R -0.91 -0.60 -0.06 0.00 3.96 
uncon -0.79 -0.44 -0.07 0.00 2.91 
average death 0.00 0.00 
Note : The number of the valid cases is 95. 
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Table 37 : The Kruskal-Wallis test of standardised feeling 
thermometer scores in the interview survey. 
health 
state 
11112 
11121 
11211 
12111 
21111 
11122 
21232 
22233 
22323 
32211 
33321 
33333 
33333R 
uncon 
age educat income hhincome fs hs thv 
3.052 11.079* 11.862 9.870 
8.005 11.500* 15.247* 16.097* 
7.119 64.151* 34.156* 10.258 
4.315 8.373 11.509 14.812* 
8.303 5.717 13.316 4.622 
7.222 8.981 14.789* 10.210* 
1.361 5.018 4.707 6.821 
3.092 4.602 3.902 3.156 
6.892 1.207 7.059 7.786 
2.340 12.112* 10.054 5.997 
4.200 7.167 3.071 9.847 
3.874 5.650 8.452 9.818 
3.924 7.200 6.760 5.515 
10.918* 8.188 7.179 5.151 
1.058 4.128 11.569 
0.415 2.127 7.530 
6.195 15.173* 36.943* 
6.180 1.976 8.403 
6.763 5.137 4.734 
1.321 3.487 10.821 
7.556 3.464 7.782 
5.716 3.810 3.224 
1.345 2.015 2.792 
2.612 2.764 7.890 
1.992 3.066 5.538 
1.909 2.425 3.663 
1.752 4.542 6.507 
1.036 3.224 3.706 
Note : See notes at Table 17. 
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Table 37 : The Kruskal-Wallis test of standardised feeling 
thermometer scores in the interview survey 
(continued). 
health 
state 
type occ smoking drinking cigar resident exercise 
11112 13. 289* 15.307* 0.336 0.245 0.009 0.553 0.974 
11121 9. 241* 3.570 3.497 2.483 3.641 0.080 0.938 
11211 73. 778* 62.633* 3.601 4.309* 2.698 0.127 12.247* 
12111 12. 454* 10-118 0.367 1.341 0.013 0.420 2.716 
21111 17. 132* 15.907* 3.512 0.908 2.876 0.834 2.993 
11122 14. 166* 5.617 1.515 1.681 0.004 0.170 0.098 
21232 25. 322* 8.690 1.051 0.295 0.100 2.334 0.270 
22233 11. 725* 6.623 2.393 0.574 0.003 1.065 0.830 
22323 10. 300* 12.720* 0.806 0.003 0.549 3.053 0.016 
32211 13. 020* 5.287 3.120 0.000 0.681 4.673* 0.669 
33321 11. 807* 2.248 0.655 0.395 0.126 6.607* 0.042 
33333 21. 949* 2.793 5.347 1.403 0.004 6.668* 0.838 
33333R 27. 665* 2.872 3.044 0.447 0.204 2.146 2.078 
uncon 24. 073* 2.630 2.518 2.855 0.106 5.949* 3.273 
Note : See notes at Table 17. 
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Table 38 The Kruskal-Wallis test of the time trade-off scores 
in the interview survey. 
health age 
state 
11112 0.162 
11121 1.626 
11211 3.676 
12111 2.709 
21111 5.275 
11122 1.233 
21232 5.083 
22233 7.920 
22323 10.085* 
32211 3.031 
33321 1.361 
educat income hhincome fs hs 
1.991 
4.954 
6.014 
5.899 
9.991 
5.797 
5.576 
7.478 
8.424 
11.505* 
10.840 
5.597 
5.508 
3.004 
8.415 
8.432 
5.734 
5.566 
11.866 
11.707 
9.614 
6.336 
10.383 
9.676 
5.092 
1.648 
2.701 
10.549 
3.979 
12.401* 
7.742 
2.343 
7.248 
4.164 6.461 
2.914 13.975* 
3.930 3.436 
0.444 14.045* 
6.474 10.542 
5.468 11.985* 
7.588 9.421 
3.308 12.268* 
1.032 8.625 
2.395 8.718 
4.725 5.686 
thv 
2.750 
2.500 
4.413 
1.463 
4.874 
2.503 
8.157 
3.711 
4.962 
12.145 
12.278 
Note : See notes at Table 17. 
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Table 38 The Kruskal-Wallis test of the time trade-off scores 
in the interview survey (continued). 
health 
state 
11112 
11121 
11211 
12111 
21111 
11122 
21232 
22233 
22323 
32211 
33321 
type occ smoking drinking cigar resident exercise 
14.699* 
9 . 970* 7.265 
6.741 
8.494* 
5.797 
9.250* 
12.939* 
11.283* 
12.367* 
14.108* 
5.952 
14.823* 
20.892* 
14.053* 
13.882* 
5.473 
2.740 
5.047 
13.101* 
7.362 
6.844 
1.775 
0.740 
0.339 
0.782 
0.745 
0.018 
3.164 
1.928 
4.340 
1.309 
0.199 
0.034 0.009 
0.010 0.094 
5.307* 0.022 
0.346 0.270 
0.946 0.031 
0.161 0.353 
0.152 0.527 
0.073 0.379 
0.388 1.585 
5.662* 0.490 
1.449 0.000 
2.495 0.005 
3.271 0.297 
7.132* 1.405 
4.958* 0.014 
5.933* 0.023 
1.337 2.169 
1.026 0.549 
0.500 1.219 
3.105 1.108 
0.052 2.559 
0.842 4.727 
Note : See notes at Table 17. 
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Table 39 : The Kruskal-Wallis test of standardised feeling 
thermometer scores in the postal survey. 
health age educat income hhincome fs 
state 
11112 3.009 7.741 5.728 8.866 
11121 10.533* 3.657 5.748 10.051 
11211 1.848 5.615 6.318 9.994 
12111 4.316 1.556 8.846 7.309 
21111 11.492* 6.152 16.088* 8.403 
11122 0.713 0.930 11.627* 7.000 
21232 7.834 1.392 7.679 6.450 
22233 6.852 8.975 1.470 7.183 
22323 4.576 4.477 6.222 2.147 
32211 1.826 2.353 4.725 3.070 
33321 4.399 6.924 5.745 1.215 
33333 2.226 3.267 3.891 1.273 
33333R 1.961 5.740 4.001 1.742 
uncon 0.392 6.076 5.036 1.206 
0.440 
0.492 
0.351 
0.303 
2.168 
0.450 
1.270 
0.937 
0.200 
0.924 
0.841 
0.143 
0.284 
0.584 
hs thv 
0.308 5.501 
6.851 5.328 
2.799 7.606 
1.379 6.416 
1.497 1.239 
3.431 3.463 
2.106 3.226 
7.239 2.025 
2.865 0.700 
1.114 5.200 
3.676 1.123 
2.996 1.593 
3.737 2.981 
4.696 5.649 
Note : See notes at Table 18. 
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Table 39 : The Kruskal-Wallis test of standardised feeling* 
thermometer scores in the postal survey (continued). 
health 
state 
type occ smoking drinking cigar resident exercise 
11112 1.101 1.059 8.512* 0.621 1.683 1.023 0.057 
11121 0.718 2.119 2.729 0.423 0.087 0.508 2.429 
11211 0.643 0.532 3.843 2.817 3.057 0.286 0.002 
12111 7.958* 0.927 0.419 3.439 0.402 0.722 0.871 
21111 5.816 2.028 1.234 0.267 1.892 1.061 0.402 
11122 0.405 1.794 0.374 0.002 0.021 0.052 0.619 
21232 0.380 0.179 0.309 0.087 voll 0.671 0.226 
22233 2.423 0.948 4.552 1.104 2.536 1.067 1.521 
22323 2.301 3.879 0.679 0.691 0.220 1.588 1.460 
32211 2.051 2.848 2.716 0.002 0.968 3.838* 0.005 
33321 4.800 5.424 1.725 0.002 0.798 3.979* 0.158 
33333 4.697 1.708 0.004 0.669 0.073 2.019 0.767 
33333R 3.406 3.472 0.151 0.364 0.006 2.142 0.653 
uncon 4.270 1.016 0.496 0.600 0.000 0.166 1.495 J1 
Note : See notes at Table 18. 
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Table 40 : Median values of standardised feeling thermometer 
scores in the interview survey according to the 
subject's health experience. 
health 
state 
health 
profession 
bronchitis 
patients 
cancer 
patients 
healthy 
people 
range 
11112 0.654 0.778 0.750 0.780 0.126 
11121 0.667 0.750 0.727 0.780 0.113 
11211 0.875 0.636 0.588 0.527 0.348 
12111 0.665 0.598 0.500 0.527 0.165 
21111 0.809 0.800 0.724 0.678 0.131 
11122 0.470 0.571 0.500 0.592 0.122 
21232 0.270 0.400 0.286 0.187 0.213 
22233 0.100 0.133 0.200 0.056 0.144 
22323 0.082 0.125 0.100 0.000 0.125 
32211 0.188 0.300 0.300 0.204 0.112 
33321 0.059 0.100 0.091 -0.025 0.125 
33333 -0.053 0.000 -0.111 -0.226 0.226 
33333R -0.071 0.000 -0.125 -0.273 0.273 
uncon -0.077 -0.098 -0.172 -0.290 0.213 
245 
Table 41 Median time trade-off scores in the interview survey 
according to the subject's health experience. 
health 
state 
health 
profession 
bronchitis 
patients 
cancer 
patients 
healthy 
people 
range 
11112 0.85 0.90 0.83 0.95 0.12 
11121 0.85 0.85 0.85 0.95 0.10 
11211 0.95 0.85 0.80 0.95 0.15 
12111 0.90 0.65 0.75 0.80 0.25 
21111 0.95 0.85 0.85 0.95 0.10 
11122 0.75 0.85 0.83 0.95 0.20 
21232 0.25 0.05 0.13 0.00 0.25 
22233 0.00 0.00 0.00 0.00 0.00 
22323 0.05 0.00 0.00 0.00 0.05 
32211 0.05 0.00 0.00 0.00 0.05 
33321 0.00 0.00 0.00 0.00 0.00 
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thermometer scores in the interview survey : the bronchitis 
patients, cancer patients, health professions and healthy 
people. On the other hand, the time trade-off scores produce 
the opposite result. The healthy people possess the highest 
median values in more health states than the others, followed 
by the health professions. The two groups of patients equally 
have the lowest values in more health states than the others 
have. 
Although both scaling methods point to the same 
background impact, they entirely contrast patterns of scoring 
raising the question : which scaling method is reliable? A 
great deal of work needs to be done before a certain 
conclusion is made. However, when considering the 
discrimination power of the valuation between the two scaling 
techniques, which might be a criterion in justifying the best 
technique, one can see that the feeling thermometer method 
does much better than the other. 
The health state 11211 still has the highest range. 
Similar to all the previous results, the ranges of the 
highest difference of the feeling thermometer scores among 
the subject's health experience groups, show no sign of the 
value segregation between the health states with one-moderate 
problem and those with many problems with respect to the 
absolute median scores. Instead, they indicate a sharp 
difference between the two in relation to the variation 
percentage. 
As one of their analysis variants is regarded as an 
attempt to standardise the health state values, Rosser et al 
(1978) discover the significant effect of the subject's 
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health experience on the values, despite the analysis based 
on the median and on only one standardised health state. They 
transform only the health state of 7,4 (confined to bed and 
severe pain) with respect to the state of 1,1 (no disability 
and no distress), which is called "gradient" and employed as 
an indication of the overall trend in the scoring. It is 
reported that the clearer differences in the valuation are 
obtained among the subject's health experience groups and 
among the Eysenck Personality Questionnaire (EPQ) score 
groupings. Unfortunately, the influences of other personal 
backgrounds on the values could not be analysed. 
It is obvious that the degree of the interpersonal 
comparisons account for the different outcomes between the 
standardised values and non-standardised ones (i. e. the 
original interval and rank order values). The subject's 
health experience effect becomes more dominant (i. e. more 
health states are statistically significant) but remains only 
one viable factor. 
However, an alternative argument, explaining the effect 
of the standardisation process on the valuation, could 
possibly be used to undermine the outcome above. The 
transformation suppresses the original values and causes the 
differences between groups lower. This can be seen as a 
manipulation to obscure the real perceptual differences, 
which lessens the effects of the income and education 
variables. If this is true, all influences should decrease 
across the broad. But the findings show that the subject's 
health experience impact increases while those of the other 
two factors decline. The valuation impact, as a result, is 
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unaffected by the standardisation process. It can be 
concluded that the effect of the health experience variable 
is sustained, no matter how the scale is varied and 
regardless of the ordinal or cardinal property of the values 
being used. 
2) The measurement process effect. 
The results of the Mann-Whitney U test for the impact of 
the survey method on the valuation for all the three data 
forms are presented in Table 42. The survey method has a 
considerable effect on the cardinal data. The valuation 
differential in ten out of the eighteen health states is of 
statistical significance. 
A possible explanation for the huge difference may be the 
derived impact of the respondents, characteristics differing 
between the two surveys. Table 43 shows that virtually all 
the numerical variables of the personal backgrounds in the 
two surveys are significantly distinctive. 
However, the influences on the ordinal data and on the 
standardised data diminish. The impact on the former exists 
in seven out of the eighteen health states and that on the 
latter appears in f ive out of the fourteen health states. The 
difference in the valuation as well as in other personal 
background variables between the two surveys is highly likely 
to be against pooling the data of the two together. Each 
valuation set may be separately employed in the cost per QALY 
computation. The calculation outcome, which can be found in 
Chapter 5, points out if there is the difference in ranking 
the health programmes by the cost per QALY values based on 
the two different survey methods. 
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Table 42 : The Mann-Whitney test for the effect of the survey 
method in the three data forms. 
Health state original data Rank order data Standardised data 
11111 6.131* 6.796 
11111R 6.604* 7.714* 
11112 0.155 1.031 1.517 
11121 1.629 0.775 2.577* 
11211 7.968* 8.154* 8.054* 
12111 0.561 0.611 1.845 
21111 0.502 0.401 2.173* 
11122 1.890 4.365* 0.523 
21232 2.375* 0.040 0.679 
22233 4.005* 1.259 1.768 
22323 5.444* 1.732 2.639* 
32211 3.743* 1.438 2.402* 
33321 4.712* 0.300 1.891 
33333 2.292* 6.358* 0.455 
33333R 0.808 7.093* 0.290 
uncon 1.969* 9.230* 1.827 
scious 
deathl 0.363 1.633 
death2 0.112 0.065 
Note :* denotes the statistical significance at 0.05. 
250 
Table 43 : The Mann-Whitney test for the difference of some 
characteristics of the samples between the two 
surveys. 
Characteristic 
1. age 
2. education level 
3. individual income level 
4. household income level 
5. health service use 
6. family size 
7. exercise 
8. cigarette smoking 
9. alcohol drinking 
10. current health status 
Mann-Whitney test statistic 
2.102* 
8.605* 
7.525* 
4.670* 
4.392* 
0.363 
5.034* 
2.139* 
3 . 970* 5.921* 
Note :* denotes the statistical significance at 0.05. 
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From Table 44, seven out of the total eleven health 
states exhibit a significant distinction between the feeling 
thermometer and the time trade-off scores. There is no 
obvious immediate explanation for this. It could be that the 
difference arises from the riskiness factor, which is taken 
into account in the time trade-off technique but which is not 
in the feeling thermometer method. Torrance et al (1982) 
adopt this argument in their work when dealing with the data 
available from the category scaling and time trade-off 
methods. An exponential conversion equation is used to 
extrapolate the category scaling values to the time trade-off 
values. Also, it is noted that the parameter of the 
conversion equation (i. e. the exponential value) could vary 
with different populations. The analysis of the value 
difference between the two scaling methods in this study 
could be further pursued along these lines but is beyond the 
scope of this study. 
3.5.2. The findings of the aggregate data analysis. 
Tables 45 - 47 indicate that there are no significant 
personal background factors affecting the valuation in the 
cardinal, ordinal and standardised form in the interview and 
postal surveys when the aggregate unit of the observation is 
employed. This is in contrast to the study by Rosser et al 
(1987), which based on the same unit of the observation find 
the impact of the respondents' health experience, as 
mentioned earlier. 
Similarly, the Mann-Whitney U test shows neither the 
survey method impact nor the scaling technique impact upon 
the aggregate valuation. The two-tailed probabilities of the 
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Table 44 : The Mann-Whitney test 
scaling method based 
thermometer and time 
interview survey. 
for the effect of the 
on the standardised feeling 
trade-off scores in the 
Health state Mann-Whitney test statistic 
11112 4.554* 
11121 5.603* 
11211 6.961* 
12111 6.294* 
21111 3.503* 
11122 10.571* 
21232 0.580 
22233 0.818 
22323 0.321 
32211 4.001* 
33321 1.010 
Note :* denotes the statistical significance at 0.05. 
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Table 45 The Kruskal-Wallis test for the feeling thermometer 
scores in the interview survey based on the 
aggregate unit analysis. 
Variable 
(the number of 
Chi-square statistic 
of the Kruskal-Wallis test 
groups is in 
parentheses) Original Rank order Standardised data data data 
1. age (5) 0.2290 0.0471 0.5522 
2. education level 0.2774 0.0477 0.5154 
(6) 
3. household income 0.4090 0.0082 0.9789 
level (6) 
4. individual income 0.8613 0.0379 1.0273 
level (8) 
5. health service 0.5583 0.0668 0.7807 
use (6) 
6. family size (5) 0.3416 0.0249 1.0673 
7. exercise (2) 0.0363 0.0304 0.0428 
8. cigarette smoking 0.0010 0.0040 0.1352 
(2) 
9. alcohol drinking 0.0000 0.0091 0.0892 
(2) 
10. current health 0.5668 0.0552 1.5409 
status (7) 
ll. health experience 0.2381 0.0013 0.9622 
(4) 
12. occupation (7) 0.1148 0.0199 0.9428 
13. smoking status 0.0652 0.0021 0.2595 
(3) 
14. residential area 0.0162 0.0161 0.1351 
(2) 
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Table 46 The Kruskal-Wallis test for the time trade-off 
scores in the interview survey based on the 
aggregate unit analysis. 
Variable Chi-square statistic 
(the number of of the Kruskal-Wallis test 
groups is in 
parentheses) original Rank order data data 
1. age (5) 1.1635 0.5359 
2. education level 1.4335 0.2569 
(6) 
3. household income 0.9002 0.8484 
level (6) 
4. individual income 1.6586 1.4421 
level (8) 
5. health service 3.3965 0.4904 
use (6) 
6. family size (5) 0.9822 0.6470 
7. exercise (2) -0.3108 0.0939 
8. cigarette smoking -0.2095 0.0047 
(2) 
9. alcohol drinking -0.6797 0.0559 
(2) 
10. current health 1.4758 0.5775 
status (7) 
ll. health experience 1.4692 0.1909 
(4) 
12. occupation (7) 3.7080 0.5472 
13. smoking status 0.0430 0.6058 
(3) 
14. residential area -0.7163 0.1932 
(2) 
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Table 47 The Kruskal-Wallis test for the feeling thermometer 
scores in the postal survey based on the 
aggregate unit analysis. 
Variable 
(the number of 
Chi-square statistic 
of the Kruskal-Wallis test 
groups is in 
parentheses) Original Rank order Standardised 
data data data 
1. age (5) 1.1053 0.0046 1.5249 
2. education level 0.8991 0.1624 2.1517 
(5) 
3. household income 2.4273 0.5219 1.3453 
level (6) 
4. individual income 2.5167 0.2699 2.9171 
level (6) 
5. health service 0.3181 0.0222 3.0027 
use (4) 
6. family size (2) 1.0023 0.0251 0.3570 
7. exercise (2) 0.0000 0.1107 1.1202 
8. cigarette smoking 0.2914 0.0815 0.1036 
(2) 
9. alcohol drinking 0.0010 0.0362 0.0190 
(2) 
10. current health 0.4650 0.1773 1.4917 
status (5) 
ll. health experience 0.7482 0.1514 1.4198 
(4) 
12. occupation (7) 1.4577 0.6606 7.3327 
13. smoking status 0.1389 0.0246 0.7442 
(3) 
14. residential area 0.0023 0.1701 1.3213 
(2) 
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cardinal, ordinal and standardised data tests between the 
interview and postal surveys are 0.5786,0.8366 and 0.8209, 
respectively. The difference between the standardised scores 
from the feeling thermometer scale and the time trade-off 
scores has a two-tailed probability of 0.7655. 
All the insignificant results in the aggregate data 
analysis may be responsible for this by the small number of 
observations available. Since the same number of the groups 
of all the variables are similar in both individual and 
aggregate unit analyses, the crucial factor is the variation 
within the groups. The individual data analysis has 354 and 
162 observations in each group for the interview and postal 
survey analyses. The aggregate counterpart has 18,14 and 11 
observations (i. e. they are the numbers of the health states 
available) for the analyses of the cardinal or ordinal 
feeling thermometer scores, the standardised scores and the 
time trade-off scores. This means that for the interview 
survey, the individual data tests have twenty times, twenty- 
five times and thirty-two times the number of observations 
that the aggregate data tests do for the tests of the 
cardinal (or ordinal) feeling thermometer' scores, the 
standardised scores and the time trade-off scores. For the 
postal survey, the figures are nine times and twelve times 
with respect to the tests of the cardinal (or ordinal) 
feeling thermometer scores and the standardised scores. 
When the values of more health states become available, 
it may be worthwhile undertaking the aggregate unit analysis 
and discovering if the number of observations is the cause of 
the statistical insignificance. 
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3.6. The analysis implications for the issue of whose values 
should count. 
So far the doctors and health administrators have played 
a key role in the Thai public health system and influence the 
decision-making of the health resource allocation. But it is 
clear in this study that their valuation differ from 
patients' and healthy people's. As a result, it is no longer 
appropriate to take into account only the former's viewpoint 
without the latter's. At least, every divided valuation set 
should be considered in the assessment of the health resource 
distribution. 
The pattern of the median valuation disparity can be used 
to explain the value differential between groups. Rosser et 
al (1978) regard the definite pattern of the value 
differentials between the health experience groups in their 
study arises from the subject's health knowledge and 
expertise. Moreover, they speculate the possibility of 
predicting a systematic computation of such differences which 
could be employed to calculate the appropriate set of the 
values in the decision-making process. 
On the contrary, this study has found no groups 
unanimously offer the highest or lowest values in all health 
states. So it may be difficult (or even impossible) to 
systematically estimate the difference of the valuations from 
all the groups and to settle it in order to reach an ideal 
target. The indefinite pattern of the impact certainly does 
indicate that the subject's health knowledge and skill, if 
they exist, are not the only factors responsible for the 
impact. Among the convincing explanations for the health 
experience impact are : that the values are inherently actual 
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preferences, that the measurement process produces a variety 
of understanding health state descriptors deviated from the 
original intention and that the health state instrument 
reflects other views instead of the genuine satisfaction. 
As the ultimate task of the decision-making is based on 
the cost per QALY value as well as ranking of health 
programmes, the different weightings created by various 
health experience groups do not create so much concern as the 
contradictory cost per QALY outcome. For instance, if 
different health experience groups make the conflicting 
priorities of health programmes, the weightings are really 
the problem. Selecting a certain ranking can satisfy some 
groups but not others. The solution may lie in an acceptable 
combination of each group's weighting or in any other value 
judgement rule. On the other hand, if all the groups' 
weightings produce the identical ranking, the diversity of 
the valuation is no longer practically problematic. This 
might be because other factors such as the quantity of life 
and the survival probability dominate the quality of life 
valuation. The influence of the subject's health experience 
on the ranking of the health programmes in this study will be 
investigated in Chapter 5. 
3.7. The analysis implications for the value aggregation 
process. 
Individual subjects have a high degree of the agreement 
on the rankings assigned to the series of the health states, 
which is meaEiýred by the Kendall coefficient of concordance 
The coefficients of the feeling thermometer scores in the 
interview survey, the time trade-off scores and the feeling 
thermometer scores in the postal survey are 0.82,0.55 and 
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0.75, respectively in their original data form. All are 
statistically significant at less than 0.0001. 
on the other hand, when the rank ordering of each 
individual health state is considered, virtually all the 
health states (except for the state 11111 and 11111 repeated) 
have their majority (in terms of case percentage) of the 
health state ranks less than 20 %, as shown in Tables 25-27. 
The Kendall coefficient of concordance test applied to 
the health state series indicates the coefficients of the 
transformed feeling thermometer scores, the time trade-off 
scores in the interview survey and the feeling thermometer 
scores in the postal survey are 0.78,0.55 and 0.74, 
respectively. All have the probability of less than 0.0001. 
These two pieces of information could mean that although 
most respondents have a similar pattern of ranking the health 
states, the ranks of individual health states disperse. The 
difficulty in aggregating the health state ranks remains. 
That the analysis, based on the individual observation 
unit finding some impacts on the valuation, is contrary to 
that based on the aggregate counterpart detecting none, may 
mean that the variation in the individuals might affect the 
valuation outcome and could be omifted by bypassing the 
individual values and going on adopting the aggregate values. 
Using the aggregate values without understanding their 
individual values in an economic evaluation study might 
produce false conclusions. Hence, it is better to analyse the 
individual valuation first before proceeding to the value 
aggregation procedure. 
260 
The statistical tests for the cardinal and standardised 
forms of the feeling thermometer scores in the two surveys, 
as well as for the time trade-off scores, reject the normal 
distribution. Therefore, an aggregation rule selected has to 
be conform to non-parametric statistical techniques. In this 
study, the median values are chosen to be the aggregate 
values. They have also been used in the analysis of the 
impact on the valuation in other studies. When the 
distribution of the responses to current individual health 
dimensions in the NHP is skewed, Kind et al (1991) use the 
median as a measure of central tendency. ý 
The value aggregation issue could induce the following 
two actions in cost utility analysis. 
1. A conflict in the different aggregation procedure used 
across levels (e. g. national, regional, provincial, 
operational and routine programmes) can occur and cause the 
waste of allotted health resources. For example, suppose that 
the resources for a health intervention concerning the health 
states with multiple problems (in the economic evaluation of 
which the aggregation process is based on the valuation of 
the patients involved) are allocated from the national 
budget. (Their weightings presumably are the highest of all 
the groups considered. ) If the health personnel, who control 
and deliver the resources, should use their own (lower) 
weightings, the benefit to the patients could be reduced and 
this would impose the resource wastes, since some of the 
available resources that are supposed to be utilised are left 
idle. To avoid such an event, a consistency in the value 
aggregation structure across levels has to be ensured. There 
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is an increase in the call for the economic assessment in 
operational level based on a compatible manner with other 
levels. There is evidence that health authorities in the UK 
are encouraged to carry out their own economic evaluation 
studies for their responsible populations (Donaldson et al, 
1991). 
2. The impact of the alternative valuation sets on the 
cost per QALY result should be tested (perhaps in the 
sensitivity analysis section), as the value aggregation 
procedure in the analysis is regarded as controversial. 
3.8. Conclusion and some implications for the health state 
measurement. 
There are at least four conclusions from the analysis of 
the Thai valuation and implications for the health state 
measurement. First, because of the different degrees of the 
interpersonal comparisons, the effects of the two variables 
diminish but that of the other one increases. The impact of 
the subject's health experience becomes more obvious, in the 
standardisation process, only in the interview survey whereas 
those of the subject Is income, household income and education 
variables decline. 
The range of the highest value dif f erence can classify 
the health states into two parts. According to the 
standardised values, the health states with one-moderate 
problem have a small range. They range, on average, between 
16-50%. On the other hand, those with multiple problems 
possess a big range, between 46-200 %. This is consistent 
with the findings of the study by Rosser et al (1978). They 
report that the variance increases with the severity of the 
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health states (magnitudes) for all the subjects and for each 
of the six groups of the subjects separately. 
It can be learnt that health resources are likely to be 
misallocated in the programmes involving a large number of 
people with sharply different health experience. It would be 
the case in the programmes dealing with many health dimension 
problems. This is because all groups, satisfaction about the 
quality of life in the programmes they provide or use are not 
met. 
Secondly, the health state valuation in the economic 
appraisal derived f rom the results of other valuation studies 
is required to check not only a disparity of the values 
between distinct groups but also the unit of the analysis it 
is based on. 
Thirdly, the findings that the bronchitis (non-severe 
disease) and cancer (fatal illness) patients' valuations are 
not significantly different suggest that the differing 
severity degrees of the patients do not affect their 
valuations. The valuations of more types of patients should 
be tested and substantiate the argument. 
Fourthly, as an application of the contradictory results 
of the analyses based on the aggregate and individual 
valuations to the real world, the information from 
individuals (or samples) affected by health programmes 
(measured by preferences over the health states concerned) 
could reflect their views more realistically, and perhaps 
uncompromisingly, than that from their representatives (e. g. 
politicians) who usually use the collective information 
derived from a majority of the people. 
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Chapter 4 
The parameter identification, measurement and estimation 
The very first step preceding the data collection process 
of the economic appraisal of any health programme is to 
identify all the parameters involved. Then comes the 
measurement of the defined parameters. Rules for valuing 
these parameters should be adopted before the data 
compilation commences. After the conduct of the data survey, 
the data gathered are ready for the computation process. 
This chapter elaborates identification, measurement and 
estimation of all the parameters needed in the cost-utility 
analysis, apart from the quality of life valuation, which has 
been done in Chapter Two. They are the health programme 
effects, side effects, costs, financial parameters and 
population parameter. Also, the issue of discounting health 
care programmes is discussed. The estimations of the health 
programme effects, side effects and costs are compiled for 
each health programme from the international and Thai 
studies. The clinical features of the diseases involved and 
the side effects of the health programmes are converted into 
the correspondent EuroQol health states and the QALY losses 
with the aid of the health state values from the survey and 
approximation. The QALY loss data, the important output of 
this chapter, and the cost data are the crucial inputs for 
the computation of the cost per QALY of the health programmes 
in this study. 
4.1. The parameter identification and measurement. 
This section discusses the identification and measurement 
concepts of the effects of the health programmes, their side 
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effects and the costs as well as the transformation of the 
two effects into health states and QALY- Also provided are 
the financial and population figures relevant to the 
calculation later on. The choice of the population data does 
not affect the main results. The impact on the cost per QALY 
result of discount rate, one of the most crucial financial 
parameters in the economic appraisal, will be tested in the 
next chapter. As the comparability of every key element of 
all the programmes analysed is central to the comparability 
of the results obtained, applying identical identification 
criteria and similar measurement methods for each parameter 
to all the programmes could secure the comparable outcomes. 
4.1.1. The effect identification and measurement. 
From the viewpoint of public health, the prevention of or 
reduction in the number of cases and deaths from any disease 
is the effect of health programmes. Such an aspect is also 
regarded as the outcome of health programmes in the economic 
assessment as well. Equally important, each diseased case and 
death carries some impaired health conditions. As a result, 
the effect of any health intervention can be classified into 
the quantitative and qualitative effects. The measurement of 
the two categories are done in two medical branches. First, 
the volume of cases and deaths saved by any health 
intervention may be estimated in an epidemiological trial. 
Secondly, a case's and a death's average ill-health 
conditions averted can be determined mainly by medical and 
clinical studies. In some studies of health interventions, 
these two effects are assessed together but most studies 
focus on one or the other. This subsection discusses some key 
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epidemiological concepts underlying the measurement of the 
quantitative effects relevant to the health programmes in 
this study. 
There are in general two concepts of the measurement of 
the health outcome : efficacy and effectiveness. They differ 
in the environment of the measurement. The efficacy is 
referred to as the measurement of effect in a controlled 
situation whereas the effectiveness is a real condition. 
The underlying concept of the efficacy is that the effect 
of a health intervention can be assessed from the difference 
of incidence rate between the health intervention recipient 
group and the control group (e. g. non-recipient group or 
other related health intervention recipient group). The 
effectiveness, based on the same procedure as the efficacy, 
evaluates the potential size of the population or the 
probability of treatment success (in the case of curative 
care) benefiting from a health intervention. Vaccination is 
used to exemplify the two concepts. For the TB treatment 
(also other health interventions), they can be acquired by 
simply replacing vaccinated and unvaccinated groups by health 
intervention recipient and control groups. 
In measuring the vaccine effect, the following is the 
standard formula for the effect computation used in most 
studies. 
Vaccine Incidence rate in - Incidence rate in 
efficacy unvaccinated qroup vaccinated qroup 
Incidence rate in unvaccinated group 
Recently, this standard measurement method has been 
challenged. Smith et al (1984) categorise the vaccine 
efficacy measures in accordance with two modes of the 
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vaccination action. First, it is supposed that the 
vaccination reduces the probability of contracting a disease 
in all vaccinees. This model, similar to the traditional 
concept of the vaccine response, results in the standard 
measurement method for the vaccine efficacy. Secondly, it is 
assumed that a vaccination can protect a proportion of the 
vaccinated group completely from a disease. The efficacy in 
this model is influenced by the disease duration. For BCG 
vaccination, it is claimed that the discrepancy of the two 
alternative estimates is small (Smith et al, 1984). 
Greenland et al (1988) advocate to use the conventional 
measurement method for the vaccine efficacy rather than the 
other by offering two reasons. First, the method retains its 
caseload reduction interpretation regardless of the need for 
additional analysis involving the delay of the disease onset. 
Secondly, despite the rival method possessing the combined 
measure of the caseload reduction and the onset delay, 
further assumptions are required to enable to make the 
economic evaluation of a vaccination programme possible. For 
instance, it is said that the competing approach cannot offer 
the amount of "healthy time" saved by BCG vaccination. In 
short, there is no significant gain in employing the 
alternative method from the point of view of programme 
evaluation. 
Since in this analysis, the diseases controlled by the 
vaccines have short lives, the results from the alternative 
measurement of the vaccine effect would not significantly 
differ from those from the conventional one. 
The effectiveness estimation shares the same computation 
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formula as the efficacy estimation except for the two 
experimental groups being replaced by the two correspondent 
groups in a real community. On the top of that, the 
effectiveness estimate of a vaccination programme could be 
computed from the data from a trial for vaccine efficacy. 
Here are two ways of the derivation of the effectiveness 
estimate involving the vaccine efficacy and incidence rate of 
vaccinated population. 
1) A direct rearrangement of the vaccine efficacy 
formula. 
Provided that the incidence of the unvaccinated 
population is known, the efficacy estimate can point out the 
incidence rate of these people saved from a disease by the 
vaccination. The total number of the protected cases from the 
application of the vaccination to a population would be 
Vaccine x the incidence rate x the number of unvaccinated 
efficacy in the unvaccinated people vaccinated by the 
people vaccination programme. 
According to the estimation formula for the vaccine 
efficacy, the incidence rate in the unvaccinated population 
can be expressed as follows. 
Vaccine Incidence rate in vaccinated group 
efficacy Incidence rate in unvaccinated group 
Incidence rate in vaccinated qroulo Vaccine 
Incidence rate in unvaccinated group efficacy 
Incidence rate in Incidence rate in vaccinated group 
unvaccinated group (1- Vaccine efficacy) 
on substitution of the incidence rate in the unvaccinated 
population in the equation above, the effectiveness of the 
prograiTme in terms of the total number of cases saved is 
expressed in the following equation. 
268 
Effectiveness Vaccine efficacy x Incidence rate in 
of the programme (1 - Vaccine efficacy) vaccinated group 
x the vaccinated population 
2) An extrapolation from the vaccine efficacy. 
Let suppose 1) the vaccine efficacy = a% 
and 2) the incidence rate in the vaccinated 
population = b. 
So the failure of the vaccine is 100% - a%. 
Since the failure of (100% - a%) is responsible for b, 
the effect of a% offers the protection of bx a% 
(100%-a%). 
That is, the vaccine could avert among the vaccinated 
population the incidence rate of 
vaccine efficacy x Incidence rate in 
(1 - Vaccine efficacy) vaccinated group 
The effectiveness in terms of the absolute reduction in 
the incidence is to multiply this equation by the vaccinated 
population of the programme. 
Effectiveness Vaccine efficacy x Incidence rate in 
(1 - Vaccine efficacy) vaccinated group 
x the vaccinated population 
Vaccine trials are important to provide the estimates for 
the vaccine efficacy and the incidence in the vaccinated 
population in computing the effectiveness. This estimation 
approach is compatible with those used by the Research 
Committee of the British Thoracic and Tuberculosis 
Association (1975), by Hart (1967) and by Hart et al (1977). 
The latter two studies have an additional parameter, namely 
the proportion of those eligible for vaccination in the 
programme. 
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There are many measurement approaches for the efficacy 
and effectiveness of health programmes. A randomised 
controlled trial is considered as the best measurement 
method. It minimises confounding impacts and biases 
interfering in the investigation of the effect so that the 
findings are reliable. However, its main problem is the 
ethical issue against the trial since in many occasions, 
subjects I health services, which can approvingly relief their 
suffering from illness, in the trial have to be withheld. 
Miller (1984) points out other two issues hampering such a 
trial, in particular the production of new vaccines. First, 
there is the need for a large number of participants in a 
trial and for substantially financial support. Secondly, a 
rise in public concern about the adverse reactions of health 
interventions reduces the number of available volunteers and 
may further provoke its ethical aspect. There are also 
logistics problems. 
Fortunately, the efficacy and effectiveness of most 
health programmes selected for this study have been 
investigated by some randomised controlled trials or its 
modified methods, which are designed to avoid the 
difficulties encountered in such a trial and to maintain the 
reliability of outcomes, despite there being a small number 
of such studies available for some programmes. Therefore, 
because of their reliable results, the trials and modified 
studies are the only' sources of the ef f icacy and 
effectiveness data used in this analysis. 
Learning other efficacy and effectiveness measurement 
methods is useful for a comparison of the estimates in 
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various economic evaluation studies of the same health 
programmes and for evaluating the results from various 
measurement methods available, and for selecting the most 
appropriate ones. The other important object of providing a 
variety of the measurement methods in this study is to widen 
the perspective about the estimations. As the ethical issue 
of testing a health intervention has been gaining more 
consideration, alternative measurement methods to the 
experimental trials may be appropriate in future studies. In 
addition, since there are many economic appraisal studies 
based on different measurement methods, they would be used to 
account for the differences of the results. 
The effectiveness could be measured by the number of 
cases and deaths from a disease before and after introduction 
of a health programme. For instance, the differential in the 
incidence rates between the pre- and Dost- Dertussis 
immunisation in England and Wales is used to estimate the 
vaccination effect (Creese, 1983). However, this method 
produces very crude findings and possibly spurious effects. 
Epidemiological models are increasingly employed to 
create a dual condition of the existence and non-existence of 
a health programme. Mathematical models are also built to 
simulate the effect estimates under various assumed 
situations. 
Creese (1983) claims that the following formula is 
popular in computing the effect of vaccination programmes. 
Li =jNiAi (Doi - Di 
i 
where Li lives saved in age group i. 
Ni number of fully immunised in age group i. 
Ai disease and age-specific attack rate. 
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Doi disease and age-specific mortality rate 
without immunisation. 
Di disease and age-specific mortality rate 
with immunisation. 
However, it is difficult to define exactly the condition 
without immunisation under the presence of an immunisation 
programme, let alone the measurement of incidence and death 
rates in the unrealistic condition. And this argument is also 
applied to the opposite situation. 
Haber et al (1991) combines the concept of the two-state 
scenario method with the standard estimation method for the 
vaccine efficacy. As a result, in addition to the vaccinated 
and unvaccinated populations, as in the usual vaccine 
efficacy measurement, the control population emerges. The 
latter is defined as the population that would behave exactly 
in the same way as the two former populations if no 
vaccination programme were undertaken. They also provide four 
equations for estimating the effectiveness of a vaccination 
programme. 
1) Direct effectiveness I- AR Q. =V ARu 
2) Indirect effectiveness 1- AR ==U ARc 
3) Total effectiveness 1- LR, 
ARc 
4) Average effectiveness 1- AR Z. =ýO ARc 
where AR, the attack rate in vaccinated population. 
ARu the attack rate in unvaccinated 
population. 
ARc the expected attack rate in control 
population. 
ARO [ (1-f) x AM + (f x ARJ 
f is a fraction of the study population 
with vaccination. 
The direct effectiveness measures an individual's gain 
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from a vaccination acquisition. The indirect effectiveness 
represents the benefit of the unvaccinated people from the 
vaccination of vaccinees. The total effectiveness is the sum 
of vaccinees, both direct and indirect protection conferred 
by a vaccination programme. The average effectiveness shows 
the combined effect of the protection in both vaccinated and 
unvaccinated populations. 
Despite the difficulty in observing and estimating the 
behaviour of a control population, it is claimed that the 
estimates based on these effectiveness concepts can be 
obtained from the data of a study population alone. However, 
no practically illustrated example was provided in their 
study to support this argument. 
The effectiveness measurement in terms of absolute 
reduction (i. e. the number of cases and deaths saved by a 
health programme) is the most desirable since it is 
independent of the usually unreliable public health data. On 
the other hand, the effectiveness in the form of a relative 
(percentage) reduction in (current) incidence and deaths f rom 
a disease can result in an underestimated number of the cases 
and deaths due to under-reporting of the disease. As 
randomised controlled trials normally offer the effectiveness 
estimates in terms of the number of cases and deaths 
prevented (absolute reduction), this adds to the support for 
using their findings. 
Moreover, the use of the controlled trial result is 
implicitly informed of the established evidence of a health 
programme's effectiveness, which is one of the recommended 
checklists for the economic assessment of health programmes 
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(Drummond et al, 1987). 
4.1.2. The side effect identification and measurement. 
Different health interventions are likely to produce 
unique side effects. Most adverse reactions could be measured 
in clinical trials and monitored by a surveillance system. 
Most vaccinations commonly create two main categories of 
adverse reactions to vaccines. 
1) All vaccinations cause local reactions, including 
pain, fever, discomfort, redness and swelling at injection 
site. These reactions hardly affect other areas of the body. 
The impacts could occur in few vaccinees or in a considerable 
proportion of them. However, such impacts do not last long. 
2) Systemic reactions affect one or more areas of 
vaccinees I body or organs. They are usually severe, long- 
lasting and even fatal, but are infrequent. Normally, each 
vaccination programme has specific systemic reactions. 
Normally, their impact on a vaccinated population can be 
assessed by longitudinal follow-ups. 
The detection of side effects of a pre-marketing vaccine 
is usually performed in the same clinical trial which 
determines the vaccine ef f icacy. in f act, such a trial is 
normally focused on one or the other activity (Office of 
Technology Assessment, 1979) . Also, they criticise randomised 
controlled trials for being insufficient to examine all 
likely adverse reactions. The reactions that rarely occur and 
that have delayed onset are most likely to be omitted. Though 
a surveillance network for these reactions is set up, the 
actual extent of them is still disguised by an incomplete 
monitoring system and the under-reporting of cases with such 
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reactions. 
one estimation method for the side effects, magnitude is 
based on the difference between the incidence of the 
reactions within the duration of side-effect risk (e. g. 10 
weeks after immunisation) and that in the pre-vaccination 
period during the same interval (Office of Technology 
Assessment, 1979). 
It is common that a wide variety of local and systemic 
reactions from vaccinations are reported. The variation is 
influenced by the method of identifying the suspected 
reactions, observation frequency, subjective reactions of the 
sufferers, periods of investigation and investigators, 
judgement (Office of Technology Assessment, 1979). A caution 
about relying on foreign findings of side effects of new 
vaccines is noted by the Office of Technology Assessment 
(1979). Differences in the type and volume of side effects 
found between subjects in foreign countries and those in 
domestic ones could stem from a difference in the perception 
of reactions, in the ability or willingness to identify them 
and in false reactions within foreign populations. 
Therefore, an incorporation of side-effect results from 
various sources could minimise the chance of excluding likely 
reactions and include true volumes in this analysis. 
4.1.3. The transformation of health effects and side effects 
into health states and QALY. 
As mentioned before, one Is impaired health avoided due to 
a health intervention -can be realised by medical and clinical 
assessments, in most instances. The key problem which remains 
is that there are differences in the severity of cases 
prevented by all health programmes. A variety of severity 
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categories, therefore, need to be converted into a common 
system of health states, the present concept of identifying 
health at the practical level. By giving each of the health 
states involved a proper value, the effect of a health 
programme can be turned into gains in health states. 
Ultimately, the effect of every health programme can be 
assessed in the same form as the gains in health states. 
Unfortunately, current medical studies do not allow us to 
use its knowledge to directly estimate the improvement in 
health states. Alternative measurement methods for health 
state gain have to be sought. Suppose that there exists a set 
of health states representing all conditions, there are two 
simple approaches to the health state assignment for all 
relevant conditions. The first is direct observation of the 
difference in health states of people undergoing a health 
programme and those suffering from the correspondent disease- 
However, this strategy may be unjustified on the grounds of 
cost-effectiveness. The second is the transformation of the 
measured health status data available into the health state 
classification being used. 
According to Williams (1988a), there are three steps for 
transformation. The first is to search for studies having 
quality of life finding for the health intervention under 
analysis. The second is to investigate the extent of the 
correspondence between the quality of life classification 
systems in the sources and the one under consideration and 
select the most appropriate one. Last, some criteria are 
needed to relate the original outcome and derived one. 
Williams (1985) employed some experts of heart diseases 
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to provide their personal judgements about the equivalent 
health states under the Rosser Index to the conditions of the 
patients involving with various health interventions. The 
transformation of health status measurement results available 
in some studies into the Rosser Index for other health 
interventions was attempted by Gudex (1986), Gudex et al 
(1988) and Williams (1988b). They all used their own 
conversion rules. 
Since health status measurements for the health 
programmes analysed here are unavailable in any clinical 
trials and medical literature, the first alternative solution 
is to elicit some experts, opinions, in accordance with the 
EuroQol health state classification, on the prognosis and 
complications of the diseases, as well as on the side effects 
of health programmes. The questionnaire presented in Appendix 
III was sent to four major institutions in the United Kingdom 
and Thailand. No reply was returned. It is possible that the 
experts chosen are unlikely to be willing to publicly give 
their opinions about the diseases and health 
programmes, though the returned questionnaire is supposed to 
be anonymous and the sources of this information are not 
disclosed. 
Symptoms, signs and clinical findings concerning diseases 
and health programmes are the only established health 
indications from which the converted EuroQol health states 
can be acquired. These fundamental elements of the health 
impact of almost all diseases and health interventions are 
reliably available in standard medical textbooks as well as 
in research works and case-study reports in medical journals. 
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The advantages of this method are the comparability of the 
clinical conditions collected within common sources or 
identified by similar standard procedures, and the ease of 
access to the information. This is the best option left for 
this analysis. 
Since for most diseases, health interventions could offer 
small important benefit in terms of symptom, function and 
prognosis improvements (Fletcher et al, 1992), this 
transformation method based on symptoms, signs and prognosis 
directly links key health effects to health states. In 
addition, Rosser (1988) suggests from the study result that 
the inclusion of prognosis could be important in output 
measurement. 
However, all the health output measurement methods 
mentioned above are open to criticism. The transformation 
process, either by experts or from reliable studies and 
sources, involves subjective opinions and is unscientific. 
The severity of these drawbacks depends on the influence of 
the quality of life weightings upon the result of the cost 
per QALY gained. For example, if the cost per QALY result is 
sensitive to the difference in health state measurements, 
there will be extreme difficulty in selecting the most 
appropriate measurement method and findings as well as the 
right cost per QALY result accordingly. 
Relying on other quality of life data could encounter the 
problem of an arbitrary weighting system for each health 
dimension or item. This may not be appropriate or desirable 
in the recipient study. The work by Gudex (1986) refers to a 
study using equal weights for all health dimensions and 
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another employing different weights to highlight uneven 
importance between health dimensions. 01 Brien (1988) points 
out that some measurement results implicitly assume an 
interval or ration scale, which has no grounds for support. 
Different sources for the quality of life transformation 
could lead to distinctive converted outcomes for same health 
intervention. Gudex (1986) reports that, not only the 
reclassified Rosser Index scores for home and hospital 
haemodialysis, but also the number of the patients in the 
same health states differ between two study sources. 01 Brien 
(1988) claims that in a study of heart transplantation, there 
is a gap in the quality of life measurement result of post- 
transplant function between the clinical judgement by the 
doctors and the self-assessment by the patients, though the 
discrepancy may arise from using two distinctive measurement 
indices (e. g. Sickness Impact Profile and Karnofsky Index). 
Some issues and likely problems in the transformation 
method used in this analysis are discussed here. It is true 
that a disease is not equally serious to everyone who 
contracts it. Based on medical publications, which normally 
describe average degrees of severity in most diseased 
persons, it is assumed that every case prevented by a health 
programme has equal gains in health states and so does every 
death avoided. The severity faced by people infected with 
vaccine-preventable diseases who have malnutrition, live in 
poor conditions and behave unhygienically is likely to be 
worse than the seriousness in ones who do not. However, the 
marginal loss of the former group or the additional gain from 
a vaccination programme for them is rarely known precisely. 
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As a result, an average gain is supposed to be obtained 
equally by everyone with a successful immunisation. 
That health benefits do not equally belong to each 
recipient can also be seen from other health interventions. 
Gudex (1986) finds that additional patients in an end-stage 
renal failure treatment programme would acquire shorter 
survival periods than would the average ones due to its 
expanded scale. 
As perfect health presumably belongs to protected 
vaccinees or successfully cured TB patients, the health gain 
is normally the sum of all the differences between perfect 
health state and possible non-healthy states. It is also 
assumed that they have an average life expectancy. 
However, to the best knowledge of the author, there is no 
study that covers a life-time span to prove this is the case. 
Too-short study times for most health interventions are one 
of the drawbacks of precise survival estimation. Normand 
(1991) comments that the quality of life-expectancy 
enhancement data for health interventions is frequently 
unsatisfactory. Another, noted by Gudex (1986), is that some 
patient characteristics like age, illness severity level, co- 
existence of other medical conditions and the pathology 
concerned could influence survival periods. 
The information loss arising from the transformation 
could cause concern. Williams (1988a) comments with respect 
to the Rosser Index that there is excessive information on 
some aspects but inadequate information on others from source 
data. He also notes that some transformation methods omit 
information from deaths and the very sick, incapable of 
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responding. These exclusions need to be allowed for in the 
derived outcome. The insufficient data from a source study 
about a shoulder joint replacement programme in the analysis 
by Gudex (1986) resulted in the assignment of the pre- 
operative condition of all patients to a combination of 
levels IV and V (disability) and C and D (distress) in the 
Rosser Index. 
Inadequate information from source data can be tackled by 
making some assumptions. In an article by Williams (1988a), 
the lack in the detailed information of each end-stage renal 
failure patient's both disability and distress dimensions 
f rom a source study led to asserting an assumption about the 
number of them in each health state. Using an appropriate 
reason to underlie such an assumption, for example that 
patients with more disability tend to be more depressed, 
would make it convincing. The result from time-series studies 
in some cases has to be represented by that from cross- 
sectional ones due to the limited time scale of the former 
studies. 
The discrepancy between source and derived data casts 
doubt over the validity and reliability of the transformed 
result compared with the quality of life outcome measured 
directly. 
An attempt to translate the York health measurement 
questionnaire into the Rosser Index by Gudex et al (1988) is 
criticised by Carr-Hill et al (1991). The criticisms focus on 
the origin, reliability and validity of the items and 
contents in the questionnaire. Like most health status 
indices, it needs standard tests to be acceptable. No grounds 
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were provided for the justification of the conversion rule. 
one of its obvious flaws is that different disability degrees 
in the York questionnaire can fall into the same disability 
level of the Rosser Index. The converted quality of life 
findings based on the Rosser Index are likely to omit the 
variation in various health dimensions that exist in the 
original one. Carr-Hill (1992) demonstrates that a person 
with extreme problems in a health dimension alone in the York 
questionnaire may be classified by the Rosser Index to be 
more severe than another person with modest problems in all 
13 health dimensions. 
According to Gudex et al (1991), it is shown that the 
transformed Rosser scores from the York questionnaire have a 
significant positive correlation with the scores based on the 
Nottingham Health Profile and general health questionnaire. 
Subjects with different health experience rated significantly 
different Rosser scores. 
Following the conversion process, the values from the 
surveyed valuation set available in Chapter Two are assigned 
to the health states involved. Since the set is inadequate to 
offer all the health states, it is necessary to estimate the 
values for some unmeasured health states. In the study by the 
office of Technology Assessment (1979), a very limited number 
of health state values available forces analysts to use the 
small number of health states. Only four values for 
approximating the health status of the patients with 
pneumococcal diseases were employed. A year of full 
functioning was given the weighting of 1.0; a year of non-bed 
disability, 0.6; a year of bed disability, 0.4; and a year of 
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death, 0. 
4.1.4. Cost identification and measurement. 
The cost of a health programme can be divided into three 
categories. First, the public cost is financed directly by 
the government, the revenue of which comes mainly from 
taxation. Secondly, the private cost is paid in various forms 
by health service recipients. It can be further divided into 
direct cost such as out-of-pocket payment for drugs and 
travelling expenses and indirect cost such as loss of 
earnings. The social cost concerns the real resource 
consumption by a health programme regardless of who pays. 
The Thai government is the main provider of immunisations 
against measles and tuberculosis. Also, its health 
institutions give a substantially large proportion of TB 
treatments. It makes preventive and curative care against the 
diseases available and accessible. Health policy and 
implementation of these health programmes are completely 
under government control. Therefore, using the government 
viewpoint to investigate the cost-effectiveness of these 
programmes is justified as far as health policy and 
implementation are concerned. 
Value judgement is involved in the selection of the 
analysis framework. The private cost takes into account the 
current income distribution. For instance, a health care 
recipient with high income has a greater indirect cost or is 
more willing to pay for health services, if any, than one 
with lower income. By contrast, the government cost does not 
take into account the current income distribution. Cost 
incurred to lower income earners and that to higher income 
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earners are valued equally. 
The argument for covering the government cost exclusively 
by public health resource allocation, as Drummond et al 
(1987) point out, is that health policy should not be 
concerned with changes in the productivity of individuals. 
Although, like many other issues involving value judgement, 
the debate over who should pay for in the economic evaluation 
of public health programmes may at present be unresolvable. 
Differences in costing viewpoint can lead to a different 
course of decision-making. The outcome derived from the 
private cost would describe an individual's optimum 
allocation of resources between health programmes (and even 
between various health and non-health activities) to produce 
his own health. On the contrary, the result based on the 
government cost prescribes the appropriate decisions about 
the public health resource distribution between the health 
programmes in promoting public health. 
Data collection poses a practical difficulty in the use 
of the private point of view. The patient's cost data could 
be gathered with many obstacles. Unlike the government Is 
costing data that are routinely compiled by responsible 
agencies and analysed and reported by researchers, they are 
not publicly available. Hence primary data compilation is 
necessary. As it is impossible to acquire data from all 
health service recipients, further questions are, what size 
of sample and how to select subjects so as to obtain a 
representative sample. 
Provided that the principal viewpoint is identified and 
other viewpoints are recognised, as Drummond et al (1987) 
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concede, the obstacles preventing the analysis from embracing 
alternative point of view (e. g. an excessive effort needed to 
obtain data) could be reasonably sufficient for it to produce 
findings in accordance with the prime point of view. 
The analyses based on private and social viewpoints are 
undertaken in Chapter 7. The cost-effectiveness ranking of 
the health programmes is examined based on these alternative 
viewpoints. 
In the empirical analysis of health programmes, average 
cost (or a unit cost) is often used and is useful for the 
performance comparison purpose (Jacobs, 1980). Moreover, its 
advantages are the availability of the required data and the 
simple computation method. Technically, the average cost is 
simply the ratio of total cost to output quantity. 
Usually, the average cost is assessed with regard to 
differing levels of a production or to a different production 
process of the same product. For the former case, traditional 
economic analysis describes the average cost curve in the 
form of a U-shape. At the beginning of the production 
processf the producer can enjoy increasing marginal 
productivity of variable factors, which is responsible for a 
decline in the average cost, followed by a constant average 
cost owing to the increase offset by the decrease in marginal 
productivity. Finally, the fall in marginal productivity 
becomes dominant and thereby the average cost rises 
(Koutsoyiannis, 1982). 
In order to make the comparison in the latter case 
meaningful, it is necessary to control for factors which vary 
between processes such as fixed input volume, quality of the 
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production and technology used. It is often found that 
producers worked on different cost curves (Jacobs, 1980). 
However, this measurement cannot provide information on 
the expansion or reduction in the size of a health programme 
(Jacobs, 1980), and neither can the analysis based on total 
cost. In other words, they cannot indicate the appropriate 
scale of service provision. 
marginal cost, which is defined as additional cost for an 
extra unit of output and whose curve is U-shaped according to 
traditional economic theory, can suggest the optimum scale. 
Warner et al (1982) argue that marginal cost is of importance 
and relevance to decision-making about health service 
programmes. Most of the operational health policies involve 
the issue of whether the existing volume of a health service 
currently provided should be increased or decreased. 
The optimum allocation of resources to various health 
programmes can be achieved as a result of shifting resources 
between programmes with the excess of the marginal cost over 
the marginal benef it and programmes with the net marginal 
benefit. Fewer resources removed from the former type of 
programme could make them more efficient. More resources 
invested in the latter type could generate a similar result. 
The optimum of the efficient resource use achieves by 
equalising the cost and benefit at the margin. The 
divisibility of health resources is a key assumption that 
makes this possible. 
There is a relationship between average cost and marginal 
cost (Koutsoyiannis, 1982) . As marginal cost is less than 
average cost, average cost decreases. This is because an 
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additional unit of production incurs lower costs. At the 
point where marginal cost equals average cost, average cost 
neither declines or increases. Also, this is the minimum 
average cost. Af ter this point, marginal cost exceeds average 
cost and average cost rises since an extra unit attracts 
more-than-average cost. 
This relationship can be summed up as follows. When 
marginal cost is less than average cost, average cost falls. 
But as marginal cost exceeds average cost, average cost 
rises. The equivalence of the two (i. e. their intersection) 
indicates the minimum level of average cost. 
The vaccination delivery strategy could govern the 
divergence between the average and marginal costs of 
programmes. If a vaccination programme is set up separately 
from other vaccine's delivery or from other service 
provision, the two costs are likely to be substantially 
different due to the fixed cost. By contrast, the addition of 
a vaccination delivery to other vaccination or to other 
health service arrangement could save most fixed inputs. It 
would incur only the recurrent cost for that vaccination. 
Therefore, the average cost and marginal cost could be 
similar. 
The common problem in the cost data issue in health care 
programme economic evaluation is that only the average cost 
is available but the marginal cost is needed. Warner et al 
(1982) claim that in many analyses the two types of cost were 
not distinguished. The unjustifiable use of the average cost 
in place of the marginal cost have serious consequences. The 
wrong forecast would be made about the optimum scale of a 
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health programme and the resource requirement. However, such 
an approximation is popular in economic assessments (Warner 
et al, 1982). For example, Tubman et al (1990) claim that the 
discrepancy between average and marginal costs of surfactant 
replacement treatment for severe neonatal respiratory 
distress syndrome is insignificant because the greatest 
proportion of the cost is for staff and additional outputs 
vary directly with extra staff. 
The assumption of marginal cost identical to average 
cost, as made in this analysis, has implications according to 
the theory of cost. The production processes of the health 
programmes are presumably in an optimum condition. That is, 
they operate at the least average cost level. The programmes 
employ the most appropriate combination of fixed and variable 
factors. 
Drummond et al (1987) mention some drawbacks of the 
calculation of the per them or average cost of a health 
programme. The average cost can be accurately applied to an 
average health care recipient. If a recipient needs more or 
less than the average service, for instance longer duration 
of hospital stay or more diagnostic tests, then there will be 
a discrepancy in the analysis finding based on the 
measurement. Some studies do not cover all health services 
provided at the institution under consideration. As a result, 
the average cost of other services excluded cannot be 
represented by the estimated average cost. Capital and fixed 
costs are likely to be disregarded in the calculation in some 
analyses. This would result in an underestimated average 
cost. 
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Warner et al (1982) advise against relying on an 
accounting approach to computing costs, which is actually a 
common practice. The economic concept of cost focuses on the 
opportunity cost of resource whereas the accounting method 
includes only explicit expenditures. The cost from the two 
sources could differ. For instance, volunteer's time has an 
economic cost but not an accounting cost. The transfer 
payment such as insurance compensation to the sick has no 
economic cost but has an accounting cost. 
These points should be taken into account in assessing 
the suitability of the application of the cost data including 
marginal cost data from other studies to one's own economic 
evaluation analysis. 
One of the issues in health programme cost estimation is 
joint production. This is when a production process can 
produce multiple health services. For example, a hospital can 
operate many different health programmes like immunisations, 
TB treatment, general medicine, surgery, dental services and 
so on. It is not sensible to estimate the cost of one service 
based on all the costs attributable to the inputs involving 
that service. Therefore, only the proportion of those inputs 
concerned should be singled out and incorporated in the 
estimation. The cost arising from this sort of input is also 
termed shared cost or overhead (Drummond et al, 1987). For 
instance, the costs of hospital administration and hospital 
space for immunisation programmes should be separated from 
those for other programmes. 
The problem of overhead costing has not been tackled 
satisfactorily (Warner et al, 1982). The same authors, 
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however, believe that there are some accounting procedures 
available for practically cost partition despite the 
arbitrary pattern. 
The difficulty of cost partition may depend on the size 
of the health programme under consideration relative to the 
total activities in a health institution. For example, if 
immunisations play a key role in a health centre where a 
minimum number of basic health services are provided, there 
may be no serious problem in costing. By contrast, it might 
be a significant problem to cost the same vaccinations in 
hospitals, which usually command a small proportion of 
resources. The TB treatment is similar. A TB treatment centre 
could offer more precise costing data for treating TB 
patients than a general hospital. 
Drummond et al (1987) describe three methods for 
apportioning overhead costs. The f irst approach is to use an 
allocation measure. Its principal attribute is to indicate 
the change in cost due to extra consumption. For example, 
given that a nurse does several different tasks, her time 
spent administering a vaccination may represent her labour 
cost to the vaccination programme. The second approach 
requires the computation of a unit cost (i. e. the average 
cost) for each input. The cost of each input in a health 
programme is the multiplication of the unit cost by the 
correspondent quantity consumed. The sum of costs of all the 
inputs involved constitutes the cost for that programme. The 
third approach is to average the overhead costs common to all 
health service recipients, for instance the hospital 
administration. The average shared cost is then added to the 
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costs of other inputs specific to the service under 
consideration. 
Despite efforts to rectify costing methods so as to 
comply with the economic concept, poor or inaccurate 
measurement and valuation of costs are a common problem 
(Drummond et al, 1987; Warner et al, 1982). The latter 
authors also note that such problems exist in the economic 
evaluation of many other disciplines. They could still be 
major problems in the future. 
These problems increase the difficulty of estimating 
marginal costs of health programmes. At the same time, they 
encourage analysts to assume marginal costs equivalent to 
average costs in order to avoid the difficulty. 
There are two types of change in the marginal cost. A 
rise in the output scale is responsible for decreasing 
marginal costs at the initial stage of production and the 
increasing marginal costs at high production levels. At any 
given size of operation, a change in some factor leads to a 
rise or fall in the marginal cost. In economic terminology, 
the former is described as a change along the marginal cost 
curve and the latter as a shift in the marginal cost curve 
(Koutsoyiannis, 1982). 
In the vaccination and TB treatment context, the coverage 
rate of the vaccination for a target group and the number of 
treated patients can be regarded as the scale of production. 
Since there is no study comparing the marginal costs of the 
Thai vaccination and TB treatment programmes at various 
output levels, it is impossible to ascertain whether the 
current stages of these programme implementations are 
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operating on decreasing, stable or increasing marginal cost 
curves. Foster et al (1992) claim that all cost studies about 
the Expanded Programmes on Immunisation investigated at 
single coverage level. 
However, the trends of the marginal costs can be inferred 
from standard economic theory. According to the law of 
variable proportions (or the law of diminishing marginal 
productivity of variable inputs), the marginal cost at an 
early stage of the vaccination process (and the TB treatment) 
falls but the marginal cost at a high coverage (a large 
number of the TB patients) is high and rising. The rationale 
behind this is that at low output levels, the productivity of 
variable inputs rises since variable factors are employed in 
lower proportions to fixed factors. At the optimum 
combination of fixed and variable factors, the gain in 
productivity disappears. Production beyond this point causes 
a fall in productivity due to the improper fixed and variable 
input proportions (Koutsoyiannis, 1982). 
For instance, a health centre trying to deliver 
vaccinations to every child according to schedule may find 
the fixed factors insufficient relative to variable ones. The 
reduction in the productivity of the information system which 
traces a child's immunisation history as a result of 
increasing the coverage rates may waste the working time of 
a nurse who would wait idly to receive instruction as to the 
appropriate course of action. As coverage rates increase, 
more registered children lead to more crowded children's 
vaccination records. Therefore, more nurse's working time is 
wasted unless the information storage system is improved. It 
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is in fact a higher cost in the form of the lost productive 
time of nurses. A higher coverage rate, as Lee (1983) 
suggests, can usually be met at the expense of a higher 
immunisation cost. 
Foster et al (1992) cite from a cost estimation study 
which found that at 80% coverage, a measles vaccination is 
costed at US$15.00 and becomes twice at 95% coverage. Between 
80% and 95% coverage, the cost increases at a rate of US$1 
per additional coverage percent. 
As will be discussed later in this analysis, the BCG and 
rotavirus vaccination programmes can be rendered in 
conjunction with other vaccinations but the measles 
vaccination programme has to be operated independent of 
others. The two types of the vaccination provision can be 
considered as two different production processes. Fixed 
factors that are shared by many activities in the joint 
vaccination condition become smaller for an immunisation than 
those that are used exclusively by a single vaccination in 
the separate vaccination condition. Therefore, the 
productivity of the variable inputs in the joint vaccination 
programmes could reach optimum and decline sooner (i. e. at a 
lower provision level) than in the separate vaccination 
programmes. Foster et al (1992) agree on the effect of the 
ratio of the fixed cost to the variable cost in the 
vaccination cost context. This implies that the marginal 
costs for the BCG and rotavirus vaccination programmes are 
likely to increase at a lower coverage rate than that for the 
measles vaccination one. 
The costs of variable inputs are directly associated with 
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the marginal cost. McGuire et al (1988) expect marginal costs 
to rise as a result of higher variable input costs as demand 
for these becomes excessive and supply is limited. For 
example, an increase in vaccine cost or in drug cost could 
lead to a higher marginal cost for the vaccination or for the 
TB treatment programmes and vice versa. 
Jacobs (1980) points out that a substitution of a less 
expensive factor for an expensive one could lower the 
marginal cost all other things being equal. It is possible to 
lower the marginal cost of the vaccination programmes by 
replacing excessively skilled personnel with less but 
sufficiently qualified ones. However, the marginal cost of 
the TB treatment programme may not be reduced by this means 
because the treatment standard does not allow such 
rearrangement of personnel. 
It is claimed that the greater severity level of patients 
could increase the marginal cost (Jacobs, 1980). The later in 
the disease that TB treatment is sought, the greater the 
severity presented at a TB treatment centre. The more severe 
case usually requires more treatment than the less severe 
case. Thus, the marginal cost depends on the proportion of 
patients seeking treatment early and those doing so late. The 
marginal cost escalates for a TB treatment programme treating 
a higher proportion of the latter group. Also, relapse 
patients consume more health resources. 
Coverage rates of irnmunisation programmes is of most 
relevance to the health policy and implementation compared 
with the other factors. The government can adjust the 
resource allocation towards efficiency through coverage 
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rates, which affects marginal costs and comparative cost- 
effectiveness. The marginal costs for the BCG and rotavirus 
vaccination programmes are more sensitive to an increase in 
coverage rates than that of the measles programme. It is 
worth reiterating that optimum coverage rates could be 
indicated by the marginal costs and marginal benefits and 
emphasising that a 100% coverage rate is not always 
economically justified (Creese, 1983). 
It can be expected from the above discussion that the 
factors external to the operations are more likely to cause 
falling marginal costs for the immunisation programmes than 
for the TB treatment progranune. 
The impact of changes in the marginal costs upon the 
cost-effectiveness finding of health programmes can be 
speculated. By assuming other things equal, the 
responsiveness of the cost per QALY of the measles 
vaccination programme to a rise in coverage rate would be 
less than that of the BCG and rotavirus counterparts. The TB 
treatment programme would have least sensitivity to the shift 
factors. 
4.1.5. Financial and population parameter identification 
and measurement. 
This analysis is based on the following financial and 
population data. 
1) Over the 1980's, the Thai annual rate of inflation was 
averaged at 3.0% (Khan, 1988). 
2) The exchange rate in 1988 was 25.24 baht/US$ (United 
Nations, 1991). 
3) The 1988 health statistics of Thailand are the latest 
publicly available at the time of study. The data on life 
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expectancy and age-group distribution based on the year 1988 
are shown in Table 48. 
4.1.6. issues of discounting health care programmes. 
4.1.6.1. An overview of discounting. 
Discounting in the economic evaluation is the way of 
handling future costs and benefits whose valuations are most 
likely to vary at different points of time. Usually, future 
costs and benefits are converted to the same period (e. g. 
present time) . The sum of the flow of the converted values is 
known as the present value. The discounting procedure can be 
specified by the following equation. 
n 
PV I Bt 
t=O 
(1+r) 
where PV = present value 
Bt net benef it at time t 
nn th (last) period (e. g. year) of project 
r= discount rate 
For example, the present value of next year's E100 is 
equivalent to E90.9 at 10% discount rate. The next 5 years' 
E100 is worth E62.1 today at the same discount rate. 
There are four conceptual expositions based on the 
economic perspective underlying the discounting technique. 
First, the opportunity cost approach, which is also known as 
the "productivity of economic good" principle (Sheldon, 
1992), considers the value of public programme on the basis 
of the return of the correspondent forsaken private 
investment. The assumptions behind this concept are that the 
resources deployed in the programme under consideration have 
alternative uses and that proceeds from the investment can be 
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Table 48 : Life expectancy and age-group distribution of 
the Thai population in 1988. 
A. Life expectancies of all age groups in 1985-1990 (predicted). 
Age group (year) average life expectancy (year) 
at birth 64.6 
1-4 67.0 
5-9 64.1 
10 - 14 59.5 
15 - 19 54.8 
20 - 24 50.2 
25 - 29 45.7 
30 - 34 41.3 
35 - 39 36.8 
40 - 44 32.4 
45 - 49 28.1 
50 - 54 24.0 
55 - 59 20.0 
60 - 64 16.3 
65 - 69 13.0 
70 - 74 10.0 
75 - 79 7.5 
80 - 84 5.4 
85+ - 
2. Age-group distribution in 1988. 
Age group (year) number (persons) 
less than 1 873842 
1- 4 5469158 
5- 9 6347000 
10 - 14 6190000 
15 - 19 6129000 
20 - 24 5778000 
25 - 29 4892000 
30 - 34 4162000 
35 - 39 3319000 
40 - 44 2550000 
45 - 49 2153000 
50 - 54 1934000 
55 - 59 1546000 
60 - 64 1187000 
65 - 69 820700 
70 - 74 576000 
75+ 603000 
Source : Division of Health Statistics, 1988. 
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reinvested over the period in question. 
Secondly, the pure time preference approach, which is 
also known as "consumer sovereignty" (Robinson, 1990) or 
,, psychological discounting" (Goodin, 1982), discounts future 
events in accordance with the individual Is preference for the 
present over the future. The discount rate based on this 
concept could be seen from the distribution between one's 
consumption at present and saving for future consumption. It 
depends heavily on the observable behaviour of individuals. 
For example, one person's myopia leading to excessive 
preference for the present may result in an illogically high 
discount rate. 
Thirdly, the diminishing marginal utility approach 
suggests that an added unit of the investment return in a 
more prosperous condition generates a less additional utility 
than that in a less prosperous one. For example, an increase 
in income level in the future leads to a less marginal 
utility for extra money earned than a rise in the present. As 
there is presumably an income growth in the future, expected 
return from investment should be discounted with respect to 
people's diminishing marginal utility. Owing to this common 
scenario, this concept is also termed the "impact of economic 
growth" (Sheldon, 1992). Empirically, the discount rate is 
determined by the rate of income growth and the elasticity of 
marginal utility of income. 
Fourthly, the existence of uncertainty and risk is taken 
into account to discount the future return from investment. 
The more uncertainty would cause the expected return to be 
smaller and therefore raises the discount rate. A key 
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assumption of this concept is that the consumer is risk- 
averse. A commonly cited reason is that uncertainty and risk 
involve one's death before the yield is delivered and 
consumed (Sheldon, 1992). 
It is sensible to believe that the discount rate 
diversifies with reference to different grounds for 
discounting. However, in theory, it can be shown that under 
the conditions of perfectly accessible capital market and 
perfect information, the same discount rate can be derived 
from the opportunity cost and the pure time preference 
approaches (Sheldon, 1992; Robinson, 1990). 
The four concepts have their own criticisms. Due to the 
existence of and accessibility to international capital 
markets, public programmes could be invested in by f oreign 
resources. The opportunity cost in terms of forgone domestic 
private investment as the valuation of a public programme and 
thereby the discount rate derived from this method would 
become inappropriate. In addition, it is possible that the 
value of the investment return could benefit domestic private 
investment in the form of stimulating more consumptions 
rather than suppressing as the conventional wisdom states. 
For example, people with improved health could consume more 
than otherwise. The longer people live, the greater their 
consumption (Sheldon, 1992). The incorporation of this 
spillover effect (though it could be taken into the benefit 
flow of a programme) could make the real discount rate less 
than one that literally counts the benefits of the forgone 
investment. 
Goodin (1982) points out some important limitations of 
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the opportunity cost criterion. It may be appropriate for 
discounting the investment yields to be reinvested but it is 
not suitable for discounting the investment returns that are 
for consumption. Discounting could be applied to the 
investment of goods whose stock can grow but it should not be 
applied to the investment of non-reproducible goods. As a 
result, for these latter goods, the discount rate with 
reference to the high predicted return of other goods 
(especially the former goods) is not sensible except one's 
own class. 
Goodin (1982) does not accept the pure time preference 
concept to be a criterion for discounting on the grounds of 
moral inadequacy. In addition, the fact that people's 
preferences change over time makes it hard to justify. 
It is not certain that the income growth will enhance in 
the future. People do not always exhibit diminishing marginal 
utility of income. In the context of health, both conditions 
are dismissed by Sheldon (1992). Therefore, it is difficult 
to approve the diminishing marginal utility approach as a 
determinant of the discount rate. Since accumulation is 
essential to this concept, it cannot be applied to goods 
which have volume which cannot be increased. 
Some may regard uncertainty and risk is a function of 
time (e. g. a further uncertain event attaches a higher risk 
than a nearer one) . But it is not correct to assume this 
relationship without establishing one. In some cases, the 
temporal effect could be separated from the effect of the 
risk and uncertainty (Goodin, 1982) . As a result, both should 
be handled properly and explicitly. 
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Moreover, the uncertain and risky elements should be 
treated independently of the discount rate. According to 
Parsonage et al (1992), some sources of risk in health 
programmes (e. g. new medical technology makes the previous 
one less effective) could be obviously identified and coped 
with without being related to the discount rate. By contrast, 
Sheldon (1992) approves combining the discount rate with a 
risk premium that allows for systematic risk. 
4.1.6.2. Discounting non-monetary benefits. 
Despite the shortcomings of the discounting concept, it 
is a consensus that future costs and benefits in monetary 
term or equivalent must be discounted under the assumption of 
rising real incomes over time (Parsonage et al, 1992). 
According to Sheldon (1992), private expenses for a 
prevention programme should not be exempted from being 
discounted at the pure-time-preference-based discount rate. 
But there is debate over the discounting of non-monetary 
benefits such as valuation of human life and health 
improvement (e. g. life-years gained and QALYs) . Parsonage et 
al (1992) argue that since there are no established links 
between health benefits (e. g. QALYs) and income at different 
times and also no association between the elasticity of 
marginal utility of health improvements and the income growth 
rate, the diminishing marginal utility approach is 
inappropriate as a basis for setting the discount rate. 
The discounting of non-monetary benefits may be justified 
by trading off between their present and future in the 
natural unit. For example, the discount rate for health 
benefits in terms of lives saved may be derived from 
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comparing the number of lives saved in a future health 
programme with that to be sacrificed in the present (Goodin, 
1982). . 
Cairns (1992) argues that the characteristics of non- 
monetary health benefits need not prevent using the 
discounting practice in economic appraisal. The crucial point 
is to find an appropriate conversion factor to transform 
health effects into monetary term (i. e. a shadow price) . Then 
they are subject to discounting just as other monetary 
returns. However, he recognises that the difficulty of shadow 
pricing depends on the tradability of health effects. 
Robinson (1990) claims that the pure time preference 
approach is acceptable to economists for estimating social 
discount rates. But it is justifiable to apply the 
opportunity cost approach to considering capital rationing 
between projects independently of discounting. 
An important implication of discounting benefits from 
long-term projects concerns inter-generational justice. There 
are two opposite views. The diminishing marginal utility 
approach advocates discounting future benefits since future 
generations would be more affluent than the present one and 
thereby additional benefits in future generations are valued 
less than those in the present one. On the other hand, to be 
fair, additional benefits should be valued equally for every 
generation. The non-discounting argument based on the ethical 
perspective is objected by Keeler et al (1983), who state 
that the present generation "should always be willing to 
transfer resources away from present health needs to buy 
additional years of life for future generations". They also 
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add that inter-generational transfers are rejected based on 
not only the economic reasoning but also some philosophical 
thoughts. 
The counter-attack on discounting by Sheldon (1992) is 
that it is bias against future generations and in particular 
is in conflict with the general principle of public health. 
He also questions the medical ethics aspect of discounting 
the future benefits that possibly leads to treating some 
patients now at the expense of efficient programmes for 
future generations. 
Health programmes with distant benefits can be given a 
relatively low priority. Parsonage et al (1992) claim that 
discounting at zero rate will enhance the prospect of 
treatments for infants and the young as well as decrease 
future generations, chance of contracting infectious 
diseases. Robinson (1990) speculates that for long-term 
public health programmes, the economist Is case is in contrast 
to the rest's. 
4.1.6.3. An appropriate social discount rate for future 
health benefits. 
Discounting in economic evaluation is a common practice 
and virtually not disputed. However, an appropriate social 
discount rate is yet to be determined (The Lancet, 1992; 
Sheldon, 1992). A variation in the discount rate is evident 
in the United States, ranging from 0% to 10%. Although a 
standard discount rate is currently set al 6% by the Treasury 
of the United Kingdom, a move to discount QALYs gained from 
the NHS health programmes with zero percent was reported 
(Sheldon, 1992). It is the discrimination against future 
generations due to the discounting that it central to the 
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disagreement (Sheldon, 1992). There are four possibilities 
for setting a social discount rate. 
1) Health benefits are not discounted (or a zero discount 
rate is used) . The article by Parsonage et al (1992) proposes 
this practice and challenges the discounting tradition in the 
economic evaluation of health programmes. It is supported by 
the ethical argument for equal weightings of health benefits 
between generations. No discounting, as they explain, 
sensibly assumes that a rise in the value of QALYs is in 
harmony with the real income growth. In other words, the 
marginal utility of QALYs with respect to the income level 
does not decline but is constant. 
A technical argument against a zero discount rate, which 
is well put forward by Keeler et al (1983), is that the cost- 
effectiveness ratio will improve by postponing the start of 
a programme since the discounting makes costs lower in the 
next period than the present one while it keeps benefits 
unchanged. 
2) Health benefits are discounted at a lower rate than 
costs. Keeler et al (1983) argue that the delayed effect from 
discounting with non-zero rate but less than the rate for 
costs is not so strong as that from no discounting. This is 
because future benefits with non-zero discount rate are 
smaller than those with zero one. However, its undesirable 
ef f ect is that the f uture perf ormance of the worst programmes 
with positive benefits could probably be ranked better than 
the best immediate one. This impact may not be critical if 
there is as sufficient budget to implement the best current 
programme and future ones passing the cost-effectiveness 
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criterion (Keeler et al, 1983). Its key implication is that 
it sets a cost-effectiveness standard against immediate 
programmes in favour of future ones. 
Parsonage et al (1992) deny the discounting of programmes 
whose benefits last beyond a lifetime on the grounds that 
discounting could disguise such benefits. This may be 
conveniently used by analysts to ignore these benefits 
accruing to next generation. 
3) Health benefits are discounted at the same rate as 
costs. According to Keeler et al (1983), only when the 
discount rate for benefits is the same as the costs, is the 
postponement effect on the programmes with distant benefits 
removed. However, they concede that unlike financial 
benefits, no direct argument for discounting future health 
benefits at the same rate as costs is now available. 
Parsonage et al (1992) respond to the postponement effect 
argument that its application is incorrect. The programmes to 
be compared for being funded by current limited resources 
should be ones that are to be implemented at same period 
(e. g. within the same budget year) . The constraint (i. e. 
having to use up the budget within a certain period) which is 
not included in the analysis by Keeler et al (1983) plays a 
significant role in the application of their argument. For 
instance, next year's projects should be considered in the 
next year's budget and not be mixed up with the present ones. 
Thi s is correspondent to the practice of real-life decision- 
making over resource allocation, which is not focused on 
where to spend the money but on which programmes within a 
given duration (Sheldon, 1992). As a result, the effect never 
305 
discourages decision-makers from implementing the current 
programmes. 
Cairns (1992) points out that the capital rationing of a 
budget needs a certain criterion. Since obviously there 
exists the opportunity cost of the capital distributed to 
various alternative programmes, the discounting based on the 
opportunity cost approach inevitably gets involved in the 
programme selection process. 
4) Health benefits are discounted at a higher rate than 
costs. Although a higher discount rate for health benefits 
has not been contemplated in any studies, it might be 
sensible on the grounds of more uncertainty for health 
benefits than for costs (Keeler et al, 1983) . However, as 
discussed before, uncertainty allowance should be dealt with 
separately from the discounting. Its vital consequence is 
that the cost-effectiveness standard is in favour of current 
health programmes. The efficiency requirement for future 
health programmes partially varies directly with time. 
Change in the discount rate principally affects the 
relative cost-effectiveness outcome of different health 
programmes. In the analysis by Parsonage et al (1992), it is 
shown that the ranking of health programmes according to cost 
per QALY alters as a result of switching from a discount rate 
of 6% to one of 0%. As expected, the health programmes with 
immediate benefits like renal dialysis are insensitive to the 
change and the performance of preventive programmes becomes 
better. Although it has no impact on a health budget, Cairns 
(1992) believes there is some pressure for it to be 
increased. 
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The empirical studies that estimate discount rate used by 
people may lend some support to either side of the 
theoretical debate over the appropriate rate. Parsonage et al 
(1992) point out that some analyses found a zero or negative 
real private discount rate for health benefits. On the other 
hand, Cairns (1992) considers such an outcome is 
unrepresentative of the literature available. There are other 
empirical works that highlight an opposite result. The 
difficulty in the empirical investigations of people's 
discount rate rests on the gap between a theoretical 
framework and an empirical model (Viscusi et al, 1989). 
The analysis by Viscusi et al (1989) estimates the 
individual's implicit time-preference discount rate for 
health status, life years in particular, in the context of 
the risk of death in job. The key finding is that the better 
educated workers had the discount rate compatible with the 
real market rate of interest. The problem of accessibility to 
capital markets for the lower educated workers would be 
responsible for their discount rate in excess of the real 
market interest rate. However, this myopia was not serious. 
The empirical analysis of discount rates for health 
benefits based on individual's pure time preference using 
observable behaviour encountered several criticisms 
(Parsonage et al, 1992; Sheldon, 1992). Health risks used in 
the analysis may not be fully perceived by all individuals. 
Some health risks are confounded with addiction. Considering 
various health risks, it is necessary to establish the 
relationship between their temporal impact and perceived 
level of risk. For example, in order to be able to use 
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smoking and drinking behaviours as health risks, it is 
essential to prove that people have less concern f or them due 
to their distant impacts than other activities with immediate 
risk like rock climbing. The methodological problem of the 
estimation models is that they cannot control fully such 
factors as preference for gambling, age effect and education 
influence. Individual variation in the discount rate that is 
evident in most analyses makes it unjustifiable to suggest a 
single discount rate for the economic evaluation. 
Economists traditionally approximate a real interest rate 
as people's rate of pure time preference (The Lancet, 1992). 
This assumption unsurprisingly originates from discounting 
financial benefits. The presumed conditions for their 
theoretically equivalence was previously discussed. Real (or 
inflation-adjusted) interest rate as discount rate can be 
obtained by subtracting an inflation rate from a nominal 
interest rate (Keeler et al, 1992). In the analysis by 
Viscusi et al (1989), the corporate Aaa bond rate (Moody's) 
as a nominal long-term financial market interest rate was 
adjusted by an inflation rate to give rise to a real interest 
rate, being compared with an estimated discount rate. 
Whether a discount rate should be uniformly applied 
through all the periods of the project's life is extremely 
difficult to be answered. The uniform discounting (i. e. using 
a compound discount rate) assumes that each period's 
opportunity cost is equal. However, Goodin (1982) claims that 
there are no theoretical and empirical reasons to support 
this assumption. He goes on to conclude that the four 
economic concepts of discounting cannot provide a case for 
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the uniform discounting. Nevertheless, the uniform 
discounting is generally adopted in most studies (Drummond et 
al, 1987). 
4.1.6.4. How a social discount rate should be set. 
The investigation of the relationship between the 
individual discount rate and the social discount rate may 
establish a derivation of the latter from the former to be 
used in the public programme discounting. There are two 
different views about the relationship. One regards 
individuals' time preferences as the reflection of the social 
discount rate and thereby suggests the same discount rate. 
The analysis by Viscusi et al (1989), for instance, is one in 
this category. This also conforms to the democratic political 
principle (Robinson, 1990). The opportunity cost criterion 
suggests the return rate from private investment be a social 
discount rate. However, some point out that market interest 
rate may not reflect the genuine opportunity cost of a public 
programme since it is difficult to predict all the effects of 
the displaced private investment in the future (Robinson, 
1990). 
The other dismisses the individual's time preference 
because of the possibility of irrationality like myopia. It 
is likely that the result based on individual's discount rate 
would be in conflict with that based on the collective 
discount rate. Also, it is difficult to compromise the 
variation in individuals, time preferences and come up with 
a single social discount rate. It is possible that people 
have a discount rate f or private decision dif f erent f rom that 
for collective one. Therefore, on the basis of the pure time 
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preference principle, social discount rate should be set 
lower than individual one (The Lancet, 1992). 
As an alternative to the two views, some suggest to 
derive a social discount rate from a combination of the 
market return rate and political approval (Robinson, 1990). 
4.1.6.5. Suggestions for the discounting of health 
programmes. 
The above discussion shows that there is no agreement 
about the socially acceptable discount rate for long-term 
health benefits. A political and ethical judgement may be 
resorted to determined this issue which is at present 
unresolvable by the economic principle (Parsonage et al, 
1992). 
Attempts to find a solution may be complicated by the 
fact that a social discount rate appropriate for one type of 
health programmes would not be suitable for others (Keeler et 
al, 1983; Sheldon, 1992). Therefore, the lack of 
generalisation from one analysis to others makes it 
reasonable to establish a social discount rate in one's 
particular context. Viscusi et al (1989) provide some 
examples that individual time-pref erence discount rates vary 
in a relatively small range for health issues. By contrast, 
there is a large differential between health and energy 
saving matters. West (1985) notes that the discount rate 
varies with time and county. Cairns (1992) suggests that due 
to the great difficulty in this issue, an analysis should be 
undertaken before a zero discount rate is accepted. 
It is noted that some scaling approaches to preference 
for health-related quality of life such as the time trade-off 
technique already incorporate the discount factor between 
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present and future health status. Therefore, it may not be 
necessary to perform discounting based on the pure time 
preference principle again (Sheldon, 1992). 
A common, popular recommendation for discounting health 
programmes is to use different discount rates to test the 
sensitivity of the analysis result (Drummond et al, 1987; 
Parsonage et al, 1992). Some suggest to additionally take 
account of a zero discount rate (The Lancet, 1992; Sheldon, 
1992). A reasonable range of the social discount rate to be 
used can be determined on the basis of the comparability 
between the studies and the earlier works accumulated in the 
economic assessment of relevant health programmes (Keeler et 
al, 1983; Drummond et al, 1987). 
4.1.6.6. The social discount rate used in this analysis. 
There is no unique discount rate used in Thailand. The 
Thai government has not suggested the appropriate discount 
rate for the Thai public programmes. To the best knowledge of 
the author, no estimation studies of the discount rate (e. g. 
consumer's pure time preferences) are at present available in 
the health context in Thailand. 
It is suggested that long-term government bond rate, 
which has a low risk and could represent people Is opportunity 
cost of their resources and pure time preference, be a 
discount rate for public programmes (United Nations, 1968; 
Drummond et al, 1987). In theory, the difference in the rates 
of return f or dif f erent types of bonds ref lects their varying 
levels of risk. With allowance for them, all the rates should 
be identical (i. e. the market rate of interest). Drummond et 
al (1987) recommend that the discount rate should be between 
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2% - 10% which is compatible with economic theory, some 
governments I recommended rates, other published works and 
current practice. 
The real rate of the long-term Thai government bond was 
about 5% in 1988 (United Nations, 1991). There have been a 
few studies about the economic evaluation of the Thai health 
service programmes in which the discount rate was explicitly 
used. A 10% discount rate was employed by Phonboon et al 
(1989a) in their cost-effectiveness assessment of the Thai 
Expanded Programmes on Immunisation. Ettling et al (1991) 
used an 8% discount rate in their economic analysis of the 
Thai malaria clinics. It should be noted that these rates 
were applied only to future monetary cost, mainly capital. 
The benefits in the natural forms (e. g. a completely 
immunised child or a case treated) were not discounted 
because only the current effects of the programmes were 
considered. 
Therefore, a reasonable range of the discount rate for 
the health programmes in this study should be in between 5% - 
10%. The average of 7.5% is used as the baseline case. The 
minimum and maximum are included to test the sensitivity of 
the results to discount rate changes. 
4.2. Parameter estimation. 
A substantial review, which is intended to include the 
true estimates of all the parameters, highlights variations 
in the estimates of some parameters between studies. The 
major factors responsible for these are the studies, 
environments, investigation methods, estimation methodologies 
and populations. In addition, a difference in the number of 
312 
studies analysing various parameters for each health 
programme is evident. Some health programmes have been 
extensively studied in numerous different populations, 
applied by many methods and methodologies, and existed for a 
long time such as BCG vaccination whereas others have 
recently been developed and restrained by ethical issues like 
rotavirus diarrhoea vaccination. 
The contexts specific to each parameter are used to 
determine the appropriate data for the base-case computation 
for the cost per QALY and the rest of the data available are 
incorporated in the sensitivity analysis. 
4.2.1. The estimation of effect. 
In this subsection, the estimated effects of the health 
programmes in this study are obtained from a selection of 
studies based on the standard efficacy and effectiveness 
measurement methods. Other studies with alternative 
measurement methods are also discussed, which in some cases 
suggest how to improve the effect of the health programmes. 
They not only provide some data for the sensitivity test but 
also offer the prospect of strengthening the health 
programmes, both of which will be used in the next chapter. 
For the vaccination programmes, the approximations of the 
protection period are acquired too. 
4.2.1-1. Estimation of effects for measles vaccination. 
a) International studies of effects for measles vaccination. 
Measles virus was first discovered in the 1950's by 
Enders and Peebles from a measles-inf ected child. Then it was 
attenuated through passage in tissue culture to produce the 
vaccine. Heat-stable strain is now available. The vaccine is 
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given subcutaneously in the arm. Most of the vaccine strains, 
for example Schwarz, Moraten, Beckentran, Edmonston-Zagrab, 
EKC and AIK-C, were developed from the original Edmonston 
strain (Foster et al, 1992). 
The estimation of effect for a measles vaccination 
programme is commonly based on randomised controlled trials 
with some modifications. Because of the difficulty in 
selecting proper controls due to the availability of the mass 
measles vaccination all over the areas that measles is one of 
the vital health problems, the assessment of its efficacy, in 
a strict sense, is to date not existent (Aaby et al, 1989). 
The efficacy estimates of the two measles vaccination 
trials in Mozambique in 1985 and 1986 were 40% and 59%, 
respectively (Cutts et al, 1990). The data involving the 
measles incidence rates in the vaccinated groups are 
available only in these studies. Based on these incidence 
rates, the effectiveness of the measles vaccination in terms 
of the absolute reduction in the measles incidence can be 
estimated. The vaccine efficacy of 50%, a median of 40% and 
59%, and the incidence rate of 0.094021392, a median of 
0.078590785 and 0.109452, based on the following formula, are 
selected for the base-case computation for the cost per QALY. 
Effectiveness =_ Vaccine efficacv x Incidence rate in 
of the programme (1 - Vaccine efficacy) vaccinated group 
0.50 x 0.094021392 
1-0.50 
0.094021392 
So within a 1000 measles -vaccinated population, there 
would be 94 vaccinees completely protected from the disease. 
A review study of the efficacy of measles vaccination 
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programmes reveals that it ranges between a 45% and a 60% 
reduction in mortality among children aged 7-35 months (Aaby 
et al, 1989). An early field trial of measles vaccination by 
Hartfield et al (1963) in Nigeria showed that the vaccination 
of children aged 6 months and 2 years old provided a 59% 
reduction in the measles cases and prevented all the deaths 
from measles, despite a high "measles -like" incidence due to 
the unavailability of specific diagnosis tests. 
Foster et al (1992) assume in their model that the 
vaccination delivered at 9 months of age offers a 29% 
reduction in morbidity and mortality in urban areas and 45% 
in rural areas. Also, if this method of delivery includes the 
effort of minimising missing opportunities of the 
vaccination, which could cause a 20% increase in the 
supervision costs and a 10% rise in the vaccine cost, then 
the vaccine effect is assumed to improve to a 39% fall in the 
morbidity and mortality incidence in urban areas and 58-59% 
in the others. 
Ginsberg et al (1990) assume the effect of the two-dose 
measles vaccination falls into three categories. The first 
vaccination at 15 months of age and the second at 6-7 years 
of age confer a 63% reduction in the measles incidence. The 
first vaccination as previously and the second at 7-17 years 
of age offer 75.2%. The first vaccination as before and the 
second at 7-27 years of age give 81.0%. 
The ef f ect of a measles vaccination programme can also be 
seen from the comparison of the incidence between the assumed 
condition of unavailable measles vaccination and the actual 
situation of an existing measles vaccination programme. By 
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comparing the measles incidence in the United States under 
the vaccination scheme with the expected number of the cases 
in the condition without the vaccination for ten years after 
the initial vaccination, Witte et al (1975) estimate a 50% 
reduction in the measles cases. Without the vaccine, the 
estimated 4.0 to 4.5 million measles cases, which was the 
average annual incidence before the vaccination period, would 
have occurred each year. During the ten years' period (1963- 
1972), it is estimated that almost 24 million cases were 
avoided. Also, it saved about 2400 lives. 
Block (1985) reassesses the outcome of the mass 
vaccination against measles in the United States, indicating 
a 90% decline in the measles incidence rate within 3 years 
(during 1966 to 1968) . Between a pre-measles vaccination year 
and 1983, the incidence rate decreased by 99.8%. Moreover, 
the measles encephalitis rate diminished by 99.7% and the 
measles SSPE rate by 80%. 
Under this estimation method, the vaccination ef f ect does 
not dwindle, though the measles incidence rate is extremely 
low. It is reasonable to assert that as long as measles is 
prevalent in other areas of the world, the potential for its 
reintroduction in the United States exists (Block, 1985). In 
addition, as the US experience in the past shows that when 
measles control activities (mainly vaccination) descend, the 
disease rapidly returns. Therefore, the substantial health 
and resource benefits due to the measles vaccination will 
continue to occur in the future. 
The fact that fluctuations in the measles incidence rate, 
are anticipated and that measles incidence persists in a 
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short period following the start of the vaccination lead some 
analysts to assess the long-term impact of the programme 
while ignoring its short-term effect. Foster et al (1992) 
agree that the short-run reduction in measles incidence by 
the vaccination is difficult to ascertain. However, the 
findings based on the effect of a considerable period may not 
be comparable to the measurement of other programmes, 
effects, which is assessed in terms of a year's period. In 
fact, the long-run effect of all the health programmes can be 
estimated as well. The assessment of health programmes based 
on long-term influences should not be overlooked and may be 
profitable in exploring a wider scope of the economic 
evaluation of the health programmes in the future. 
Fine et al (1983) criticise the estimation of the measles 
vaccination effect based on the pre- and post -vaccination 
scenario. With reference to the measles control experience in 
England and Wales, they point out similar rates of measles 
incidence for before and after the vaccination; as opposed to 
most forecasts of the models. Only two apparent effects are 
the elimination of major measles epidemic and the shift in 
the susceptible age from 4.5 to 5.5 years old. Many 
predictions of the mathematical models for the measles 
control fail (Foster et al, 1992). 
The models forecasting the measles vaccination effect, 
especially towards the elimination of the disease in the 
United Kingdom, are unsuccessful due to their unrealistic 
assumptions; the transmission model of measles, constant 
measles incidence rates for all age groups, the stability of 
the relationship between population size and fadeout 
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probability, and the homogeneity of population. 
Their argument certainly implies that the measles 
vaccination effect findings based on the two-state scenario 
approach are not as rigorous as the findings obtained from 
the clinical trials. Moreover, Foster et al (1992) note that 
the epidemiological models do not precisely represent the 
measles transmission patterns in developing countries. 
However, the fact that the models also forecast a 52-60% 
reduction in measles incidence both in developed and 
developing countries surprisingly resembles the results 
indicated by the trials. The models may be useful to the 
design of the programme evaluation rather than the economic 
appraisal. 
Taking the seroconversion rate (immunological efficacy 
rate) of 80-90% and the vaccination coverage rate of 45-90% 
into the two-state scenario method for computing the measles 
vaccination effect on the diarrhoeal complication of measles, 
Feachem et al (1983) find that the programme could produce a 
30-68% reduction in measles incidence. Their estimates are 
consistent with those obtained from the clinical trials and 
other two-state scenario models, despite a wider range. 
Creese (1986) uses the following two equations for 
calculating the measles vaccination effect on all kinds of 
diarrhoea: 
Bi 5xIx Ri xE 
Bm 5xMxR. xE 
where Bi measles vaccination effect on diarrhoeal 
morbidity. 
Bm measles vaccination effect on diarrhoeal 
mortality. 
55 years covered by the vaccination. 
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total diarrhoea morbidity among 
children 0-59 months (assuming 2-4 
episodes a child). 
M total diarrhoea mortality among 
children 0-59 months (assuming 10-20 
deaths per 1000). 
Ri reduction rate in I (assuming 3.4%). 
R. reduction rate in M (assuming 25.2%). 
E vaccine efficacy (seroconversion rate, 
rather) (assuming 85%). 
This formula can be criticised on two grounds. First, the 
non-discounted effectiveness over 5-year immunity period 
overstates the ef f ect of a measles vaccination. Nevertheless, 
the excess is expected to be small, as claimed in the study. 
Secondly, the reduction in the morbidity and mortality, which 
are highly likely to be derived from the two-state scenario 
method, are purely hypothetical and have no support from any 
studies. 
It should be noted that there is a confused use of the 
efficacy definition in the studies about the measles 
vaccination effect. The standard term, and the one used in 
this study, for the efficacy value is the probability of the 
reduction in contracting measles between the unvaccinated and 
vaccinated groups due to the measles vaccination effect. 
However, some studies have used the term for the 
seroconversion of measles vaccination as a result of a rise 
in appropriate antibodies in the tests (Foster et al, 1992). 
it is not necessary that all seroconverted vaccinees secure 
protection from measles. Foster et al (19 92) of f er an example 
that in 1985-1986,9 of the 175 original seroconverters 
developed measles in a measles outbreak in British Columbia. 
other studies encounter this problem too. Therefore, the two 
are not equivalent and the former concept is appropriate in 
the economic appraisal of the programme. No trials have ever 
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reported the efficacy of more than 60%. So it would be 
suspected if a study states the measles vaccination effect as 
high as 90%, that the value is derived from other methods of 
the effect estimation (e. g. the pre- and post -vaccination 
period method). It is suggested that the analysis of a 
measles vaccination programme should state the method from 
which the efficacy estimate is taken. 
Three important factors affect the effectiveness of the 
measles vaccination. First, the effectiveness can increase by 
expanding the coverage of the vaccination (Aaby et al, 1989). 
Secondly, correcting the mistakes and misconduct in the 
vaccination process could provide a rise in the vaccine 
effect. Cutts et al (1990) mentions several actions of 
incorrect practices in measles vaccination. 
1) The cold chain is unreliable. 
2) Vaccination is counted without actually giving the 
vaccine. 
3) The application of disinfections to sterilize syringes 
destroys measles vaccine. 
Halsy et al (1989) support these points and estimate 
their occurrence in about 1% of the vaccinations provided. 
The factors responsible for the low vaccine efficacy is 
discussed in Foster et al (1992). 
Thirdly, most studies of the efficacy measurement of 
measles vaccination are allegedly subject to methodological 
biases and errors. It is likely that the number of reported 
measles cases, measured by mothers, recall of measles cases, 
could be underestimated (Cutts et al, 1990). 
Strategies towards increasing the effectiveness of a 
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measles vaccination programme are undertaken in many areas 
and others are under study. It is suggested that the Ezeject 
syringe is more effective than the 3 c. c. syringe, which has 
been used in routine vaccinations, owing to its capability of 
improving the level of antibody of the vaccinees (Halsy et 
al, 1989). In order to tackle the problem of understated 
measles cases from the recall method, the use of a narrow age 
group of children, who are still in the period of a high risk 
of measles and have short recall lengths, could acquire the 
more accurate number of the cases (Cutts et al, 1990). 
There is a claim that the protection effect of a measles 
vaccination extends beyond the measles aversion. It reduces 
the chance of contracting other diseases predisposed by the 
measles infection. By following up the children infected with 
measles and those never infected, Aaby et al (1989) find that 
the former group had a higher excess risk of dying after 
acute infection than did the latter. Also, the former had 
more delayed morbidity than the latter. In a study, the 
vaccinated group's overall mortality risk was 31% lower than 
the unvaccinated group's for a follow-up period between 6 
months and 3 years (Aaby et al, 1989). As an alternative 
measure of the additional effect of a measles vaccination 
programme, the total mortality in a hospital within a year, s 
observation was halved as a result of the measles vaccination 
provision, given the unchanged practices of its major 
treatments (Aaby et al, 1989). Ndiknyeze et al (1988) also 
report that prolonged illness, frequent infections and 
malnutrition are common sequelae of the measles infection. 
This issue, in fact, has been increasingly examined but 
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referred to in a different classification. Foster et al 
(1992), as well as other studies reviewed in their study, 
deal with this impact under the topic of child survival as a 
result of the vaccination. A 36% and a 45% decline in overall 
mortality rates (from all causes of deaths) were estimated in 
Bangladesh. 
Unfortunately, such indications of the extra effects of 
measles vaccination have not been quantified so that they 
could be combined with its standard ef f ects available in this 
assessment. Of course, when their magnitudes are available, 
the measles vaccination programme ought to be reassessed. 
After following up more than 5000 measles vaccinated 
children for 12 years in the UK, the Measles Sub-Committee of 
the Committee on Development of Vaccines and Immunisation 
Procedure (1977) concludes that the protection period could 
be at least 12 years. According to their serological 
confirmation, 95% of the vaccinees were found to have 12-year 
protection however. UNICEF (1985) states that the vaccine 
could create a long-lasting immunity. It might be a life-long 
immunity as occurred to survivors of measles. This study 
assumes a baseline protection length of 15 years for 95% of 
the vaccinees. 
b) Thai studies of effects for measles vaccination. 
The measles immunisation for Thai children at 9 months of 
age commenced in 1984 as part of the Thai national 
immunisation programme. The timing of vaccination is 
supported by evidence that Thai children's acquired maternal 
measles antibody disappears between the age of 6 and 8 months 
(Lumbiganon et al, 1988). Moreover, this is the period 
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recommended for most developing countries by WHO, based on 
the epidemiological and seroconversion data of age-specific 
measles incidence. 
Unfortunately, there have been no Thai studies measuring 
the effect of measles vaccination. Instead, a number of 
trials focus on assessment of the seroconversion from the 
measles vaccine. Lumbiganon et al (1988) estimate a rise of 
95.6% in Thai 9-14 month old's antibody response. Although 
there appears to be a link between the antibody build-up and 
the protective effect of the vaccine, the antibody evaluation 
result is useless in the computation of vaccine efficacy and 
effectiveness, as remarked above. 
Therefore, the efficacy of the Thai measles vaccination 
programme in this analysis has to rely on international 
studies. Fortunately, the range of efficacy estimates is in 
a narrow band. As only one dose of a measles vaccine is 
rendered in Thailand, the efficacy estimates for this 
analysis are assumed to be 40%, 45%, 59% and 60%. 
Moreover, according to the Thai government's health 
planning, a 50% reduction in annual measles incidence was 
expected after the year 1986. This figure, which is within 
the range of the efficacy estimates, appears to be an 
appropriate approximation for efficacy in the sensitivity 
analysis. 
An unpublished paper by the ministry of Public Health 
comments that the coverage of the measles vaccination 
programme, currently 60%, is less likely to be higher than 
the coverage of the last DPT vaccination since the measles 
vaccination, which needs contact following the last dose of 
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vaccination, may have a higher drop-out rate than the DPT 
counterparts, as predicted by an inverse relation between the 
order of vaccination and the number of vaccination 
recipients. 
4.2.1.2. Estimation of effects for rotavirus diarrhoea 
vaccination. 
a) International studies of effects for rotavirus 
vaccination. 
At present, the vaccine against rotavirus diarrhoea has 
been centred on the RIT bovine and rhesus rotavirus vaccines. 
The descriptions of the two vaccines and their production can 
be found in Kapikian et al (1989). Both vaccines prevent 
serious rotavirus diarrhoea. Their major distinction is that 
the bovine vaccine principally protects against rotavirus 
serotype 1 whereas the other, serotype 3. 
Since the rotavirus vaccines, which have currently 
reached the stage of experimental trial at the time of 
writing, have not been applied to a genuinely uncontrolled 
situation, only the efficacy measures are known from 
randomised controlled trials. Hanlon et al (1987) indicate 
that in their study the bovine vaccine conferred efficacy of 
33% but did not reduce the severity of diarrhoea. However, 
their efficacy measure, as opposed to other studies, was 
based on the antibody rise. 
Vesikari et al (1990), investigating the protection of 
the bovine rotavirus vaccine in Finnish infants aged 6 to 12 
months, conclude that the vaccine exhibited an 80% protection 
effect against severe rotavirus diarrhoea. By contrast, De 
Mol et al (1986) argue that the bovine rotavirus vaccine does 
not provide protection with respect to diarrhoea incidence, 
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protection duration and seroconversion rate. 
Moreover, the low efficacy estimates of the bovine 
vaccine in different populations are increasingly revealed. 
Due to a higher challenge dose of rotavirus in developing 
countries, the bovine vaccine may not confer the same level 
of protective efficacy found in developed countries as in 
developing countries (Gothefors et al, 1989) . With reference 
to trials in Rwanda and the Gambia, it is argued that the 
bovine vaccine is unsuitable in the environments of 
developing countries (Hanlon et al, 1987). 
The rhesus rotavirus vaccine trial in Venezuela by Flores 
et al (1987) provided an overall vaccine efficacy of 68%. The 
findings of the rhesus vaccination trial conducted by 
Gothefors et al (1989) can be summed up as follows. 
1) The protective ef f icacy rate was 48% during 2 winters 
follow-up (but in the f irst winter, the vaccine ef f icacy rate 
was 29%). 
2) The severity of rotavirus diarrhoea among the 
vaccinees was less than that among unvaccinated children. 
on the other hand, in addition to concluding the efficacy 
rate of 29% in their analysis, Rennels et al (1990) point out 
that the mean severity, measured by scores for the diarrhoea 
severity, in the vaccinees and unvaccinated children do not 
differ statistically significantly. Like the bovine vaccine, 
it is also argued that the rhesus rotavirus vaccine is 
protective in some, but not all, situations. Vesikari et al 
(1990) examining the efficacy of the rhesus vaccine in Sweden 
find no protection against either the rotavirus of specific 
serotypes or the rotavirus of undefined serotypes. 
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Due to the unavailability of the effectiveness estimate 
from the rotavirus vaccination trials, it may be estimated, 
in terms of the number of rotavirus diarrhoea cases 
prevented, by the following equation as used in the 
computation for other vaccination programmes: 
Effectiveness Efficacy x diarrhoea notifications 
(1 - Efficacy) in vaccinated group 
The total number of rotavirus diarrhoea cases prevented 
in a population can be directly computed by multiplying this 
equation by the number of vaccinees. 
The studies above, identified rotavirus diarrhoea cases 
and provided enough information for the significant efficacy 
estimates along with other relevant data needed for the 
effectiveness computation (incidentally all involving the 
rhesus vaccine). Thereby, the effectiveness estimates with 
small magnitudes are obtained. In terms of a 1000 vaccinee 
population, Rennels et al's trial (1987) offers a protection 
of 70 cases; Flores et al's (1987), 88 cases and Gothefors et 
al's (1989), 154 cases. The last seems to be exceptionally 
high. 
Though the vaccine could avert 113 cases in 1000 
vaccinees from serious diarrhoea to mild one (Flores, 1987), 
the approximated impact of the vaccine is not useful in the 
economic appraisal since the trial measured severity in terms 
of the specific scoring system, from which improvement in 
relevant symptoms and signs is unknown. Therefore, it is 
impossible to convert it into a gain in health states. 
Combining the efficacy concept with the two-state 
scenario method in his analysis, Creese (1986) estimates the 
effect of the rotavirus vaccination programme on the 
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reduction in morbidity and mortality of all diarrhoeas by the 
same two equations as used in the calculation for the measles 
vaccination effect, as shown below. 
Bi =5xIx Ri xE 
BM =5xMxR, 
where Bi = rotavirus vaccination effect on diarrhoeal 
morbidity. 
BM = rotavirus vaccination effect on diarrhoeal 
mortality. 
5=5 years covered by the vaccination. 
I= total diarrhoea morbidity among 
children 0-59 months (assuming 2-4 episodes 
a child). 
M= total diarrhoea mortality among 
children 0-59 months (assuming 10-20 deaths 
per 1000). 
Ri = reduction rate in I (assuming 5%). 
Rm = reduction rate in M (assuming 16%). 
E vaccine efficacy (seroconversion rate, 
rather), (assuming 70-90%). 
Again, it should be noted that the vaccine efficacy here 
is implicitly def ined as the seroconversion of the vaccinees, 
not the standard efficacy definition in a controlled trial. 
It is generally agreed that the vaccine efficacy depends 
on the serotype of rotavirus diarrhoea strain in the 
population to which the vaccine is rendered. The greater the 
diarrhoea incidence from the serotype contained in the 
vaccine, the higher protective effect the vaccine offers. The 
low efficacy and effectiveness estimates of the rotavirus 
vaccines are most likely to stem from the difference of the 
rotavirus strains in the vaccines to those afflicting 
experimental populations. 
As to the protection duration of the rotavirus vaccines, 
Gothefors et al (1989) claim that both bovine and rhesus 
vaccines could confer protection over 2 years. 
Almost all studies have pointed out that the appropriate 
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timing for a rotavirus vaccination is at 6 months of age, 
when an infant's maternal immunity against the disease wanes 
(Senturia, 1986; Block, 1985; Oyejide et al, 1988). 
b) Thai studies of effects for rotavirus vaccination. 
Rotavirus has been found to be one of the major causes of 
acute diarrhoea in Thailand during the cool and dry months, 
November-February (Thongkrajai et al, 1990). As no key 
rotavirus trial has been launched in Thailand at present, the 
effect of the rotavirus vaccination in the economic appraisal 
has to be based on the international trials mentioned above. 
Some note that acute diarrhoea in Thailand is less serious 
than that in most countries, so over-estimation of the 
rotavirus vaccination effect is likely if descriptions of 
rotavirus diarrhoea impacts on health from the international 
sources are applied to the calculation of rotavirus vaccine 
effect. Since there is no means to correct such a 
discrepancy, the overstated rotavirus vaccination effect 
should be recognised. 
As the vital period of acquired immunity against 
rotavirus diarrhoea for Thai infants and young children is 
the first two years of life and since seroepidemiological 
studies find the antibodies against the disease in about 80% 
of Thai children aged under 2 years (Akatani et al, 1989), 
the protection length is presumably 1.5 years. 
The coverage of rotavirus vaccination could be 
approximated from the second dose of DPT and OPV vaccinations 
since they could be provided simultaneously at 6 months of 
age without adverse interaction. The coverage rate of the 
rotavirus vaccination could reach 80% (UNICEF, 1990). 
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As routine rotavirus vaccination is not ready to be a 
diarrhoea control measure, current Thai strategies for the 
prevention of diarrhoea are the provision of safe and 
adequate water supply, promotion of breast-feeding and proper 
weaning and health education for personal hygiene. The use of 
oral rehydration therapy, preventing mortality, is the main 
treatment. 
4.2.1.3. Estimation of effects for BCG vaccination. 
a) International studies of effects for BCG vaccination. 
In order to measure the protective effect of BCG 
vaccination, it is essential to know the process of infant's 
immunity against tuberculosis and its influence in the rest 
of his/her life. Following primary infection, most infected 
infants limit the progress of tuberculosis by producing 
immunity against the disease. For those without such 
immunity, a BCG vaccination can stimulate it before they 
acquire infection. As a result, most babies stop or suppress 
the tuberculosis advance. 
As their immunity, either actively or passively obtained, 
wanes in later life, reactivation of latent bacilli is 
capable of developing TB. A decline in immunity leaves the 
person susceptible to reinfection from exogenous sources of 
infection such as contact with a person infected with 
tuberculosis. 
Generally, the effect of a BCG vaccination falls into two 
categories. The direct effect is to avert the number Of TB 
cases and deaths among the susceptible. The prevention of the 
sequelae of childhood TB should also be taken into account 
(Houston et al, 1990). Although BCG vaccine cannot protect 
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against every form of TB, it avoids some serious and 
important forms. 
The indirect effect is mainly to reduce risk of infection 
by forming an extended community protection (Barnum et al, 
1980). Some regard this as a reduced transmission of TB. The 
measurement of this effect is based on the reduction in the 
number of TB cases in an unvaccinated population. However, 
since the real source of infection is confined to smear- 
positive cases, the effect is accurately determined by a 
decrease in the number of these cases in a population, which 
could be estimated by a tuberculin survey. 
In an environment with the high risk of infection, a BCG 
vaccination programme has no significant impact on 
transmission conditions. This implies that a trivial indirect 
effect is offered by the vaccine. The protection against TB 
reinfection is least conferred by the vaccine. 
Some consider that the BCG vaccine has a protective 
effect against leprosy too. But the effect has not been 
confirmed by proper clinical trials (Fine et al, 1990). 
It is argued that the efficacy measurement of BCG 
vaccination only accounts for the direct effect, excluding 
the indirect counterpart (The Research Committee of the 
British Thoracic and Tuberculosis Association, 1975; Haber et 
al, 1991). On the contrary, the effectiveness measurement 
covers these two effects. From the viewpoint of immunology, 
effectiveness is assessed in terms of an increase in herd 
immunity; that is, the collective immunologic status of a 
population against TB is improved by a BCG vaccination 
programme. 
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The randomised controlled trial has so far been the 
dominant method of investigating the efficacy of the BCG 
vaccination. Despite numerous trials of the vaccine efficacy 
since its production, the ambiguous outcome of efficacy has 
not been resolved. The inconclusive result and the lengthy 
duration of trials undermine the applicability of the trials. 
A modification of such a trial seems to enable the continued 
evaluation of the vaccine efficacy. 
Though the randomised controlled trial is believed to 
produce the most reliable assessment of vaccine efficacy 
(Fine et al, 1990), the trials have indicated a wide range of 
efficacy estimates. In some cases, the results are 
contradictory. A maximum efficacy of 80% and a minimum of 
-56% raise debate over the issue. Recent analyses are likely 
to conclude the positive but modest effect. For example, 
Houston et al (1990) report a 53% efficacy (14.7-74.6% with 
95% confidence interval). However, few of them directly 
examine BCG efficacy in infants and the effect of vaccination 
at birth. Hart (1967) assumes that the vaccine confers 40% to 
70% efficacy in preventing TB in children aged 0-14 years old 
when given at birth. 
A variation of vaccine efficacy in different populations 
becomes a more important issue in assessing the merits of the 
BCG vaccine use. One trial finds that Indonesian children 
produced a lower protective effect than the French 
counterparts (64% versus 88%) by a test of tuberculin 
hypersensitivity (Milstien et al, 1990). Living conditions, 
previous atypical mycobacterial infections of the children 
and genetic characteristics were used to explain the 
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different efficacy estimates. A discussion on the key 
explanations for variation in BCG vaccination efficacy is 
comprehensively made by Fine (1988). Inaddition, routineBCG 
vaccination programmes in many populations demonstrate little 
protection against the disease (Fine et al, 1990). It is 
recommended that local estimates of BCG vaccination efficacy 
should be encouraged. Some regard it crucial for planning 
vaccination strategy at national level (Rodrigues et al, 
1990). 
Two aspects of efficacy variation have been investigated. 
First, differing factors in high efficacy and low efficacy 
studies are claimed to be responsible for the variation. Each 
suspected factor alone fails to account for this. A 
combination of some factors such as the BCG strain and 
mycobacterial ecology, by contrast, is likely to produce 
variant efficacy estimates (Fine et al, 1990). 
Secondly, the difference in study methodology could lead 
to contrasting results. Clemens et al (1983) analyse the 
possibilities of susceptibility bias, surveillance bias, 
diagnostic-testing bias and diagnostic interpretation bias in 
a number of major trials of vaccine efficacy. Although 
conclusions about the biasedness of each trial could not be 
drawn because none were independent of all biases, they imply 
that the high ef f icacy rates should be accepted. This is 
because the trials with high protective efficacy 
statistically exclude low protective ef f ect rates but the 
trials with low efficacy incorporate the high rates. 
Another important result of the randomised controlled 
trials of BCG vaccination is to determine of the vaccine 
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protection duration. As in studies of efficacy, a wide range 
of immunity periods has been reported. Fine et al (1990) 
state that BCG-induced immunity actually has an unknown 
duration. The existence of the effect for more than 15 years 
is suggested by Hart (1967), though there has never been such 
evidence in developing countries. Rodrigues et al (1990) 
suggest more than 10 years' protection effect. Nevertheless, 
most agree that the vaccination effect has not been 
maintained over time (Hart et al, 1977). Without the known 
extent of the immunity change over time, it is necessary to 
assume constant effect throughout the supposed immunity 
period. 
In developing countries, due to economic constraints, 
difficulty in seeking unvaccinated subjects 
of the high vaccination coverage and the 
ethical issue, the analysis of BCG vaccin 
from the randomised controlled trial. Smith 
alternative approaches. 
The case-control or cohort study is the 
at random because 
awareness of the 
ation has shifted 
(1988) elaborates 
best prospect. In 
such a study, the protection ef f ect of the vaccine can be 
determined within a routine BCG vaccination programme, in 
which improper vaccine storage and incorrect vaccine delivery 
are taken into account. Also, far less resources are needed 
for such a study. Follow-up monitoring of vaccine efficacy 
over time or in different regions of a country can be simply 
incorporated into the existing health service system. 
moreover, the analysis requires less time. 
The case-control study uses standard estimation of 
vaccine efficacy, though there are some changes in the 
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definition and measurement of the parameters involved. Since 
this method is based on local conditions and data, another 
advantage is that the effectiveness estimated from the study 
would be close to that measured f rom real conditions. 
However, the main disadvantage of the method is the lack 
of sample allocation in a random pattern. As a result, 
confounding or spurious effects on the estimates obtained 
could arise and undermine study findings. Confidence in study 
results and in their use can be secured by examining likely 
confounding factors. 
Miceli et al (1988) investigate the efficacy of the BCG 
vaccination provided to children at birth to 6 years old in 
Buenos Aires by a case-control study. The efficacy estimate 
was 73% (62-82% with 95% confidence interval). In addition, 
different types of TB identification produced different 
efficacy rates. The specific method such as bacteriology 
offered a 96% efficacy whereas the method of X-ray and 
clinical evidence together, the least specific method, 
indicated only a 51% ef f icacy. Between the two are laboratory 
tests other than bacteriology (85%) and a combination of X- 
ray, clinical evidence and positive source history (60%). 
Examining the programme of BCG vaccination of newborn 
children of Indian origin in the UK by a matched case-control 
study, Rodrigues et al (1991) estimate 49% efficacy, which is 
lower than a similar Study in Birmingham (64%) and a classic 
trial of British school children vaccination (80%). 
The Research Committee of the British Thoracic and 
Tuberculosis Association (1975) estimates the effectiveness 
of the British BCG vaccination programme in terms of the 
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number of protected cases, which is the excess of the 
incidence rate of TB cases in the tuberculin-negative 
unvaccinated population over that in vaccinated population. 
The notifications of TB in 15-19 year olds in the year 1973 
were used to assess the school BCG vaccination programme. The 
notification rate in the vaccinated population was 2.72 cases 
per 100000 population and in the other, 12.95 per 100000. 
Therefore, estimated TB prevented cases amounted to 10.23 
cases per 100000 population. 
A simpler version of calculating vaccine effectiveness in 
the form of the absolute number of prevented cases, as also 
shown in the Research Committee's study, is extrapolation 
from the vaccine efficacy rate, available from a BCG 
vaccination trial at that time. 
The number of notification rate in x Efficacv 
cases prevented BCG vaccinated group (1 - Efficacy) 
A computation example according to this method is 
provided in their analysis and is briefly presented here. By 
using an efficacy rate of 80% and the notification rate in 
the vaccinated group of 2.72/100000, the number of the cases 
averted was 
2.72/100000 x 80/(1-80) 10.88 per 100000 population. 
The need for less information and a similar effectiveness 
result to the principal method make this simple estimation 
method popular. Since the survey data in their study were 
only 72.3% of the official notifications reported in 1973, it 
is necessary to allow for missing cases by a direct 
extrapolation. The eventual figure of BCG vaccination 
effectiveness was between 14 and 15 cases within 100000 
vaccinated population. 
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The fact that vaccinees with negative tuberculin response 
are eligible to BCG protective effect whereas those with 
positive response are ineligible, leads Hart (1967) to 
formulate the following equation for the effectiveness 
measure. 
Effectiveness 100 Ux L(100-E) + 100 x I(100-L) 
(U x L) + I(100-L) 
where E = the vaccine efficacy (per cent). 
U = the expected subsequently annual attack 
rate of TB in the eligible if they are not 
vaccinated (cases per 1000 eligible 
persons). 
L = the proportion of the total population 
group who are regarded as eligible for 
vaccination fper cent). 
I = the annual TB attack rate in the 
ineligible (cases per 1000 ineligible 
persons). This parameter is known from a 
tuberculin survey. 
From this equation, the result is shown as the percentage 
reduction in the TB current incidence rate. It is claimed 
that the relative reduction rate is not useful to public 
health administrators (Hart, 1967). However, the 
International Union Against Tuberculosis Committee on 
Prophylaxis (1982) sees the opposite, arguing that the 
estimate appeals to decision-makers. 
Hart (1967) also offers the estimation method for BCG 
vaccination effectiveness in the form of absolute reduction; 
namely, the number of cases prevented. Compared with relative 
reduction method, the absolute estimate is simpler because it 
measures the decline in the disease within the eligible 
population only. 
Effectiveness ExUxL 
100 
The absolute estimate is regarded as more desirable than 
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the relative one (Hart, 1967; Hart et al, 1977) . Table 49 
presents the findings of these two estimates of the BCG 
vaccination effectiveness in five studies provided by Hart 
(1967). 
There are few analyses of the indirect effect of a BCG 
vaccination, separated from the direct effect. The 
examination of indirect effects by Styblo et al (1976) is 
based on a theoretical model, a number of assumptions and 
various data sources. The findings point out that BCG 
vaccination at birth could decrease annual risk of infection 
by less than 1% in a whole population (whatever the basic 
level of the risk of infection is used). Compared with the 
direct effect of 63% reduction in the TB smear-positive cases 
at baseline risk of infection in Styblo et al (1976), the 
indirect effect is minute. It is also suggested that due to 
this small indirect effect, the assessment of a BCG 
vaccination programme should be based only on the direct 
effect. This is reinforced by the fact that the BCG 
vaccination campaign in the 1940s was justified by merely the 
direct effect. In addition, according to Haber et al (1991), 
the formidable difficulty of indirect effect estimation 
arises from a change in age distribution of TB infection, 
rebound effect after the honeymoon period, the expansion of 
the interepidemic interval and variation in the disease 
pattern over time. 
A classical approximation method of the total effect of 
the vaccination compares the trends of TB incidence rate in 
various age groups in a country providing BCG vaccination 
(Norway and Denmark) with those in a country giving no BCG 
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Table 49 Estimated relative and absolute reduction in TB 
from five studies. 
Source of Age group Efficacy Relative Absolute 
study (year) reduction reduction 
(per cent (cases per 
per year) 100000 per 
year) 
1. Britain 14 79 57 70 
2. Puerto Rio 1-8 31 8 8 
3. Geogia/ 5 and over 14 5 1 
Atlanta 
4. Chicago infant - 74 74 128 
, South India all 60 16 28 
Source : Hart (1967). 
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vaccination (The Netherlands) (Styblo et al, 1976). However, 
this approach is unjustified on many grounds. First, it 
cannot control for impacts of the differences in existing TB 
control measures on the vaccination programmes. Secondly, 
there is variation in the definition and corresponding 
measurement of TB cases in different countries. Finally, 
their TB incidence rate, representing TB burden in the 
population, is not comparable. 
The two-state scenario estimation method (existence 
versus non-existence of a BCG vaccination programme) is 
claimed to be compelling when built on the mathematical 
relationships of TB epidemiology (Hanly et al, 1985). 
However, its key methodological setback is the absence of 
data on same ages or cohort-specific parameters in the 
models. In that study, the estimated result diverges from the 
real data to such an extent that they advise constant checks 
of model findings against those under the real conditions. 
In the study by Barnum et al (1980), the analysis of the 
Indonesian BCG vaccination programme avoids many serious 
problems outlined above. The effect of the programme is 
estimated by the dif f erence in the number of survivals, cases 
prevented and averted deaths. The measurement of the effect 
is based on the follow-up of BCG vaccinated cohorts over the 
protection period and the simulated findings of the TB 
infection model assuming the absence of the BCG vaccination 
programme over the same period. 
Different effectiveness estimation methods applied to an 
identical population do not necessarily create similar 
results. A refined method of effectiveness estimation has 
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found an overestimation of BCG vaccination effectiveness in 
the past (Kochi, 1991). The low effectiveness of BCG 
vaccination may explain the fact that, after more than four 
decades of the worldwide mass BCG vaccination campaign, TB is 
still a substantial health problem in many populations. The 
more precise estimation methods of BCG vaccination 
effectiveness are those based on the efficacy estimate, the 
trials for which are the randomised controlled trial and 
case-control study. 
b) Thai studies of effects for BCG vaccination. 
As noted earlier, the case-control study of the BCG 
vaccination effect increasingly replaces the randomised 
controlled trial. This is also true in Thailand. Padungchan 
et al (1986), using a case-control study, was the first and 
only study to date to investigate the BCG vaccination effect 
in the context of Thailand. The procedure is used on account 
that TB in most young children stems from intrafamilial 
infection. The samples were 0-5 year olds having household 
contact with smear-positive TB patients detected at the 
central chest clinics in Bangkok. The standard computation 
methods for vaccine efficacy and effectiveness were employed 
in their analysis, as shown below. 
Efficacy % of incidence in % of incidence in 
unvaccinated qroup vaccinated group 
% of incidence in unvaccinated group 
Effectiveness Efficacy -x 
incidence rate x vaccinated 
of the BCG (1 - Efficacy) in vaccinated population 
programme group size 
Since infants and young children normally do not develop 
obvious forms of TB, there is no precise single definition of 
these TB cases, and also no measurement. In their study, a 
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number of diagnostic criteria were used to specify cases. As 
a result, the dilemma is that less specific diagnostic 
criteria create over-estimation of TB incidence due to 
inclusion of unreal TB cases whereas the stringent criteria 
produce under-estimation because of the exclusion of the 
latent cases. Therefore, the overstated TB cases determined 
by loose diagnostic tests cause exaggerated effectiveness 
estimates of BCG vaccination and vice versa. 
For instance, the study calculates 72% efficacy and 18 
protected cases for such specific diagnosis as bacteriology 
and histology. On the other hand, for hilar adenitis and 
infiltration or other types of TB (the lesser-specific 
tests), the efficacy became 61% and 69 cases could be 
prevented. Moreover, categorising 55 samples without a scar 
or a vaccination record into the unvaccinated subjects, the 
analysis estimates a 53% efficacy and 208 saved cases. 
Nevertheless, the low efficacy of 53% is criticised for 
having a TB incidence rate which is too high in the 
unvaccinated group (32%). 
In order to make these findings applicable to the 
assessment of the Thai BCG vaccination programme, the 
effectiveness estimates, based on the effectiveness 
estimation formula discussed before and the data in the 
study, -can be derived in the following thiýee equations. 
1) 0.72 x 0.00399 x vaccinated = 0.01026 x vaccinated 
(1-0.72) population population 
size size 
2) 0.61 x 0.0351 x vaccinated = 0.0549 x vaccinated 
(1-0.61) population population 
size size 
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3) 0.53 x 0.1544 x vaccinated 0.17411 x vaccinated 
(1-0.53) population population 
size size 
This simply means that for a 1000 BCG vaccinated 
population, there are 10 vaccinees protected from TB 
according to the bacteriology and histology test and 55 
protected vaccinees or up to 174 ones based on the less 
specific tests. 
Though vaccine efficacy based on the less-specific tests 
is lower than that on the specific one, the former's high 
incidence rate makes the preventive effect great. The 
effectiveness estimate based on the diagnosis of enlargement 
hilar lymph nodes (equation 2) is considered irrelevant by 
two reasons (Padungchan et al, 1986). First, the prevention 
of this symptom is not the significant effect of a BCG 
vaccination but that of haematogenous spread of TB is a 
significant effect. Secondly, this symptom, which has found 
to be common among Thai children (about 40%), should not 
seriously be regarded as a TB indication. (Equation 3 can 
also be made invalid by the similar accounts. ) The high 
efficacy and low effectiveness are implicitly advocated in 
that analysis (equation 1). However, the same study notes 
that a possibility of low efficacy might not be ruled out in 
other populations due to malpractice of BCG vaccination 
delivery (e. g. dose used and vaccine handling). 
Although a case-control study cannot accurately assess 
the protection duration conferred by the vaccine, the length 
may be observed from the vaccine ef f icacy in some age groups. 
Because of a similar efficacy rate in the 0-2 and 0-4 age 
groups, it is concluded that the protective effect from the 
342 
BCG vaccination does not wane in the first few years of life. 
Bhunbhu (1989) agrees that the effect of Thailand's BCG 
vaccination at birth could persist until 4 years of age. He 
further comments that BCG vaccination effect should be 
determined within the 0-4 age group only. However, the small 
percentage of officially reported TB cases in this age group 
is not sufficient to enable conclusive assessment of its 
impact. 
The estimation methods of BCG vaccination ef f ect based on 
a tuberculin sensitivity survey may not be appropriate in 
Thailand due to the unaccountability of the survey findings. 
Padungchan et al (1986) find that as many as 30% of the TB 
cases (including bacteriologically confirmed ones) did not 
react to tuberculin. 
A simple but less accurate method of measuring 
vaccination effect is based on estimated trend of the disease 
reduction, which is usually used to set a target of decline 
in TB incidence rate by the Thai government. The government 
proposed a 60% fall in annual incidence of central nervous 
system related TB and other forms in children by 1986 
(Bhunbhu, 1989). It is reliably reported that the BCG 
vaccination coverage in Thailand was 96% in 1987 (Bhunbhu, 
1989). 
4.2.1.4. Estimation of effects for short-course anti-TB 
chemotherapy treatment. 
a) International studies of effects for treatment. 
The anti-TB chemotherapy treatment programme set out to 
identify and treat smear-positive cases, who are mostly 
adults. Case-identification and TB treatment methods in 
developing countries are well described in Fox (1988). The 
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treatment produces two major outcomes which are fundamental 
to its economic evaluation. First, TB cases avoid mortality 
and suffering from the disease. Secondly, a diminishing 
number of TB patients in the population reduces the risk of 
infection, which could contribute to long-term TB control. 
In practice, the effect of a treatment episode is the 
reduction in a case's symptoms and signs as well as his/her 
probability of death. There are formidable difficulties in 
estimating the treatment effect on the reduction in infection 
risk or in TB cases among unprotected population, as 
discussed below. 
At present, for normal and most TB patients, virtually 
all the studies have concluded that the short-course (6 
months) chemotherapy regimen is superior to the standard (12 
months) regimen as well as all to other TB treatment 
regimens, despite the higher cost of the former. Three 
predominant aspects of the short-course regimen are listed 
here. 
1) With the short-course regimen it is easier to achieve 
a high cure rate by securing patient compliance. 
2) It reduces the number of patients under treatment at 
a given time. The treatment rapidly makes smear-positive 
cases non-infectious. 
It prevents the reactivation of drug-resistant 
bacilli, especially when combined tablets 
(isoniazid/rifampicin) are used. 
Therefore, not only this study but the current analyses 
of TB treatment programme focus on the short-course regimen. 
The effect of the short-course treatment depends on the 
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success rate of treatment and the accuracy of case detection. 
In many areas, treatment is less than 60% successful 
(Rodrigues et al, 1990). Fortunately, higher figures are 
increasingly reported. In many countries, case detection is 
poor. One explanation is that the tuberculin test frequently 
gives a false result, making it difficult to diagnose TB 
cases (notably elderly patients). More sophisticated 
techniques of identifying tuberculosis infection are not 
normally employed, especially in developing countries. The 
undetected infectious cases continue to be sources of 
infection. The treatment effect and its assessment are 
further affected by the under-reported cases. Like the 
undetected cases, the infected people in the under-reported 
group spread the disease. The proportion of under-reported 
cases, estimated by Murray et al (1990), could be 20% of the 
maximum number of reported cases in the past ten years. 
These obstacles decrease the influence of treatment on 
reducing the risk of infection, as indicated by the findings 
of studies and surveys on transmission risk. Therefore, many 
studies consider only the effect on cases and deaths averted 
by treatment. 
A simple and straightforward measure of treatment effect 
is to compare the treatment recipients with the controls. A 
randomised controlled trial, regarded as the best procedure 
of treatment effect measurement, should have been undertaken 
to measure the effect of the short-course chemotherapy 
regimen. Unfortunately, the ethical issue prohibits such a 
trial; it is unethical to withhold the treatment in the 
control group since the treatment alleviates the illness. 
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By contrast, the fact that there exist many infected 
people who in reality never acquire medical services makes 
these cases parallel the controls in the trial situation, who 
are supposed to experience the natural course of the disease. 
As a result, the treatment effect can be estimated by 
comparing the treated patients with the untreated cases under 
a non- experimental condition. The findings of some studies 
based on this method are discussed as follows. 
Rodrigues et al (1990) show the Indian and pre-war 
British impacts of TB in the absence of treatment. By 
following up 5 years, both sources gave similar findings. 
Fifty per cent of smear-positive cases died; thirty per cent 
were naturally cured; and 20% remained alive and infectious. 
The mortality rate is comparable to that found in developing 
countries before the availability of treatment, that is, a 
50%-60% death rate (Murray et al, 1990). 
By comparing the condition of 100 smear-positive cases 
with no treatment in South India with that of 100 similar 
cases with the short-course regimen in Tanzania, Murray et al 
(1990) report the effect of treatment within 5 years, follow- 
up, as shown in Table 50. 
As mentioned above, the short-course chemotherapy 
treatment is effective in converting smear-positive patients 
into smear-negative ones within a few months, the gain in 
cases prevented is achieved totally in the first year. By 
contrast, the ef f ect on death prevention occurs over a 5-year 
period, despite a small gain in each year. 
In a similar fashion, Grzybowski (1987) investigates the 
treatment effect based on untreated Indian cases and treated 
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Table 50 : Fate of 100 cases of smear-positive TB with 
no treatment (South Indian results) and with 
the short-course chemotherapy (Tanzanian 
results) for 5-year follow-up. 
Year No treatment (case) With treatment (case) 
cured dead cured dead 
0 0 0 0 0 
1 18.5 20.1 79.6 8.8 
1 
2 27.8 30.2 81.3 11.4 
3 27.8 33.6 81.3 12.7 
4 30.3 40.5 81.3 .5 13.5 
5 32.5 44.9 82.5 14.5 
Source : Murray et al (1990). 
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Dutch patients. Table 51 shows the study outcome. The case- 
fatality ratio of TB patients in the pre-chemotherapy era in 
many industrialised countries is also in the order of 50-60% 
(Murray et al, 1991). 
This estimation method of TB treatment effect is 
criticised for a number of reasons. First, the study 
populations are not randomly selected and allocated into case 
and control groups. The cross-national populations cannot 
avoid misleading effects of factors such as the level of the 
infection risk, living standard, existing TB control measures 
and age distribution. The period of study of treated and 
untreated groups is dissimilar. In the analysis by Grzybowski 
(1987), the Indian study is longitudinal (i. e. the follow-up 
period was more than 5 years) whereas the Dutch study was 
conducted during 1975-1976. It is assumed that these 
drawbacks do not substantially affect the findings of the 
treatment programme assessment. 
b) Thai studies of effects for treatment. 
The short-course (6 months) anti-TB chemotherapy 
treatment is the most effective regimen in Thailand at 
present, as shown by Jittinandana (1989). His study compared 
four drug regimens in 962 patients at the TB Division Clinics 
in Bangkok during 1985-1988. 
The effective regimen (2HRZ/4HR), consisting of daily 
doses for 2 months of 300 mg/d isoniazid (H) , 450-600 mg/d 
rifampicin (R) and 1500-2000 mg/d pyrazinamide (Z), and over 
the next 4 months, daily doses of 300 mg/d isoniazid and 450- 
600 mg/d rifampicin. 85% of patients completed the treatment, 
and 97% of them had the sputum conversion. There was 3% non- 
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Table 51 : The effect of the anti-TB chemotherapy treatment 
programme. 
TB status No treatment With treatment Gain 
(Indian study) (Dutch study) M 
1. number of deaths 50% 1% 49% 
2. number of negative 32% 98% 66% 
sputum patients 
n er of positive 18% 1% 17% 
sputum patients 
I 
Source : Grzybowski (1987). 
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conversion rate and 3% relapse rate. The effectiveness rate, 
defined by the proportion of successfully-treated patients, 
was 79%. For the 2HRZ/4H2R2 regimen, which differs from the 
above regimen by giving isoniazid and rifampicin twice a week 
over the second half of the treatment episode, the number of 
the patients completing the treatment became 83% and 95% of 
them had the sputum conversion. There were 5% of the sputum 
non-converters and 3% of the relapse patients. The 
effectiveness rate was 75%. 
By investigating three types of short-course regimen and 
a standard regimen in Thailand, Kamonratanakul et al (1990) 
confirm the effectiveness of the two regimens mentioned 
above. Their analysis is based on retrospective examination 
of all new cases with sputum positive, who obtained their 
treatment at five TB treatment centres sampled from all parts 
of Thailand during January 1987 to September 1988. 
There were three key diagnostic tests for identifying TB 
cases and for case monitoring. Sputum examination was done at 
each patient visit, every three months after the end of the 
treatment for 2 years. On average, each patient needed 7 
sputum smears and 1 culture. Chest X-ray was performed before 
and after treatment. Other laboratory tests depended upon 
such factors as the complication of the disease and the side 
effects of treatment. Diagnosis findings indicate that 50% of 
patients had lung cavities according to the X-ray. The 
primary sputum examination found that 98.8% of the sputum 
samples were positive. 60% of positive cases were confirmed 
by culture. 
The insignificant impact of such suspected confounding 
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factors as the patients' characteristics, socio-economic 
status, symptoms presented before treatment, the method of TB 
diagnosis and the follow-up result are also emphasised. 
The two most effective regimens, one with superior 
effective outcomes (2HRZ/4HR) and the other with the lowest 
cost (2HRZ/4H2R2) 1 will be used in this study. The main 
effects of the two regimens are presented in Table 52. 
The benef it of anti-TB treatment based on the comparison 
between treatment and non-treatment has never been determined 
in the context of the Thai population. The comparison of TB 
notifications between pre-treatment and treatment eras in 
Thailand is likely to create setbacks due to poor case- 
recording and crude diagnostic techniques in the pre- 
treatment period. It is unlikely to obtain a useful and 
reliable estimate of treatment effect. The treatment effect 
estimated by Murray et al (1990), on which their economic 
assessment of the TB control programme in developing 
countries is based, may well be used to represent the effect 
of Thailand's anti-TB treatment programme. 
As in other countries, Thai patients' compliance to the 
regimen considerably influences the success rate of 
treatment - Jittinandana (1989) points out that the compliance 
of Thai TB patients varies directly with distance between 
patient Is home and the treatment site. The availability of TB 
treatment at rural facilities and a better referral system 
for TB patients would lessen barriers to treatment and could 
promote the regimen's effectiveness. Economic support such as 
free services, subsidy for patient's travel cost and 
compensation for their time cost by the government as well as 
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Table 52 : The main effects of the two short-course 
(6 months) anti-TB chemotherapy regimens. 
Effect 2HRZ/4HR' 2HRZ/4H2R21 
1. complete treatment M 93.0 84.7 
2. sputum conversion (%) 91.5 83.7 
3. sputum non-conversion M 0.7 1.0 
4. sputum relapse (%) 0.0 0.5 
5. drop-out M 5.6 14.8 
6. 2 effectiveness 93.7 83.7 
Notes 1. See the text for the abbreviation. 
2. Effectiveness is computed according to the following 
formula. 
Effectiveness = the number - the number - the number - the number 
of patients of drop- of sputum of relapse 
treated outs non-conver case 
ted cases 
the number of patients treated 
Source : Kamonratanakul et al (1990). 
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social support are proposed to tackle the compliance problem 
and enhance programme effectiveness. Apparently, they are 
outside the current national policy towards the TB treatment. 
A method may be selected from a number of methods to 
measure, monitor, supervise and evaluate patients I compliance 
to their regimens. Each method varies in the compliance rate 
and the operational cost. An optimal amount of supervision 
and corresponding compliance rate should be determined 
according to specific institutional and cultural 
characteristics of the community in question. Chaulet (1987) 
proposes appropriate methods: 
1) The most reliable method is to determine drug levels 
in the blood or drug metabolite levels in the urine. However, 
it is too complicated and expensive to be used in routine 
supervision. 
2) A qualitative urine test, detecting the presence of 
isoniazid metabolites, can reveal drugs taken by a patient 
the day before the test. It is easy to operate, sensitive and 
not too expensive. However, two conditions must be met. 
First, the isoniazid prescribed has to be in the same tablet 
with thiacetazone or rifampicin. Secondly, the test result 
can be maximised if patients and nurses do not know the 
behaviour check objective of the test. Fox (1988) advocates 
the random urine test for use in developing countries. 
3) Monitoring a patient's attendance at the time of drug 
administration or the receipt of drugs may not be sensitive 
enough but is low cost. Also, there are less effective 
methods than those above, which are normally used such as 
counting the tablets handed out at the supervision session, 
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checking drug omission by a special interview and estimating 
drug compliance in the patient Population from the results of 
bacterial resistance studies and from drug consumption 
analysis. 
The causes of non-compliance to the regimens and the 
strategies to improve the compliance are discussed by Goldman 
(1986). 
4.2.2. Estimation of side effects. 
This section focuses on side effects and their incidence 
rates in each health programme. As most side-effect analyses 
are not perfect, a comprehensive review has to be based on 
various information sources reporting side effects such as 
clinical trials, case reports, follow-up articles and so on. 
4.2.2.1. Estimation of side ef f ects f or measles vaccination. 
a) International studies of the side effects of measles 
vaccination. 
As measles and its complications recede, the attention is 
drawn to the vaccination side effects. Two categories of 
adverse reactions are expected from a measles vaccination. 
Mild impacts consist of the following conditions (Halsy et 
al, 1989). 
1) rhinorrhoea and cough 
2) fever within 30 days after vaccination, occurring in 
25% of the vaccinees 
3) rash within 4-6 weeks after vaccination, found in less 
than 4% of the vaccinees 
4) local signs at the site of injection 
5) temporarily arm immobility (24-48 hour period) but 
very infrequently happen 
The following are the serious impacts of a measles 
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vaccination (Ginsberg et al, 1990). 
1) pneumonia =1 per 100000 vaccinees 
2) convulsion =6 per 10000 vaccinees 
3) brain damage =1 per 1000000 vaccinees 
4) death = less than 1 in 10000000 vaccinees 
5) encephalitis or encephalopathy within 30 days of 
vaccination = 0.34 per 1000000 vaccinees 
6) serious neurological illness from seizures or 
encephalopathy within 14 days after vaccination, which 
can be normal within one year =1 per 87000 vaccinees 
It is suggested that a surveillance system should be set 
up to report adverse reactions from measles vaccination 
during the 4 weeks after the vaccination starts (Block, 
1985). The system could signify a change in the side effects, 
particularly serious ones, though it could not produce 
precise estimates. 
Thai studies of the side effects of measles vaccination. 
Conducting a measles vaccination trial and following up 
Thai vaccinees for 2 weeks after the vaccination, Lumbiganon 
et al (1988) find that 28.7% of the vaccinees had fever, 
which in the majority of the sufferers lasted for 1-4 days. 
Rash occurred in 8.1% but rhinorrhoea, cough and diarrhoea 
were infrequent. The incidence rates of these impacts found 
in the Thai study are similar to those reported in the 
international studies. 
Fortunately, no serious or prolonged reactions occurred 
in Thai children who already had measles antibody detected 
prior to the vaccination as well as in those who were 
vaccinated with DPT and OPV and measles vaccines 
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simultaneously. 
As the follow-up period of vaccination side effects was 
short, some serious effects might not yet emerge. It is also 
likely that the vaccination-induced illness could be 
identified as other diseases when the sufferers sought their 
treatment elsewhere. Therefore, six serious conditions as 
well as their magnitudes shown in one of the international 
studies outlined above are assumed to represent the possible 
serious effects from the Thai measles vaccinations. 
4.2.2.2. Estimation of side effects for rotavirus diarrhoea 
vaccination. 
a) International studies of the side effects of rotavirus 
vaccination. 
Virtually none of the controlled trials on the bovine 
vaccine against rotavirus diarrhoea, referred to above, 
reported side effects (De Mol et al, 1986; Hanlon et al, 
1987) . It 
is possible that unnoticed side effects result from 
their short follow-up periods. Hanlon et al (1987) had 
monitored post -vaccination side ef f ects of the bovine vaccine 
daily for 7 days. 
On the other hand, most trials on the rhesus vaccine 
encountered two forms of the adverse reactions. The most 
usual reaction is severe fever (Gothefors et al, 1989). They 
reported fever in 79% of vaccinees. Kapikian et al (1989) 
point out the high dose vaccine (10' pfu) produced febrile 
reaction in 64% of the vaccinees but the lower dose vaccine 
did not. However, another trial finds that this lower dose 
vaccine caused fever in 26% of vaccinees (Vesikari et al, 
1990). Fever, normally makes infants irritable and restless. 
it is noted that the severity of fever is inversely related 
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to the vaccinees' age (Gothefors et al, 1989). 
Diarrhoea, which is def ined as having 3 or more stools 
for at least 1 day, is regarded as a side effect of rotavirus 
vaccination. It is found in a smaller number of vaccinees 
than fever. 42% of vaccinees suffered from post-vaccination 
diarrhoea according to Gothefors et al (1989). Kapikian et al 
(1989) conclude from most trials that diarrhoea occurs in 20% 
of vaccinees. 
As with other vaccines in their pre-marketing period, 
rotavirus vaccine has had a small number of samples in its 
trials and a short period of observation for adverse 
reactions. Reported adverse reactions are possibly 
understated. 
Thorough detection of side effects requires the 
establishment of a surveillance system to report reactions 
over a sufficiently long period and in various populations. 
The assessment of a rotavirus vaccination programme ought to 
be updated whenever more precise magnitude estimates and/or 
new types of side effects are disclosed. 
b) Thai studies of the side effects of rotavirus vaccination. 
Since there have been no rotavirus vaccination trials 
specific to the Thai population, it is assumed that the 
vaccine side effects as well as their incidence rates found 
in the studies reviewed above can be applied to Thai 
vaccinees if a rotavirus vaccination programme is implemented 
in Thailand. The adverse effects of rotavirus vaccination 
reported in international studies are therefore employed in 
the economic appraisal of the Thai rotavirus vaccination 
programme. 
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4.2.2.3. Estimation of side effects for BCG vaccination. 
a) International studies of the side effects of BCG 
vaccination. 
The side effects of BCG vaccination are divided into two 
categories. First, vaccinees can suffer from systematic 
dissemination of the bacillus. However, the probability of 
contracting such a serious complication is remote (Goldman, 
1986). UNICEF (1985) states that the death rate from TB 
infection after a BCG vaccination is between 0.2 and I per 
1000000 vaccinees. Secondly, the vaccination produces local 
adverse reactions. At the site of injection, cutaneous 
nodules may appear and there is swelling of the regional 
lymph nodes, known as a primary complex. Other concurrent 
symptoms include pain at the local area of vaccination, 
erythema, abscess formation and discharge and ulceration. 
These local reactions normally take place about 10 weeks 
after vaccination (Hanly et al, 1985). Without any treatment, 
these conditions persist for several weeks or months. Infants 
feel discomfort (Goldman, 1986). Foster et al (1973) indicate 
that it takes 2 to 6 months before the conditions disappear 
and a small scar is formed. 
The number of cases with these reactions go up with a 
rise in subcutaneous injection and with the increasing number 
of positive-tuberculin vaccinees. A study of local adverse 
reactions from BCG vaccination in a number of countries shows 
that the regional suppurative adenitis and osteitis occur in 
0.1-38 cases per 1000 vaccinees and 0.1-330 per million 
vaccinations, respectively (Milstien et al, 1990). 
For patients with lesions, reactions can be cured by 
erythromycin or isoniazid for '2-4 weeks (Goldman, 1986). 
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Although treatment effectiveness is never demonstrated, the 
prescription of the drug can create a psychological benefit 
f or the parents of most children suf f ering with these ef f ects 
since they usually expect some form of treatment. This 
treatment is safe as the drug causes no further undesirable 
effects. Erythromycin may be given to the cases developing 
the secondary bacterial infection at the injection site 
(Hanly et al, 1985). The treatment no doubt incurs some 
expenses to the health service system, which should be 
included in the cost of the BCG vaccination programme. 
However, Milstien et al (1990) argue that since the 
suppurative lymphadenitis and other local reactions are self- 
healing, treatment is unnecessary. 
The issue of side effects can become important as it is 
found that in most countries there has been an outbreak of 
BCG-associated lymphadenitis for the past several years. Its 
unnoticed outbreak could stem from under-reporting in many 
countries (Milstien et al, 1990). The reaction implicates a 
change in the vaccine strain. The concentration of the 
vaccine, the age of the vaccinees, the use of proper 
intradermal injection techniques, the method of vaccine 
preparation and the characteristics of the vaccine recipient 
population are also found to affect the incidence of regional 
suppurative adenitis. Although it is unclear about factors 
accountable for osteitis in the vaccinees, it is speculated 
that the active case-finding, vaccine strain, manufacturing 
technique and body site of the vaccination are responsible 
for this effect. 
Adverse effects of BCG vaccination could arguably affect 
359 
an increase in drop-out rate of the vaccination as well as in 
the withdrawal of other childhood vaccinations because of 
parents' fear of side effects (Milstien et al, 1990). These 
authors also predict that a BCG vaccination programme would 
encounter problem if the incidence rate of the regional 
lymphadenitis occurs in more than 1% of the vaccinated 
population. 
b) Thai studies of the side effects of BCG vaccination. 
There are no studies on detecting adverse reactions from 
Thailand's BCG vaccination programme. There is no good reason 
why side effects from BCG vaccination described above could 
not happen in Thailand. Therefore, the type and volume of 
side ef f ects caused by the Thai BCG vaccination programme are 
presumably in accordance with the findings of international 
studies. As indicated above, about 30% of Thai infants were 
found to be insensitive to tuberculin test and vaccinees with 
low tuberculin response are at risk from minor local adverse 
reactions. It is assumed that 30% of the Thai vaccinees 
suffer from pain, abscess and ulceration at the injection 
site. 
Each mild adverse condition is presumably healed by 
itself within 2-4 weeks. Because Thailand's BCG vaccination 
programme does not provide treatment of the side effects and 
because the cost of treatment, which is left outside the 
responsibility of the programme, is unknown, this analysis 
does not take into account the side-effect treatment as well 
as its cost. 
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4.2.2.4. Estimation of side effects for short-course anti-TB 
chemotherapy treatment. 
a) International studies of the treatment side effects. 
Only recently have the side effects from the anti-TB 
chemotherapy treatment become a centre of attention in the 
analysis of the treatment. According to the frequency and 
scale of the damages done to the treated patients, there are 
common and complicated side effects. 
Common and widely recognised reactions are vertigo, 
jaundice and hypersensitivity. Hepatitis is reported to be a 
major side effect from isoniazid, followed by death at a 
lesser extent. International Union Against Tuberculosis 
Committee on Prophylaxis (1982) estimates about 0.4% of the 
drug recipients are at the risk of hepatitis from this drug. 
it can be observed within the first three months of the 
treatment in more than half the cases. 1.4 cases in 10000 
persons are found to die from taking the drug in 12- and 52- 
week regimens. Hepatotoxicity is likely to happen in patients 
aged over 35. These reactions are manifested in the early 
weeks of the treatments (Horne, 1984). 
In contrast, psudomenbranous colitis, acute renal 
failure, acute thrombocytopenia and the precipitation of 
adrenal crisis are serious conditions but happen 
infrequently. These impacts are mainly a result of 
rifampicin. The patients concurrently taking contraceptive 
pills or anti-coagulant drugs are highly vulnerable (Horne, 
1984). 
Due to the relation to the side effect issue, the relapse 
of TB is discussed under this category. Goldman (1986) 
summarises the causative factors of treatment failure as 
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follows. 
1) Insufficient regimens are prescribed in the treatment. 
2) Drug toxicity arises. 
3) Patients discharge themselves from treatment 
prematurely. 
4) Patients do not comply with the drug regimen by 
stopping taking drugs or by irregularly taking them, though 
they are present at the treatment centre. 
5) Drug-resistant infection develops at the start of 
treatment. 
Styblo et al (1984) estimate the magnitude of the relapse 
of TB in the pre -chemotherapy era and in the chemotherapy 
era. In the former, there were 4.4% annually in the first 5 
year period of the observation and 1.6% annually in the 
second 5 year period. In other words, at the end of the f irst 
10 years, the total relapse cases were about 30%. In the 
latter, the TB relapse cases reduced to between less than 
0.1% and below 1% per year. The extent of the relapse in a 
population depends on the prevalence of the active TB cases, 
their age and sex distribution, the proportion of these cases 
who have no or poor chemotherapy, and case-finding methods 
(e. g. indiscriminately active case-finding in a routine 
culture examination versus a passive case-finding for the 
cases that develop symptoms). 
b) Thai studies of the treatment side effects. 
jittinanadana (1989) finds that the short-course 
chemotherapy treatment caused 1% death and 3% drug side 
effects among the Thai treated patients in his study. 
Although the drug side effects were not categorically 
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elaborated in his study, it can be understood that the 
symptoms and clinical features of the effects, described in 
the international studies outlined earlier, are applicable to 
the Thai patients. 
Kamonratanakul et al (1990) indicate that 6.3% of the 
patients treated with the 2HRZ/4HR regimen suffered from the 
side effects and so did 5.8% of those with the 2HRZ/4H, R2 
regimen. Again, the details of the side effects were not 
disclosed. 
4.2.3. A method of the conversion of the diseases and side 
effects into health states as well as QALY loss. 
There are four steps of the conversion process based on 
the symptoms, signs and prognoses. First, the key clinical 
features of each disease are gathered. Secondly, a rule 
assigning a health dimension in the EuroQol instrument 
classification to each fundamental symptom/sign is 
established and used to express all the clinical features 
involved into the correspondent health states. Thirdly, each 
converted health state is given a value from the survey and 
a valuation model. Finally, the average QALY loss from the 
diseases and side effects are computed based on the 
probability of each health state's manifestation, each health 
state's duration and its quality of life value. In order to 
maintain compatibility and comparability, all same symptoms 
and signs of the diseases and side effects are supposed to be 
identical. Only symptoms, signs, complications and side 
effects mentioned in this study are dealt with. 
4.2.3.1. Clinical features of the diseases. 
The main clinical features of the diseases include 
symptoms and/or signs, their duration and the possibility of 
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their manifestation. For the short-term diseases like measles 
and rotavirus diarrhoea, the features are grouped into 
general symptoms/signs and complications. For the long-term 
ones such as TB in infants and adults, prognosis or 
developing stages of the diseases are considered. It is 
presumed that the clinical findings gathered from various 
international sources can describe the Thai cases. 
A) Clinical features of measles. 
Measles is a childhood common disease and easily 
recognised. Following an incubation period of 10 to 12 days, 
there are fever, malaise, conjunctivitis, coryza, 
tracheobronchitis manifestation, such as cough and rash, all 
of which last for at least 2-4 days (Foster et al, 1992) or 
3-7 days (UNICEF, 1985). 
Measles can also cause other serious damage to infected 
people in many forms. The following is a collection of the 
type and magnitude of the measles complications from various 
sources. Some conditions are not regarded by all as the 
complicated effects but all the conditions are accepted by 
most. 
a) Diarrhoea. It was found in 6% of measles cases in 
industrialised countries but 37% in Sri Lanka (Foster et al, 
1992). It is also found that more than half the diarrhoeal 
episodes from measles lasted longer than 7 days in Nigeria. 
In 1989, the Thai surveillance network reporte6 that 1.8% of 
measles cases developed acute diarrhoea (Department of 
Epidemiology, 1989). The very low diarrhoea-complicated 
measles incidence rate is strongly suspected to be due to 
under- reporting. Probably because such a condition can be 
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confused with other types of diarrhoea and is highly likely 
to be subject to lack of motivation to report it. As with 
other diarrhoeas, it can give rise to dehydration and 
malnutrition, which are the complications accompanying 
diarrhoea, in infants and children. But their severity is far 
less than that from rotavirus diarrhoea. Judged by their 
small volumes, the dehydration and malnutrition from the 
measles-complicated diarrhoea are disregarded in this 
analysis. 
b) Otitis media. This complication has been found similar 
in both industrialised and developing countries, affecting 6- 
7% of measles cases (Foster et al, 1992) . However, Block 
(1985) estimates the incidence rate at 2.5%. 
c) Pneumonia. It is found to affect 3.8% of measles cases 
(Block, 1985), 4% (Foster et al, 1992), 5% (Ginsberg et al, 
1990) and 5% in Thailand (Department of Epidemiology, 1989). 
Similar to the diarrhoeal complication, the Thai under- 
reporting data of measles-induced pneumonia is possible 
(Department of Epidemiology, 1982). The incidence rate is 
high in Sri Lanka, about 30% (Foster et al, 1992). 
d) Measles encephalitis. This complication has been 
considered the most serious of all the complications and 
extensively studied. As a whole, its incidence rate is 
assumed at 0.2% of measles cases (Foster et al, 1992), 0.1% 
(Block, 1985), 0.1% (Axnick et al, 1969) and 0.18% in 
Thailand (Department of Epidemiology, 1989). it is likely to 
be accurately reported in Thailand (Department of 
Epidemiology, 1982). Ginsberg et al (1990) divide this 
complication into non-neurologic measles encephalitis and 
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that with definite neurological impacts. They suppose 0.021% 
of measles cases suffering from the former and 0.0087% from 
the latter. Block (1985) categorically offers the incidence 
rate of six critical conditions as the potential consequences 
of measles encephalitis. 
1) coma in 40-45% of measles encephalitis cases 
2) convulsion in 45-50% of measles encephalitis cases 
3) involuntary movement in 19% of measles encephalitis 
cases 
4) paralysis in 12% of measles encephalitis cases 
5) ataxia in 10% of measles encephalitis cases 
6) death in 27% of measles encephalitis cases 
In this study, the survivals of measles encephalitis, 57% 
of who were followed up to 2-10 years, showed that the 
following features could be with them for the rest of their 
life. 
1) mental retardation in 10-25% of the survivals 
2) residual seizures in 1-11% of the survivals 
3) hemiparesis in 8% of the survivals 
4) visual impairment in 3% of the survivals 
5) ataxia in 2% of the survivals 
6) major behaviour disorder in 2% of the survivals 
7) dysarthria, aphasia and deafness are infrequent 
Similarly, Anwick et al (1969) assume that 10% of measles 
encephalitis patients die and 33% have mental retardation or 
other central nervous system damage. 
e) Subacute sclerosing panencephalitis (SSPE). This was 
recently discovered in measles patients. SSPE occurs about 7 
years after measles occurs. According to a study, all known 
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cases reported in 1964-1969 were children under 10 years of 
age (Ginsberg et al, 1990) . Although 
it has a prospect of 
self-improvement, the majority of the patients suffer from 
mental deterioration over a period of months or years before 
convulsions, coma and eventually death occur. Ginsberg et al 
(1990) assume that the fatal SSPE happens in 0.0232-0.0657% 
of measles cases and the non-fatal SSPE in 0.09256-2.0212%. 
Foster et al (1992) estimate the incidence rate at 0.001%. 
f) Conditions involving behaviour change, irritability, 
confusion, seizure and convulsion occur in about 0.1-0.2% of 
measles cases (Block, 1985). On the contrary, convulsion 
alone in Sri Lanka was found to be around 2% (Foster et al, 
1992). 
g) Blindness. Due to vitamin A deficiency, it is a long- 
term disability caused by this disease. Foster et al (1992) 
state that in Africa, the measles-induced blindness occurred 
in about 1 in 1000 pre-school children infected with measles. 
Holden et al (1987) assume an incidence rate of 1 in 400 
measles cases. 
h) Death from complication. Its incidence rate is 
supposed to be 0.2% of measles cases with any complication 
(Foster et al, 1992). In Thailand, it was 1% and 0.5% in 1984 
and 1985, respectively (Department of Epidemiology, 1984 and 
1985). As a result, this can be extrapolated that the 
incidence rate of measles complication-induced death was 
0.04725-0.0945% of measles cases in Thailand in 1989. 
B) Clinical features of rotavirus diarrhoea. 
Basically, diarrhoea is defined as an increased number of 
stools of liquids or semi-liquid passed during a 24 hour 
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period (Foster et al, 1992) . According to the World Health 
Organisation, it is further regarded as clinical 
manifestation if diarrhoea and other related symptoms persist 
longer than 48 hours with more than three loose stools in 
each 24 hour interval. Rotavirus is a major cause of acute 
diarrhoea in infants and young children throughout the world 
(Oyejide et al, 1988; vesikari et al, 1983). 
Rotavirus is responsible for a large proportion of 
diarrhoeal diseases in both developed and developing 
countries. Kapikian et al (1989) find that it was associated 
with 35-50% of severe diarrhoeal diseases in children younger 
than 2 years of age. In the US during 1974 and 1982 and in 
Japan during 1974 and 1981, rotavirus was the cause for 34.5% 
of 1537 children with diarrhoea and 45% of 1910 children 
admitted to hospital, respectively (Kapikian et al, 1989). 
Oyejide et al (1988) report that in developing countries 
33% to 61% of the hospitalised children were the result of 
rotavirus diarrhoea. In a highly susceptible population, its 
attack rate could be very high in pre-school children (62% of 
all kinds of gastroenteritis) and in infants (40%). 
Rotavirus diarrhoea is, in general, mild and self- 
limiting. But, in some children, it becomes more severe and 
fatal. Main symptoms consist of the daily occurrence of a 
number of diarrhoea episodes, vomiting and fever. Each 
symptom has a short duration. Senturia (1986) describes the 
symptoms of rotavirus diarrhoea as beginning with the loss of 
absorptive capacity in the small intestine. Then there is 
often early vomiting followed by explosive and watery 
diarrhoea, lasting for 5-7 days. 
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Oyejide et al (1988) report the following key symptoms 
among the identified rotavirus cases in Nigeria. The length 
of a rotavirus diarrhoeal episode ranged from 5 to 12 days, 
with a mean of 8 days. Fever was found in 68% of the cases 
and vomiting in 64%. Their outcomes are claimed to be similar 
to another study of this disease in a rural Bangladeshi 
community. 
Main concerns about the disease are its complication 
impacts in the form of dehydration, malnutrition, impaired 
growth and death in infants and young children. Dehydration 
and protein-energy malnutrition (PEM), which is a popular 
term for malnutrition from such illness as diarrhoea, are two 
main, voluminous consequences. Though related, they are 
separated because the variation in the length of the impacts. 
Dehydration is one of the causes responsible for PEM. But it 
is essentially to be restored in a proper period or the 
sufferers, particularly infants and young children, are very 
susceptible to death. However, malnutrition may take longer 
period f or the recovery and could inf luence upon inf ants I and 
young children's growth. It could impair both the physical 
and mental development in children and the working and 
earning capacity in adults (UNICEF, 1990). It is also 
reported that the mental consequences due to the impaired 
nutrition may reduce memory capacity, damage ability to 
concentrate and cause poor emotional development (Goldsmith 
et al, 1989). 
it is unfortunate that in acute diarrhoea, the 
concurrence of dehydration and PEM makes it difficult to 
diagnose the latter condition. Moreover, the mental 
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retardation, usually occurring in chronic cases, is hard to 
diagnose and observe because the children already shy of 
social participation (Goldsmith et al, 1989). 
There are a very small number of studies about the extent 
of diarrhoeal impact on PEM. Goldsmith et al (1989) refer to 
a study that estimates that 26% of the malnutritional 
Bangladeshi children are attributable to diarrhoea. During 
1980-1987, UNICEF (1990) reports that Thailand had 4% of 
children aged 0-4 suffering from severe underweight. If it is 
assumed that the severe underweight is equivalent to PEM and 
that 26% of the cases arise from rotavirus diarrhoea, then 
the PEM incidence rate, due to the disease, could be 1.04% of 
the rotavirus diarrhoea victims. 
The demand for quantifying the severity of the symptoms 
of diarrhoea is responded to by the production of a scoring 
system to assess the seriousness of infantile acute diarrhoea 
(Flores et al, 1987), as is presented in Table 53. But, 
unfortunately, it cannot be converted into a health state 
classification. 
Compared with other causes of acute diarrhoea, rotavirus 
creates more severity of the symptoms. Black (1981) points 
out that rotavirus diarrhoea creates more serious dehydration 
and a greater number of medical uses than diarrhoea caused by 
E. coli and other aetiologies, as quoted in Table 54. 
Moderate-and severe dehydration stemming from diarrhoea can 
be referred to as a persistent skinfold plus at least one of 
the following signs sunken fontanelle, dry mouth and 
tongue, sunken eyes, reduced urinary output, weak pulse, 
sleepy or irritable condition (Victora et al, 1990). Victora 
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Table 53 :A scoring system of evaluating the severity of 
infantile diarrhoea. 
Clinical symptom and sign Score 
Duration of diarrhoea 
1.1. <2 days 1 
1.2 2-4 days 2 
1.3 >4 days 3 
2. Maximum number of diarrhoea stools in 24 hours 
2.1.3 stools 1 
2.2.4-5 stools 2 
2.3. >5 stools 3 
3. Duration of vomiting 
3.1. no vomiting 0 
3.2.1-2 days 1 
3.3.3 days and over 2 
4. Fever (rectal temperature) 
4.1. <38.1 *c 0 
4.2.38.1 *c or greater 1 
5. Dehydration 
5.1. none 0 
5.2.5% or less than 5% 2 
5.3. > 5% 3 
6. Hospital admission necessary 
6.1. yes 2 
6.2. no 0 
Source : Flores et al (1987). 
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Table 54 : Severity of dehydration and treatment requirement 
caused by various diarrhoeal agents. 
Indication Diarrhoeal agent 
rotavirus E. coli Others 
1. Total dehydration 19 10 12 
1.1. mild dehydration (%) 15 9 1 
1.2. moderate dehydration 4 1 1 
2. Visiting treatment centre 13 4 4 
Source : Block et al (1988). 
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et al (1990) argue that rotavirus diarrhoea includes a higher 
fever and the more frequent occurrence of vomiting than other 
diarrhoeas. Also, in many occasions, rotavirus diarrhoea 
patients need more extensive care than others such as 
nosogastic tube and i. v. fluids due to the presence of 
acidosis. However, Phonboon et al (1986) note that acute 
diarrhoea diseases in Thailand appear to have less severe 
outcomes compared with those reported internationally. 
c) Clinical features of TB in infants. 
Infant's tuberculosis is analysed separately from adult's 
tuberculosis because of the differences in symptoms, signs 
and prognosis, in case-finding methods, in the volume of the 
infected cases resisting to the disease and in appropriate 
control measures. 
Wallgren (1948) makes two points about the study of TB 
prognosis. First, the known prognosis is derived from an 
average (minority) TB cases due to the uncertain course of 
the disease in most cases. Secondly, the occurrence of each 
stage of TB is in a wide interval rather than a definite 
point of time. 
Foster et al (1973) describe the main features of 
infantile tuberculosis as follows. The large majority of 
children do not manifest clinical symptoms following 
infection. Goldsmith et al (1989) state that 5-15% of TB 
infected persons develop full tuberculosis. In the initial 
stage of the disease, a mild non-specific feverish illness 
occurs at the time of tuberculin conversion, so-called 
,, initial fever", lasting for 5-8 weeks. Occasionally erythema 
nodosum or phyeyctenular conjunctivitis develops. Then comes 
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the primary complex. Haematogenous dissemination results in 
miliary tuberculosis or in tuberculosis meningitis. Bronchial 
dissemination leading to bronchopneumonia tends to occur 
within the next six months and in most cases within one year 
of the first infection. Local complications from the primary 
complex, such as pulmonary segmental collapse or obstructive 
emphysema, come a little later, usually 6 to 18 months after 
infection and may persist much longer. The same applies to 
the complications of cervical and mesenteric adenitis. 
Individual organ tuberculosis such as that of the bones and 
kidneys comes even later : two or more years after tuberculin 
conversion. Finally, chronic pulmonary tuberculosis comes 
many years after the first infection. The clinical features 
in this advanced stage for child patients are likely to be 
the same as for adult patients. Hence, to avoid repetition, 
the clinical features in this stage are given only in the 
clinical features of TB in adults. 
Moreover, in comparison between young and older children, 
if the first infection occurs in adolescence, the adult type 
of pulmonary tuberculosis is likely to follow soon. 
D) Clinical features of TB in adults. 
As in infant's tuberculosis, adult's tuberculosis is 
usually unnoticed initially. The duration from infection to 
the conversion of a tuberculin skin test, also known as 
primary lesions, is 6 to 8 weeks (Goldsmith et al, 1989). 
During 5 to 8 weeks from the first infection, the patient has 
signs of malaise, discomfort, fever, night sweats, weight 
loss, breathlessness, pain in the side or shoulder, cough, 
abundance of sputum, blood spitting, a primary lesion in 
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lung, anorexia, lassitude, strength loss, actual emaciation, 
chest pain, female amenorrhoea and male impotence. 
The disease develops with uncertain rate, depending on 
the patient's condition. In this second stage, the clinical 
condition is mainly the intensification of those present in 
the first stage. There is more cough and the spit is thick 
and yellow. The patient becomes much weaker, greatly lost in 
weight, swing fever, vomiting and diarrhoea. A key sign in 
this stage is the falling in the chest over the excavated 
area. 
The advanced stage may progress within the six months, 
which includes organ damages, serious debilitation, 
disfiguring and crippling (Dubos, 1953; Smith, 1988; 
Packed, 1989). Large cavities have formed in the lung, 
troublesome diarrhoea, haemorrhage, extreme emaciation, bed- 
sores, swing temperature, excessive sweats, cough. Throughout 
the disease, there is often a curious mental state known as 
the spes phthisica. The sufferer is brought up by the daily 
recurring belief that he/she is better and is beginning to 
recover. 
Although most cases of the active disease have pulmonary 
TB, virtually any organ may later be af f ected. Their symptoms 
and signs vary accordingly. According to the Thai public 
health reports, pulmonary TB happened in about 93-95% of the 
total TB cases during 1984-1989 (Department of Epidemiology, 
1984 to 1989; Division of Health Statistics, 1988). Death is 
highly possible without treatment. 
Murray et al (1991) point out that in 80% of all the TB 
cases, clinical symptoms appear during the first two years 
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following the primary infection. 
Kamonratanakul et al (1990) report the common symptoms 
and signs of the Thai TB patients, as shown in Table 55, from 
the passive case-finding before their treatment, which are 
consistent with those in the early stage of TB described 
above. 
Though the symptoms and signs are simple indications for 
TB, less than half the Thai TB cases (42.4%) were found to be 
smear-positive in 1987 (Department of Epidemiology, 1987). 
4.2.3.2. The conversion of the clinical features into the 
EuroQol health states. 
There are two steps in the conversion. In the first step, 
the clinical features and the correspondent health dimensions 
are matched. The second step involves the assignment of the 
severity level of the former to that of the latter. It should 
be stressed that this conversion approach, like any others in 
other studies (e. g. Williams, 1988a), is built on the value 
judgement. 
In this transformation method, the basic unit of the 
clinical features is a general symptom or sign. Indirect or 
ensuring diseases (e. g. some complications) have to be broken 
down into fundamental symptoms/signs. This is done by 
consulting a standard medical dictionary (Havard, 1990) . Most 
of debility and disability as a whole are connected more 
closely with health outcomes and health states than general 
symptoms/signs. Therefore, they should be directly 
transformed into health states. Table 56 shows the 
transformation of the clinical features of the study diseases 
and side effects into the correspondent EuroQol health 
dimension descriptors. 
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Table 55 : TB patients' key symptoms and signs presented at 
the TB treatment centres in Thailand. 
Symptoms Per cent of cases 
1. cough 87.0 
2. fever 46.6 
3. malaise 46.6 
4. weight loss 43.1 
5. chest pain 42.9 
* haemolysis 35.2 
Source : Kamonratanakul et al (1990). 
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Table 56 : The conversion of the clinical symptoms/signs 
into the EuroQol health dimension descriptors. 
Clinical symptoms, signs 
debility and disability 
EuroQol health 
dimension descriptor 
A. General 
1. abscess 
2. acute thrombocytopenia 
3. acute renal failure 
4. amenorrhoea 
5. anorexia 
6. bed-sores 
7. blood spitting 
8. breathlessness 
9. cervical and menseteric adenitis 
10. coma 
ll. confusion 
12. conjunctivitis 
13. convulsion 
14. coryza 
15. cough 
16. diarrhoea 
17. discomfort 
18. emaciation 
19. erythema 
20. fever 
21. hepatotoxicity 
22. hepatitis 
23. haemorrhage 
(as well as haemoptysis) 
24. hypersensitivity 
25. irritability 
26. jaundice 
27.1assitude 
28. malaise 
29. male impotent 
30. night sweats 
31. obstructive emphysema 
32. otitis media 
33. osteitis 
34. pain (in any where) 
35. precipitation of adrenal crisis 
36. psudomenbraneous colitis 
37. rash 
38. regional suppurative adenitis 
39. rhinorrhoea 
40. seizures 
41. spes phthisica 
42. ulceration 
problem in discomfort 
problem in discomfort 
problem in pain 
problem in anxiety/depression 
problem in discomfort 
problem in discomfort 
problem in pain 
problem in discomfort 
problem in discomfort 
unconsciousness 
problem in anxiety/depression 
problem in discomfort 
problem in usual activities, 
discomfort and anxiety/ 
depression 
problem in discomfort 
problem in discomfort 
problem in usual activities 
and discomfort 
problem in discomfort 
problem in discomfort 
problem in pain 
problem in discomfort 
problem in discomfort 
problem in discomfort 
problem in pain 
problem in discomfort 
problem in anxiety/depression 
problem in discomfort 
problem in discomfort 
problem in usual activity 
and discomfort 
problem in anxiety/depression 
problem in discomfort 
problem in discomfort 
problem in discomfort 
problem in pain 
problem in pain 
problem in pain 
problem in pain 
problem in discomfort 
problem in discomfort 
problem in discomfort 
problem in discomfort 
problem in anxiety/depression 
problem in discomfort 
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Table 56 : The conversion of the clinical symptoms/signs 
into the EuroQol health dimension descriptors 
(continued). 
Clinical symptoms, signs 
debility and disability 
43. vertigo 
44. vomit 
45. weight loss 
Indirect disease 
1. encephalitis 
1.1. ataxia 
1.2. behavioural impairment 
1.3. behaviour disturbance 
convulsion 
1.5. delirium 
1.6. emotional impairment 
1.7. epilepsy 
1.8. hemiparesis 
1.9. intellectual impairment 
1.10. involuntary movement 
1.11.1imb paralysis 
1.12. neurological disorder 
1.13. neurological impairment 
1.14. neurological retardation 
1.15. psychological impairment 
1.16. residual seizures 
1.17. visual impairment 
2. encephalopathy 
2.1. convulsion 
2.2. delirium 
2.3. headache 
3. pneumonia (as well as 
3.1. breathing difficulty 
3.2. cough 
3.3. cyanosis 
3.4. diminished movement 
the affected areas 
3.5. dyspnoea 
3.6. fever 
3.7. pleuritis pain 
problem 
problem 
problem 
in discomfort 
in discomfort 
in discomfort 
in discomfort 
in discomfort 
in discomfort 
in pain 
EuroQol health 
dimension descriptor 
problem in discomfort 
problem in discomfort 
problem in discomfort 
problem in mobility 
problem in usual activities 
problem in usual activities 
and discomfort 
problem in usual activities, 
discomfort and anxiety/ 
depression 
problem in discomfort 
problem in anxiety/depression 
unconsciousness 
problem in mobility 
problem in self-care 
and usual activities 
problem in discomfort 
problem in mobility 
problem in anxiety/depression 
problem in anxiety/depression 
problem in self-care, 
usual activities and 
anxiety/depression 
problem in anxiety/depression 
problem in discomfort 
problem in discomfort 
problem in usual activities, 
discomfort and anxiety/ 
depression 
problem in usual activities 
problem in pain 
bronchopneumonia) 
problem 
problem 
problem 
of problem 
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Table 56 : The conversion of the clinical symptoms/signs 
into the EuroQol, health dimension descriptors 
(continued). 
clinical symptoms, signs 
debility and disability 
EuroQol health 
dimension descriptor 
4. subacute sclerosing panencephalitis 
(SSPE) 
4.1. coma unconsciousness 
4.2. convulsion problem in usual activities, 
discomfort and anxiety/ 
depression 
4.3. mental deterioration problem in anxiety/depression 
C. Debility and disability 
1. blindness 
2. brain damage 
crippling 
4. disfiguring 
5. dehydration 
6. malnutrition (PEM) 
7. serious debility 
problem in self-care, 
usual activities and 
discomfort 
problem in self-care, 
usual activities, 
discomfort and anxiety/ 
depression 
problem in mobility, 
self-care, 
usual activities 
and discomfort 
problem in mobility, 
usual activities, 
discomfort, 
and anxiety/depression 
problem in usual activities 
and discomfort 
problem in self-care 
usual activities 
and anxiety/depression 
problem in usual activities 
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This transformation method differs from those in other 
studies available at present (e. g. Gudex, 1986 and Williams, 
1988a) in two ways. First, in this method the basic unit of 
the derived outcome is a health dimension whereas it is a 
health state in the others. This means that this method 
handles converted health outcome at a more fundamental level 
than the others do. Secondly, this method relies on only 
descriptive measurement of health outcomes from its sources 
while the others depend not only on the measurement, but also 
on the correspondent valuation. The derived outcomes in the 
latter approaches to some extent are influenced by the 
grading system in the original results. Though to some 
people, verbal modifications accompanying symptoms/signs, for 
example "extreme", "serious" or "severe", are implicitly a 
ranking system, they are regarded here to generate virtually 
no adverse effect compared with a numerical system. Despite 
the fact that the former is independent of the impact of an 
arbitrary or different weighting system, its difficulty is 
how to grade the severity level in each health dimension. 
In many instances, medical sources provide better 
information for pain/discomfort, mobility and 
anxiety/depression dimensions than for usual activities and 
selfcare ones. This is because the latter health dimensions 
normally are not concerned in the traditional medical 
investigation. Compared with the former dimensions, the 
latter ones are more difficult to be rectified by medical 
procedures and involve prolonged manifestation. To realise 
them, it is necessary to follow up patients in their routine- 
life condition. 
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The severity degrees in the latter dimensions depend, to 
some extent, on those of the f ormer ones. For instance, one Is 
extreme pain could interfere with a person's usual 
activities. Some indications, like the need for admission to 
an inpatient department, may be another piece of the 
information regarding the usual activities and selfcare 
restrictions. Such considerations are taken into the author's 
judgement about categorising the severity levels in some 
dimensions. 
The following three rules are made to categorise the 
severity level of a symptom/sign. 
1. A symptom/sign is first assumed to create a moderate 
problem in a correspondent health dimension except for that 
meeting the second rule. 
2. A symptom/sign that is modified by such an adjectival 
word as "extreme", "most troublesome", "profound", "serious" 
or "severe" in its original source is assigned an extreme 
severity level in a correspondent health dimension. 
3. Since there are many occasions when different 
symptoms/signs affect a same health dimension concurrently 
although the marginal impact may not be significant, their 
impacts in that health dimension should not equal the 
combination of the separate severity levels. It is assumed 
that only the symptom/sign causing the highest severity level 
in a dimension counts. 
The transformed health states of each disease and side 
effect are presented in Table 57. 
4.2.3.3. The valuation of the health states from the 
survey and approximation. 
Following the establishment of the health states for the 
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Table 57 Converted EuroQol health states for the diseases 
and side effects. 
Disease and side effect 
1. Measles 
General symptoms and siqns 
EuroQol health state 
descriptor 
fever, malaise, conjunctivitis, no problems in walking about, 
coryza, cough and rash no problems with self-care, 
some problems in performing usual 
activities, 
moderate pain/discomfort, 
not anxious/depressed 
B. Complications 
1. diarrhoea no problems in walking about, 
no problems with self-care, 
some problems in performing usual 
activities, 
moderate pain/discomfort, 
not anxious/depressed 
2. otitis media 
3. pneumonia 
measles encephalitis 
no problems in walking about, 
no problems with self-care, 
no problems in performing usual 
activities, 
moderate pain/discomfort 
not anxious/depressed 
no problems in walking about, 
no problems with self-care, 
no problems in performing usual 
activities, 
moderate pain/discomfort 
not anxious/depressed 
some problems in walking about, 
some problems washing/dressing, 
some problems in performing usual 
activities, 
moderate pain/discomfort 
extremely anxious/depressed 
and a possibility of 
unconsciousness 
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Table 57 : Converted EuroQol health states for the diseases 
and side effects (continued). 
Disease and side effect 
5. subacute sclerosing 
panencephalitis 
6. irritability, confusion, 
seizures and convulsion 
7. blindness 
EuroQol health state 
descriptor 
no problems in walking about, 
no problems with self-care, 
some problems in performing usual 
activities, 
moderate pain/discomfort 
extremely anxious/depressed 
and a possibility of 
unconsciousness 
no problems in walking about, 
no problems with self-care, 
some problems in performing usual 
activities, 
moderate pain/discomfort 
moderately anxious/depressed 
no problems in walking about, 
some problems washing/dressing, 
some problems in performing usual 
activities, 
moderate pain/discomfort, 
not anxious/depressed 
C. The side effects of measles vaccination 
fever no problems in walking about, 
no problems with self-care, 
no problems in performing usual 
activities, 
moderate pain/discomfort, 
not anxious/depressed 
2. rash no problems in walking about, 
no problems with self-care, 
no problems in performing usual 
activities, 
moderate pain/discomfort, 
not anxious/depressed 
3. pneumonia no problems in walking about, 
no problems with self-care, 
no problems in performing usual 
activities, 
moderate pain/discomfort, 
not anxious/depressed 
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Table 57 : Converted EuroQol health states for the diseases 
and side effects (continued). 
Disease and side effect EuroQol health state 
descriptor 
4. convulsion no problems in walking about, 
no problems with self-care, 
some problems in performing usual 
activities 
moderate pain/discomfort, 
moderately anxious/depressed 
5. brain damage no problems in walking about, 
unable to wash/dress oneself, 
unable to perform usual 
activities, 
moderate pain/discomfort, 
moderately anxious/depressed 
6. encephalitis some problems in walking about, 
some problems washing/dressing, 
some problems in performing usual 
activities, 
moderate pain/discomfort, 
extremely anxious/depressed 
and a possibility of 
unconsciousness 
7. encephalopathy no problems in walking about, 
no problems with self-care, 
some problems in performing usual 
activities, 
moderate pain/discomfort, 
moderately anxious/depressed 
Rotavirus diarrhoea 
A. General sYmPtoms and siqns 
diarrhoea, vomiting and fever no problems in walking about, 
no problems with self-care, 
some problems in performing usual 
activities, 
moderate pain/discomfort, 
not anxious/depressed 
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Table 57 : Converted EuroQol health states for the diseases 
and side effects (continued). 
Disease and side effect EuroQol health state 
descriptor 
B. comi: )lications 
1. dehydration no problems in walking about, 
no problems with self-care, 
some problems in performing usual 
activities, 
moderate pain/discomfort, 
not anxious/depressed 
2. malnutrition (PEM) no problems in walking about, 
some problems washing/dressing, 
some problems in performing usual 
activities, 
moderate pain/discomfort, 
moderately anxious/depressed 
C. The side effects of rotavirus vaccination 
fever no problems in walking about, 
no problems with self-care, 
no problems in performing usual 
activities, 
moderate pain/discomfort, 
not anxious/depressed 
2. diarrhoea no problems in walking about, 
no problems with self-care, 
some problems in performing usual 
activities, 
moderate pain/discomfort, 
not anxious/depressed 
3. Infant' tuberculosis 
A. Prognosis 
Stage 1 
fever, erythema, no problems in walking about, 
conjunctivitis no problems with self-care, 
no problems in performing usual 
activities, 
moderate pain/discomfort, 
not anxious/depressed 
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Table 57 : Converted EuroQol health states for the diseases 
and side effects (continued). 
Disease and side effect 
Staqe 
bronchopneumonia, 
obstructive emphysema, 
cervical and mensen- 
teric adenitis and 
coma 
Stage 
diarrhoea, haemorrhage, 
extremely emaciation, 
bed-sores, swing fever, 
excessive sweat, cough, 
serious debilitation, 
disfiguring, crippling 
EuroQol health state 
descriptor 
no problems in walking about, 
no problems with self-care, 
no problems in performing usual 
activities 
moderate pain/discomfort, 
not anxious/depressed 
and a possibility of 
unconsciousness 
some problems in walking about, 
some problems with washing/dressing, 
unable to perform usual activities, 
extreme pain/discomfort 
moderately anxious/depressed 
B. The side effects of BCG vaccination 
pain, abscess, ulceration no problems in walking about, 
at the injection site no problems with self-care, 
no problems in performing usual 
activities, 
moderate pain/discomfort, 
not anxious/depressed 
2. regional suppurative no problems in walking about, 
adenitis no problems with self-care, 
no problems in performing usual 
activities, 
moderate pain/discomfort, 
not anxious/depressed 
3. osteitis no problems in walking about, 
no problems with self-care, 
no problems in performing usual 
activities, 
moderate pain/discomfort, 
not anxious/depressed 
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Table 57 : Converted EuroQol health states for the diseases 
and side effects (continued). 
Disease and side effect 
4. Adult's tuberculosis 
A. Proqnosis 
Stage 1 
malaise, discomfort, 
fever, night sweats, 
weight loss, breath- 
lessness, pain in 
chest/side/shoulder, 
cough, blood 
spitting, anorexia, 
lassitude, strength 
loss, emaciation, 
female amenorrhoea, 
male impotence 
EuroQol health state 
descriptor 
no problems in walking about, 
no problems with self-care, 
some problems in performing usual 
activities 
moderate pain/discomfort, 
moderately anxious/depressed 
Stage 
more of cough, spit, 
strength loss, weight 
loss, swing fever, 
vomit and diarrhoea 
coma 
no problems in walking about, 
no problems with self-care, 
unable to perform usual activities, 
moderate pain/discomfort, 
moderately anxious/depressed 
Stage 
diarrhoea, haemorrhage, 
extremely emaciation, 
bed-sores, swing fever, 
excessive sweat, cough, 
serious debilitation, 
disfiguring, crippling 
some problems in walking about, 
some problems washing/dressing, 
unable to perform usual activities, 
extreme pain/discomfort 
moderately anxious/depressed 
B. The side effects of TB treatment 
1. vertigo, jaundice, hypersen- no problems in walking about, 
sitivity, hepatotoxicity and no problems with self-care, 
hepatitis no problems in performing usual 
activities, 
moderate pain/discomfort, 
not anxious/depressed 
2. psudomembranous colitis, 
acute renal failure, acute 
thrombocytopenia and the 
precipitation of adrenal 
crisis* 
no problems in walking about, 
no problems with self-care, 
no problems in performing usual 
activities, 
extreme pain/discomfort, 
not anxious/depressed 
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Table 57 : Converted EuroQol health states for the diseases 
and side effects (continued). 
Note By taking into account that during treatment, 
earlier signs usually alert doctor to avoid the 
full development of the potential serious effects 
by stopping giving drugs or by changing the 
regimen, a far less severity of these conditions 
is taken. 
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diseases and side effects, each health state is assigned a 
value. It is unfortunate that only the valuation for some 
health states needed is available from the survey in Thailand 
: perfect health, health states 11211 and 11121, unconscious, 
and death. 
The insufficient valuation for all the health states may 
not be sensibly tackled by collecting more valuations through 
surveys because of the cost reason and other relevant 
factors. A long-term solution is to model the valuation based 
on a sound theoretical framework and supplement this with 
empirical tests. However, a short-term solution is to 
approximate the values for unmeasured health states from the 
data available. 
Some simple models are attempted and intensively analysed 
in Chapter six. In order not to interrupt the continuing 
theme, the values from the best model determined in that 
chapter are employed here. The values are based on the 
feeling thermometer scores in the interview survey. All the 
values have an upper scale reference (score = 1) , which is 
represented by the health state 11111, and a lower reference 
(score = 0), the dead state. The time trade-off scores will 
not be used because there are too small a number of the 
health states available to provide values for modelling the 
valuation (i. e. there are only 7 health states that most 
respondents gave non-zero values) . As shown in Chapter three, 
pooling the data from the interview and postal surveys is 
inappropriate. The estimated valuation based on the postal 
scores will be used in a test for the impact on the health 
programme ranking in the next chapter. 
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The surveyed and approximated values are based on the 
adults, valuation but most of the health programmes studied 
here involve infants and children. Therefore, it is assumed 
that infants' and children's valuation could be represented 
by the available surveyed and approximated valuation. This 
is, in fact, the usual assumption when the economic 
evaluation concerns people incapable of providing the 
valuation, such as mental handicapped persons, infants and 
children. Torrance et al (1989) support the fact that 
children's utility can be approximated by their parents, and 
adult's in the general public. 
4.2.3.4. Average OALY loss from the diseases and side effects. 
The case-fatality ratio and the age vulnerability, 
showing the probability of death and the potential life year 
loss or permanently impaired-health duration, are two 
important pieces of information in the computation for 
average QALY loss from the diseases. The data of both are 
compiled for each disease. Also, recent morbidity and 
mortality incidence rates of the diseases are exhibited to 
provide the latest scale of the diseases, problems in the 
Thai public health. 
A) Morbidity, mortality, case-fatality ratio and age of 
susceptibility of measles. 
The Thai measles vaccination is mainly targeted at 
infants under 1 year of age, whose measles incidence during 
1984-1989 is shown in Table 58. 
Although the case-fatality ratio of hospitalised measles 
patients in Thailand, 2.3% (Feachem et al, 1983), was 
comparable to that in other developing countries, 2-4% (Aaby 
et al, 1989), the case-fatality ratio of Thai measles infants 
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Table 58 : Measles morbidity and mortality in infants 
under I year of age in Thailand during 
1984-1989 
year morbidity mortality morbidity mortality case- 
(case) (death) per 1000 per 1000 fatality 
infants infants ratio 
M 
1984 4645 30 4.9 0.0 0.6 
1985 3314 17 3.4 0.0 0.5 
1986 2501 11 2.6 0.0 0.4 
1987 3547 17 4.0 0.0 0.5 
1988 n. a. 9 n. a. 0.0 n. a. 
1989 1553 4 n. a. n. a. 0.3 
Note : n. a. = not available. 
Sources Department of Epidemiology (1984,1985,1986, 
1987,1988 and 1989) and Division of Health 
Statistics (1988). 
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has been low (0.3-0.6%). This may be explained by the fact 
that the hospitalised measles patients are at higher risk 
than usual ones and that the death from measles in the 
infants is under-reported or classified into other causes of 
death (the last diagnosis) - In other words, the government 
figures of infants' measles death are under-estimated while 
the numbers based on the hospital reports are over-estimated 
for infants. Nevertheless, the less severe and non-life 
threatening measles in Thailand supports the low case- 
fatality ratio (Feachem et al, 1983). 
As the age susceptibility of measles in many countries is 
under 2 years old (UNICEF, 1985), the age group of 0-4 years 
old has long been the highest vulnerable group in Thailand 
(Department of Epidemiology, 1984,1985,1986,1987,1988 and 
1989). The susceptible age group can be used to evaluate life 
years lost from the measles death and the length of the non- 
fatal measles complications. For example, according to the 
average life expectancy of Thai infants, they might lose 
about 64.6 years from the measles death or suffer the same 
duration of the life-long consequences of the measles 
complications. 
B) Morbidity, mortality, case-fatality ratio and age of 
susceptibility of rotavirus diarrhoea. 
Since there is no routine survey to show how many acute 
diarrhoeal morbidity and mortality cases arise from rotavirus 
in Thailand, the disease's incidence is to be approximated 
from a small test. The Department of Epidemiology (1987) 
reports that according to its aetiological identification of 
acute diarrhoea in 147 patients, rotavirus was found in 58 
cases or about 39.46% of the patients. Comparable rotavirus 
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diarrhoea incidence rates have been found among infants less 
than 1 year of age in other countries, for example, 42% 
(Senturia, 1986) and 40% (Oyejide et al, 1988). 
Table 59 shows the recent morbidity and mortality of 
acute diarrhoea in infants under 1 year old in Thailand. 
However, the data are criticised of under-reporting. An 
increase in the incidence is simply due to the improvement in 
the data collection. 
A considerable gap in the data can be found between the 
official reporting system and a field survey (Pinfold et al, 
1991). During 1978-1983, the former estimates about 2952 
diarrhoea cases annually in 100000 children under 5 years of 
age whereas the latter suggests around 2 episodes per child 
per year in the same age group. The magnitude of the 
discrepancy varies with location and time. Phonboon et al 
(1986) indicate that the age-specific mortality rate of the 
reported diarrhoeal deaths among children aged 0-4 years (3.8 
per 100000) is ten times lower than that determined from a 
field survey (39 per 100000) . The difference in the morbidity 
rate is much larger than that in the mortality rate mainly 
due to substantial under-reporting of the illness. However, 
the improvement in the reporting procedure of acute diarrhoea 
gradually pushes the official data towards the real ones, 
though the gap is still huge. 
According to Thai public health statistics, the case- 
fatality ratio in the past few years was 0.42%. However, the 
Fact Finding Commission (1987) reports 0.14%, which is in 
line with a study by Martines et al (1991) offering 0.2% 
among children under S. However, the hypothetical case- 
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Table 59 : Morbidity and mortality of acute diarrhoea in 
infants under 1 year of age in Thailand during 
1984-1989 
year morbidity mortality morbidity mortality case- 
(case) (death) per 1000 per 1000 fatality 
infants infants ratio 
M 
1984 80846 352 84.5 0.4 0'. 42 
1985 78906 333 81.0 0.3 0.42 
1986 99764 366 105.5 0.4 0.24 
1987 101350 245 114.6 0.3 n. a. 
1988 n. a. 298 n. a. 0.3 n. a. 
1989 116384 86 n. a. 0.3 n. a. 
Note : n. a. = not available. 
Sources Department of Epidemiology (1984,1985,1986, 
1987,1988 and 1989) and Division of Health 
Statistics (1988). 
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fatality ratio in a study by Feachem et al (1983) is as high 
as 0.7%. Though the diarrhoea's case-fatality ratio for all 
age groups is low in Thailand, the large absolute number of 
deaths from the disease makes it the second most common cause 
of infant death. 
The rotavirus diarrhoea susceptibility is during 6 months 
and 2 years of age with the peak vulnerability at 9-12 months 
of life (Black, 1981; Senturia, 1986). Like with measles, 
Thai infants dying from rotavirus diarrhoea would forgo 64.6 
years and bear the same period of the life-long consequences 
of the diarrhoeal complications. 
C) Morbidity, mortality, case-fatality ratio and age of 
susceptibility of TB in infants. 
Despite the fact that in the first few years of life 
children are vulnerable to tuberculosis, infants and young 
children are the group with the lowest morbidity and 
mortality. The TB mortality incidence of Thai infants under 
I year of age during 1984-1988 available from Division of 
Health Statistics (1988) is shown in Table 60. The absolute 
number of the mortality in that age group is low. It is 
agreed that a steep rise in incidence and prevalence of TB 
associates with increasing age in some tropical countries 
(Sutherland, 1988). Unfortunately, the existing information 
does not allow us to compute the case-fatality ratio of the 
disease for this age group. 
The TB death of infants, according to the average life 
expectancy of Thai people, would deprive them of 64.6 years. 
But for the survivors, as the prolonged disease develops, 
ill-health life spans in accordance with the prognosis 
described above. 
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Table 60 Mortality incidence of tuberculosis in infant and 
selective adult age-groups in Thailand during 
1984-1989. 
Age group 1984 1985 1986 1987 1988 
<1 year old - 14 3 13 2 5 
15 - 24 146 139 142 121 109 
25 - 34 354 315 320 300 276 
35 - 44 562 543 547 542 475 
45 - 54 1176 1265 1189 1219 913 
55 - 65 1378 1511 1472 1610 1296 
65+ 1387 1437 1282 1485 1279 
Source : Division of Health Statistics (1988). 
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D) Morbidity, mortality, case-fatality ratio and age of 
susceptibility of TB in adults. 
A contrast in morbidity and mortality reported incidence 
rates of TB in Thailand from two public sources leads this 
analysis to employ the one with the highest numbers of TB 
mortality in adult age groups, which is reproduced in Table 
60. The TB death toll, despite its under- reporting, indicates 
the age-group of 55-65 years old as the high risk age groups 
in recent years. The case-fatality ratio cannot be obtained 
directly from the data available. The ratio in a community 
available with anti-TB chemotherapy treatment is about 15% 
(Murray et al, 1990), although it is recognised that the 
ratio can vary between communities because of the condition 
of concurrent infection and nutritional status within the 
population. 
The Department of Epidemiology (1984 to 1989) shows that 
the highest rates of TB morbidity and mortality were found in 
age groups beyond 35 years old, followed by 25-34 and 15-24 
during 1984-1989. Unlike rotavirus diarrhoea and measles 
which have a definite vulnerable age group, the susceptible 
age group for adult tuberculosis spans a wide interval. This 
makes it difficult to estimate the average life year loss 
from TB death. Nevertheless, it can be approximated in 
relation to the life year loss in each age group and to their 
mortality proportion. In other words, the duration loss can 
be obtained by weighting all age groups I life expectancy with 
the probability of their deaths, as shown in Table 61. The 
computation indicates that the average life year loss for a 
Thai TB case was 22.14 years in 1988. 
In the following computations for average QALY loss from 
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Table 61 : The estimation of the average life year loss 
from TB death in Thailand in 1988. 
Age group average 
life expectancy 
(year) 
% of TB deaths 
in 1988 adjusted 
for unknown age* 
weighted 
life 
expectancy 
at birth 64.6 0.11 7.11 
1 -4 67.0 0.61 40.87 
5 -9 64.1 0.41 26.28 
10 - 14 59.5 0.32 19.04 
15 - 19 54.8 0.86 47.13 
20 - 24 50.2 1.61 80.82 
25 - 29 45.7 2.47 112.88 
30 - 34 41.3 3.78 156.11 
35 - 39 36.8 3.88 142.78 
40 - 44 32.4 6.89 223.24 
45 - 49 28.1 8.16 229.23 
50 - 54 24.0 12.53 300.72 
55 - 59 20.0 14.35 287.00 
60 - 64 16.3 15.03 244.99 
65 - 69 13.0 12.85 167.05 
70 - 74 10.0 8.14 81.40 
75 - 79 7.5 4.69 35.18 
80 - 84 5.4 2.31 12.47 
80+ - 1.00 0.00 
total 100.00 2214.30 
Source :* Division of Health Statistics (1988). 
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the diseases and side effects, a health state is the basis 
for the QALY calculation. The percentage of cases in a health 
state (reflecting the probability of being in that health 
state), its duration and its quality of life value loss are 
three components constituting a QALY. The computation for the 
average QALY loss of an average case due to the diseases is 
a combination of the QALY loss of an average survival case 
and that of a dead counterpart. The computations for each 
disease and health programme's side effects can be performed 
as below. 
Average QALY loss from the diseases. 
Basically, the Quality Adjusted Life Year (QALY) lost 
f rom a disease is the duration in non-healthy states weighted 
by their appropriate quality of life values. In the context 
of this study, a QALY loss can be computed from the 
multiplication of a health state period with its 
corresponding value of the quality of life. It is essential 
to take into account that each disease involves more than one 
ill-health state, for the occurrence of which there is a 
likely chance. As a result, the chances of all the health 
states have to be included in the calculation. A single QALY 
loss in an average case is obtained by summing up the 
weighted QALYs from all the health states. It can be 
recapitulated in the following equation. 
Average QALY loss (g x P. x HSVJ + (c, x Pc, x HSVcl) + 
from a disease C2 x Pc2 x HSVC2) ++ 
of an average case Cn X Pcn x HSVcn) 
where G, C1, C2, Cn = health states in a disease. 
g, cl, c2, cn = per cent of the cases in 
health states G, C1, C2, 
Cn 
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Pc i PC1 I 
PC2 I, *, I PCn 
HSVG, HSVcl, HSVC2,1 
HSVc,, 
periods of health 
states G, C1, C2, ..., Cn the quality of life values 
lost in health states 
G, C1, C2, ..., Cn 
The dead state can be considered as either one of the 
non-healthy states in the equation or a unique state 
occurring in a certain proportion to the disease incidence. 
The latter results in another equation for the death only. 
The distinction between the two methods is that the former 
supposes a dead case suffers non-healthy states before 
his/her death whereas in the latter, he/she takes on only the 
dead state. 
The latter is preferable on a number of grounds. First, 
the dead are likely to be too weak to go through the whole 
episode due to being ill health through inferior socio- 
economic factors and/or poor access to health care in time 
for critical treatment and the like. Secondly, since most 
dead cases who undergo all non-healthy states occur as a 
result of complications, such deaths already count in the 
diseases' complications. Thirdly, it is compatible with the 
data collection of the disease incidence, which usually 
divides morbidity and mortality cases. Finally, the case- 
fatality ratio, which most epidemiological studies employ as 
one of the indicators of disease severity, indicating a death 
toll out of the total incidence, is the only source for the 
mortality information of the diseases obtained in this study. 
With a known case-fatality ratio (CFR), the QALY loss of the 
survivals and the deaths due to a disease can be calculated 
by the following two equations. 
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Average QALY loss = (1-CFR) gxP. x HSVJ + 
from a disease C, x Pc, x HSVcl) + 
of an average C2 X PC2 x HSVC2) ++ 
survival case Cn X PCn x HSVCn) I 
Average QALY loss = CFR x PD x HSVD 
from a disease 
of an average 
dead case 
Average QALY loss = average QALY loss + average QALY loss 
from a disease of from a disease of from a disease of 
an average an average an average dead 
case survival case case 
where CFR = case-fatality ratio. 
D= dead state. 
PD = loss of life expectancy due to death. 
HSVD = the quality of life value lost from death, 
which is 1.0. 
The computation for the QALY loss of each disease below 
is based on the following points. in order not to complicate 
the computation, the duration of all the life-long ill-health 
states of infants simply take on the period of the life 
expectancy at birth (64.6 years). For the simplicity of the 
calculation, 64.6 years discounted at a rate of 7.5% are 
replaced in the computation by 14.202897 present years and 
22.14 years by 11.4134803 present years. In the baseline 
analysis, the case-fatality ratios (CFR) of measles and 
rotavirus diarrhoea in Thailand are 0.0046 and 0.0042, and 
those of infant's and adult's TB are equally assumed to be 
15%. As mentioned before, most Thai TB patients seeking the 
treatment are in the first stage of the disease and they do 
not benefit from treatment in averting these symptoms in the 
first stage of the disease. Therefore, only the QALY loss in 
stages 2 and 3 averted by treatment is concerned in the 
computation. 
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Table 62 shows the quality of lif e value loss in each 
health state of the four diseases. The health state duration 
and a case Is chance in each health state, which are extracted 
from the earlier subsections, are regrouped in Table 63. Here 
are the computations for the QALY loss of each disease. 
1.1) Measles 
Average QALY loss = (1-0.0046)[(100% x 0.013699 x 0.52) + 
of an average ( 18% x 0.019178 x 0.52) + 
survival case ( 5% x 0.019178 x 0.25) + 
( 5% x 0.019178 x 0.25) + 
(0.18% x 14.202897 x 1.05) + 
(0.55% x 14.202897 x 0.92) + 
(1.075% x 14.202897 x 0.66) + 
(0.275% x 14.202897 x 0.75) + 
(0.07088% x 14.202897 x 1.00) 1 
= 0.247096272 QALY 
Average QALY loss = 0.0046 x 14.202897 x 1.00 
of an average 
dead case = 0.065333326 QALY 
Average 0.247096272 + 0.065333326 
QALY loss of an 
average case 0.312429598 QALY 
1.2) Rotavirus diarrhoea 
Average QALY loss (1-0.0042) P100% x 0.0219178 x 0.52) + 
of an average 19% x 0.019178 x 0.52) + 
survival case (1.04% x 14.202897 x 0.81)] 
0.13237891 QALY 
Average QALY loss 0.0042 x 14.202897 x 1.00 
of an average 
dead case 0.059652167 QALY 
Average 0.13237891 + 0.059652167 
QALY loss of an 
average case 0.192031078 QALY 
1.3) Infant's tuberculosis 
Average QALY loss (1-0.15) P100% x 0.125 x 0.25) + 
of an average (100% x 1.00 x 0.71) + 
survival case (100% x 14.202897 x 0.97)] 
12.3403511 QALYs 
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Table 62 : Converted EuroQol health states and their values of 
the diseases and side effects. 
The disease and 
side effect 
1. Measles 
EuroQol health health state value 
descriptor* value decline 
A. General symptoms and siqns 11221 0.48 0.52 
B. Complications 
1. diarrhoea 11221 0.48 0.52 
2. otitis media 11121 0.75 0.25 
3. pneumonia 11121 0.75 0.25 
4. measles encephalitis 22223, unconscious 0.07, -0.17 1.05** 
5. subacute sclerosing 11223, death 0.17,0.00 0.92** 
panencephalitis 
6. irritability, confusion, 11222 0.34 0.66 
seizures and convulsion 
7. blindness 12221 0.25 0.75 
8. death dead state 0.00 1.00 
C. The side effects of measles vaccination 
1. fever 11121 0.75 0.25 
2. rash 11121 0.75 0.25 
3. pneumonia 11121 0.75 0.25 
4. convulsion 11222 0.34 0.66 
5. brain damage 13322 0.05 0.95 
6. encephalitis 22223, unconscious 0.07, -0.17 1.05** 
7. encephalopathy 11222 0.34 0.66 
8. death dead state 0.00 1.00 
Rotavirus diarrhoea 
A.. General symptoms and signs 11221 0.48 0.52 
B. Complications 
1. dehydration 11221 0.48 0.52 
2. malnutrition (PEM) 12222 0.19 0.81 
C. The side effects of rotavirus vaccination 
1. fever 11121 0.75 0.25 
2. diarrhoea 11221 0.48 0.52 
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Table 62 : Converted EuroQol health states and their values of 
the diseases and side effects (continued). 
The disease and 
side effect 
3. Infant' tuberculosis 
A. Prognosis 
Stage 1 
Stage 2 
Stage 3 
EuroQol health 
descriptor* 
11121 
11121, unconscious 
22332 
health state value 
value decline 
0.75 
0.75, -0.17 
0.03 
0.75 
0.75 
0.75 
0.00 
0.25 
0.71** 
0.97 
B. The side effects of BCG vaccination 
1. pain, abscess, ulceration 11121 
at the injection site 
2. regional suppurative 11121 
adenitis 
3. osteitis 11121 
4. death dead state 
4. Adult's tuberculosis 
A. Prognosis 
0.25 
0.25 
0.25 
1.00 
Stage 1 11222 0.34 0.66 
Stage 2 11322 0.17 0.83 
Stage 3 22332 0.03 0.97 
B. The side effects of TB treatment 
1. vertigo, jaundice, hypersen- 11121 
sitivity, hepatotoxicity and 
hepatitis 
2. psudomembranous colitis, 11131 
acute renal failure, acute 
thrombocytopenia and the 
precipitation of adrenal 
crisis 
3. death dead state 
0.75 
0.36 
0.00 
0.25 
0.64 
1.00 
Note See the EuroQol classification of the health states 
in Chapter two. 
An average of the two values. 
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Table 63 : The duration and occurrence chance of each 
health state in the diseases and side effects. 
The disease and EuroQol health Duration % of the 
side effect descriptor (year) infected 
being in 
health state 
1. Measles 
A. General symptoms and siqns 11221 1.3699xlO-l 100.0 
Complications 
1. diarrhoea 11221 1-9178X10-2 1.8 
2. otitis media 11121 n. a. * 5.0 
3. pneumonia 11121 n. a. * 5.0 
4. measles encephalitis 22223, unconscious 64.6 0.18** 
5. subacute sclerosing 11223, death 64.6 0.55068** 
panencephalitis 
6. irritability, confusion, 11222 64.6 1.075 
seizures and convulsion 
7. blindness 12221 64.6 0.175 
8. death dead state 64.6 7.088xl 0-2 
The side effects of measles vaccination 
1. f ever 11121 6.849xlO-' 28.7 
2. rash 11121 6.849xlO-' 8.1 
3. pneumonia 11121 n. a. *** 
1. OXIO-3 
4. convulsion 11222 64.6 6 OXJ. 0-2 
5. brain damage 13322 64.6 1.0X10-1 
6. encephalitis 22223, unconscious 64.6 3.4xlO-I 
7. encephalopathy 11222 64.6 1.14 qX10-3 
8. death dead state 64.6 I. Oxlo-" 
2. Rotavirus diarrhoea 
A. General symptoms and sicfns 11221 2.19178X10 -2 100.0 
B. complicat ons 
1. dehydration 11221 n. a. **** 19.0 
2. malnutrition (PEM) 12222 64.6 1.04 
C. She side effects of rotavirus vaccination 
1. fever 11121 1.9178X10-2 71.5 
2. diarrhoea 11221 1.9178xl 0-2 31.0 
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Table 63 : The duration and occurrence chance of each health 
state in the diseases and side effects (continued). 
The disease and EuroQol health Duration % of the 
side effect descriptor (year) infected 
being in 
health state 
3. Infant' tuberculosis 
A. Proqnosis 
Stage 1 11121 0.125 100***** 
Stage 2 11121, unconscious 1.00 loot**** 
Stage 3 22332 64.6 ioo***** 
B. The side effects of BCG vaccination 
1. pain, abscess, ulceration 11121 5.692xl 0-2 30.0 
at the injection site 
2. regional suppurative 11121 5.692xl 0-2 1.9 
adenitis 
3. osteitis 11121 5.692xl 0-2 3.3xl 
0-2 
4. death dead state 64.6 6. Ox1O-I 
4. Adult's tuberculosis 
A. Proqnosis 
Stage 1 11222 0.125 100***** 
Stage 2 11322 0.26923 100***** 
* Stage 3 22332 22.14 ioo **** 
B. The side effects of TB treatment 
1. vertigo, jaundice, hypersen 11121 0.25 6.3******, 
sitivity, hepatotoxicity 5.8****** 
and hepatitis 
2. psudomembranous colitis, 11131 0.25 6.3******, 
acute renal failure, acute 
thrombocytopenia and the 
precipitation of adrenal 
crisis 
3. death dead state 22.14 1.00 
Notes Assume the same period as diarrhoea = 0.019178 year. 
Average values. 
It is likely to be viral pneumonia which has a 
shorter period of sick than the bacterial 
counterpart. So its length is presumably 0.019178 
year. 
Assume the dehydration interval is restored within 
1 week, otherwise death is highly likely. So the 
assumed duration is 0.019178. 
This is a full development of a TB case. 
The first figure belongs to the 2HRZ/4HR regimen 
and the second, the 2HRZ/4H2R2 regimen. 
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Average QALY loss = 0.15 x 14.202897 x 1.00 
of an average 
dead case = 2.13043455 QALYs 
Average = 12.3403511 + 2.13043455 
QALY loss of an 
average case = 14.4707856 QALYs 
1.4) Adult's tuberculosis 
Average QALY loss = (1-0.15) P100% x 0.26923 x 0.83) + 
of an average (100% x 11.4134803 x 0.97)] 
survival case = 9.60035627 QALYs 
Average QALY loss = 0.15 x 11.4134803 x 1.00 
of an average 
dead case = 1.71202205 QALYs 
Average = 9.60035627 + 1.71202205 
QALY loss of an 
average case = 11.3123783 QALYs 
An episode of the infant's TB appears to cause the 
highest QALY loss, followed by the adult's TB (stages 2 and 
3), measles and rotavirus diarrhoea. The QALY loss from an 
infant's TB is about 75 times that from a rotavirus 
diarrhoea; that from an adult's TB, 59 times; and that from 
measles, only 1.6 times. 
In all the diseases, morbidity impinges on the QALY loss 
more than mortality. The influence of the morbidity on the 
QALY loss is much greater than that of the mortality in both 
types of tuberculosis (85% of the total QALY loss). For 
measles and rotavirus diarrhoea, the morbidity effect 
accounts for about 79% and 69% of the total QALY loss, 
respectively. 
2) Average QALY loss from the side effects. 
The computation procedure for the QALY loss from the side 
effects of the health programmes is similar to that from the 
diseases except that dead state is directly combined with 
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other non-healthy states. The reason for the difference is 
that most studies have reported dead incidence as an adverse 
reaction of the interventions in terms of the number or 
percentage of cases. The typical formula for the QALY loss 
computation for the side effects is given below, followed by 
the calculation presentation. 
Average QALY loss s, 
from the side S2 
effects of a health Sn 
programme of an 
average service 
recipient 
x Ps, X HSVsj) + 
X P. 2 x HSVS2) ++ 
x P., x HSVs, ) 
where S1, S2, Sn health states of the side ef f ects 
sl, s2, sn per cent of the cases in health 
states S1, S2, ..., Sn PS111 Ps2,1 
... 
Psn periods of health 
states S1, S2, ..., Sn HSV, j, HSVr. 2,1 the quality of life values lost 
HSVr. n 
in health states S1, S2, ..., Sn 
2.1) Measles vaccination 
Average QALY loss = (28.7% x 0.006849 x 0.25) + 
from the measles (8.1% x 0.006849 x 0.25) + 
vaccination (0.001% x 0.019178 x 0.25) + 
side effects of (0.06% x 14.202897 x 0.66) + 
an average (0.00001% x 14.202897 x 0.95) + 
vaccinee (0.000034% x 14.202897 x 1.05) + 
(0.001149% x 14.202897 x 0.66) + 
(0.000001% x 14.202897 x 1.00) 
= 0.006368771 QALY 
2.2) Rotavirus vaccination 
Average QALY loss (71.5% x 0.019178 x 0.25) 
from the rotavirus (31% x 0.019178 x 0.52) 
vaccination 
side effects of 
an average 
vaccinee 0.006519561 QALY 
2.3) BCG vaccination 
Average QALY loss = (30% x 0.05692 x 0.25) + 
from the BCG (1.9% xO. 05692 x 0.25) + 
vaccination (0.033% x 0.05692 x 0.25) + 
side effects of (0.00006% x 14.202897 x 1.00) 
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an average 
vaccinee 0.004552588 QALY 
2.4) Anti-TB chemothera- 
2.4.1) The 2HRZ/4HR reg 
Average QALY loss 
from the treatment 
of an average 
patient 
pv treatment 
imen 
(6.3% x 0.25 x 0.25) + 
(6.3% x 0.25 x 0.64) + 
(1.0% x 11.4134803 x 1.00) 
0.128152303 QALY 
2.4.2) The 2HRZ/4H2R2 regimen 
Average QALY loss (5.8% x 0.25 x 0.25) + 
from the treatment (5.8% x 0.25 x 0.64) + 
of an average (1.0% x 11.4134803 x 1.00) 
patient 
0.127039803 QALY 
The QALY loss from the side effects of the three 
vaccinations is comparable, about 4.6-6.5 QALYs per 1000 
vaccinees. On the other hand, a TB patient could lose 0.127- 
0.128 QALY in a treatment. The treatment side effects could 
cause around 19.5-28 times the QALY loss from the side 
effects of a vaccination. 
In weighting the QALY loss between the diseases and the 
side effects, a BCG vaccination is the least risky, followed 
by a TB treatment, a measles vaccination and a rotavirus 
vaccination. The ratio of the QALY loss from the disease to 
that from the side effects is 3179,89,49 and 29 for BCG 
vaccination, TB treatment, measles vaccination and rotavirus 
vaccination respectively. 
4.2.4. The cost estimation. 
This analysis does not use the primary costing data of 
the health programmes, whose collection involves substantial 
amounts of expenses, effort and time. Nor can it get access 
to the secondary data gathered by some researchers or 
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available in some sources. Therefore, it has to rely on the 
costing findings of some relevant studies. 
The marginal costs of the health programmes are the most 
important cost data in this analysis. It would determine 
their optimum size and suggest efficient scales of provision. 
Unfortunately, there have been no studies estimating their 
marginal costs. This may be because they all encountered 
difficulties, in the estimation as discussed before. The 
estimates of the average costs were reported in all of them. 
In order to further this analysis, it is necessary to assume 
the average costs from the various sources used here to be 
the marginal costs. 
The cost study on single vaccination programmes in 
Thailand is not available. Instead, the existing studies have 
centred on the cost of providing a complete set of the 
vaccines against childhood diseases (e. g. BCG, DPT and OPV) 
under the Expanded Programme on Immunisation (EPI) . There are 
two marked Thai studies about the vaccination cost. Both have 
a similar foundation. The main difference is the period of 
the studies : 1979 as against 1986. Since the latest 
information may be more appropriate and its timing more 
compatible with other parameters, only the latter study is 
used and elaborated here. 
Phonboon et al (1989a) analyse the cost of providing a 
child with a complete set of the vaccines, measured in 
practice by the third DPT and OPV, from 8 district hospitals 
and 14 health centres in high and moderate vaccination 
coverage areas during 1986. To comply with EPI Is guidance for 
the vaccination costing,, the time allocated to the 
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immunisation activities and others was used as a basis for 
computing salaries and transportation costs. Ten per cent of 
the discount rate was applied to capital items. Building was 
assumed to have a working time length of 30 years; furniture, 
vehicles and refrigerators 10 years; and the cold chain 
equipment 4 years. Distributions of the central costs 
(national, regional and provincial) to the local facilities 
were based on the size of the population and the number of 
the health facilities. The percentage distribution of the 
component costs in both types of the facilities was similar. 
The findings indicate that the average hospital cost was 
348.31 baht (US$13.80) for a completely immunised child (a 
range of 300.36 baht (US$11.90) to 398.79 baht (US$15.80) 
except for one hospital with 600.71 baht (US$23.80). The 
health centre's average cost was 297.83 baht (US$11.80) (a 
wider range of 133.77 baht (US$5.30) to 837.97 baht 
(US$33.20) ). The average cost of the outreach vaccinations of 
the hospitals and that of the health centres was 487.13 baht 
(US$19.30) and 340.74 baht (US$13.50) - The outreach services, 
in fact, are not a key and routine strategy of the 
vaccinations. This is because most of these services are 
provided on an infrequent basis (e. g. in a campaign against 
a disease likely to become epidemic). Their main purpose is 
to serve remotely rural people. They can give a considerably 
smaller proportion of the vaccinations than can the 
institutional services. Therefore, they are not considered in 
this analysis. 
Adjusted to the 1988 price level, the average hospital 
vaccination would cost 369.52 baht (US$14.64) and the average 
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cost in the health centres, 315.97 baht (US$12.52). The 
average vaccination cost for a completely immunised child in 
both places would become 342.76 baht (US$13.58). 
Though the expansion of the vaccination coverage 
increases the expenditures of the programmes slightly, the 
cost per completely immunised child could be reduced since a 
rise in the number of completely immunised children would 
offset the increasing expenses. Moreover, Phonboon et al 
(1989b) argue that in the long run, the decrease in the 
average cost would depend on the salaries and major capital 
costs. However, according to EPI's new strategies to meet the 
goal of completely immunising all eligible children by 1990, 
the vaccination programmes would incur additional costs for 
accommodating the following recommended activities : 
establishing a service network supporting the control of the 
vaccine-preventable diseases, improvement in the vaccine 
storage, upgrading the vaccine delivery system, strengthening 
health education and training activities and motivating 
health personnel with incentives. It is difficult to 
speculate that in the end, taking into account all possible 
changes, the average cost of the completed childhood 
vaccinations would increase, decrease or stabilize. 
An increase in the average cost of Thailand's vaccination 
programmes due to some changes during 1979 and 1986 could be 
detected when the average cost estimate in 1979 is compared 
with that in 1986. In terms of the 1988 price level, the 
average cost in the 1979 study was about 286.22 baht 
(uS$11.34) and in the 1986 study, 342.76 baht (US$13.58). 
They differ by 56.54 baht (US$2.24). The differential could 
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be accounted for by some innovations in the vaccination 
programmes over the period. This also reinforces an argument 
for employing the latest cost study findings in this 
analysis. Other issues, advocating the compatibility of the 
recent study with the present situation of the vaccination 
provision, include changes in the structure of the cost 
components and in the strategy of the vaccination policy over 
the past decade, though they are difficult to support with 
quantified evidence. 
It can be noted that almost all the outlined alterations 
in the vaccination programmes in the past as well as in the 
future involve, to a large extent, fixed costs, so the 
marginal cost of the vaccinations is highly likely to be 
least affected. 
Another cost study available deals with major health 
service categories in Thailand's basic health service 
provision institutions during 1980 (Health Planning Division, 
1980a and b). Because a department was used as a unit of the 
analysis, its findings are not appropriate to approximate the 
vaccination cost and the TB treatment cost. But it could 
provide the cost of hospital i sat ion, since there have been to 
date no other studies offering a figure of hospitalisation 
cost in Thailand. Hence, the findings of the study are 
employed in the cost estimation of the TB hospitalised 
treatment. It is summarised as follows. 
The study is based on the cost data of the 1980 fiscal 
year (during lrt October 1979 to 301h September 1980) . The 
institutions participated consist of 14 health centres, 9 
district hospitals and 12 provincial hospitals. Three main 
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cost components were used : labour costs, material costs and 
capital costs. A double apportionment method was used as a 
basis of allocating the three cost components into the unit 
cost of each health activity. 
The findings show that the cost of inpatient care 
adjusted to the year 1988 was 230.55 baht (US$9.13) for a 
day's stay in the district hospitals (a range of 114.79 baht 
(uS$4.55) to 351.09 baht (US$13.91)) and 214.08 baht 
(US$8.48) for a day in the provincial hospitals (a range of 
140.61 baht (US$5.57) to 297.09 baht (US$11.77)). 
Since the cost of the study vaccination programmes have 
not been directly estimated, other information available may 
be helpful in approximating the cost estimates of each 
vaccination programme f rom the available cost data of the 
completed childhood vaccinations. Also, it may be useful to 
learn the cost estimations f rom other international studies. 
The comparison of the cost estimates between the Thai 
programmes and other countries I could be a beneficial by- 
product. 
4.2.4.1. Cost estimation of measles vaccination. 
a) International studies of the measles vaccination cost. 
Feachem (1986) assumes that the measles vaccination cost 
is US$2.00 for each child. Despite the availability of the 
cold chain and the reduced price of the measles vaccine, the 
administering of the vaccination is still not cheap, apart 
from inconvenient, due to the required use of sterile needles 
and syringes or of jet injector guns (Hopkins et al, 1982). 
Hendrickse (1975) points out that the cost of measles 
vaccination is higher than the annual average cost per head 
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of health services in many developing countries. He also 
states that the vaccination cost could be partly absorbed 
into the delivery of other vaccines concurrently provided at 
4-6 months of age. 
The cost of a measles vaccination programme, like any 
other vaccination programme, is expected to rise as it is 
rendered to more marginal populations (Jamison et al, 1990). 
The following cost estimates of measles vaccination 
programme in some countries are taken from Foster et al 
(1992). An additional measles vaccination to an existing EPI 
programme was estimated at US$1.35 per a vaccination (in 
1982) . On the contrary, an 
independent measles vaccination 
programme in COte d Ivoive costed US$12.30 for a vaccination 
(in 1980), accounting for 75% of the EPI cost. In 1982, 
Zambia's measles vaccination programme spent US$8 to US$14 on 
a vaccinated child in rural areas and US$2 to US$5 in urban 
areas. 
Key variables accounting for the variation in the cost 
estimates are the levels of vaccination activity (i. e. the 
volume of the vaccinees), ratio of the fixed costs to 
variable costs, prices of main inputs, types of technology 
used and productivity of personnel involving in the services 
(Foster et al, 1992), some of which could be subject to cost 
control. 
Foster et al (1992) also point out that in complying with 
EPI's guidelines for the measles morbidity and mortality 
reduction target in 1995, a substantial improvement in the 
measles surveillance is necessary. As a result, extra 
expenditure for this upgrading is inevitably incurred. 
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b) Thai studies of the measles vaccination cost. 
As a result of Thailand's measles vaccination being 
effectively provided at 9 months of age, as mentioned before, 
the vaccination cost may not be shared by other existing 
vaccinations such as DPT and OPV vaccinations, the last dose 
of which is officially scheduled at 6 months of life. A 
separate contact for a measles vaccination seems to be 
inevitable and is presumed in this analysis. 
Without any available costing study of the Thai measles 
vaccination programme in particular, the cost is approximated 
from those of the completed childhood vaccinations, which 
have been elaborated previously. As this is supposed to be 
equivalent to one contact of the three visits of the 
completed childhood vaccinations, a Thai child's measles 
vaccination is costed at one-third of the cost of his 
completed vaccinations. This means that the baseline marginal 
cost of the vaccination is 113.17 baht (US$4.53). The costs 
to the two institutions, which will be used in the 
sensitivity analysis, become 105.33 baht (US$4.17) and 123.17 
baht (US$4.88). All are priced in 1988 prices. 
4.2.4.2. Cost estimation of rotavirus diarrhoea 
vaccination. 
a) International studies of the rotavirus vaccination cost. 
Feachem (1986) estimates the cost of a rotavirus 
vaccination at US$2.00 for a vaccinee provided that the 
vaccination can be delivered in conjunction with other 
existing vaccination programme. 
b) Thai studies of the rotavirus vaccination cost. 
It is most likely that the rotavirus vaccination can be 
incorporated into one of the existing routine programmes of 
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the childhood vaccination, though its appropriate schedule is 
not yet determined. 
The costs of the vaccine and required accessories could 
represent the expenses of the rotavirus vaccination programme 
joined to an existing vaccination programme. Due to 
unavailable commercial production of the vaccine at the time 
of writing, the cost data are not available. Therefore, it is 
assumed that Thailand's rotavirus vaccination programme would 
pay for at the costs of the other childhood vaccine, cold 
chain and sterilisation. According to a study by Phonboon et 
al (1989a), the costs of these components were about 10% of 
the total immunisation cost in the hospitals and 13.5% of 
that in the health centres. 
According to the 1988 completed vaccination cost data, 
the marginal cost of a rotavirus vaccination for the baseline 
analysis is assumed to be 39.81 baht (US$1.58) and the 
marginal cost in the two health facilities for the 
sensitivity analysis, 36.95 baht (US$1.46) and 42.67 baht 
(US$1.69), respectively. 
4.2.4.3. Cost estimation of BCG vaccination. 
a) International studies of the BQG vaccination cost. 
Most international studies of BCG vaccination programmes 
render only an illustrated, hypothetical cost estimate for 
local BCG programme analyses, remotely related to the genuine 
conditions. To get precise conclusions from the programme 
evaluation, it is essential to estimate the BCG vaccination 
cost according to the pricing structure in local areas. 
b) Thai studies of the BCG vaccination cost. 
The fact that the Thai BCG vaccination programme intends 
418 
to deliver the vaccination at birth and that those 
unvaccinated at that time can be identified from their health 
record and vaccinated at other contacts to health facilities 
characterise the BCG vaccination as a joint programme. Its 
expenditure, therefore, comprises mainly the vaccine and its 
components. Like the rotavirus vaccination cost, the 1988 
adjusted marginal cost of the Thai BCG vaccination for a 
child, on average, is presumed to be 39-81 baht (US$1.58). 
The cost in the hospitals is 36.95 baht (US$1.46) and the 
cost in the health centres, 42.67 baht (US$1.69). As with the 
analysis of other programmes in this study, the first cost 
estimate is used in the base-case computation while the last 
two are used in the sensitivity analysis. 
4.2.4.4. Cost estimation of short-course anti-TB 
chemotherapy treatment. 
a) International studies of the treatment cost. 
The main components of the treatment cost are staff 
payment, hospitalisation, drug and transportation. The drug 
cost of the short-course chemotherapy is estimated at about 
20% to 40% of the total treatment cost (Murray et al, 1990). 
These authors also break down the 1986 illustrative cost of 
the Tanzanian TB chemotherapy treatment, as quoted in Table 
64. 
Despite the fact that various forms of TB need different 
regimens and have different costs, in order to simplify the 
analysis, it is reasonable to assume that all of the TB forms 
can be treated at the same cost as the short-course treatment 
(Murray et al, 1990). 
The hospitalisation partly functions as an option of a 
close supervision of a patient's compliance in the initial 
6 
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Table 64 : Budgeted costs of TB chemotherapy in Tanzania, 
1986 (US$). 
Cost category Short-course Retreatment 
treatment 
A. Diagnosis 
1. slides/reagents 0.10 
2. sputum container 1.95 
B. Bacteriological 
1. monitoring 0.81 
2. culture 1.50 
3. sensitivity 1.50 
C. Drug 40.00 65.00 
D. Administration 2.85 2.85 
E. Labour costs and hospitalisation 90.20 169.12 
F. Transport 20.35 20.35 
G. Training 2.37 2.37 
H. Supervision 2.90 2.90 
I. Capital 20% depreciation 3.22 3.22 
Total cost per case 168.25 271.21 
Source : Murray et al (1990). 
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intensive phase. Since the short-course chemotherapy 
treatment can convert smear-positive patients into smear- 
negative persons within two months in 90% of cases, TB 
patients are normally admitted to hospital for 2 months at 
most provided that there are no other serious complications. 
Converselyl Fox (1988) does not agree with using 
hospitalisation for the supervision of drug taking mainly 
because of the high hospitalisation cost and the waste of the 
resource for other more useful health services. Moreover, 
such a supervision method has never been proved to be 
effective or to fulfil the objective. The hospitalisation 
should be determined by the patient's critically ill 
conditions. According to his opinion, a short duration, one 
or two weeks, is appropriate in most serious cases. It is 
desirable to transfer patients to obtain the treatment at 
ambulatory outpatient departments. 
Joesoef et al (1989) find that the unit costs of drugs 
purchased by the Indonesian TB treatment programme in 1983 
were US$24.23 for the standard regimen, US$35.93 for the 
short-course regimen and US$124.14 for the retreatment 
regimen. Other cost components include overheads, manpower, 
capital, treatment for adverse drug reactions and case- 
holding costs. These costs were not estimated in their 
analysis. However, they point out that the case-holding cost 
is closely associated with the compliance rate, which in turn 
is directly related to treatment effectiveness. 
Without the actual TB treatment cost, Barnum et al (1980) 
approximate the costs of inpatient care and outpatient care 
for treating TB patients from those of treating tetanus and 
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diphtheria patients. The cost of inpatient care is the 
product of the average length of stay of the patients with 
these two diseases and the daily cost of paediatric hospital 
care for sick children. The cost embraces drugs, food, 
nursing, laboratory testing and doctor's salary. The cost of 
outpatient care is based on the costs of specific treatment 
regimens for pertussis and tuberculosis. 
The regimen cost could differ between countries and 
between organisations (domestic agencies versus WHO/UNICEF) 
(Fox, 1988). He also suggests that since the costs in 
individual developing countries might change rapidly in any 
possible direction, the cost re-estimation should be made 
annually. 
The cost estimates of the short-course treatment and 
retreatment in three study countries from the analysis by 
Murray et al (1991) are presented in Table 65. However, their 
cost estimates of the Tanzanian short-course anti-TB 
chemotherapy treatment obviously differ from those in their 
previous study (1990). This could arise from various factors 
such as cost definitions, data collecting procedure, cost 
computation method and inflation. They did not compare 
between the two sets of the costs, nor did they point out the 
differentials as well as the underlying reasons. 
Although the introduction of the short-course 
chemotherapy regimen to the existing TB treatment programme 
requires no extra reorganisation, efficiency in the 
organisation could contribute to the achievement of the 
potential successful rate of the treatment (Fox, 1979) . In 
order to acquire an 85% cure rate in some countries, Kochi 
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Table 65 : Estimated average, average incremental and marginal 
costs per case treated with the short-course 
regimens and retreatments in Malawi, Mozambique 
and Tanzania (US$ in 1989). 
Regimen Malawi Mozambique Tanzania 
1. Short-course regimen with 
hospitalisation 
1.1. average cost 160 217 174 
1.2. average incremental cost 99 155 127 
1.3. marginal cost 69 140 101 
2. Ambulatory short-course regimen 
2.1. average cost 139 196 152 
2.2. average incremental cost 75 132 103 
2.3. marginal cost 46 117 77 
3. Retreatment cost with 
hospitalisation 
3.1. average cost 209 323 252 
3.2. average incremental cost 141 232 182 
3.3. marginal cost 97 206 146 
Notes : 1) Malawi's ambulatory costs are hypothetical. 
2) 60 days' hospitalisation for the short-course 
regimen and 90 days, for retreatment. 
Source : Murray et al (1991). 
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(1991) states that the treatment network management ought to 
improve a regular supply of anti-TB drugs and study the 
outcome of treating all sputum smear-positive patients at all 
treatment centres. These alterations incur some expenses in 
the programme, though no estimates are made. Murray et al 
(1990) suggest that in order to maximise patient compliance, 
anti-TB chemotherapy treatment should be free. Also 
recommended are the improvement in transportation to 
treatment centres and the appropriate timing of treatment 
provision. Implemented according to these guidelines, the 
treatment programme could have put up with the 
extraordinarily high cost. 
b) Thai studies of the treatment cost. 
jittinanadana (1989) estimates that in 1988 the cost for 
the 2HRZ/4HR regimen was about US$80 and that for the 
2HRZ/H2R21 US$52. According to Kamonratanakul et al (1990), 
the average costs of these two regimens and other necessary 
tests from the five TB treatment centres in Thailand in 1988 
were US$76 and US$64. They are summarised in Table 66. 
By assuming that hospitalised TB treatment needs no more 
supervision and care than other inpatient treatments and by 
following Murray et al's suggestion (1990) of 2-month 
hospitalisation for the effective supervision and the high 
rate of the drug compliance, the cost of treating a 
hospitalised TB patient consists solely of ambulatory TB 
treatment cost plus two months I hospital cost. Therefore, the 
average cost of a hospitalised TB case in 1988 would be 
15248.34 baht (US$604.12) for the 2HRZ/4HR regimen and 
14954.40 baht (US$592.49) for the 2HRZ/H2R2 regimen. The 
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Table 66 : The costs of the two short-course anti-TB 
chemotherapy regimens in Thailand, 1988. 
Item Baht (US$) 
1. Average total routine service cost 803.60 (31.84) 
for 7 visits 
1.1.87.8% for labour costs 
1.2.8.5% for material costs 
1.3.3.7% for capital costs 
2. Average total diagnostic test 26.80 (1.06) 
2.1. sputum examination 
2.2. chest X-ray 
3. Average total drug cost 
3.1.2HRZ/4HR 1078.74 (42.74) 
3 . 2.2HRZ/4H2R2 785.10 (31.11) 
4. Average cost of the regimens for 
treating a TB case 
4.1.2HRZ/4HR 1909.14 (75.64) 
with a range of 1758.71 (69.68) to 
2338.98 (92.67) 
4.2.2HRZ/4H2R2 1615.50 (64.01) 
with a range of 1465.07 (58.04) to 
1945.34 (77.07) 
Notes : 1) The exchange rate of 25.24 baht/US$ is used. 
2) The direct allocation method was employed. 
Source : Kamonratanakul et al (1990). 
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minimum TB hospitalised treatment cost, which is based on the 
lowest limits of the ambulatory treatment and hospitalisation 
costs, would be 8646.11 baht (US$342.56) for the former 
regimen and 8352.47 baht (US$330.92) for the latter regimen. 
The maximum would be 23404.38 baht (US$927.23) and 23010.74 
baht (US$911.68), respectively. 
At this point, all the essential data for the calculation 
of the cost per QALY of the, four health programmes, which 
will be performed in the next chapter, are obtained. The data 
of most parameters do not cause any dif f iculty. However, some 
have variations and controversies, which have not been 
resolved by the current state of the data collection. As far 
as the objective of the economic assessment is concerned, 
their impacts on the analysis outcome in terms of the health 
programme ranking and cost per QALY are used to judge the 
seriousness of the drawbacks, which will become clear in 
Chapter Five. 
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Chapter 5 
The computation of the cost per QALY of the health programmes 
In this chapter, there are four main sections. First, the 
cost per QALY of the four health programmes is computed based 
on the baseline data. Also, the two controversial issues 
about the health state valuation, which have been discussed 
in Chapter three, are investigated. The significantly divided 
valuations of the quality of life from the four health 
experience groups in the interview survey and the two sets of 
the valuation based on the interview and postal surveys are 
tested for their effects on the ranking of the health 
programmes according to the cost per QALY. 
Secondly, the sensitivity analysis shows the 
responsiveness of the alternative data of each key parameter, 
obtained from the review in the previous chapter, to the cost 
per QALY result of each health programme and the health 
programme ranking as a whole. It therefore indicates the 
rigour of the outcome. Thirdly, the findings of some 
international economic evaluation studies of these health 
programmes, which are used in comparison to the results of 
this study, are assessed. The selected studies are in the 
form of both individual and collective programme analyses. 
Finally, the study results are employed to suggest a health 
policy towards the efficient resource allocation for these 
four health programmes and assess the efficiency aspect of a 
health policy. 
5.1. Base-case data analysis. 
The analyses in this section are based on an appropriate 
set of the data from the most accountable estimation methods, 
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sources and studies, especially the data in the context of 
Thailand. 
The computation structure is outlined below. Primarily, 
the size of vaccination recipients in a population is found 
for each vaccination programme. The effectiveness of a health 
programme determines the number of the protected vaccinees 
from the disease among the vaccinated population. For the BCG 
vaccination, the number of the protected cases from TB has to 
be weighted by the probability of developing TB among TB- 
infected infants, which is 5-15%. A median of 10% is 
employed. The total health gain is the product of the number 
of the protected vaccinees and an average case Is averted QALY 
loss from the disease. As the protection effects are 
prolonged for a certain period, the present and all the 
discounted future gains have to be aggregated to the total 
present gain. The net gain is the total gain subtracted by 
all the vaccinees I average QALY loss f rom the side ef f ects of 
the health programme. The loss is presumed to occur only once 
at the time of the service acquisition and, therefore, is not 
subject to being discounted. The net gain for a vaccination 
is acquired by dividing the net gain by the total number of 
the vaccinees. Finally, the cost per QALY of the programme is 
the ratio of the cost per vaccination to a vaccination's net 
effect. 
Since the TB treatment programme concerns mainly with the 
aversion of TB advance in a TB patient and no further 
protection length is assumed, its computation procedure is 
shorter than this. First of all, the average QALY loss of an 
average TB case averted is multiplied by the regimen's 
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effectiveness estimate. The net gain is the difference 
between this gain and the QALY loss from the treatment side 
effects. The cost per QALY is the ratio of the treatment cost 
to the net gain. 
The cost of the health programmes is not discounted since 
it is assumed that all the vaccination costs occur at the 
time of the delivery and that the TB treatment cost spans 
only 6 months (as does its treatment length). 
According to this calculation method, it should be noted 
that the number of population and the vaccination coverage do 
not influence the resultant cost per QALY, but affect the 
absolute number of the vaccine-protected population, the 
total volume of the net QALY gained and the total cost of the 
health programmes. 
The measles vaccination T)roqramme. 
a. The number of the infant population = 873842 infants 
b. The measles vaccination coverage = 60% 
C. The number of the vaccinees = 524305 infants 
(a x b) 
d. The vaccination effectiveness = 94/1000 
estimate infants 
e. The protected population from 49285 vaccinees 
measles (c x d) 
f. A protected vaccinee's health gain 0.312429598 
QALY 
g. Total gain 15397.9955 
QALYs 
(e x f) 
h. The protection length 15 years for 
95% of the 
protected 
vaccinees 
i. Total present value gain = 139578.149 
QALYs 
j. A vaccinee's QALY loss from the = 0.006368771 
side effects of the vaccination QALY 
k. Total QALY loss from the side = 3339.1798 
effects QALYs 
(C x j) 
1. Net gain from the vaccination = 136238.969 
QALYs 
(i - k) 
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m. Net gain from a measles vaccination = 0.259846687 
QALY 
(1 / c) 
n. Cost per measles vaccination = 113.17 baht 
(US$4.48) 
o. Cost per QALY gained of a measles = 435.53 baht 
vaccination (US$17.43) 
(n / m) 
The calculation result shows that in 1988 there were 
about 49285 Thai infants saved from measles by the measles 
vaccination programme, which would create a total of 136239 
QALYs. The programme spent 435.53 baht (US$17.43) for a QALY 
gained. 
B) The rotavirus vaccination proqramme. 
a. The number of the infant population = 873842 infants 
b. The rotavirus vaccination coverage = 80% 
C. The number of the vaccinees = 699074 infants 
(a x b) 
d. The vaccination effectiveness = 88/1000 
estimate infants 
e. The protected population from 61518 vaccinees 
rotavirus diarrhoea (c x d) 
f. A protected vaccinee's health gain 0.192031078 
QALY 
g. Total gain 11813.4594 
QALYs 
(e x f) 
h. The protection length 1.5 years for 
all the 
protected 
vaccinees 
i. Total present value gain 17308.0917 
QALYs 
j. A vaccinee's QALY loss from the 0.006519561 
side effects of the vaccination QALY 
k. Total QALY loss from the side =-4557.65305 
effects QALYs 
(c x j) 
1. Net gain from the vaccination = 12750.4386 
QALYs 
(i - k) 
M. Net gain from a rotavirus = 0.01823ýWb 
vaccination QALY 
(1 / C) 
n. Cost per rotavirus vaccination = 39.81 baht 
(us$1.58) 
o. Cost per QALY gained of a rotavirus = 2182.68 baht 
vaccination (US$86.63) 
(n / m) 
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Despite a large number of the vaccinees saved from 
rotavirus diarrhoea (61518 infants), the net gain from the 
vaccination could be small (12750 QALYs). Such a small gain 
obviously accounts for a high cost for the vaccination 
programme to gain a QALY (2182.68 baht or US$86.63). 
C) The BCG vaccination programme. 
a. The number of the infant population = 873842 infants 
b. The BCG vaccination coverage = 96% 
c. The number of the vaccinees = 838888 infants 
(a x b) 
d. The vaccination effectiveness = 10/1000 
estimate infants and a 
10% probability 
of full TB 
development 
e. The protected population from TB = 839 vaccinees 
(c x d) 
f. A protected vaccinee's health gain = 14.470'/bbb 
QALYs 
g. Total gain = 12139.373 
QALYs 
(e x f) 
h. The protection length 4 years for all 
the protected 
vaccinees 
i. Total present value gain 43708.1251 
QALYs 
j. A vaccinee's QALY loss from the = 0.004552588 
side effects of the vaccination QALY 
k. Total QALY loss from the side = 3819.1126 
effects QALYs 
(c x j) 
1. Net gain from the vaccination = 39889.0125 
QALYs 
(i - k) 
M. Net gain from a BCG vaccination = 0.047549848 
QALY 
(1 / c) 
n. Cost per BCG vaccination = 39.81 baht 
(US$1.58) 
0. Cost per QALY gained of a BCG = 837.23 baht 
vaccination (US$33.23) 
(n / m) 
The small number of the protected infants from TB is 
compatible with the wide accepted belief that the BCG vaccine 
confers a limited effect. The TB reduction (in 100 cases out 
of 100000 vaccinees due to the BCG vaccination estimated in 
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this study) falls in a range of the absolute reduction in TB 
incidence, 1-128 cases per 100000 per year, found in the 
major BCG vaccination programmes shown by Hart (1967). 
However, the net QALY gained from the programme was high 
because of a large averted QALY loss of an average TB case. 
The BCG vaccination programme would use 837.23 baht 
(US$33.23) to produce a QALY. 
D) The short-course anti-TB chemotherapy treatment lDroqramme. 
1) The 2HRZ/4HR regimen 
a. The treatment effectiveness estimate = 93.7% 
b. A cured patient's average health gain = 11.3123783 
QALYs 
c. Total gain = 10.5996985 
QALYs 
(a x b) 
d. A patient's QALY loss from the side = 0.128152303 
effects of the treatment QALY 
e. Net gain from the treatment = 10.4715462 
QALYs 
(c - d) 
f. Cost per ambulatory treatment = 1901.14 baht 
(US$75.64) 
g. Cost per QALY of the ambulatory = 181.55 baht 
treatment with 2HRZ/4HR regimen (US$7.22) 
(f / e) 
h. Cost per hospitalised treatment 15248.34 baht 
(US$604.12) 
i. Cost per QALY of the hospitalised 1456.17 baht 
treatment with 2HRZ/4HR regimen (US$57.69) 
(h / e) 
The 2HRZ/4H7R;, reqimen 
a. The treatment effectiveness estimate = 83.7% 
b. A cured patient's average health gain = 11.3123783 
QALYs 
c. Total gain 9.46846065 
QALYs 
(a x b) 
d. A patient's QALY loss from the side 0.127039803 
effects of the treatment QALY 
e. Net gain from the treatment 9.34142085 
QALYs 
(c - d) 
f. Cost per ambulatory treatment 1615.50 baht 
(US$64.01) 
g. Cost per QALY of the ambulatory 172.94 baht 
treatment with 2HRZ/4H2R2 regimen (US$6.85) 
(f / e) 
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h. Cost per hospitalised treatment = 14954.40 baht 
(US$592.49) 
i. Cost per QALY of the hospitalised = 1600.87 baht 
treatment with 2HRZ/4H2R2 regimen (US$63.43) 
(h / e) 
one regimen is not absolutely superior to the other. The 
health gain of the 2HRZ/4HR regimen exceeds that of the 
2HRZ/4H2R2 regimen by a QALY. However, the latter had a lower 
treatment cost in both ambulatory and hospitalisation 
treatments. The efficiency of the TB treatment, therefore, 
would depend on the strategy of the treatment. The 2HRZ/4H2R2 
regimen is better than the 2HRZ/4HR regimen for the 
outpatient treatment, but the reverse is true for the 
inpatient counterpart. 
In comparison of the f our health programmes, Table 67 
shows that the anti-TB chemotherapy ambulatory treatment is 
the most cost-effective. This is followed by the measles 
vaccination, BCG vaccination, hospitalised TB treatment and 
rotavirus vaccination. Therefore, based on this result, the 
resource allocation among the four health programmes would be 
ef f icient if the Thai public health sector gave them priority 
in the following order : the short-course anti-TB 
chemotherapy ambulatory treatment, measles vaccination, BCG 
vaccination, short-course anti-TB chemotherapy hospitalised 
treatment and finally rotavirus vaccination. 
For the TB control, the curative measure like the short- 
course chemotherapy ambulatory is more cost-effective than 
the preventive one such as the BCG vaccination. For a QALY 
gained, the latter would spend more than four times the 
amount that the former would. However, the reverse is true if 
the treatment needs hospital isat ion. The cost per QALY of the 
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Table 67 : The comparison of the cost per QALY of the four 
Thai health programmes (the 1988 price level) 
Health programme Cost per QALY gained 
baht US$ 
Short-course anti-TB chemotherapy 
ambulatory treatment 
1.1. the 2HRZ/4H2R2 regimen 172.94 6.85 
1.2. the 2HRZ/4HR regimen 181.55 7.22 
2. Measles vaccination 435.53 17.43 
3. BCG vaccination 837.23 33.23 
4. Short-course anti-TB chemotherapy 
hospitalised treatment 
4.1. the 2HRZ/4HR regimen 1456.17 57.69 
4.2. the 2HRZ/4H2R2 regimen 1600.87 63.43 
5. Rotavirus vaccination 2182.68 86.63 
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TB hospitalised treatment programme is about 1.7-1.9 times 
that of the BCG vaccination programme. 
As the diarrhoea control measures, the measles 
vaccination would be a more cost-effective choice than would 
the rotavirus vaccination. To produce a QALY gained, the cost 
of the rotavirus vaccination is 5 times that of the measles 
vaccination. 
Among the three vaccination programmes, the rotavirus 
vaccination programme would produce the highest number of the 
protected infants from rotavirus diarrhoea. On the other 
hand, the BCG programme could protect only 839 infants from 
contracting and developing full TB. The measles vaccination 
programme would create the largest volume of the QALY gained, 
followed by the BCG vaccination programme and rotavirus 
vaccination programme. 
As found in Chapter 3, the difference in the standardised 
feeling thermometer scores between the four health experience 
groups is of statistically significance. The impact of the 
difference on the cost per QALY and health programme ranking 
is tested using the baseline data of all the other 
parameters. The four health experience groups I values for all 
the health states involved, most of which are estimated based 
on the best valuation model analysed in Chapter 6, are 
presented in Table 68. 
The finding indicates that there is no change in the 
ranking of the health programmes from their base-case 
positions, according to their cost per QALY seen in Table 69. 
This means that the division in the valuation from these four 
health experience groups, which was found to reveal the 
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Table 68 : The surveyed and estimated values for the health 
states from the four health experience groups. 
Health Health 
state Professions 
Bronchitis 
patients 
Cancer 
patients 
Healthy 
people 
11121 0.67 0.75 0.75 0.79 
11131 0.32 0.37 0.36 0.38 
11221 0.64 0.53 0.46 0.43 
11222 0.45 0.35 0.33 0.31 
11223 0.22 0.17 0.16 0.15 
11322 0.14 0.11 0.11 0.10 
12221 0.48 0.26 0.24 0.21 
12222 0.32 0.21 0.17 0.17 
13322 0.08 0.05 0.05 0.04 
22223 0.15 0.07 0.06 0.05 
22332 0.07 0.04 0.03 0.03 
uncon -0.06 -0.08 -0.14 -0.29 
scious 
Number of 53 81 75 94 
the samples 
Note : The values of the health state 11121 and unconscious state 
in this table differ slightly from those in Table 40 
since the values in this table are based on the values 
of the basic health states, which can give the solutions 
to the model. 
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Table 69 The four health experience groups, cost per QALY 
(baht per QALY) of the four health programmes 
(the 1988 price level). 
Health 
state 
Health 
professions 
Bronchitis 
patients 
Cancer 
patients 
Healthy 
people 
1. Short-course 
anti-TB 
chemotherapy 
'ambulatory 
treatment 
1.1.2HRZ/4H2R2 179.09 174.24 172 . 73 172 . 68 
regimen (US$ 7.10) (US$ 6.90) (US$ 6.84) (US$ 6.84) 
1.2.2HRZ/4HR 188.00 182.91 181.33 181.28 
regimen (US$ 7.48) (US$ 7.28) (US$ 7.21) (US$ 7.21) 
2. Measles 
vaccination 
486.54 440.84 432.84 422.69 
(US$ 19.48) (US$ 17.65) (US$ 17.33) (US$ 16.92) 
3. BCG vaccination 897.49 847.15 837.77 822.79 
(US$ 35.62) (US$ 33.62) (US$ 33.25) (US$ 32.66) 
4. Short-course 
anti-TB 
chemotherapy 
hospitalised 
treatment 
4.1.2HRZ/4HR 1507.87 1467.08 1454.38 1453.95 
regimen (US$ 59.74) (US$ 58.12) (US$ 57.62) (US$ 57.60) 
4.2.2HRZ/4H2R2 1657.80 1612.88 1598.90 1598.43 
regimen (US$ 65-68) (US$ 63.90) (US$ 63.35) (US$ 63.33) 
5. Rotavirus 2635.93 2212.54 2144.35 2091.56 
vaccination (US$ 104.62) (US$ 87.81) (US$ 85.11) (US$ 83.01) 
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highest significant influence on the diversity in the health 
state valuation, does not affect the priority ranking of the 
study health programmes. 
In each health programme, the variation in the cost per 
QALY is slight except for the rotavirus vaccination 
programme, the cost per QALY of which is given so high by the 
health professions that it is out of line with those by the 
other groups. Their cost per QALY is 20% higher than that 
based on the aggregate valuation. In comparison with the 
baseline cost per QALY of each programme, the rotavirus 
vaccination programme has the widest deviation (a minimum 
that is 4% less than the underlying cost per QALY and a 
maximum, 20% more than the figure), followed by the measles 
vaccination (a minimum with 3% less than the baseline cost 
per QALY and a maximum with 12% greater). The other health 
programmes vary similarly (0%-2% lower and 4%-7% higher). 
In all the health programmes, the cost per QALY of the 
healthy people group is the lowest whereas' the health 
profession group's is the highest. 
The difference in the cost per QALY and health programme 
ranking between the interviewed and postal valuations, 
another issue following the analysis in Chapter 3, is 
investigated. This is done by only replacing the surveyed and 
estimated health state values based on the interview survey 
by those based on the postal one. The latter's estimated 
values are also based on the same, best valuation model, 
which can be seen in Chapter 6. 
The result, presented in Table 70, shows no dif f erence in 
the health programme ranking between the two methods of the 
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Table 70 : The comparison of the cost per QALY of the four 
Thai health programmes based on the valuation in 
the postal survey (the 1988 price level). 
Health programme Cost per QALY gained 
baht US$ 
1. Short-course anti-TB chemotherapy 
ambulatory treatment 
1.1. the 2HRZ/4H2R2 regimen 179.20 7.10 
1.2. the 2HRZ/4HR regimen 188.12 7.48 
2. Measles vaccination 522.46 20.91 
3. BCG vaccination 844.56 33.52 
4. Short-course anti-TB chemotherapy 
hospitalised treatment 
4.1. the 2HRZ/4HR regimen 1508.82 59.78 
4.2. the 2HRZ/4H2R2 regimen 1658.82 65.72 
5. Rotavirus vaccination 2291.32 90.94 
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valuation survey. In all the health programmes, the cost per 
QALY based on the postal valuation exceeds that derived from 
the interviewed one. The differential varies from less than 
1% to 5% (except for the measles vaccination programme where 
the discrepancy is 20%). 
5.2. Sensitivity analysis. 
All the programmes are subject to being tested for their 
responsiveness of the cost per QALY to the changes in the 
health programmes' effect and cost, as well as the discount 
rate. Also examined are the vaccine protection length, the 
occurrence chance of some health states and some health 
states' duration as well as the probability of developing 
full TB among TB-infected infants and the TB case-fatality 
ratio. 
The sensitivity test of the discount rate uses 5%, 7.5% 
and 10%. A change in the discount rate has an impact on the 
average QALY loss due to the prolonged effects of the 
diseases averted by the health programmes. A low discount 
rate, in general, reduces the future gain less than a high 
one does. As a result, the cost per QALY with the low 
discount rate is expectedly less than that with the high 
rate, assuming other things remain unchanged. 
For measles and rotavirus diarrhoea, many studies 
indicate a variety of the chances of the manifestations of 
some health states, which has been measured in terms of the 
proportion of the cases with a certain symptom/sign/ 
complication (health state) to the total infected cases. The 
availability of the data widens the choices of their 
combination to be used in the sensitivity test. As a result, 
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the change in this parameter is sensibly divided into the 
minimum and maximum chances of those health states, 
occurrence. The two scenarios can be interpreted as mildly 
and as extremely virulent situations of the diseases. Table 
71 lists the two sets of the parameters' estimates. 
As with the health states' occurrence chances, the 
estimates of the health state duration are divided into the 
minimum and maximum lengths. The two sets of the parameter's 
estimates for measles and rotavirus diarrhoea are presented 
in Table 72. 
The test for the impact of other valuation models will be 
undertaken in the next chapter. Alternative estimates of 
other parameters, which are available in the previous 
chapter, are discussed specifically in each health 
programme's sensitivity analysis. 
5.2.1. The measles vaccination programme. 
Table 73 shows the result of the sensitivity analysis of 
the measles vaccination programme. The changes in each 
parameter and the results are discussed as follows. 
a) Change in the vaccine effect. 
most measles vaccination trials divide in their vaccine 
efficacy estimate and in their measles incidence rate of the 
vaccinated population. Therefore, these two factors are dealt 
with separately. The vaccine efficacy ranges 40% to 60% and 
the incidence rate between 78.590785 and 109.452 per 1000 
population. Therefore, with a median measles incidence rate 
of 94.021392 per 1000, five alternative vaccine efficacy 
estimates; 40%, 45%, 50%, 59% and 60%, are used in the test. 
That is, the numbers of the measles protected vaccinees are 
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Table 71 Minimum and maximum chances of an infected 
case in each health state of measles and 
rotavirus diarrhoea. 
The disease and EuroQol health Minimum Maximum 
side effect descriptor* chance chance 
of an of an 
infected infected 
case case 
(per cent) (percent) 
1. Measles 
A. General symptoms and siqns 11221 100 100 
B. Comlications 
1. diarrhoea 11221 1.8 37 
2. otitis media 11121 2.5 7 
3. pneumonia 11121 3.8 30 
4. measles encephalitis 22223, unconscious 0.1 0.2 
5. subacute sclerosing 11223, dead state 1.0XIO-1 2.02 
panencephalitis 
6. irritability, confusion, 11222 0.1 2.0 
seizures and convulsion 
7. blindness 12221 0.1 0.25 
8. death dead state 4.72E; XJO-2 9.45X10-2 
The side effects of measles vaccination 
1. fever 11121 25 28.7 
2. rash 11121 4 8.1 
3. pneumonia 11121 1. OX10-1 1. OX10-1 
4. convulsion 11222 6. OxIO-1 6xlO-2 
5. brain damage 13322 1. OX10-1 1. OX10-1 
6. encephalitis 22223, unconscious 3. 4xlO-I 3.4xlO-' 
7. encephalopathy 11222 1.149xlO-l 1.149xlO-l 
8. death dead state 1. OX10-1 1. OXJO-6 
Rotavirus diarrhoea 
A. General SYmPtoms and siqns 11221 100 100 
B. Complications 
1. dehydration 11221 19 19 
2. malnutrition (PEM) 12222 1.04 1.04 
C. The side effects of rotavirus vaccination 
1. fever 11121 64 79 
2. diarrhoea 11221 20 42 
Note See the EuroQol classification of the health states 
in Chapter 2 
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Table 72 : Minimum and maximum durations of each health state 
of measles and rotavirus diarrhoea. 
The disease and 
side effect 
1. Measles 
A. General sVmptoms and siqns 
B. Complications 
1. diarrhoea 
2. otitis media 
3. pneumonia 
4. measles encephalitis 
5. subacute sclerosing 
panencephalitis 
6. irritability, confusion, 
seizures and convulsion 
7. blindness 
8. death 
EuroQol health Minimum Maximum 
descriptor* duration duration 
(year) (year) 
11221 5.4794 SX10-3 1.91781X10-2 
11221 1.91781X10-2 1.91781X10-2 
11121 1.91781xl 0-2 3.83562xl 0-2** 
11121 1.917 SIX10-2 3.83562xl 0-2** 
22223, unconscious 64.6 64.6 
11223, death 64.6 64.6 
11222 64.6 64.6 
12221 64.6 64.6 
dead state 64.6 64.6 
C. The side effects of measles vaccination 
I. f ever 
2. rash 
3. pneumonia 
4. convulsion 
S. brain damage 
6. encephalitis 
7. encephalopathy 
8. death 
2. Rotavirus diarrhoea 
11121 2.73973xlO-' 1.09589XIO-2 
11121 2.73973xl 0-3 1.09589xl 0-2 
11121 1.91781xlO-' 3.83562xl 0-2** 
11222 64.6 64.6 
13322 64.6 64.6 
22223, unconscious 64.6 64.6 
11222 64.6 64.6 
dead state 64.6 64.6 
General symptoms and siqns 11221 1.3699XJO-2 3.2877 JX10-2 
B. Complications 
1. dehydration 11221 1.9178 jX10-2 3.83562xl 0-2** 
2. malnutrition (PEM) 12222 64.6 64.6 
C. The side effects of rotavirus vaccination 
1. f ever 
2. diarrhoea 
11121 1.91781X10-2 1.9178IX10-2 
11221 1.9178 jX10-2 1.91781X10-2 
Notes See the EuroQol classification of the health states 
in Chapter 2. 
Suppose the maximum length is twice the minimum 
one. 
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Table 73 The result of the sensitivity analysis of 
the measles vaccination programme (the 1988 
price level). 
Parameter Cost per QALY gained 
baht US$ 
A. Base case 435.53 17.43 
B. Sensitivity analysis 
1. Effect 
1.1. vaccine efficacy 
1.1.1.63/1000 vaccinees 657.77 26.33 
1.1.2.77/1000 vaccinees 534.57 21.40 
1.1.3.94/1000 vaccinees (base case) 435.53 17.43 
1.1.4.135/1000 vaccinees 301.01 12.05 
1.1.5.141/1000 vaccinees 288.00 11.53 
1.2. incidence rate 
1.2.1.79/1000 vaccinees 520.64 20.84 
1.2.2.94/1000 vaccinees (base case) 435.53 17.43 
1.2.3.109/1000 vaccinees 374.33 14.98 
2. Cost 
2.1. separate progra=e 
2.1.1.105.33 baht (US$ 4.17) 405.35 16.05 
2.1.2.113.17 baht (US$ 4.48) 435.53 17.43 
(base case) 
2.1.3.123.17 baht (US$ 4.88) 474.01 18.78 
2.2. additional programme 
2.2.1.36.95 baht (US$ 1.46) 142.20 5.62 
2.2.2.39.81 baht (US$ 1.58) 153.21 6.08 
2.2.3.42.67 baht (US$ 1.69) 164.21 6.50 
3. Discount rate 
3.1.5% 269.30 10.78 
3.2.7.5% (base case) 435.53 17.43 
3.3.10% 635.47 25.44 
4. Protection period 
4.1.12 years 498.33 19.95 
4.2.15 years (base case) 435.53 17.43 
4.3.64.6 years 289.17 11.57 
5. Health states' occurrence chances 
5.1. minimum chances 1100.76 44.06 
5.2. base case 435.53 17.43 
5.3. maximum chances 224.37 8.98 
6. Health state duration 
6.1. minimum lengths 441.04 17.65 
6.2. base case 435.53 17.43 
6.3. maximum lengths 431.47 17.27 
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63,77,94,135 and 141 out of a 1000 vaccinated population. 
By assuming a 50% vaccine efficacy, three alternative 
incidence rate; namely 78.590755,94.021392 and 109.4521 per 
1000, are employed. Their correspondent numbers of the 
protected vaccinees are 79,94 and 109 for a 1000 vaccinated 
population. 
When the vaccine efficacy is lowest (40%), the cost per 
QALY rises to 657.77 baht (US$26.33), a 51% increase from the 
base-case figure. On the contrary, the highest vaccine 
efficacy (60%) reduces the cost per QALY to 288.00 baht 
(US$11.53), a 34% decline. The low incidence rate increases 
the cost per QALY to 520.64 baht (US$20.84) (a 20% rise) . On 
the other hand, the high rate lowers it to 374.33 baht 
(US$14.98) (a 14% decline) . The impact of the 
incidence rate 
change is less than that of the vaccine efficacy change. 
b) Change in the vaccination cost. 
Two approaches of rendering a measles vaccination 
programme are usually assumed in most studies, these being 
independent and joint vaccination programmes. Though the Thai 
measles vaccination is officially scheduled at 9 months of 
life, it is possible to bring infants to receive the vaccine 
after 9 months at the same time as they or their family 
members obtain other services. 
For the separate programme, a vaccination would cost 
105.33 baht (US$4.17) at hospitals and 123.17 baht (US$4.88) 
at health centres. Their median, used in the baseline 
analysis and repeated in the sensitivity analysis for the 
comparison, is 113.17 baht (US$4.48). On the contrary, the 
additional programme would spend 36.95 baht (US$1.46) in 
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hospitals and 42.67 baht (US$1.69) in health centres, with a 
median of 39.81 baht (US$1.58). 
The cost per QALY alters in the exact proportion to the 
change in the vaccination cost. The changes of the separate 
programme are between 7%-9% and those of the additional one, 
7%. The vaccination cost and the cost per QALY of the 
separate programme are about 2.9 times those of the joint 
counterpart. 
c) Change in the discount rate. 
With the 5% discount rate, the cost per QALY falls to 
269.30 baht (US$10.78), a 38% reduction from the base case. 
By contrast, with 10% rate, the cost per QALY rises to 635.47 
baht (US$25.44), a 46% increase. 
Though an equal deviation of 2.5% from the base-case 
discount rate in each direction is employed, the percentage 
increase in the cost per QALY (due to a high discount rate) 
exceeds the percentage decrease (owing to a low one) by about 
8%. 
d) Change in the protection lenath. 
It is possible that a measles vaccination could create 
immunity for up to 12 or 15 years of age or for a life-long 
protection period. 
As the protection period expands, the cost per QALY 
decreases. With the 12-year protection duration, the cost per 
QALY increases by 14% from the base case with the 15-year 
immunity to be at 498.33 baht (US$19.95). But the life-long 
protection makes the cost per QALY around two-thirds the 
base-case cost per QALY or 289.17 baht (US$11.57). 
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e) Change in the occurrence chances of some health states. 
The result indicates that when fewer measles cases 
manifest the symptoms/signs and complications or, when the 
occurrence chances of some health states diminish, the cost 
per QALY becomes higher and vice versa. The cost per QALY 
with the minimum occurrence probabilities is 2.5 times the 
base case. On the other hand, the cost per QALY with the 
maximum counterparts is about half. 
f) Change in the health state duration. 
The findings show that the longer the symptoms/signs and 
complications persist, the lower the cost per QALY and vice 
versa. However, the change in the cost per QALY is minute 
(around 1%) . All the health states with unknown or uncertain 
durations have short periods while more than half of the 
health states apparently involve life-long impacts. 
It can be concluded that the change in the measles 
vaccination cost arising from a move towards the joint 
vaccination programme has the greatest impact on the cost per 
QALY, followed by the change in the health states I occurrence 
chances. The influences of the discount rate, vaccine effect 
and protection length are modest whereas that of the health 
state duration are minimal. Only the impacts of the 
vaccination cost could make the measles vaccination programme 
more cost-effective than the TB ambulatory treatment. On the 
contrary, the minimum probabilities of the health states' 
manifestation could rank it after the BCG vaccination 
programme. 
5.2.2. The rotavirus vaccination programme. 
The results of the sensitivity analysis of the rotavirus 
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vaccination programme are presented in Table 74. 
a) Chanqe in the vaccination effect. 
There are three estimates of the rotavirus vaccine 
effectiveness : 70,88 and 154 protected vaccinees out of 
1000 vaccinees. As can be expected, the greater the 
effectiveness, the lower the cost per QALY and vice versa. 
The impact of the effectiveness is substantial. The cost per 
QALY with the lowest effectiveness is 3021.68 baht 
(us$119.93), a 38% rise from the base case whereas that with 
the highest is 1081.56 baht (US$42.93), a 50% decline. 
b) Change in the vaccination cost. 
Similar to the result in the measles vaccination 
programme, the vaccination cost varies in equal proportions 
(7%) to the cost per QALY of the rotavirus vaccination 
programme. 
c) Change in the discount rate. 
A 2.5% reduction in the discount rate from the baseline 
7.5% results in the low cost per QALY of 1416.67 baht 
(US$56.23), a 35% fall. On the contrary, a 2.5% rise 
increases the cost per QALY to 3094.85 baht (US$122.83), a 
42% increase. 
d) Change in the 'protection period. 
It is assumed that the vaccinees are further protected up 
to 5 years old, when most children are not vulnerable to 
diarrhoea. Therefore, the extra 3 years' protection on the 
top of 1.5 years reduces the cost per QALY substantially to 
656.37 baht (US$26.05), a 70% fall. 
e) Chanqe in the occurrence chances of some health states. 
This health programme's minimum and maximum occurrence 
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Table 74 The result of the sensitivity analysis of 
the rotavirus vaccination programme (the 1988 
price level). 
Parameter Cost per QALY gained 
baht US$ 
A. Base case 2182.68 86.63 
B. Sensitivity analysis 
1. Effect 
1.1.70/1000 3021.68 119.93 
1.2.88/1000 (base case) 2182.68 86.63 
1.3.154/1000 1081.56 42.93 
2. Cost 
2.1.36.95 baht (US$ 1.46) 2025.87 80.05 
2.2.39.81 baht (US$ 1.58)(base case) 2182.68 86.63 
2.3.42.67 baht (US$ 1.69) 2339.49 92.66 
3. Discount rate 
3.1.5% 1416.67 56.23 
3.2.7.5% (base case) 2182.68 86.63 
3.3.10% 3094.85 122.83 
Protection period 
4.1. up to 2 years old 2182.68 86.63 
(base case) 
4.2. up to 5 years old 656.37 26.05 
5. Health states' occurrence chances 
5.1. minimum chances 2021.26 80.22 
5.2. base case 2182.68 86.63 
5.3. maximum chances 2372.12 94.15 
6. Health state duration 
6.1. minimum lengths 2250.38 89.31 
6.2. base case 2182.68 86.63 
6.3. maximum lengths 2071.93 82.23 
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chances produce contrast results to the common expectation. 
This is because the change affects exclusively all the side 
ef f ects. The minimum chances of the side ef f ects lead to the 
low cost per QALY and the maximum chances lead to the high 
one. The minimum chances decrease the cost per QALY to be at 
2021.26 baht (US$80.22), a 7% reduction. On the other hand, 
with the maximum chances, the cost per QALY is higher than 
the base-case figure by 9% or it rises to 2372.12 baht 
(US$94.15). 
f) Change in the health state duration. 
In contrast to the change in the occurrence chances of 
some health states, there are no alterations in the health 
state length of all the side effects. The minimum lengths 
increase the cost per QALY by 3% whereas the maximum depress 
it by 5%. 
The cost per QALY of the rotavirus vaccination programme 
is considerably sensitive to the change in the protection 
length. It responds moderately to the changes in the vaccine 
effectiveness and discount rate. Only the 5-year protection 
period and highest effectiveness estimate could improve its 
comparative cost-effectiveness. That is, the protection 
period could make it become more cost-effective than the BCG 
vaccination and hospitalised TB treatment programmes. The 
highest effectiveness estimate could promote its rank before 
the hospitalised TB treatment only. 
5.2.3. The BCG vaccination programme. 
Table 75 shows the findings of the sensitivity analysis 
of the BCG vaccination programme. Since the data of the 
occurrence chances of the health states and the health state 
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Table 75 : The result of the sensitivity analysis of 
the BCG vaccination programme (the 1988 
price level). 
Parameter Cost per QALY gained 
baht US$ 
A. Base case 837.23 33.23 
B. Sensitivity analysis 
1. Effect 
1.1.10/1000 vaccinees (base case) 837.23 33.23 
1.2.55/1000 vaccinees 141.16 5.60 
1.3.174/1000 vaccinees 44.13 1.75 
2. Cost 
2.1.36.95 baht (US$ 1.46) 777.08 30.70 
2.2.39.81 baht (US$ 1.58)(base case) 837.23 33.23 
2.3.42.67 baht (US$ 1.69) 897.37 35.54 
3. Discount rate 
3.1.5% 562.38 22.32 
3.2.7.5% (base case) 837.23 33.23 
3.3.10% 1139.14 45.21 
4. Protection period 
4.1.4 years (base case) 837.23 33.23 
4.1.12 years 343.85 13.65 
5. Case-fatality ratio 
5.1.15% (base case) 837.23 33.23 
5.2.30.2% 840.27 33.35 
5.3.50% 844.28 33.51 
6. Probability of developing TB among TB-infected infants 
6.1.5% 1851.75 73.49 
6.2.10% (base case) 837.23 33.23 
6.3.15% 540.89 21.47 
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duration of infant's TB gathered in this study are likely to 
have no significant variations, their changes are not 
considered in the test. 
a) Change in the vaccination effect. 
Three common types of the TB diagnostic tests in the Thai 
BCG vaccine study provide three alternative estimates of the 
vaccine effect. The base case, based on the specific test, 
offers the BCG immunity to 10 vaccinees out of their 1000 
fellow vaccinees. The other two, less specific tests, 
indicate that the BCG effect might exist in 55 and 174 out of 
1000 vaccinees. 
Like all the other health programmes, the effectiveness 
has a negative relationship with the cost per QALY. As 
explained in Chapter 4, there is an inverse association 
between the efficacy estimate and incidence rate. The 
inf luence of the latter of f sets that of the f ormer, theref ore 
at a high incidence rate a large number of the vaccinees 
could be protected f rom TB with the low ef f icacy vaccine. 
With the less specific diagnosis, the cost per QALY falls to 
one-sixth the baseline one or be at 141.16 baht (US$5.60). 
Furthermore, with the least specific test, the cost per QALY 
slumps to remain at one-nineteenth the base-case f igure or at 
44.13 baht (US$1.75). 
b) Chanqe in the vaccination cost. 
Like the two previous vaccination programmes, the 
vaccination cost and cost per QALY of the BCG vaccination 
programme alter in the same direction and in the same 
proportion (7%) . 
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c) Change in the discount rate. 
The cost per QALY with 5% discount rate is lower than 
that with the baseline rate by 33% or it declines to 562.38 
baht (US$22.32) . On the other hand, a 10% rate 
increases the 
cost per QALY by 36% or the cost per QALY is 1139.14 baht 
(US$45.21). 
The percentage changes in the cost per QALY due to the 
same discount rate change are similar among the three 
vaccination programmes. 
d) Change in the protection period. 
The assumption of the 12-year TB protection duration 
reduces the cost per QALY considerably to 343.85 baht 
(US$13.65) or 59% of the base-case cost per QALY. 
e) Change in the case-fatality ratio. 
A 50% case-fatality ratio, which was reported similarly 
in Grzybowski (1987), Rodrigues et al (1990) and Murray et al 
(1990 and 1991), as reviewed in Chapter 4, is employed in the 
test as the maximum. A moderate case-fatality ratio (30.2%) 
is also used for a comparison purpose. (This ratio was found 
in the second-year observation by Murray et al (1990) and has 
been shown in Table 50. ) 
There is a minute change in the cost per QALY, when the 
case-fatality ratio is varied. The explanation for this is 
that without considering a case-fatality ratio, the QALY loss 
averted from TB morbidity is very slightly greater than that 
from TB mortality. A shift in the benefit from the morbidity 
avoidance towards the mortality prevention (i. e. a rise in 
the ratio) switches the source of the QALYs gained from the 
former to the latter results in the net decline of the total 
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gain and leads to a higher cost per QALY accordingly. 
f) Chanqe in the -probability of developing full TB 
The influence of this parameter is inversely associated 
with the cost per QALY. The magnitude of the impact is 
substantial in both directions. At a low probability of 5%, 
the cost per QALY is 2.2 times that of the base case or at 
1851.75 baht (US$73.49). On the other hand, a high 
probability of 15% lowers the cost per QALY to be two-thirds 
the baseline cost per QALY or, 540.89 baht (US$21.47). 
The major influential parameter is the methods of the TB 
identification, followed by the vaccine protection period, 
the probability of the full TB advance and the discount rate. 
Only when the less specific diagnostic tests could confirm 
the TB cases would it be more cost-effective than the anti-TB 
chemotherapy ambulatory treatment and measles vaccination 
programmes. 
The reduction in the probability of a TB-infected case 
developing towards proper TB could increase the cost per QALY 
so that it could lose the cost-effectiveness ranking to the 
TB hospitalised treatment programme. 
5.2.4. The short-course anti-TB chemotherapy treatment 
programme. 
Table 76 shows the results of the sensitivity analysis of 
the TB treatment programme. 
a) Change in the treatment effect. 
The decrease in the treatment effect leads to a higher 
cost per QALY in both regimens and in both treatment 
strategies. The cost per QALY of the 2HRZ/HR regimen with the 
79% treatment effectiveness is up to 215.83 baht (US$8.59) 
for the ambulatory option and 1731.07 baht (US$68.58) for the 
454 
Table 76 : The result of the sensitivity analysis of 
the short-course anti-TB chemotherapy treatment 
programme (the 1988 price level). 
Cost per QALY gained (baht) 
Parameter 2HRZ/HR regimen 2HRZ/H2R2 regimen 
ambula hospita- ambula hospita- 
tory lisation tory lisation 
A. Base case 181.55 1456.17 172.94 1600.87 
(US$ 7.22) (US$ 57.69) (US$ 6.85) (US$ 63.43) 
B. Sensitivity analysis 
1. Effect 
1.1.93.7% for 181.55 1456.17 172.94 1600.87 
2HRZ/HR (US$ 7.22) (US$ 57.69) (US$ 6.85) (US$ 63.43) 
regimen and 
83.7% for 
2HRZ/H2R2 
regimen 
(base case) 
1.2.79.0% for 215.83 1731.07 193.31 1789.39 
2HRZ/HR (US$ 8.59) (US$ 68.58) (US$ 7.66) (US$ 70.90) 
regimen and 
75.0% for 
2HRZ/H2R2 
regimen 
Cost 
2.1. minimum 167.95 
(US$ 6.65) 
2.2. median 181.55 
(base case) (US$ 7.22) 
2.3. maximum 223.37 
(US$ 8.85) 
825.68 
(US$ 32.71) 
1456.17 
(US$ 57.69) 
2235.05 
(US$ 88.55) 
156.84 894.13 
(US$ 6.21) (US$ 35.43) 
172.94 1600.87 
(US$ 6.85) (US$ 63.43) 
208.25 2463.30 
(US$ 8.25) (US$ 97.60) 
3. Discount rate 
3.1.5% 150.34 1205.79 143.20 1325.61 
(US$ 5.98) (US$ 47.77) (US$ 5.67) (US$ 52.52) 
3.2.7.5% 181.55 1456.17 172.94 1600.87 
(base case) (US$ 7.22) (US$ 57.69) (US$ 6.85) (US$ 63.43) 
3.3.10% 214.15 1717.59 203.99 1888.27 
(US$ 8.52) (US$ 68.05) (US$ 8.08) (US$ 74.81) 
4. Case-fatality ratio 
1456.17 
(US$ 57.69) 
1453.82 
(US$ 57.60) 
1450.76 
(US$ 57.48) 
172.94 1600.87 
(US$ 6.85) (us$ 63.43) 
172.66 1598.28 
(US$ 6.84) (US$ 63.32) 
172.30 1594.92 
(US$ 6.83) (US$ 63.19) 
4.1.15% (base case) 181.55 
(US$ 7.22) 
4.2.30.2% 181.26 
(US$ 7.21) 
4.3.50% 180.88 
(US$ 7.20) 
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hospitalisation counterpart, 19% increase from the baseline 
cost per QALY in both options. Similarly, the cost per QALY 
of the 2HRZ/H2R2 regimen with the 75% treatment effectiveness 
raises to 193.31 baht (US$7.66) for the ambulatory option and 
1789.39 baht (US$70.90) for the hospitalisation counterpart, 
12% rise in both strategies. 
b) Change in the treatment cost. 
The cost per QALY of both regimens changes in a similar 
percentage in both ambulatory and hospitalisation treatments. 
Their cost per QALY decreases by about 7-9%, due to the 
lowest cost of the ambulatory treatment, but increases by 20- 
23% owing to the highest counterpart. In their 
hospitalisation strategy, the lowest cost of the treatment 
reduces the cost per QALY to be slightly more than half the 
underlying cost per QALY but the highest cost of the 
treatment raises it to be about one and half times the 
baseline cost per QALY. 
c) Change in the discount rate. 
The discount rate affects both regimens as well as both 
strategies alike. The 5% rate lowers the cost per QALY for 
all by about 17% whereas the 10% rate raises it by 18%. 
d) Change in the case-fatality ratio. 
Like the BCG vaccination programme, a 50% and a 30.2% 
case-fatality ratios are used as alternative estimates for 
this parameter. The impacts of the case-fatality ratio 
changes on the cost per QALY are almost nil. However, the 
direction of the impacts is opposite that found in the BCG 
vaccination programme analysis because, given that every 
other thing is equal, the QALY loss averted by treatment 
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through the aversion of the chronic prognosis is offset by 
the QALY loss avoided by treatment through the revival of the 
potential death. 
The discount rate has the most influence on the reduction 
in the cost per QALY for the two ambulatory regimens whereas 
the treatment cost has the greatest effect on their 
hospitalisation options. The high treatment costs have the 
greatest impact on the increase in the cost per QALY of the 
two regimens and of the two strategies. 
Within the range of the values changed in these tested 
parameters, the two short-course anti-TB chemotherapy 
ambulatory regimens are the most cost-effective of all the 
study programmes. The minimum cost of the 2HRZ/HR 
hospitalised treatment allows the cost per QALY to be 
slightly lower than the baseline cost per QALY of the BCG 
vaccination programme. On the other hand, the maximum cost of 
the hospitalised TB treatments could make it less cost- 
effective than the rotavirus vaccination programme. 
5.3. A review of the results of some international economic 
appraisal studies on these health programmes for 
the purpose of a comparison with those of this study. 
This section shows the single-programme cost- 
effectiveness analysis results and collective counterparts of 
BCG vaccination, anti-TB chemotherapy treatment, rotavirus 
vaccination and measles vaccination. It also focuses on the 
conclusions about the efficient health resource allocation 
among these health programmes and suggestions for 
implementing them. 
The result of the cost-benefit studies are not considered 
here because they could contribute a little to cost-utility 
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analysis in this study. The cost-benef it studies of these 
health programmes can be found in Creese (1986) and Prescott 
et al (1983). 
S. 3.1. The results of individual -programme Cost-ef f ectiveness 
studies. 
A) BCG vaccination proqramme 
Though a very small number of the BCG vaccination studies 
reviewed have shown that a joint BCG vaccination programme is 
marginally more cost-effective than a TB treatment programme, 
there are increasing conclusions suggesting that a BCG 
vaccination programme becomes less cost-effective mainly due 
to a decline in the BCG vaccination effect. However, BCG 
vaccinations are still encouraged to be rendered in areas of 
the high TB infection risk. 
Houston et al (1990) claim that the merit of a BCG 
vaccination exceeds its risk and cost in communities with a 
high TB prevalence. Azuma (1975) points out that during 1953- 
1978, the Japanese BCG vaccination programme was more cost- 
effective than the TB treatment, despite its slow effect. His 
evaluation method of the two tuberculosis control measures is 
different from the present standard assessment approach. The 
cost ratio of the vaccination to the treatment was compared 
with the proportion of the number of vaccinations to a 
treatment, producing similar effects. The effects include 
case-years prevented, deaths prevented and new cases averted. 
Barnum et al (1980) estimate that the Indonesian BCG 
vaccination programme, in conjunction with an existing 
vaccination programme, spent US$130 for a death averted from 
tuberculosis. The cost of an average case prevented was about 
one-third of the treatment cost. Their sensitivity analysis 
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shows that the BCG vaccination programme's cost-effectiveness 
would continue until the estimated cost of the BCG 
vaccination programme rises by 20% and the estimated cost of 
the TB treatment programme declines by 33%. The full 
utilisation of the BCG vaccination programme's capacity could 
further decrease the cost of a death's prevention to US$122 
and the cost of a case's avoidance to US$8.72. However, the 
BCG vaccination programme separated f rom any other available 
vaccination programme exhibited less cost-effective than did 
the treatment programme. By using a 3% discount rate, the 
cost per death averted by the joint BCG vaccination programme 
was US$144 and that by the independent counterpart, US$644 
based on the 1986 price level (Murray et al, 1990). 
Many argue that the cost-effectiveness of BCG vaccination 
programme is affected by some epidemiological parameters. A 
decline in the risk of tuberculosis infection and a shift of 
TB mortality away from infants and young children contribute 
to the higher cost per death averted (The Research Committee 
of the British Thoracic and Tuberculosis Association, 1975). 
Kochi (1991) points out that a high risk of infection in a 
population is the only condition for the continuation of the 
BCG vaccination programme. Fine et al (1990) state that the 
cost-effectiveness of BCG vaccination programme could be 
improved if it is devised to target the population with the 
highest risk of TB infection. This strategy is also in favour 
of the equity objective of the public health policy. 
In developing countries, the benefit of the BCG 
vaccination effect as well as its cost-effectiveness decrease 
as a result of a high prevalence of non-specific 
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mycobacterial infection, which destroys the immunity build-up 
against TB by the BCG vaccine. In order to avoid the 
infection and enhance the cost-effectiveness, the vaccination 
is advised to be delivered early in life before the 
mycobacterial infection takes place (Hart, 1967). Murray et 
al (1990) indicate a possibility of the less cost- 
effectiveness of a BCG vaccination programme on the grounds 
that it is incapable of preventing adult-formed TB in 
children, that it fails to decrease the risk of infection and 
that its full coverage has a small impact on the mortality 
aversion in a whole population. Fox (1988) claims that there 
is an acceptance that a BCG vaccination programme plays only 
a minor role in the tuberculosis control whereas the 
combination of case-finding and treatment plays a leading 
one. 
In addition to clearly asserting a less effective measure 
of the TB control in tropical countries, Sutherland (1988) 
offers two issues that make a TB treatment programme superior 
to a BCG vaccination one. First, the former can reduce the 
number of smear-positive patients and consequently the risk 
of infection more rapidly than the latter can. Secondly, the 
treatment can entirely cover a target population whereas the 
vaccination, though at its full coverage, can hardly render 
the protection to all, particularly persons infected with TB 
in the past who still remain the potential sources of the 
infection. 
However, the comparability of the cost-effectiveness 
between a BCG vaccination and an anti-TB chemotherapy 
treatment programmes is not supported by Murray et al (1991) 
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on the grounds that the former, at its best, can reduce 4-7% 
of the mortality whereas the latter, more than 90%. Despite 
a low cost-effectiveness of a BCG vaccination programme, they 
suggest that a combination of the two programmes in many 
countries should be a policy for TB control. Nevertheless, 
the comparability may be justifiable due to their mutually 
exclusive outcome. Padungchan et al (1986) points out that 
the two measures of the TB control in Thailand have had 
insignificant effect on the risk of infection and not 
interfered with each other's effect. 
Most studies suggest that the guidelines for implementing 
and allocating resources to a BCG vaccination programme 
should be made conditionally. As long as the BCG vaccination 
programme funding does not dilute the resources employed in 
a highly cost-effective measure for TB control, it is 
justified (Fine et al, 1990) . Houston et al (1990) also agree 
on this suggestion and add that unless the risk of 
transmission declines, the status quo of a BCG vaccination 
programme should be sustained until a more effective measure 
of TB control emerges. Noordeen et al (1988) urge for 
producing more effective vaccines for TB control. 
These cost-effectiveness analysis findings from the 
international studies based on some specific populations are 
unlikely to be generalised with other populations mainly 
because of differences in the programme costs and the extent 
of the prevailing risk of infection. Creese (1983) finds that 
the DPTT vaccination, which was more cost-effective than the 
BCG vaccination in Indonesia, was less cost-effective than 
the BCG vaccination in Morocco. The contrast in the 
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comparative cost-effectiveness of the BCG vaccination 
programme between the two countries was accounted for by the 
relatively higher tuberculosis death rate in Morocco. 
The cost-effectiveness of a local BCG vaccination 
programme should be determined on the basis of the relevant 
parameters' estimates of the population. It should be 
reassessed whenever the new data and information as well as 
changes in key epidemiological variables, which are provided 
by an on-going TB surveillance system, come to light (Fine el 
al, 1990; Barnum, 1980). Moreover, the fact that decisions on 
the schedule and the number of doses, as well as the strain 
of the BCG vaccine, in various countries vary in conformity 
with their own conditions supports the argument for the 
programme evaluation at domestic level (Fine, 1988). 
Resource allocation to a local BCG vaccination programme 
such as a move to the programme expansion, depends upon the 
location and timing of the implementation in a specific 
population (Murray et al, 1990). Even the Expanded Programme 
on Immunisation (EPI) is not in a position to suggest how a 
BCG vaccination programme in each country should be provided 
(Murray et al, 1991). 
B) Anti-tuberculosis chemotherapy programme. 
Murray et al (1990) estimate that for average TB cases 
treated with a short-course chemotherapy regimen, the cost 
per case cured at 18 months was US$314 and the cost per death 
averted was US$514 (the 1986 price level), based on the 
Tanzanian TB treatment programme. By taking account of 
reducing one round transmission of TB, the cost per death 
averted became US$243. 
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Their later cost-effectiveness study of the same 
country's TB treatment programme gives a significantly 
substantial decline in the cost per each effect of the 
treatment (Murray et al, 1991). The cost-effectiveness 
outcomes of the treatments in the three countries in their 
study are quoted in Table 77. 
They also show that the treatment programmes have similar 
cost-effectiveness when the treatment output is estimated in 
terms of the discounted years of life lost. For example, by 
taking into account the difference in the discounted life 
year loss between the 0-4 and 35-40 age groups, their costs 
per discounted year of life lost differ by no more than 20%. 
Murray et al (1991) demonstrate that the treatment of 
smear-negative pulmonary TB patients is the less cost- 
effective strategy for the treatment programme. It could be 
10-20 times the cost per death averted by treating smear- 
positive TB patients. 
Tuberculosis treatment programme is not free from wrong 
practices. Murray et al (1990) observe that the tasks of 
identifying and diagnosing tuberculosis are frequently 
performed poorly in developing countries due to the presence 
of atypical mycobacterial infections and the microscopists, 
insufficient training. Any mistakes. in the treatment 
programme waste its resources. The actual cost-effectiveness 
of the programme can be estimated by allowing for these 
unproductive activities. The true cost-effectiveness is 
acquired by dividing the estimated cost per death averted by 
the predictive value positive (i. e. the ratio of correctly 
identified tuberculosis cases to the total number of tested 
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Table 77 : Average incremental unit costs per case cured, 
per direct death prevented, per total death averted, 
and per year of life saved of the short-course 
chemotherapy treatments for Malawi, Mozambique and 
Tanzania (US$ in 1989). 
Regimen Malawi Mozambique Tanzania 
1. Short-course regimen with 
hospitalisation 
-per cure 165 232 202 
-per direct death averted 200 267 236 
-per total death averted 38 57 47 
-per year of life 1.7 5.6 2.1 
2. Ambulatory short-course regimen 
-per cure 107 81 101 
-per direct death averted 130 94 117 
-per total death averted 25 20 23 
-per year of life 1.1 0.9 1.1 
Notes 1) Malawi's ambulatory costs are hypothetical. 
2) The model is only applicable to a population where 
a high compliance rate can be maintained with daily 
supervised chemotherapy in the intensive phase such 
as that in urban areas. 
3) The total deaths averted are based on the assumption 
of a 50% reduction in the transmission rate. 
Source : Murray et al (1991) 
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cases) (Murray et al, 1990). This can also be applied to the 
cost per case prevented. 
According to Houston et al (1990), the comparative cost- 
effectiveness of the treatment programme suggests that the 
available money and manpower should be directed towards this 
programme. The cost-effectiveness can be improved by 
employing additional resources to increase the cure rate of 
the treatment, especially through the supervision of the pill 
consumption. 
To the lesser extent, the acquired drug resistance and 
the level of the infection risk also influence the cost- 
effectiveness. A decline in the risk of infection hardly 
af f ects the cost per death averted by the treatment programme 
but makes it more cost-effective than a BCG vaccination 
programme due to a rise in the cost per case and cost per 
death in the latter (Murray et al, 1990). 
Though TB treatment programme, particularly the short- 
course chemotherapy, is at present proved cost-effective in 
most international studies, the programme's cost- 
effectiveness should be locally demonstrated and the 
appropriate treatment selected in relation to domestic 
settings, programme feasibility and resource availability 
(Houston et al, 1990; Kochi, 1991). 
C) Rotavirus vaccination proqramme. 
Feachem et al (1983) assume an annual diarrhoea morbidity 
rate of 200 per 100 children under 5 years of age, annual 
diarrhoea mortality rate of 1.4 per 100 children and US$2.00 
for a child vaccination. The cost-effectiveness of a 
rotavirus vaccination would be US$5.00 per diarrhoeal case 
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averted, varying from US$3 to US$30, and US$220 per 
diarrhoeal death avoided, ranging US$140 and US$1400. 
A small number of the cost-effectiveness studies of 
diarrhoea control measures available, including the rotavirus 
vaccination, are a result of the incomparable health effects 
of the measures. Most diarrhoeal agents produce the 
distinguished level of the diarrhoeal severity. For instance, 
cholera and rotavirus diarrhoea appear to be more serious 
than other types of diarrhoea (Phillip et al, 1986). They 
also have their specific susceptible age groups. For example, 
young inf ants suf f er f rom rotavirus diarrhoea more of ten than 
older children and adults. On the contrary, the reverse is 
true for cholera. 
Martines et al (1991) claim that according to the 
criteria of feasibility and effectiveness, there are 18 
programmes for diarrhoeal control, which are listed in their 
study. However, it is found that only 7 of them are commonly 
analysed by the cost-effectiveness method. 
These arguments might be used against taking account of 
the efficiency investigation alongside other issues in the 
consideration of implementing a rotavirus vaccination 
prograrnme as well as other diarrhoeal control programmes. For 
instance, Vesikari et al (1984) suggest that a 70% decrease 
in all the infants contracting all kinds of diarrhoea from 
the rotavirus vaccination alone is justified for giving the 
vaccine in Finland and in other industrialised countries. 
D) Measles vaccination proqramme. 
Most studies conclude that a measles vaccination 
programme is cost-effective for measles control and one of 
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the most cost-effective vaccination programmes available at 
present (Hendrickse, 1975; Fine et al, 1983; Jamison et al, 
1990). Also, Jamison et al (1990) claim that the measles 
vaccination programme with virtually universal coverage is 
likely to stand its cost-effectiveness. Most cost-benefit 
studies of measles vaccination programme, an extensive 
collection of which can be found in Foster et al (1992), also 
support the argument. 
Creese (1983) mentions a study by Barnum in Kenya that 
the measles vaccination programme was the most cost-effective 
of all the available vaccination programmes (DPT, OPV, BCG 
and measles), no matter whether it was a single or joint 
vaccination programme. The cost per life saved in the 
independent vaccination programme was about US$50 and that 
with an additional measles vaccination to the existing one 
was reduced to US$26. 
Foster et al (1992) compare the cost-effectiveness of the 
measles vaccination programmes in three countries. Based on 
the 1980 price level, the cost per case prevented was 
estimated at US$1.96,3.30 and 14.00 in Gambia, Cameroon and 
Ivory Coast, respectively. The cost per death avoided was 
us$41,30-60 and 480. The cost per discounted healthy life 
year gained was US$49 in Cote d Ivoire and US$56 in Zambia 
(the 1977 price level). 
The main objective of the study by Foster et al (1992) is 
to investigate the cost-effectiveness of the four following 
strategies in increasing coverage of a measles vaccination 
programme. 
1) measles vaccination at 9 months (current practice) 
2) measles vaccination at 9 months and decreasing missed 
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opportunities 
3) high titer E-Z or equivalent measles vaccine at 6 
months 
4) high titer E-Z or equivalent measles vaccines at 6 and 
12 months 
They assume a 48/1000 birth rate, 100/1000 infant 
mortality rate, 3.5% population growth and that 34% of the 
population are aged under 10 in both urban and rural areas. 
The estimation excludes the herd immunity f rom the measles 
vaccination. The cost per discounted healthy life year gained 
is based on 1) the death prevention with an assumed 60-year 
life expectancy, 2) a 3% discount rate for future life, 3) no 
consideration of disability. Table 78 shows the results of 
the cost-effectiveness analysis in the two hypothetical 
populations in various forms of the cost and effect. The most 
cost-effective strategy in both areas is to administer the 
vaccination at 6 months of age. The vaccination in the urban 
areas is less expensive than that in the rural areas. 
When treated as a measure against the diarrhoeal problem, 
the measles vaccination programme remains more cost-effective 
than most of the other measures such as the cholera 
vaccination, the breast feeding promotion and improving 
weaning practices (Feachem, 1986). He also estimates that a 
measles vaccination would cost US$6.00 in preventing a 
diarrhoeal case in the hypothetical population with a 
diarrhoeal morbidity rate of 200 per 100 children under 5 
years of age and with a US$2.00 vaccination cost. Foster et 
al (1992) estimate that the cost per diarrhoeal case 
prevented is US$7-00 and that the cost per diarrhoeal death 
prevented is US$143 (the 1982 price level). Apparently, the 
inclusion of other main effects of a measles vaccine, namely 
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Table 78 : Cost-effectiveness analysis result of the four strategies 
of delivering measles vaccination in urban and rural 
areas. 
Strategy TC per 
case 
prevented 
TC per 
death 
prevented 
IC per 
case 
prevented 
IC per 
death 
prevented 
TC per 
DHLY 
IC per 
DHLY 
A) Urban areas. 
1 17.23 432.00 - - 14.90 - 
2 18.44 461.97 22.05 551.66 15.93 19.02 
3 10.99 275.37 5.27 131.90 9.50 4.55 
4 14.87 372.87 13.37 335.14 12.86 11.56 
B) Rural areas. 
1 77.33 524.57 - - 18.09 - 
2 12.12 560.89 14.50 669.54 19.34 23.09 
3 10.10 455.87 7.62 327.27 15.72 11.29 
4 13.31 610.81 15.56 706.33 21.06 24.36 
Notes 1) TC total cost 
2) IC incremental cost. 
3) DHLY = discounted healthy life year gained. 
4) Strategy 1= measles vaccination at 9 months. 
5) Strategy 2= measles vaccination at 9 months and 
decreasing missed opportunities 
6) Strategy 3= high titer E-Z or equivalent measles 
vaccine at 6 months 
7) Strategy 4= high titer E-Z or equivalent measles 
vaccines at 6 and 12 months 
Source : Poster et al (1992) 
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reductions in fever, rash, encephalitis and SSPE, make it 
more cost-effective than this. 
Despite the overwhelming cost-effectiveness, there are a 
variety of considerations for promoting a measles vaccination 
programme and in redirecting the resources from other lower 
cost-effective health programmes towards this programme. 
Hendrickse (1975) strongly suggests that an expanded measles 
vaccination programme should not be financed by the averted 
resources from health programmes providing principally basic 
health services. This is because without the well- 
established, fundamental health services preceding an 
enlarged measles vaccination programme, it is impossible to 
realise the estimated cost-effectiveness of the programme. 
Fine et al (1983) state that in many countries, the 
optimisation of their measles vaccination programmes should 
be determined on the association between the vaccine 
allocation and its subsequent impact. Since the future cost 
and benefit of a measles vaccination programme are not 
absolutely certain, there should not be a high expectation of 
its most cost-effectiveness. In other words, the cautions 
about reallocating resources for a measles vaccination 
programme arise from the underlying fact that the programme's 
cost-effectiveness is sensitive to many factors, including 
the availability of basic health services as well as the 
distribution of the vaccinations and its ensuing effects. 
5.3.2. The results of collective -programme cost-effectiveness 
studies. 
Creese (1986) finds that under a normal circumstance of 
the risk of measles infection, the cost-effectiveness of 
measles and rotavirus vaccination programmes overlap. The 
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rotavirus vaccination programme is more cost-effective in 
reducing the diarrhoeal morbidity but less in preventing the 
mortality than the measles vaccination one, as can be seen in 
Table 79. 
Based on the "Health Sector Priorities Review" series, 
which analyses key diseases and their corresponding health 
interventions in developing countries under the sponsorship 
of the World Bank, Jamison et al (1990) reassess the health 
interventions' outcome in terms of "discounted healthy life 
year" (DHLY) gained and, in turn, rank them according to the 
cost per DHLY. This unit is defined as the number of years 
between the age at which the death would have occurred due to 
a disease and the individual's expected age at death, given 
survival to the given age, with discounting future years 
gained to present ones. Non-healthy life years are assigned 
lower weights than healthy ones so that the programme effect 
on morbidity, disability, and mortality can be compared. 
Without having a common set of the weights for these health 
states, all the analysts used different means to weight these 
states according to their individual appropriate situation. 
As a result, their comparability should be treated with care. 
Table 80 presents the selective health programmes' 
results from Jamison et al (1990). Due to their estimates 
based on the safest values for the parameters, these 
programmes in real conditions, as they claim, may be more 
cost-effective by an order of 2 to 10 times their figures. 
They also set the priorities of these programmes in 
accordance with their cost-effectiveness (cost per DHLY) , as 
shown in Table 81. 
471 
Table 79 : Cost per diarrhoeal morbidity and cost per diarrhoeal 
mortality prevented by rotavirus and measles 
vaccinations. 
A) Cost per diarrhoeal morbiditV avoided. 
Health programme 
Rotavirus vaccination 
Measles vaccination 
1.1 to 2.9 
1.7 to 3.5 
B) cost per diarrhoeal mortality avoided. 
Health programme 
Rotavirus vaccination 
Measles vaccination 
69 to 179 
47 to 93 
Note It is assumed US$ 1 per fully immunised child. 
So the cost per case (death) averted with other 
presumed cost per fully immunised child can be 
acquired by multiplying this figure with that cost. 
Source : Creese (1983). 
Cost per case averted 
(US$ in 1982) 
Cost per death averted 
(US$ in 1982) 
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Table 80 : The cost-effectiveness estimates for some selected 
health programmes. 
Health programme and 
its specific character 
1. Measles vaccination against diarrhoea 
and acute respiratory infections 
2. Measles vaccination against diarrhoeal 
death only 
3. Measles vaccination against acute 
respiratory infection mortality 
only (costs separated from DPT 
vaccinations) 
4. Rotavirus vaccination (when 
available) 
5. BCG vaccination (excluding the 
effect on leprosy) 
6. Passive case-finding and the 
short-course chemotherapy 
treatment 
cost per DHLY 
(US$ in 1989) 
1.5 - 40 
2.0 - 45 
12 (with a high 
mortality rate) to 
200 (with a low 
mortality rate) 
5.0 - 50 
10 (with the high 
risk of infection) 
to 
75 (with the low 
risk of infection) 
8.0 - 10 
source : Jamison et al (1990) 
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Table 81 : The priority ranking of some selected health 
programmes according to the cost per DHLY 
Rank Health programme and cost per DHLY 
its specific character (US$ in 1989) 
1 Measles vaccination (in high 5 
mortality environments) 
2 Anti-TB short-course chemotherapy 10 
treatment* 
3 BCG vaccination (in high risk 10 
environments) 
4 Rotavirus vaccination (when 25 
available) 
5 Measles vaccination (in low 40 
mortality environments) 
6 BCG vaccination (in low risk 75 
environments) 
Note Despite the same cost per DHLY of the anti-TB 
short-course chemotherapy treatment and BCG 
vaccination (in high risk condition) programmes, 
the former is regarded to have a bigger burden 
to deal with and set to a higher priority. 
Source : Jamison et al (1990) 
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There are two other key conclusions about the health 
programmes by them. First, most of the health interventions 
for children are more cost-effective than most of those for 
adults. Secondly, whether preventive programmes or case 
management programmes are more cost-effective cannot in 
general be determined. 
Nevertheless, their intention to promote the cost per 
DHLY unit as one of the universal cost-effectiveness measures 
for all health programmes is withheld by their suggestion 
that the cost-effectiveness of the health interventions for 
children should be considered separately from that of those 
for adults. It is claimed that people would value "adult's 
DHLYs" differently from "child's DHLYs". This assertion has 
no theoretical or empirical ground to support. On the other 
hand, the studies of some European and Thai health state 
valuations have shown insignificant age effect on the 
preference of some health states across age groups, as seen 
in Chapter 3. Though such tests based on children and persons 
under 18 years of age are unavailable, there are no reasons 
why their preferences would differ from those of older 
people. 
The comparison between this and Jamison et al's studies 
indicates that based on the low risk of measles and 
tuberculosis, the priority ranking pattern of the selected 
health programmes is similar except for the rotavirus 
vaccination programme. This study has ranked it the last 
whereas in the other study it was ranked second. 
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5.4. Policy implication. 
5.4.1. The result interpretation and implementation of 
the four health programmes. 
The findings according to the base-case cost per QALY 
could lead to two actions in the Thai public health service 
sector. First, if the assumption of the unchanged cost per 
QALY in relation to the volume of the services provided is 
held and if reorganising the health programmes I structure is 
possible, then the redistribution of the existing resources 
among the four health programmes in this study, which is 
described next in principle, would achieve efficiency. The 
national Thai public health budget should be, first of all, 
used to treat every TB case with ambulatory 2HRZ/4H2R2 regimen 
(or 2HRZ/4HR regimen if there is a clear evidence that this 
regimen is appropriate, for example the supervision purpose) . 
The next task is to make as many infants receive the vaccine 
against measles as possible. The consideration for the BCG 
vaccinations follows and its budget share is determined from 
the remainder. The option of treating non-critical TB cases 
within hospital is possible provided that the remaining 
budget is adequate to do so. If the rotavirus vaccination 
were ready for implementation, it would be the last in the 
application for the fund and command only the last portion of 
the budget. 
in reality, many have pointed out the rising total, 
average and marginal costs of both completed childhood 
immunisations (Foster et al, 1992) and individual 
vaccinations (Jamison et al, 1990). Therefore, the 
possibility of restructuring the existing resource allocation 
for the health programmes is unlikely. 
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Secondly, when the reallocation of existing resources is 
preferable to being kept intact, the results can be 
appropriate for the distribution of additional public health 
fund to the health programmes. The fund should be firstly 
allotted in the way that all TB cases are treated with the 
short-course ambulatory regimens and new cases are identified 
and treated. The following are the strategies of heightening 
the number of cured cases suggested in most studies reviewed 
in Chapter Four. The problem of the treatment compliance can 
be tackled by removing the existing snags such as distance 
between the treatment site and patient's home and the timing 
of the treatment provision. The set-up of the treatment 
centres in remote rural areas as well as the better referral 
network would reduce the drop-out rate. The extended service 
hours to meet patients, convenient time could attract more 
cases and maintain the continuing treatment of the currently 
treated cases. Moreover, some advise that some resources 
should be used in stabilising the anti-TB drug supply and 
should be spent researching the treatment effect. 
The second priority of the fund is the provision of 
measles vaccinations. Its share should be used on the 
activities that expand the size of the measles vaccinees. At 
present, the Thai measles vaccination coverage is about 60% 
and rising. The spending towards the higher coverage would be 
an obvious means to attain the increasing number of the 
vaccinees. However, some expect it could reach 80%, as 
similar to the coverage of the third dose of DPT and OPV 
vaccines, and probably no more than that. The corrections of 
the mistakes and misconduct in the measles vaccinations could 
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improve the number of the genuine vaccinees in the vaccinated 
population. This strategy may involve more training of the 
manpower in the measles vaccination programme and the 
purchase of better equipment like the Ezeject syringe. 
The BCG vaccination programme is the third priority. As 
the current BCG vaccination coverage is high (96%), there is 
little room for manoeuvre in getting more new vaccinees. Like 
the measles vaccination, the rectification of the incorrect 
practices in the vaccine delivery, in terms of the dose use 
and vaccine handling, could no doubt improve the size of the 
infants with the successful BCG immunisation. As the BCG 
vaccination programme could be lef t with a small budget, the 
latter option may be more attractive since it may cost less 
than the former. 
The next priority is to render more hospitalised TB 
treatments. Again, the decision about the rotavirus 
vaccination provision would have been made in the end if it 
were ready for launching as a routine vaccination programme. 
The sensitivity analysis indicates two important issues. 
First, the ef f iciency situation is not static. It is possible 
for the cost per QALY of the health programmes to change and 
their comparative cost-effectiveness to shift due to 
improvements in some key parameters or deteriorations in 
others. 
It is possible that the ranks of the f irst three most 
cost-effective programmes, namely the anti-TB ambulatory 
treatment, measles vaccination and BCG vaccination, could 
swap, according to the minimum and maximum costs per QALY 
from the sensitivity analysis section as shown in Figure 2. 
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Figure 2: The minimum and maximum cost per QALY of 
the health programmes (the 1988 price level). 
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This is also true for the measles vaccination, BCG 
vaccination, hospitalised TB treatment and rotavirus 
vaccination programmes. It is highly unlikely that the TB 
ambulatory treatment programme is ranked below the 
hospitalised TB treatment and rotavirus vaccination 
programmes. 
Secondly, the improvements in all the health programmes 
are possible since they all are sensitive to some key 
parameters. In common with all the vaccination programmes, 
there are two important controllable improvements. 
1) The vaccines should be developed to produce higher 
effectiveness than at present. The malpractice in the 
vaccination process could be reduced so that the 
effectiveness levels of the routine vaccination programmes 
would increase. 
2) The issue of the vaccine protection length has 
appealed less to vaccine developers so far and, has been kept 
to a minimum in most vaccine studies. As it is demonstrated 
that the protection duration is crucial to the efficiency 
prospect of the vaccine provisions, an attempt to promote 
this issue to the top agenda of vaccines, research is 
recommended. 
5.4.2. Application of the findings to assessing Thailand's 
priority-setting of the health programmes. 
The Fact Finding Commission (1987) launched a priority- 
setting principle for Thailand's public health programmes 
based on the country's current health problems. It was 
modified from a priority-setting method of WHO, in which 
there are three main categories of the parameters. 
1) Disease's magnitude parameter consists of morbidity 
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rate, mortality rate, case-fatality rate, years of potential 
life lost (YPLL) and average length of hospital stay. Five 
scores, the meaning of which is shown in Table 82, are used 
to rate the importance of diseases. 
2) Disability parameter has f ive levels : none, mild, 
moderate, less severe and severe. The scores 1-5 (1 
none and 5= severe) are used to represent the levels. 
The extent of disability is determined at the time patients 
are discharged from hospital. The measurement of this 
parameter, based on judges' experience, is entirely 
subjective. 
3) Treatability and preventability parameters fall into 
low, medium, and high levels. These parameters reflect the 
current medical technology available to treat and/or prevent 
diseases. This is evaluated by judges, opinions, which 
support by their experience and expectation. 
This priority- setting method can be classified under "the 
traditional epidemiological approach to needs assessment", 
which is referred to by Donaldson et al (1991). According to 
this approach, "need" in a population, measured by various 
ill-health outcomes due to diseases, is used to set 
priorities for allocating resources to various health 
interventions against diseases. 
According to the Fact Finding Commission's ranking the 
three diseases relevant to this study, the main criteria 
suggest a high priority to diarrhoea, against which a 
rotavirus vaccination programme may be selected as a control 
measure. Tuberculosis is ranked second. This may mean that 
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Table 82 : The scoring rule of and scores for the parameters 
for measles, diarrhoea and tuberculosis 
based on the Fact Finding Commission's study. 
I. The scoring rule. 
Rating score 
Parameter 
12345 
1. Morbidity rate 0-9 10-49 50-99 100-499 500+ 
(per 100000) 
2. Mortality rate <1 1-4 5-9 10-19 20+ 
(per 100000) 
3. Case-fatality 0-4 5-9 10-19 20-49 50+ 
ratio M 
4. YPLL (year) <1000 1000-4999 5000-19999 20000-49999 50000+ 
5. Hospital stay <1 1 2 3 4+ 
(week) 
II. Parameters' scores. 
Measles Diarrhoea Tuberculosis 
A) Main criteria 
1. Morbidity rate 3 5 3 
2. Mortality rate 1 1 1 
3. Disability 1 1 2 
4. YPLL 2 3 3 
Total score 7 10 9 
B) Other criteria 
1. Case-fatality ratio 1 1 1 
2. Hospital stay 2 1 5 
3. Preventability High Medium Medium 
4. Treatability High High High 
The rank out of 26 11 19 
38 diseases 
considered 
Source : The Fact Finding Commission (1987). 
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the short-course ambulatory treatment, BCG vaccination and 
hospitalised TB treatment programmes are given the second 
priority. The last rank for measles could imply the measles 
vaccination programme would obtain the lowest priority. it is 
possible that the priority ranks of the health programmes 
according to the Fact Finding Commission's study and those 
based on this study do not match. Donaldson et al (1991) note 
that the priorities based on the needs assessment could 
differ from those derived from the economic evaluation. They 
add that the difference arises from two main drawbacks in the 
needs assessment approach :a continuing change in need 
fulfilled and the omission of health interventions' 
costs. 
Therefore, one can predict that the resource allocation 
based on the Fact Finding Commission's findings does not 
achieve efficiency. Nor does it guarantee that the disease 
burden could subside or, more precisely, how many cases are 
saved and/or averted from diseases. In contrast, the cost- 
utility analysis findings could provide the estimated returns 
of spending on the health programmes (i. e. the volume of the 
healthy life years gained from a health programme's allotted 
expenditures). 
Moreover, the ranking results of the Fact Finding 
Commission's analysis have limitations for practical uses. 
Some further evaluations and decisions have to be made before 
the implementation of specific health programmes can be 
launched. A major setback of the needs assessment approach, 
as Donaldson et al (1991) point out, is that it is unable to 
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set the appropriate amount of resources to health 
interventions or measures against diseases. 
By contrast, cost-utility analysis could offer some 
information and data as inputs in planning for health 
programmes. 
The concept of the Fact Finding Commission's priority- 
setting method can further be challenged. Take the years of 
potential life loss (YPLL) for an example. The importance of 
diseases could be distorted and biased by using the current 
morbidity and mortality as a basis for calculating the YPLL. 
For diseases' present incidences measure only a part of the 
disease problems that are set out to be dealt with by 
potential health programmes. But it does not indicate the 
other part of the problems that have already been coped with 
by existing health programmes. In other words, it does not 
genuinely reflect the total impact of the diseases 
independent of the health programmes. Nor does it take into 
account the potential capacity of health programmes in 
reducing the disease incidences. In addition , it is based on 
the non-discounted years of life loss. The duration loss from 
morbidity and mortality is treated similarly in terms of the 
scale of time without including the dif f erence in the quality 
of life between morbidity and mortality. 
In reality, the ranking of health programmes, priorities 
is implicitly made and not announced publicly. Moreover, due 
to the availability of other aims governing the priority- 
setting apart from efficiency, the efficiency assessment of 
the resource uses becomes difficult. 
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In such a condition, efficiency can be 
retrospectively evaluated by comparing the actual outcomes 
of health programmes' implementation with the findings of the 
cost- utility analysis. For instance, among the health 
programmes in this study, the f irst issue that has to be 
examined is whether the additional resources in the public 
health service sector were used in treating more TB cases 
with the short-course ambulatory regimens and/or any other 
activities in achieving this objective. If this is fulfilled, 
then the second issue is to investigate whether the 
additional budget is employed to increase the volume of 
vaccinees with measles vaccinations. If this is attained, 
the next issue becomes the inspection of a rise in the number 
of the BCG vaccinees or a decline in the wrong practices of 
the BCG vaccinations, followed by the issue of more TB 
patients treated with the short-course hospitalised 
regimens. 
The actual implementations deviating from these 
arrangements means the inefficient use of the fund. 
Therefore, the reallocation complying with the result of this 
study could bring about efficiency. 
A use of the findings of cost-utility analysis 
recommended to the UK health authorities in allocating health 
care resources and replacing the needs assessment approach is 
exemplified by Donaldson et al (1991). 
This cost-utility study is almost completed. The 
priorities regarding efficiency of the study health 
programmes have been set. However, cost-utility analysis is 
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continuing. There are many issues to be tackled. In the 
next chapter, valuing health states, one of the most 
important issues, will be explored. 
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Chapter 6 
The comparisons of international surveys of 
the EuroQol health state valuation and the valuation models 
In this chapter, the results of the Thai health state 
valuation are compared with the findings of other 
international valuation surveys based on the EuroQol 
instrument. The models for health state valuation are 
employed to tackle some key problems of valuing health 
states. Some models are proposed and tested broadly with all 
the data from the international sources and in depth with the 
Thai and Finnish data sets. 
The tests of the models with the Thai data could be made 
on a larger number of health states by using the valuation of 
self-classified current health states available in the survey 
and for the property of the diminishing marginal values of 
health states. Finally, the suggestions for developing the 
valuation models as well as the proposed criteria for the 
model performance's test are put forward. 
6.1. The comparisons of international surveys of the health 
state valuation based on the EuroQol instrument. 
In this section, the findings of the EuroQol health state 
valuation surveys in various populations available are 
gathered. The comparisons of the surveyed data between the 
Thai source and the rest are made on the basis of individual 
health states. The comparison based on an early version of 
the EuroQol instrument is presented first and followed by 
that based on the current one. 
There are at least six major differences between the two 
versions. The early version is displayed in Appendix IV. 
First, the number of the dimensions used differs. The 
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original had six domains whereas the current one only five 
due to the combining of the main activity and social 
relationships dimensions into the usual activities one. 
Secondly, the division of the severity levels in some health 
dimensions is different. The present version gives three 
levels of the severity for the usual activities dimension, 
whose equivalent dimensions in the original, namely the main 
activity and social relationships dimensions, had only two 
severity degrees. It also broke down the original's 
anxious/depressed problems into moderate and extreme levels. 
Thirdly, most of the health states in both versions were not 
matched as a result of a different combination of the 
severity levels in the dimensions. Only three health states 
remain identical. Fourthly, an unconscious state, which was 
not available in the early version, was included in the 
present one. Fifthly, the repetitive health states in the 
original were 112222 and dead states whereas those in the 
current version, 11111,33333 and dead states. Finally, the 
early version included dead states in boxes whereas in the 
other the valuation f or dead states, which were not presented 
alongside the other health states, comes at the end of the 
valuation in each page. 
Three assumptions are made in order to enable to compare 
this study's results with the valuation findings based on the 
original version (The EuroQol Group, 1990; Nord, 1991a). 
Firstly, the combination of the main activity and social 
relationships dimensions in the early version is equal to the 
usual activities dimension in the present one. Secondly, the 
problems in the combined main activity and social 
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relationships dimension correspond to the extreme severity 
level in the usual activities dimension. Thirdly, the anxious 
or depressed problems in the mood dimension in the early 
version are equivalent to the moderate severity degree in the 
anxiety/depression dimension in the current one. 
Since a small number of the health states could be 
brought into the comparison, mild conclusions can be made. 
Table 83 shows mean, median and standard deviation of the 
valuation of five health states from six data sets. The 
values for perfect health from all the data sets are similar. 
Both mean and median values of the health states 11121,11112 
and 11122 differ slightly between the Thai and other sources. 
Conversely, the values for the dead states from the Thai data 
sets are considerably higher than those from any others. 
Another marked distinction among these data sets is their 
number of "worse than death" states. The valuation surveys in 
Lund, Frome and BoZ have no such states with regard to the 
median values. But in relation to the mean values there are 
two states (322232 and 332232) worse than death in the 
swedish survey, three (232232,322232 and 332232) in the 
British one and four (222232,232232,322232 and 332232) in 
the Dutch. The Thai interview valuation data set has two 
"worse than death" states (33333 and unconscious) with 
respect to both mean and median values. However, its postal 
counterpart contains such four states (22323,33321,33333 
and unconscious) in relation to the mean values but only two 
(33333 and unconscious) with respect to the median values. 
The survey outcomes based on the current version of the 
EuroQol instrument at the time of writing are available from 
489 
Table 83 : Mean, median and standard deviation of five 
health states' valuation from six data sets 
based on the early and current EuroQol 
instruments. 
A. Mean valuations. 
Health Lund' Frome 2 DOZ3 Norway' BKK 5 BKK 6 
state 
11111 93 95 93 94 94 87 
11121 83 81 81 86 73 73 
11112 69 67 71 61 73 73 
11122 64 65 69 68 59 54 
dead 10 10 19 n. a. 21 23 
B. Median valuations. 
Health Lund' Frome 2 BOZ3 Norway' BKK5 BKK6 
state 
11111 100 99 95 100 100 92 
11121 86 84 86 90 80 80 
11112 75 70 75 60 80 74 
11122 70 68 70 71 60 58 
dead 0 1 3 n. a. 20 11 
Standard deviation. 
Health Lund' Frome 2 1BoZ3 Norway' BKK 6 BKK 7 
state 
11111 13 10 13 1 9 16 
11121 16 14 19 4 9 21 
11112 21 18 22 3 16 19 
11122 20 17 21 2 18 23 
dead 24 21 25 n. a. 19 26 
Notes 1. 
2. 
3. 
4. 
5. 
6. 
Swedish study in Lund 
British study in From, 
Dutch study in Bergen 
Norwegian study (n=60 
Thai study in Bangkok 
Thai study in Bangkok 
(n=208; postal survey) 
e (n=310; postal survey) 
op Zoom (n=74; postal survey) 
to 211; postal survey) 
(n=354; interview survey) 
(n=162; postal survey) 
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the United Kingdom (Frome) , Sweden, Finland, Health Economics 
in Developing Course members (HEDC) and Thailand (Bangkok), 
as presented in Table 84. The valuation data in most sources 
available were reported in the form of the median transformed 
feeling thermometer scores. This central tendency measure is 
appropriate for the analysis due to its representativeness of 
a small number of samples. Unlike the valuation comparison 
based on the early version of the EuroQol instrument, the 
transformed values are presented with respect to a unit scale 
of 100, whose upper reference is the health state 11111 (100) 
and the lower one, dead state (0). 
A remarkable finding is that in six out of fourteen 
health states excluding the reference health states, the 
valuations in both Thai surveys are lower than those in the 
others. There are no "worse than death" states in the British 
studies but one to three in the others. The Swedish study and 
the Finnish study each have the health state 33333 as the 
only "worse than death" -state. In the HEDC study, one of the 
health states 33333 and the unconscious state, sharing the 
same value, are the two "worse than death" states. The two 
health states 33333 and the unconscious state are "worse than 
death" states in both Thai surveys, the values for which are 
sharply different from those for the "worse than death" 
states in all the other studies. 
The reason underlying the differences between the Thai 
and others, valuations may be the environment component of 
the society in which the respondents live. Death is a much 
more familiar state for the Thai people than the extremely 
severe health state and the unconscious state, which often 
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Table 84 : Median values of sixteen health states from 
eight data sets based on the current EuroQol 
instrument version. 
Health 
state 
Fromel Frome 2 Frome 3 Swen' Finn5 BKK 6 BKK 7 HEDC9 
11111 100 100 100 100 100 100 100 100 
11112 79 70 79 65 60 74 77 79 
11121 79 76 76 75 79 75 82 72 
11211 82 80 86 78 82 63 90 70 
12111 65 74 75 70 75 55 60 63 
21111 69 61 67 81 85 76 81 75 
11122 59 50 56 55 50 55 50 55 
21232 26 28 32 26 33 28 22 30 
22233 14 19 29 12 22 11 6 25 
22323 10 is 22 12 18 7 0 8 
32211 29 38 31 34 38 25 16 22 
33321 10 12 17 9 17 5 0 9 
33333a' 0 11 3 -2 0 -11 -6 -2 
33333b9 0 6 3 0 -4 -11 -6 0 
uncon 0 4 1 0 0 -17 -7 -2 
scious 
dead 0 0 0 0 0 0 0 0 
Number 82 10 8 65 ill 354 95 8 
of vali d 
cases 
Notes 1. The British study in Frome, Somerset general public 
(postal survey) 
2. The British study in Frome, Somerset southern health 
authority members (postal survey) 
3. The British study in Frome, Somerset eastern health 
authority members (postal survey) 
4. The valuation of Swedish hospital staff. 
5. The Finnish study in Oulu (interview survey). 
6. The Thai study in Bangkok (interview survey) 
7. The Thai study in Bangkok (postal survey) 
8. The valuation of members of the Health Economics in 
Developing Countries course, University of York 
(self-administering survey). 
9. The repetitive health states 33333 on successive pages 
of the questionnaire. 
Sources : 1. Alan Williams (Personal communication) 
f or Frome', Frome 2, Frome 3, Swen 4 and HEDC8. 
2. Arto Ohinmaa (Personal communication) 
for Finn'. 
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involve chronic and complicated diseases. To put it another 
way, the death rate from any cause is high enough to make the 
Thai people consider death commoner than (and preferable to) 
the two extremely severe health states, which are rare in the 
Thai population. On the other hand, in most European 
countries, success in maintaining a long life expectancy and 
in sustaining life, even in the state of extreme severity, as 
a result of development of high medical technology, makes 
living score higher than or, at worst, slightly less than 
death. 
The valuation difference could be accounted for by 
referring to the definition of health-related quality of life 
(Patrick et al, 1988; Walker et al, 1988). It suggests that 
diseases, accidents or treatments influence the level of 
well-being and satisfaction of people. When diseases, 
accidents, treatments and like factors differ, dissimilar 
patterns of satisfaction reflected by the valuation follow. 
As Thailand not only experiences an increase in the death 
rate reduction and the extension of life expectancy but also 
familiarises gradually the extremely severe health states as 
a result of imported high medical technology, the Thai 
valuation might move towards the values found in the Western 
societies. 
On the basis of some data performances, for instance, the 
slight difference in most health states, values between the 
surveys, some investigators stress the similarity of the 
valuations and tend to share the valuation findings and their 
relevant research outcomes in the future (Nord, 1991a) . On 
the other hand, other indications, like the different number 
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of "worse than death" states between the studies and the low 
scores for a substantial number of the health states in the 
Thai data sets, may make Thai decision-makers and analysts 
cautious to rely on using the valuations based on other 
populations and discourage them from using the 
internationally pooled data. Generally, there are more value 
variations between the Thai valuation and the rest than those 
among European valuations. Possible explanations may lie on 
the distinctions in culture, living standard and environment. 
As a result, the domestic valuation would be more appropriate 
for Thailand's health programme economic evaluation than any 
foreign valuation. 
However, this should not be interpreted so as to rule out 
the consideration of the valuation findings from imported 
sources. The international cooperation on the valuation study 
needs to be expanded. Issues of what factors attributable to 
the international valuations, discrepancy would make better 
understanding about this useful tool in cross -populations and 
consequently improve the EuroQol instrument as well as health 
state measurement and valuation. Eventually, a global health 
status measure could hopefully be established, which was 
cited as one of the key objectives of the EuroQol Group. 
6.2. The health state valuation models. 
As health state valuation, as part of cost-utility 
analysis, has developed, a rise in the number of health 
programmes to be appraised has required too many measured 
health states to be coped with in normal surveys and causes 
too much expense and effort in completing the task. 
Therefore, these are immediate obstacles preventing cost- 
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utility analysis from being widely applied. This issue 
obviously concerns this cost-utility study. To explore a 
means to tackle it is the focus of this section. 
Though in some cases the surveyed data for health states 
involved may be sufficient, their qualitative aspects are 
still a problem for the valuation. They are frequently 
criticised for not only the lack of the proof of their 
generalisation to the whole population affected by the health 
programmes under assessment but also their subjective 
judgement basis. As a result, the findings and applications 
of cost-utility analysis could be undermined. The reliability 
of respondents' judgement is questionable and the issue of 
the dependence of the measurement result on certain 
characteristics of evaluators is raised. Most studies have 
found that the utility values of health states are affected 
by many factors (Llewellyn-Thomas et al, 1984; Boyle et al, 
1984). 
Modelling respondent's health state valuation could solve 
the problem of insufficient surveyed data and partly improve 
the quality of the valuation data employed in the analysis. 
For example, the valuation models could offer the predicted 
values for all the health states needed in cost-utility 
analysis and remove some fluctuated bias of the surveyed 
results. Llewellyn-Thomas et al (1984) remark that a 
valuation model might keep the influences of personal 
background factors on the valuation constant, although 
completely unaffected values are impossible to obtain. 
This section contains a background discussion of the 
concept and framework of the utility theory, which primarily 
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underlies the valuation behaviour and measurement methods. It 
then presents the application of the multiattribute utility 
theory, which is a modified utility model to deal with 
multiattribute objects, to the valuation of health states. 
The concepts and models that are appropriate for the 
multidimensional characteristics of health states are 
proposed based on the elimination-by-aspects model (Tversky, 
1972a and 1972b) and the regression model. 
6.2.1. An overview of the health state valuation models. 
Valuation models have been advocated since the early 
1970s, concurrent with the model of health status indexes 
(Berg, 1973). Unfortunately, the lack of success of these 
models and their evolved valuation models is due mainly to 
their premature step in the development of modelling the 
valuation. They had no uniquely operative health status 
definitions and measurements. The scaling methods were not 
well developed. There existed very few valuation surveyed 
results on a very small number of health states to be 
assessed and tested for the proposed models. On the contrary, 
it was hoped that the establishment of the models could 
resolve some problems encountered in the health status index 
construction. Despite these setbacks, the exploration and 
setting up of some models has contributed some guidance 
towards better models in the light of more information 
available. 
The most popular and conventional utility theory is the 
expected utility theory. This theory is the basis for the 
standard gamble technique, developed by von Neumann and 
Morgenstern, for measuring empirical utility. The two 
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following equations denote the basic utility functions of the 
theory and the measurement technique, respectively. 
(1) U( px + (1 - P) Y)= pu (X) + (1-P) U (Y) 
(2) U (Zi) = qU(Zl) + (1-q)U(ZO) 
where U( )= utility function 
X, Y, ZO, = objects in consideration 
Z1, and Zi 
p and q the probabilities of objects X and Y 
occurring (e. g. winning a lottery); 
and the probabilities of objects Zo, 
Z1, and Zi occurring 
A key characteristic of this technique is the component 
of riskiness. As a result, the attitude towards risk of 
evaluators is involved in the measurement result. It is both 
an advantage and a disadvantage of this technique, regarding 
the purpose of the result uses. Since the attitude towards 
risk exists in the real world, its inclusion in any valuation 
model would reflect the genuine behaviour of utility 
judgement. On the other hand, it unnecessarily complicates 
the use of utility estimates to represent the whole 
population because of its unknown and variant attitudes 
towards risk. 
The crucial part of the application of the expected 
utility theory to health status indexes is to define the 
object in consideration. The expected utility theory and 
standard gamble technique are normally used in measuring 
quantifiable objects like money. However, there is no 
consensus on quantified health, despite the existence of 
operative health definitions and measures. 
Health outcomes from health interventions are the best 
approximations for health used in the valuation models based 
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on the expected utility theory and scaling methods. Two major 
health outcomes are the improved conditions of health status 
and the extension of time length in those conditions. 
Torrance (1976) combines these two outcomes into a single 
"additional healthy time". It is assumed that the utility of 
additional healthy time as well as that of additional non- 
healthy time (but preferred to death) increase with the 
extended time but at a declining rate. 
Figure 3 outlines utility functions of "additional 
healthy time" and of "additional non-healthy time". The 
concave graphs are consistent with the increasing function of 
utility and with its decreasing rate of change. At any point 
of time gained, the graph of the utility function of the more 
severe state is below that of the less severe one (e. g. at 
tio U3 (t) ": ý U2 (t) < U1 (t) ; where the health state 3 is less 
healthy than the health state 2 and the health state 2 is 
less healthy than the health state 1). 
To enable the utility value for any health state within 
a given time interval to be computed, two assumptions are 
made. The "Proportionality of utility functions" assumption 
supposes that the utility of a non-healthy state is a 
fraction of the utility of additional healthy time, which is 
called a weighting factor (bj) , given that the time in the 
non-healthy and healthy states are identical (t). The 
following equation best summarises this assumption. 
uj (t) bj U, (t) 
or Hi (t) bj 
ul (t) 
where j=2 nd ,3 rd 14 
th 
I ... ,n 
th 
non-healthy states 
1= healthy state 
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Figure 3: Utility functions of Nadditional healthy time" 
and "additional non-healthy time". 
U3 (t) 
ul (t 0 
U2 (ti) 
U3 (t L) 
ti t 
499 
The "Independence of dysfunctional state time" assumption 
merely changes in the previous assumption the time reference 
from the absolute period between non-healthy and healthy 
states to the differential period. It can be expressed in the 
equation below. 
jjj (, & t) bj 
U, (, &t) 
where &t =a time interval 
The second assumption becomes more useful than the first 
one in that the weighting factor (bj) can be independent of 
and unaffected by the beginning of non-healthy states. Also, 
the weighting factor is less affected by the length of time 
in the second assumption than in the first. The use of the 
estimated weighting factors from the second assumption, 
therefore, becomes easy when applied to health interventions 
with complicated prognoses. 
The fact that time is a uniquely measurable unit whereas 
health states are not makes the measurement issue of the 
latter more important than that of the former. Torrance 
(1976) states that the utility functions of additional 
healthy time with respect to the time dimension in most 
health status index models assume either a linear form (e. g. 
ul(t) = t) or an exponential form (e. g. ul(t) =1- e-It/r ; 
where r= discount rate and e= natural logarithm) . on the 
other hand, the weighting factors for various health states 
have no models to base on. In some studies, they are set 
arbitrarily while in other studies they are estimated from 
respondents by a variety of scaling methods. 
In later development of the health state utility 
valuation based on the expected utility theory, analysts have 
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paid particular attention to dealing with the utility 
function of health state. Health outcome in the form of 
additional healthy days (or years) as well as non-healthy 
ones is simply the product of the. extended length of time and 
the utility of health states involved affected by health 
intervention. This simplifies a great deal for the utility 
measurement of such a health outcome. 
There are two options in obtaining the utility values for 
different health states. One choice is to define (and 
estimate) the utility function. The other is to directly 
measure the utility values for the health states in 
consideration by describing those health states accurately 
and applying a scaling method to an appropriate sample of 
respondents. Torrance et al (1972) believe that the second 
choice is far simpler than the first. Most studies in the 
past have relied on this option. Also, like other measurement 
studies in psychophysics, it is agreed that the consensus of 
the utility values is supposed to be determined empirically 
(Stevens, 1966). The choice is practicable for a manageable 
size of health states. 
Unfortunately, the number of health states, as a result 
of the possible combinations of severity levels in all health 
dimensions in most of the present classifications is too 
large for valuation surveys under normal circumstances to 
produce utility values for all health states, which might be 
made available for cost-utility analysis of a wide variety of 
health programmes. To acquire the valuation for all health 
states needs a huge amount of resources. This very fact 
encourages researchers to turn their attention towards the 
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other option, the specification and estimation of the utility 
function of health states. 
6.2.2. The multiattribute utility theory for the health state 
valuation model. 
For the purpose of tackling the problem of an excessive 
size of health states to be measured, the multiattribute 
utility theory (MAUT) is the one commonly used to construct 
a model of valuation. It was fully adopted and developed in 
Torrance et al 's health status index model (Torrance et al, 
1982; Boyle et al, 1984). 
Based on von Neumann-Morgenstern's utility function 
(Fishburn, 1988), it simplifies the utility assessment of a 
certain group of objects (e. g. X1, X21 X31 ... # X, ) by 
assuming that its utility function can be decomposed into 
algebraic combinations of its individual objects, functions. 
The utility values for the sets of any combined objects of 
interest can be determined without actually measuring the 
collection but rather with individuals' utility values. 
Fishburn (1988) points out two of the simplest decomposed 
forms for utility functions (U) based on this theory : (1) 
additive form and (2) multiplicative form. 
(1) U (X1 
I 
X21 X31 Xn) U1 (X1) + U2 (X2) + U3 (X3) + 
+ Un (Xn) 
(2) kU (XI, X21 X31 Xn) +1 [kU, (X, )+ll [kU2 (X2) +11 
(kU3 (X3) +11 ... [kUn 
(Xn) +11 
where Uj(Xj) is a utility function on Xi 1,2,3, 
n 
and k is a non-zero constant 
The requirement for the additive model is that Xi is 
value independent. The multiplicative model, though the value 
independence of Xi is not necessary, needs utility 
502 
independent conditions (i. e. the utility of every attribute 
is independent of their complements). A formal derivation of 
these conditions can be found in Fishburn (1988). 
Boyle et al (1984) highlight the prospect of this theory 
applied to the health state valuation that "the success of 
this approach depends on selecting the "correct" mathematical 
model for estimating the values of the unmeasured health 
states". The best model is decided upon using the empirical 
evidence. 
In both additive and multiplicative forms of their model, 
the basic (decomposed) utility function of each attribute 
(health dimension) to be determined empirically is the 
multiplication of two functions. The first function is the 
individual attribute's single attribute utility function, 
U, *(X, ). This is scaled relative to the utility of the best 
level of one's own attribute ( the utility value of which is 
set to be 1) and the utility of the worst (the utility value 
= 0), given all other attributes constant. The second is the 
multiattribute utility for the health state with the best 
level of the corresponding attribute but the worst for all 
the others, U* (X. *, XIO) , two scale references of which are the 
best levels in all attributes (= 1) and the worst levels in 
all (= 0). The basic utility function of an individual 
attribute can be expressed in the following notation. 
[U, * (X, ) u* (xý, *, x311) 1 
where aa th attribute or health dimension 
a all other attributes 
U,, *( single attribute utility function 
U*( multiattribute utility function 
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Xa = the attribute a at the level of interest 
Xa = the attribute a at the best level 
X50 = the other attributes at the worst level 
Therefore, the basic unit of this approach can be viewed 
as the utility value for an individual attribute with a 
certain severity level as being relative to the best and 
worst levels in that attribute, which is in turn relative to 
that attribute Is best level and the others I worst levels. The 
utility value for any multiattribute (multidimensional) 
health state can be acquired by computing the measured 
utility values of individual basic units through the best 
mathematical equation for the collective utility function. 
Their empirical analysis points out that the data 
collected were consistent with the conditions underlying the 
multiplicative model rather than the additive one. The model 
was tested with the surveyed utility values for two non- 
healthy states. The finding showed that the predicted values 
underestimated the surveyed ones by 0.17 and 0.30 (for a unit 
scale with 1= the best levels in all four health dimensions 
and 0= the worst in all). 
There are two main sources responsible for these 
discrepancies. First, the errors in the measurements may be 
as a result of the unclear contents of the health state 
description and the overload of the attribute size in the 
scaling procedure. Secondly, the model produces some errors. 
It is believed that the errors from the model are greater 
than those from the measurements. The model could violate the 
assumption of mutual utility independence when applied to a 
large range in the health state system. A model formulation 
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other than the multiplicative may be more appropriate. Some 
parameters could be wrongly estimated because of a reliance 
on other studies, results, which had different subjects, 
characteristics. The last two explanations give rise to a 
vital implication, that a model of health state valuation for 
a population may not be able to generalise its findings to 
other populations. Therefore, it is recommended that each 
study should determine its own appropriate model based on the 
data from its population. 
All the predicted and surveyed results of the valuation 
were incorporated in the ensuing COst-utility analysis. As 
the upper limit of the utility value range in their study's 
sensitivity analysis, the estimated utility values were added 
with two times of the standard error of the mean of the 
surveyed values for the seven health states (which was 0.0 6) . 
The values for the lower limit were the predicted values from 
the model based on the unadjusted values from category rating 
method minus two times of the standard error. 
Two important points can be learnt from this approach for 
building other models of the health state valuation without 
resorting to its complicated procedure. First, a model could 
be formed simply, like additive and multiplicative forms. 
Secondly, attributes (health dimensions) and their severity 
levels are central to the modelling and estimating of the 
valuation for health states, particularly under the present 
health state systems in which the health dimensions and 
severity levels are dominant. 
6.2.3. Some alternative models for the valuation based on the 
Euro0ol instrument. 
Inaccuracy of the predicted values of the valuation model 
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based on the multiattribute utility theory leads to an 
exploration of alternative valuation models. In this section, 
two major approaches quite different to those based on the 
expected utility theory and the multiattribute utility theory 
attempt to predict the values for unmeasured health states in 
this study. One vital criterion for selecting and employing 
these two approaches is that they can be modified without 
requiring special treatments in the scaling procedure. As a 
result, they could offer some appropriate models to the 
valuation data available. 
First, psychology-based utility theories state that a 
person's decision-making over alternative choices depends on 
the aspects of the choices. Af inal decision arrives as a 
result of the comparisons of each aspect between the 
alternatives. These theories have been developed a great deal 
at theoretical level. However, the empirical investigations 
for applied subjects are limited. Secondly, statistical 
methods are used to f ind the appropriate relationship and 
magnitudes of the valuation components in determining the 
valuation of health states from the available data. 
Regression analysis can assess various possible 
specifications of the models and estimate the parameters 
concerned. The underlying concepts of the two approaches, the 
derived models for the valuation data in this study, the 
estimation and the result interpretation -are now discussed in 
detail. 
a) The "aspect" model. 
Schoemaker (1982) points out that the failure of the 
expected utility theory arises from the lack of psychological 
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elements in explaining decision-making. Psychological aspects 
in the utility theory contain such characteristics as human Is 
cognitive simplification, which are not available in the 
economic-based utility theory. 
one group of such psychological theories for explaining 
decision-making states that in the assessment of 
multidimensional alternatives, each choice is first 
decomposed into individual dimensions, which are in turn 
compared between alternatives (i. e. one dimension at a time) 
(Schoemaker, 1982). The key and basic theory of this group is 
the elimination-by-aspects (EBA) , which was first proposed by 
Tversky (1972a and b) . The concept of this theory can best be 
shown in his own writing. 
"Suppose that each alternative consists of a 
set of aspects or components, and that each 
aspect possesses a weight. Suppose further 
that at each state in the process one selects 
an aspect (from those included in the 
available alternatives) with probability that 
is proportional to its weight. The selection 
of an aspect eliminates all the alternatives 
that do not include the selected aspect and 
the process continues until all alternatives, 
save one, are eliminated. " (Tversky, 1972b). 
A feature that distinguishes this theory from the others 
in the group is that it needs no pre-set standards in 
decision-making (Schoemaker, 1982). Therefore, one's 
dimension specification is formed within the available 
alternatives. The comparison of decomposed dimensions between 
the alternatives can be directly made. 
Though the prime objective of the theory, as shown in 
Tversky Is papers, is to establish the decision-making pattern 
in choice selection, its underlying concept (e. g. the aspects 
selected by a decision-maker in a given set of alternatives) 
507 
and process (e. g. the comparison of decomposed dimensions 
between the alternatives) can be employed to formulate a 
health state valuation model. In addition, another key 
property of this theory which could simplify the valuation 
model is the assumption of independence among aspects. 
This theory can be used to rank the alternatives, which 
was demonstrated in Tversky (1972b). The procedure to obtain 
the ranking, as quoted, is to ,[... I apply the same 
partitioning process to the eliminated as well as the 
selected alternatives at each stage, we would eventually 
obtain a complete ranking of the set of alternatives" 
(Tversky, 1972b) . That this theory can give rise to a scaling 
technique would gain it further consideration in the 
modelling of health state valuation. 
Nevertheless, a setback arising from the application of 
this theory to the valuation data available in this study is 
that the theory defines the aspect variable in terms of 
probability. Probability as a measurement has two functions 
(Tversky, 1972a) . First, probability in a model serves to 
account for observed inconsistency and reported uncertainty. 
Secondly, it allows for one to psychologically change states 
of mind in different time periods, which can lead to the 
selection of different choices at different moments in time, 
given all other things equal. 
The implication is that the probability measurement is 
crucial for testing the model with the genuine data in 
explaining the valuation behaviour. Without such a 
measurement for the data in this study, the validity of the 
theory in this context cannot be tested. Fortunately, the 
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aspect variable can presumably take on a constant scale value 
as it does in the additional random aspect model (ARA), a 
theory closely similar to the elimination-by-aspects one. 
Their key similarities, relevant to decision-making are 
mentioned in Tversky (1972b) . The non-probabilistic models 
based on the decision-maker's aspect principle are also 
evident in other applied subjects. Tversky (1972a) mentions 
Lancaster's work (1966) in applying a similar principle to 
economic goods, using non-probabilistic aspect variables. As 
far as the purpose of the model in this analysis is 
concerned, the non-probabilistic measurement is essential for 
the valuation prediction. This is also supported by the fact 
that the effect of decomposed aspects on alternatives at any 
moment in time is absolutely deterministic (Tversky, 1972a). 
The theoretical development and proof of the elimination- 
by-aspects theory in the context of the health state 
valuation are not provided here because they are beyond the 
scope of this study. They are undoubtedly issues for further 
inquiry, as Tversky (1972b) urges, in order to increase the 
theory's applicability, the theoretical model is in need of 
development. 
To the best of the author Is knowledge, there have been to 
date no works applying this theory to the health state 
valuation. Llewellyn-Thomas et al (1984), exploring some 
possible models to estimate the valuation, refer the prospect 
of this theory's application to the health state valuation. 
Tversky (1972a) mentions that some vital elements of this 
theory have been used in explaining consumer choice over 
economic goods by Lancaster (1966). An economic good in 
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Lancaster's model is characterised to have (or create) 
multiple aspects in fixed proportions, which are the basis 
for a consumer to compare alternatives and select the most 
appropriate one. 
The following model for health state valuation, called 
the aspect model hereafter, is formulated on the basis of the 
above theories' interpretations and illustrations. They 
suggest that the issue of selecting aspects of health states 
in modelling the valuation is vital. Therefore, the most 
important part of the model depends on which aspects of 
health states evaluators select to base their valuations on 
and the relationships between the aspects. 
This investigation proposes that the number of non- 
healthy dimensions in health states and their degrees of 
severity are two major aspects of health states that 
evaluators use in their valuation. The additive model is 
assumed here, which allows the value for a health state to be 
specified as an additive function of the values for the two 
aspects (i. e. the value for a health state is the sum of the 
values from two aspects) (Tversky, 1972b). 
It is also assumed that the influence of the extreme 
degree of severity on the valuation is twice that of its 
moderate counterpart. The following equations present the 
proposed model based on the EuroQol instrument. 
U (HS) =E (X1 I X2) 
According to the assumption of an additive function, 
U (HS) =f (X1) +f (X2) I 
on the basis of the definitions of the two aspects of 
health states, the two component functions can be specified 
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as follows. 
fI (Xi) 
fI (X2) 
Ul (HSabcde) 
where U 
U/ 
HS 
[(a-l)A * (b-l)B * (c-l)C * (d-l)D * 
(i * DII 
(b-l)B * (c-l)C * (d-l)D 
DII 
an utility function 
an estimated utility function 
(i. e. scale value) 
a health state 
f( )= 
f'( )= 
X2 
a function 
an estimated function 
(i. e. scale value) 
the severity level aspect 
the number of the non-healthy 
dimensions aspect 
a, b, c, the severity levels in the five 
d and e dimensions in the EuroQol instrument 
(1,2 and 3 represent no, moderate and 
extreme level problems) 
A, B, C, the parameter of the effect of the 
D and E severity level in each dimension in a 
health state 
DI the parameter of the effect of the 
number of the non-healthy dimension in 
a health state 
the number of the non-healthy 
dimensions in a health state (1 to 5) 
the mathematical operation representing 
the relationship between the severity 
levels and that between the number of 
the non-healthy dimensions 
Since the aspects are defined with regard to the non- 
healthy dimensions, the healthy dimensions are not considered 
in the model (i. e. the coefficient of the severity degree 
parameter in a healthy dimension vanishes in the first term 
and that dimension is also counted zero in the second). On 
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the right hand side of the last equation, the a, b, c, d and 
e use 2 or 3 in the computation procedure. 
Various relationships between severity levels and the 
number of non-healthy dimensions are investigated to reveal 
which combination is the best for the model based on the data 
available. Therefore, four main possible combinations of the 
two aspects can be shown as follows. 
1) the sum of the values for the severity degrees and the 
product of the values for the number of the non-healthy 
dimensions 
2) the sum of the values for the severity degrees and the sum 
of the values for the number of the non-healthy 
dimensions 
3) the product of the values for the severity degrees and the 
product of the values for the number of the non-healthy 
dimensions 
4) the product of the values for the severity degrees and the 
sum of the values for the number of the non-healthy 
dimensions 
Furthermore, each aspect (term) can be specified into a 
normal expression or its inverse (i. e. one over the normal 
expression). As a result, there are 16 possible equations 
(models). With the values for the health states available 
from most surveys based on the EuroQol instrument, the values 
from three basic health states are used to estimate the 
dimension aspect parameter. The following example, which is 
in the category of the inverse-product form of both aspects 
and is the best model as shown in the next sections, 
illustrates how to obtain the estimates, using the Thai 
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valuation data. 
Ul (HSabcde) 1 + 1 
(a-l)A (b-I)B (c-l) C (d-l)D (e-l)E (DI)' 
We have U(HS11112) 0.74 1+ 1 
E DI 
or 1= 0.74 -1 
E DI 
and Ul (HS11121) 0.75 1+ 1 
D DI 
or 1= 0.75 - 
D DI 
and Ul (HS11122) 0.55 1+ 1 
D xE (DI)2 
On substitution of t he first two equations into t he 
third, the DI parameter can be solve d. 
Ul (HS11122) 0.55 ((0.75 -1) (0.74 -1+ I 
DI DI (DI)2 
0.55 = 0.555 - 1.49 + 1+ 
1 
DI (DI 
--1 TDI) 
0 = 0.005 - 1.49 + 2 
DI (DI )2 
Finally, it is (DI )2- 298DI + 400 = 0. 
Since the equation has an unknown variable (DI) with the 
exponential power of two, there are two possible solutions 
for the unknown DI. By replacing the estimates of DI back to 
UI(HS11112) and UI(HS11,21), the estimates for both parameters D 
and E can be obtained. The parameters A, B and C can be 
estimated by repeating this in UI(HS21110, UI(HS, 21,1) and 
UI(HS11211). Then one can use these six basic estimates for 
computing the value of any health state through the equation 
above. 
Some of the 16 equations involve the third or fourth 
degree power equations. In addition, there is an 
indeterminant model (i. e. the equation system is linearly 
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dependent). 
The model may be made further complicated by taking into 
account the interaction of the two aspects, which hopefully 
gives better valuation models. However, the added term not 
only imposes some difficulty in the computation by turning 
the equations into the higher-than-second degree power 
equations but also contributes nothing to the best model 
without the term. 
b) The regression model. 
That there exists a definite pattern in valuing health 
states among respondents, represented by an appropriate model 
specification, is the foundation of the regression analysis. 
In its basic model formulation, the valuations are determined 
by the health dimensions and their severity levels. The 
explanatory variables consist of at least 5 terms, which 
correspond with the five dimensions in the EuroQol 
instrument. 
A healthy dimension is supposed to have a maximum 
component value. In contrast, the value f or a non-healthy one 
reduces by a certain proportion in relation to the healthy 
one. The size of the value reduction is dependent upon the 
severity level. A variable can he assigned to each severity 
level in a health dimension. In order to he consistent with 
the aspect model, it is assumed that the value of any extreme 
severity level is twice that of its moderate one. The effect 
of the interactions between the dimensions on the valuation 
could he incorporated into the model. The simplest 
relationship between the variables is the additive and linear 
one. 
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The model in this analysis is formed in a manner that 
enable the value from a non-healthy dimension to be 
subtracted from the intercept term. 
The intercept term represents a health state with no 
effects from all the non-healthy dimensions (or a health 
state with all the healthy dimensions) . In other words, it is 
not only the estimated value for the health state 11111 but 
the upper end of all the estimated values. The derivation of 
the model can be shown as follows. 
HSVj C- B11X11 - B12X12 - B21X21 - B22X22 - B31X31 - B32X32 
-B 41X41 - B 42X42 -B 551X51 -B 52X52 + e, 
where HSV the value of a health state 
c the intercept term 
B 11, B12, B211 the coef f icients of X11, X121 X21,1 
B 51, B 52 ... I 
X511 X52 
X11 
I 
X1241 X21,1 the parameter of the first 
X51 and X52 dimension's (mobility) moderate 
severity level, that of the 
first dimension's (mobility) 
extreme severity level, that of 
the second dimension's 
(selfcare) moderate severity 
level,..., that of the fifth 
dimensionls(anxiety/depression) 
moderate severity level, that 
of the fifth dimension's 
(anxiety/depression) extreme 
severity level; respectively 
ith observation 
e error term 
The parameter of each dimension's "no problem" level is 
excluded in order to avoid the perf ect multicollinearity. The 
interpretation of the estimated coefficients is made with 
regard to these "no problem" levels. 
By assuming that the values for the moderate severity 
levels are half those of the extreme ones, the parameter of 
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the moderate severity level in each dimension can be 
expressed in terms of the parameters of the extreme severity 
level in that dimension, and vice versa. Therefore, the 
following equation can be finally obtained for the 
estimation. 
HSVi C- B1IX11 - 2B1IX1I - B21X21 - 
2B21X21 - B31X31 
- 2B31X31 - B41X41 - 2B41X41 - B51X51 - 2B 51X51 + ei 
Take the health state 21232 for example. A respondent's 
value for this health state enters the dependent variable in 
the left hand side of the equation and in the right hand side 
the coefficients for the independent variables, 0.5,0,0.5, 
1 and 0.5. (The numbers selected to represent the 
coefficients do not affect the outcome at all as long as the 
sequences conform to the assumption and the result is 
interpreted appropriately. ) This can be expressed by the 
following equation. 
HSVi for 21232 =c-0 . 5X11 - OX21 -0 . 5X31 - 1X41 -0 . 5X51 
The result produces the estimates for the extremely 
severe level variables. Those for the moderate counterparts 
can be acquired by dividing the estimates by two. The 
estimated value for any health state can be obtained by 
substituting the estimated weightings for all the dimensions 
concerned as well as the appropriate numbers for the severity 
levels into the model. 
Statistics such as F-test and t-test can assess how good 
the model and estimates are. The small noise (error term) in 
the regression model is of importance (An unpublished note by 
a research group at the Centre for Health Economics). Also, 
various tests can be done to look for some major potential 
incompatibility between the data and the assumptions of 
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regression method, like heteroscedasticity, in order to 
increase confidence in the result. 
The valuation data available can be classified into two 
categories for the regression analysis. On the basis of an 
individual respondent, the values for only 16 health states 
are available. With respect to one of the measured health 
states, the number of the observations is the number of the 
respondent samples. This analysis combines the two because 
the number of the measured health states available is not 
large enough to generate the reliable outcome and also 
because the collective values for the health states are more 
important than the individual counterparts in the cost- 
utility analysis of public health programmes. 
The values for dead and unconscious states could be 
incorporated in the model by adding, f or example, special 
explanatory variables for them. However, in this analysis, 
their estimated values may not be needed for two reasons. 
First, the added variables in the model may contribute 
nothing to account for the valuation for other health states 
because they cannot be broken down into the five health' 
dimensions. Secondly, these two health states were measured 
in most surveys, so they are not included in the model. 
Regression analysis has been employed by researchers at 
the Centre for Health Economics at the University of York 
(Paul Kind, personal communication and an unpublished note) 
to estimate the main effects of the health dimensions and 
severity levels on the valuation and also to predict the 
values for unmeasured health states. In one of their 
analyses, the underlying concept of the basic model is that 
517 
the mean value of a health state is the sum of the number of 
components, whose effects depend on their severity levels. 
In the estimation, in order to comply with the classical 
regression model's requirements, the error term was assumed 
to distribute normally with constant variance and zero 
covariance. However, the heteroscedasticity arose in the 
ordinary least-square method. The logit model was also used, 
enabling one to deal with the problem. The outcomes of the 
two methods are similar. 
Since their data were based on an early version of the 
EuroQol instrument and since their model contained parameters 
for dead state and nationality, a comparison of the results 
between their analysis and this study cannot be made. 
In the next sections, the two models are employed, using 
the valuation data from various surveys. Their outcomes are 
tested for accuracy. They are also used to predict the values 
for the unmeasured health states in the Thai cost- utility 
analysis. 
6.3. The results of the valuation models based on the five 
international valuation data sets. 
In this section, the five unpublished data sets based on 
the EuroQol instrument : Somerset General Public, Somerset 
Southern Health Authority Members, Somerset Eastern Health 
Authority Members, Swedish Hospital Staff and Health 
Economics in Developing Countries Course Members. 
Since individual respondents' data are not available, the 
regression model's findings based upon the median value data 
cannot be accepted because all the t-tests are not 
significant. Therefore, the regression results are not 
presented. However, the analysis based on the median values 
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could be useful because they are an aggregate measurement of 
the valuations. It is possible that the insignificance of the 
estimates may arise from technical aspects, for example, a 
low degree of freedom due to a small number of median value 
observations. 
The median valuations are used in the computation 
procedure of the aspect model. Table 85 presents the 
predicted values of the best aspect model for the six health 
states from these five sources. 
In this analysis, the model performance is determined by 
the discrepancy between the predicted and surveyed values for 
those measured health states not involved in the model 
calculation. The model best approximates the Swedish 
Hospital Staff data. The value variations range between 0.02 
and -0.08. The second best fit is the Somerset General Public 
data set. The value differences vary from 0.01 to -0.12. 
The Southern Health Authority Members data set is the next 
best with the value deviations ranging between 0.13 and - 
0.03, followed by the Health Economics in Developing 
Countries Course Members data set. The model underestimates 
the values for all the health states in the Somerset Eastern 
Health Authority Member data set and produces the biggest 
inaccuracy of 0.24. 
When the value discrepancies of the six health states 
produced by the best model from the five data sources are 
compared with those made by the model based on the 
multiattribute utility theory by Torrance et al (1982), the 
maximum discrepancies in most of the data sets are less than 
their smallest counterpart in Torrance et al's model. The 
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Table 85 : The results of the aspect model for the health state 
valuations based on the five international data sets. 
Health Predicted Discrep- Predicted Discrep- Predicted Discrep- 
state value for ancy of value for pancy of value for pancy of 
data set data set 'data set data set data set data set 
112233 
21232 0.16 -0.10 0.25 -0.03 0.15 -0.17 
22233 0.05 -0.09 0.18 -0.01 0.05 -0.24 
22323 0.05 -0.05 0.18 0.03 0.05 -0.17 
32211 0.17 -0.12 0.35 -0.03 0.20 -0.11 
33321 0.03 -0.17 0.25 0.13 0.04 -0.13 
33333 0.01 0.01 0.18 0.09 0.01 -0.02 
Health Predicted Discrepancy Predicted Discrepancy 
state value for of data set value for of data set 
data set 4 data set 5 
4 5 
21232 0.19 -0.07 0.14 -0.16 
22233 0.07 -0.05 0.04 -0.21 
22323 0.07 -0.05 0.04 -0.04 
32211 0.26 -0.08 0.16 -0.06 
33321 0.05 -0.04 0.03 -0.06 
33333 0.01 0.02 0.01 -0.04 
Notes 1. data set I Somerset General Public 
survey (n = 82) 
data set 2 Somerset Southern Health Authority 
Members survey (n = 10) 
data set 3 Somerset Eastern Health Authority 
Members survey (n = 8) 
data set 4= Swedish Hospital Staff survey 
(n = 65) 
data set 5= Health Economics in Developing 
Countries Course Members survey 
(n = 8) 
2. Discrepancy = predicted value - surveyed value 
Source : Alan Williams (personal communication) 
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comparatively smaller imprecision of the estimated values 
from the model in this analysis supports the rigour of the 
proposed aspect model. 
Nevertheless, the model needs to be tested in a large 
number of health states and with data from more diverse 
sources. 
6.4. The results of the valuation models based on the Thai 
data. 
This section analyses the two valuation models, using 
exclusively the Thai interview and postal valuation data 
sets. The estimation is based on their original data and 
standardised data (a 0-1 scale with respect to the health 
state 11111 and death) The results of the aspect model and a 
test of the model performance are presented first, followed 
by those of the regression model. Finally, the results of the 
two models are compared. 
The assessment of model performance is based on the 
accuracy of the estimates (i. e. the difference between the 
estimated and surveyed values of the measured health states) . 
This method makes a distinction between the two models' 
assessment in this analysis. The evaluation of the regression 
model outcome is based on the values for the measured health 
states available, the same data also being used in the 
estimation. In the aspect model result, the six health states 
are employed in the computation and, as a result, their 
estimated values are virtually identical to their surveyed 
ones. The values for the six other health states, which are 
independent of the estimation, are appropriate for the 
assessment. This fact perhaps makes the test of the aspect 
model findings more rigorous than their regression counterparts. 
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To simplify the precision assessment, numerous data are 
consolidated. By using 0.05-point intervals, the discrepancy 
is divided into 23 ranges, including under -0.50,0 and over 
0.50 bands. 
6.4.1. The result of the aspect model. 
The best aspect model for the Thai interview and postal 
valuation data sets as well as for the original and 
standardised forms is shown below. 
Ul (HSabcd, ) I+1 
(a-l)A (b-l)B (c-l)C (d-l)D (e-l)E (DI)' 
Each set of the parameter estimates is specific to an 
individual respondent. The number of the sets, therefore, is 
the same as the number of the respondents I valuations used in 
the computation, so it is no use presenting all the 
coefficients here. As an illustration, the estimates based on 
the median interview standardised values are reported and 
interpreted accordingly. The estimates for the parameters A, 
B, C, D, E and DI are 1.31,1.81,1.58,1.33,1.35 and 
-299.34; respectively. 
There is almost no effect from the number of non-healthy 
dimensions on the valuation. Therefore, the severity level 
plays a predominant role in the valuation. A rise in a 
severity level leads to a decline in the valuation. The 
effect from the five dimensions on the valuation can be 
ranked in accordance with the magnitudes of their estimates, 
the most influential being the selfcare dimension. This is 
followed by the usual activity dimension. The effects from 
the anxiety/depression, pain/discomfort and mobility 
dimensions are close to one another. It should be noted that 
the ranking of these five parameters' effect is similar to 
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that of the values of the five single-moderate health states 
(i. e. the health states 12111,11211,11112,11121 and 21111). 
The accuracy assessment of the estimated values from the 
aspect model indicates that f or the original individual data, 
12% to 42% of the total samples are in a discrepancy range of 
0 to ±0.10 and 53% to 71% in a range of 0 to ±0.20. Smaller 
percentages are found for the standardised data, in which the 
first range captures 27-38% and the second 48-59%. Thus, the 
aspect model accounts for the original individual data better 
than its standardised counterpart. 
In addition, the aspect model, as opposed to the 
regression model, does not allow to the creation of a single 
set of estimated collective values from individual valuation 
data. 
Nevertheless, the comparison between the estimated values 
based on the median value data and the median values of the 
estimated individual values could indicate whether or not the 
valuation aggregation affects the aspect model's estimation 
outcome. The estimated values based on the original median 
value data and the median values of the estimated values 
based on the original individual data for six health states 
are similar (see Table 86), as are their value discrepancies 
between the estimated and the surveyed values. Table 87, 
showing such a comparison for the standardised counterpart, 
indicates the insignificant differences between the estimates 
of the aggregate valuations and the aggregates of the 
estimated valuations. 
The postal values for most health states possess 
relatively larger discrepancies than the interviewed values. 
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Table 86 : The comparison of the median values of surveyed 
Thai original data, the estimated values based on 
median original value data and the median values of 
the estimated values based on the original 
individual data from the aspect model. 
Health Median Estimated Median Value 
state value of value based value differential 
Thai on median of the 
surveyed original estimated 
original value values 
data data based on 
the original 
individual 
data 
21232 0.40 0.36 0.36 -0.04 
22233 0.30 0.28 0.28 -0.02 
22323 0.25 0.28 0.28 0.03 
32211 0.40 0.46 0.46 0.06 
33321 0.20 0.36 0.36 0.16 
33333 0.05 0.28 0.28 0.23 
Notes 1. For simplicity, the values all are presented on 
a 0-1 scale. 
2. Value differential is predicted value minus surveyed 
value. 
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Table 87 : The comparison of the median values of the surveyed 
Thai standardised data, the estimated values based on 
median standardised value data and the median values 
of the estimated values based on the standardised 
individual data from the aspect model. 
Health Median Estimated Median Value 
state value of value based value differential 
Thai on median of the 
surveyed standardised estimated 
standardi- value values 
sed data data based on 
the standard- 
ised individual 
data 
21232 0.28 0.13 0.13 -0.15 
22233 0.11 0.04 0.03 -0.07 
(-0.08) 
22323 0.07 0.04 0.03 -0.03 
(-0.04) 
32211 0.25 0.13 0.12 -0.12 
(-0.13) 
33321 0.05 0.02 0.02 -0.03 
33333 -0.11 0.00 0.00 0.11 
Notes : 1. For simplicity, the values all are presented on 
a 0-1 scale. 
2. Value differential is predicted value minus surveyed 
value. 
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However, the former cover more samples in'the two ranges of 
the value discrepancy than the latter. This might be the 
effect of a large number of missing values in the computation 
for the postal data. The small number of the samples could 
reduce the variation. 
6.4.2. The result of the regression model. 
The regression model fits well to the original 
interviewed data due to a high R2 but poorly to the 
standardised counterparts. All the estimates of both data 
forms are statistically significant. In Table 88, the 
regression result indicates that, for the original data, the 
component value of the selfcare dimension is the highest, 
followed by those of the usual activity, mobility, 
pain/discomfort and anxiety/depression dimensions. The 
estimated value for the health state 11111 is 0.80. It can be 
interpreted that the extreme severity level in the selfcare 
dimension subtracts 19 points from the value for the health 
state 11111; in the usual activity dimension, 17.1 points; in 
the mobility dimension , 15 points; in the pain/discomfort 
dimension, 13.3 points; and in the anxiety/depression 
dimension, 10.5 points. 
The result based on the standardised data compares 
favourably with the above except for a swapping of the ranks 
between the pain/discomfort and anxiety/depression 
dimensions. The valuation is deducted from the intercept term 
by 22.1,20.7,17.5j, 15.8 and 10.2 points due to the 
existence of the severity levels in the selfcare, usual 
activity, mobility, anxiety/depression and pain/discomfort 
dimensions; respectively. 
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Table 88 : The result of the regression model based on 
the Thai original and standardised individual 
data. 
A. The weighting findinqs. 
Dimension original 
estimated 
weighting 
data 
rank 
Standardised 
estimated 
weighting 
data 
rank 
1. Mobility(Xj) 15.0* 3 17.5* 3 
2. Se 1f care (X2) 19.0* 1 22.1* 1 
3. Usual Activity 17.1* 2 20.7* 2 
(X3) 
4. Pain/discomfort 13.3* 4 10.2* 5 
(X4) 
S. Anxiety 10.5* 5 15.8* 4 
/Depression(X5) 
Constant 79.9* 70.8* 
R2 0.698** 0.101** 
B. The estimated values for the health states and the 
discrepancies between the surveyed median and predicted values. 
1) The original datal. 
Health 
state 
Surveyed 
median 
value 
Predicted 
value 
Value 
13 differentia 
11111 1.00 0.80 -0.20 
11111R 1.00 0.80 -0.20 
11112 0.80 0.75 -0.05 
11121 0.80 0.73 -0.07 
11211 0.70 0.71 0.01 
12111 0.60 0.70 0.10 
21111 0.80 0.72 -0.08 
11122 0.60 0.68 0.08 
21232 0.40 0.45 0.05 
22233 0.30 0.31 0.01 
22323 0.25 0.29 0.04 
32211 0.40 0.47 0.07 
33321 0.20 0.22 0.02 
33333 0.10 0.05 -0.05 
33333R 0.05 0.05 0.00 
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Table 88 : The result of the regression model based on 
the Thai original and standardised individual 
data (continued). 
2) The standardised data 2. 
Health 
state 
Surveyed 
median 
value 
Predicted 
value 
Value 
differentia 13 
11112 0.74 0.63 -0.11 
11121 0.75 0.66 -0.09 
11211 0.63 0.60 -0.03 
12111 0.55 0.60 0.05 
21111 0.76 0.62 -0.14 
11122 0.55 0.58 0.03 
21232 0.28 0.34 0.06 
22233 0.11 0.15 0.04 
22323 0.07 0.09 0.02 
32211 0.25 0.32 0.07 
33321 0.05 0.05 0.00 
33333 -0.11 -0.16 -0.05 
Notes t-test is significant at 0.001. 
F-test is significant at 0.001. 
1. The estimation with the original data uses 15 
health states and has 354 samples. For 
simplicity, the values are presented on a 0-1 
scale. 
2. The estimation with the standardised data uses 
13 health states and has 346 samples. 
3. Predicted value - surveyed value. 
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The magnitude differentials between the weightings in the 
two sets vary between 2.5 and 5.3. Their intercept terms 
differ by about 9. 
For the original individual data, there are 28-75% of the 
total samples in a discrepancy range of 0 to ±0.10 and 40- 
100% in a range of 0 to ±0.20 among 15 health states. For the 
standardised counterpart, the numbers are smaller: 20-38% in 
a0 to ±0.10 range and 43-63% in a0 to ±0.20 range for the 
13 health states. This suggests that the regression model 
approximates for the original data better than for the 
standardised ones. The large number of the missing values in 
the postal data set makes the regression model fit to the 
postal valuation poorer than the interviewed valuation. The 
R2 of the original form is 0.58 but that of the standardised 
one, 0.04. Again, the samples in the two discrepancy ranges 
are artificially high in this data set. 
6.4.3. The comparison of the two valuation models' results. 
This subsection compares the precision of the two models I 
valuation estimates. The appropriate health states for the 
comparison of the two sets of the estimated values from the 
two models are health states 21232,22233,22323,32211, 
33321 and 33333. The exclusion of health states 11112,11121, 
11211,12111,21111 and 11122 is due to their use as "input" 
health states in the computation for the aspect model. Their 
estimates are in fact the surveyed values. Because the 
estimate for the health state 11111 is not produced by the 
aspect model, it is also excluded. 
Table 89 reveals a larger variation in the estimated 
values from the two models for the interviewed standardised 
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Table 89 : The comparison of the estimated values between 
the aspect model and the regression model 
based on the Thai interviewed original and 
standardised data. 
A. The original data comparison. 
Health eal' 1 Aspect Regression Value 
model model differential* 
32 
[212 
0.36 0.45 0.09 
2 2223 2233 0.28 0.31 0.03 
2 2232 2323 0.28 0.29 0.01 
3221 32211 0.46 0.47 0.01 
3332 33321 0.36 0.22 -0.14 
3333 33333 0.28 0.05 -0.23 
B. The standardised data comparison. 
Health eal 1 Aspect Regression Value 
model model differential* 
32 
[212 
0.13 0.34 0.21 
2 2223 2233 0.03 0.15 0.12 
2 2232 2323 0.03 0.09 0.06 
3221 1 32211 0.12 0.32 0.20 
3332 2 33321 0.02 -0.10 -0.12 
3332 2 33333 0.00 -0.16 -0.16 
Note :* The regression value - the aspect value. 
530 
data than for the original ones. For the original data, the 
regression model has a higher number of samples in the ranges 
of 0 to ±0.10 and 0 to ±0.20 than the aspect model, in most 
of the health states. However, the opposite is true for the 
standardised data. 
one reason for the result of the regression model being 
better than that of the aspect model for the original data 
may be that the former uses the values from all the available 
health states whereas the latter depends on six fundamental 
health states. 
Hence, the sensitivity analysis of this cost-utility 
study, using the estimated standardised values from the 
aspect model with a variation range of 0 to ±O. lo, would 
cover 27-38% of the total sample but the selection of the 
estimates from the regression model with the same range would 
represent 20-32%. If the variation increases from 0 to ±0.20, 
the former estimates include 48-59% and the latter, 43-56%. 
As a result, the aspect model is a better choice for the 
valuation estimation for unmeasured health states for usage 
in this Thai cost-utility analysis than the regression model. 
However, the size of the samples, precise valuation, based 
upon the standardised individual data, in a range of 0 to 
±0.20 may not be impressive. The standardisation of the 
estimates based on the original data therefore may create a 
higher degree of accuracy than the estimates based on the 
standardised data. Nevertheless, it is found that there is no 
improvement in applying the scale transformation to the 
estimates based on the original data. 
It follows that by using the predicted values for 
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unmeasured health states in this cost-utility study, the 
result based on the former range could represent about a 
third of the respondents' valuation and its approximation 
based on the latter range amounts to about an half. 
In the sensitivity analysis of the cost-utility analysis 
concerning health state valuation, the value range is likely 
to be constrained by the upper limit (i. e. 1.00). In other 
words, any variation that results in a value beyond 1.00 
would be invalid. For example, a ±0.30 value range based on 
the aspect model would make some health states (e. g. health 
state 11121) exceed the value of 1.00. Therefore, there is a 
naturally limited scope in employing the value ranges. In 
this analysis, the 0 ±0.20 value range is the highest 
variation range for the aspect and regression models. 
The results of the cost per QALY of the four Thai health 
programmes based on the two sets of the predicted values from 
the two models, whose estimated values for all the health 
states are given in Appendix V, are presented in Table 90. 
It indicates that the previous priority ranking is still 
maintained. The aspect model offers the lower cost per QALY 
for all the health programmes than does the regression model. 
6.5. The results of the valuation models based on the Finnish 
data. 
Like the previous section, this section applies the two 
valuation models to the Finnish original and standardised 
data sets. The precision of the estimates is assessed and 
compared for both models. 
6.5.1. The results of the aspect model. 
The best form of the aspect model for both Finnish data 
sets is the same as that for the Thai sets. The parameter 
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Table 90 : The cost per QALY of the four Thai health 
programmes' sensitivity analysis on the 
predicted values of the health states based on the 
interviewed data by the aspect and regression 
models. 
I. Base-case analysis. 
Health programm aspect regression 
model model 
Short-course anti-TB 172.94 188.40 
chemotherapy ambulatory (US$6.85) (US$7.47) 
treatment with the 
2HRZ/4H2R2 regimen 
Short-course anti-TB 181.55 197.77 
chemotherapy ambulatory (US$7.22) (US$7.87) 
treatment with the 
2HRZ/4HR regimen 
Measles vaccination 435.53 500.06 
(US$17.43) (US$20.02) 
BCG vaccination 837.23 943.60 
(US$33.23) (US$37.45) 
Short-course anti-TB 1456.17 1586.21 
chemotherapy hospitalised (US$57.69) (US$62.84) 
treatment with 
the 2HRZ/4HR regimen 
Short-course anti-TB 1600.87 1744.03 
chemotherapy hospitalised (US$63.43) (US$69.10) 
treatment with 
the 2HRZ/4H2R2 regimen 
Rotavirus vaccination 2182.68 2850.20 
(US$86.63) (US$113.12) 
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Table 90 : The cost per QALY of the four Thai health 
programmes' sensitivity analysis on the 
predicted values of the health states based on the 
interviewed data by the aspect and regression 
models (continued). 
II. Sensitivity analvsis. 
a) A value range of 0±0.10. 
Health program aspect regression 
model model 
Short-course anti-TB 158.68 171.81 
chemotherapy ambulatory (US$6.29) (US$6.81) 
treatment with the to to 
2HRZ/4H2R2 regimen 189.51 208.55 
(US$7.51) (US$8.26) 
Short-course anti-TB 166.60 180.77 
chemotherapy ambulatory (US$6.63) (US$7.18) 
treatment with the to to 
2HRZ/4HR regimen 198.92 218.88 
(US$7.91) (US$8.71) 
Measles vaccination 405.09 457.80 
(US$16.22) (US$18.32) 
to to 
476.34 550.92 
(US$19.07) (US$22.05) 
BCG vaccination 728.89 886.44 
(US$28.93) (US$35.18) 
to to 
888.03 1008.64 
(US$35.24) (US$40.03) 
Short-course anti-TB 1336.20 1446.66 
chemotherapy hospitalised (US$52.94) (US$57.31) 
treatment with to to 
the 2HRZ/4HR regimen 1595.50 1755.56 
(US$63.21) (US$69.55) 
Short-course anti-TB 1468.83 1590.41 
chemotherapy hospitalised (US$58.19) (US$63.01) 
treatment with to to 
the 2HRZ/4H2R2 regimen 1754.25 1930.51 
(US$69.50) (US$76.49) 
Rotavirus vaccination 2152.13 2798.36 
(US$85.42) (US$111.06) 
to to 
2214.10 2904.02 
(US$87.87) (US$115.26) 
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Table 90 : The cost per QALY of the four Thai health 
programmes' sensitivity analysis on the 
predicted values of the health states based on the 
interviewed data by the aspect and regression 
models (continued). 
b) A value range of 0±0.20. 
Health programme aspect 
model 
regression 
model 
Short-course anti-TB 146.74 157.90 
chemotherapy ambulatory (US$5.81) (US$6.26) 
treatment with the to to 
2HRZ/4H2R2 regimen 209.90 233.52 
(US$8.32) (US$9.25) 
Short-course anti-TB 154.08 165.78 
chemotherapy ambulatory (US$6.13) (US$6.60) 
treatment with the to to 
2HRZ/4HR regimen 220.30 245-04 
(US$8.77) (US$9.75) 
Measles vaccination 376.91 422-13 
(US$15.09) (US$16.90) 
to to 
522.26 613.30 
(US$20.91) (US$24.55) 
BCG vaccination 751.27 835.82 
(US$29.82) (US$33.17) 
to to 
945.40 1083.31 
(US$37.52) (US$42.99) 
Short-course anti-TB 1235.80 1329.68 
chemotherapy hospitalised (US$48.96) (US$52.68) 
treatment with to to 
the 2HRZ/4HR regimen 1766.95 1965.39 
(US$70.00) (US$77.87) 
Short-course anti-TB 1358.32 1461.65 
chemotherapy hospitalised (US$53.82) (US$57.91) 
treatment with to to 
the 2HRZ/4H2R2 regimen 1943.04 2161.64 
(US$76.98) (US$85.64) 
Rotavirus vaccination 2122.43 2748.33 
(US$84.24) (US$109.08) 
to to 
2246.45 2959.92 
(US$89.16) (US$117.47) 
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estimates based on the median standardised data are used to 
explain the mechanism of the aspect model. The estimates for 
the parameters A, B, C, D, E and DI are 7.31,27.20,9.37, 
13.03, -8.83 and 1.40; respectively. Unlike the Thai result, 
the effect of the number of non-healthy dimensions on the 
Finnish valuation is greater than that of the severity 
levels. A rise in the number of non-healthy dimension results 
in a fall in the valuation as does an intensification in a 
severity level. It should be noted that the severity level 
parameter of the anxiety/depression dimension (E) has a 
negative value. This means that problems in the 
anxiety/depression dimension make the effects of problems in 
all dimensions worse than no problem in that dimension does. 
This implies that the anxiety/depression dimension produces 
the greatest impact on the Finnish valuation. The second most 
influential is the selfcare dimension, followed by the 
pain/discomfort, usual activity and mobility dimensions. 
In the original data set, between 42% and 51% of the 
total samples are in a discrepancy range of 0 to ±0.10 and 
69-87% in a range of 0 to ±0.20 for the six tested health 
states. In these two ranges, the standardised data set has 
29-58% and 50-93%; respectively. The estimation of the aspect 
model for one data set is not decisively better than that for 
the other. 
In comparison between the estimates based on the median 
value data and the median values of the estimated individual 
values, Tables 91 and 92 indicate that for both original and 
standardised data, the predicted values from the median value 
estimation are almost identical to the median values of the 
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Table 91 : The comparison of the median values of the 
surveyed Finnish original data, the estimated 
values based on the median original value data 
and the median values of the estimated values 
based on the original individual data from the 
aspect model. 
Health Median Estimated Median Value 
state value of value based value differential 
Finnish on median of the 
surveyed original estimated 
original value values 
data data based on 
the original 
individual 
data 
21232 0.32 0.25 0.25 -0.07 
22233 0.22 0.18 0.18 -0.04 
22323 0.20 0.18 0.18 -0.02 
32211 0.39 0.36 0.35 -0.03 
(-0.04) 
33321 0.15 0.25 0.25 0.10 
33333 0.00 0.18 0.18 0.18 
Notes 1. For simplicitY, the values all are presented 
on a 0-1 scale. 
2. Value differential is predicted value 
minus surveyed value. 
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Table 92 The comparison of the median values of the 
surveyed Finnish standardised data, the 
estimated values based on the median 
standardised value data and the median 
values of the estimated values based on the 
standardised individual data from the aspect 
model. 
Health Median Estimated Median Value 
state value of value based value differential 
Finnish on median of the 
surveyed standardised estimated 
standardi- value values 
sed data data based on 
the standard- 
ised individual 
data 
21232 0.33 0.26 0.26 -0.07 
22233 0.22 0.18 0.19 -0.04 
(-0.03) 
22323 0.18 0.18 0.19 0.00 
(0.01) 
32211 0.38 0.36 0.36 -0.02 
33321 0.17 0.26 0.26 0.09 
33333 0.00 0.18 0.19 0.18 
(0.19) 
Notes 1. For simplicity, the values all are presented 
on a 0-1 scale. 
2. Value differential is predicted value 
minus surveyed value. 
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predicted values from the individual estimation in the six 
health states. This finding is consistent with that found in 
the Thai data sets. 
In addition, since the worse-than-death states in the 
Finnish data are non-existent or insignificant, the estimated 
values from the two data forms are very close. 
6.5.2. The results of the regression model. 
The regression model produces a slightly high R2 for the 
original data and a modest R2 for the standardised data. All 
the estimates of the two data forms are statistically 
significant. 
Table 93 indicates that the ranking order of the 
estimated weightings for the five dimensions between the 
original individual data analysis and the standardised 
counterpart is similar. Their magnitudes differ by 0.7 to 
2.6. The difference in the intercept term is 5.8. 
Due to a very small number of the worse-than-death states 
with respect to the individual valuation or the non-existence 
of such a state regarding the median values, the difference 
in the estimated values between the two data forms is 
relatively moderate, 0.05 to 0.07. 
For the original data, there are 16-76% of the total 
samples in a discrepancy range of 0 to ±0.10 and 58-100% in 
a range of 0 to ±0.20. However, for the standardised data, 
22-52% are in the first range and 55-84% in the second. 
Again, the regression model points in favour of the original 
data. 
6.5.3. The comparison of the two valuation models' results. 
In the sensitivity test of a cost-utility analysis, a 
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Table 93 : The result of the regression model based on 
the Finnish original and standardised data. 
A. The weighting findinqs. 
Dimension original data 
estimated rank 
weighting 
Standardised 
estimated 
weighting 
data 
rank 
i. Mobility(XI) 19.8* 2 19.1* 2 
2. Se 1f care (X2) 15.8* 3 18.4* 3 
3. Usual Activity(X3) 10.8* 5 10.5* 5 
4. Pain/discomfort 15.1* 4 13.9* 4 
(X4) 
5. Anxiety 22.1* 1 23.4* 1 
/Depression(X5) 
Constant 82.3* 76.5* 
k2 0.725** 0.635** 
B. The estimated values for the health states and the 
'ýiscrepancies between the surveyed median and Predicted values. 
1) The original data'. 
Health 
state 
Surveyed 
median 
value 
Predicted 
value 
Value 
differential' 
11111 1.00 0.82 -0.18 
11111R 1.00 0.82 -0.18 
11112 0.60 0.71 0.11 
11121 0.80 0.75 0.05 
11211 0.80 0.77 0.03 
12111 0.75 0.74 -0.01 
21111 0.85 0.72 -0.13 
11122 0.50 0.64 0.14 
21232 0.35 0.41 0.06 
22233 0.25 0.22 -0.03 
22323 0.20 0.24 0.04 
32211 0.40 0.49 0.09 
33321 0.20 0.28 0.08 
33 0.02 -0.01 -0.03 
33333R 0.05 -0.01 -0.06 
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Table 93 : The result of the regression model based on 
the Finnish original and standardised data 
(continued). 
2) The standardised data 
Health 
state 
Surveyed 
median 
value 
Predicted 
value 
Value 
13 differentia 
11112 0.61 0.65 0.04 
11121 0.79 0.70 -0.09 
11211 0.83 0.71 -0.12 
12111 0.75 0.67 -0.08 
21111 0.85 0.67 -0.18 
11122 0.48 0.58 0.10 
21232 0.31 0.36 0.05 
22233 0.22 0.15 -0.07 
22323 0.17 0.17 0.00 
32211 0.39 0.43 0.04 
33321 0.14 0.22 0.08 
33333 0.00 -0.09 -0.09 
Notes t-test is significant at 0.001. 
F-test is significant at 0.001. 
1. The estimation with the original data uses 15 
health states and has 108 samples. For 
simplicity, the values are presented on a 0-1 
scale. 
2. The estimation with the standardised data uses 
13 health states and has 103 samples. 
3. Predicted value - surveyed value. 
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variation range of 0 to ±O-10 could account for 35-58% of the 
total samples by using the estimates from the aspect model. 
The estimated values with an expanded range of 0 to ±0.20 
could approximate for 71-93% of the total valuations. 
For the original data, the difference of the estimated 
values between the two models is relatively high in some 
health states. It is much lower however in most health states 
for the standardised counterpart, as seen in Table 94. 
The discrepancy comparison indicates that for the 
original data, the aspect model represents a higher number of 
samples within some inner ranges than the regression model 
does with regard to most health states. 
The aspect model would be a reasonable option for the 
value estimation based on the standardised data for the 
Finnish cost-utility analysis. By using the estimates from 
the aspect model, a range of 0 to ±0.10 covers 35-58% of the 
total samples whereas the estimates from the regression model 
could account for only 30-52% in that range. If the range 
varies from 0 to ±0.20, the former estimates could expand to 
approximate 72-93% of the total samples, valuation while the 
latter only 62-84%. 
6.6. Some further tests of the valuation models for the Thai 
data. 
In this section, two more tests of the valuation models 
are applied to the Thai valuation data. First, the models are 
employed to explain the valuation for some extra health 
states. 
Secondly, as the diminishing marginal utility hypothesis 
is postulated in the expected utility theory and evident in 
many studies of other areas (e. g. the utility of money), the 
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Table 94 : The comparison of the estimated values between 
the aspect model and the regression model 
based on the Finnish original and standardised 
data. 
A. The original data comparison. 
Health Aspect Regression Value 
model model differential* 
21232 0.25 0.41 0.16 
22233 0.18 0.22 0.04 
22323 0.18 0.24 0.06 
32211 0.35 0.49 0.14 
33321 0.25 0.28 0.03 
33333 0.18 -0.01 -0.19 
The standardised data comparison. 
Health Aspect Regression Value 
model model differential* 
21232 0.26 0.36 0.10 
22233 0.19 0.15 -0.04 
22323 0.19 0.17 -0.02 
32211 0.36 0.43 0.07 
33321 0.26 0.22 -0.04 
33333 0.19 -0.09 -0.28 
Note :* The regression value - the aspect value. 
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valuation and the predicted valuation from the model are used 
to test the hypothesis of the diminishing marginal values of 
the health states. Llewellyn-Thomas et al (1984) note that 
the valuation data from surveys would be accepted if they 
could create a predictable pattern of the valuation. Such a 
test could gain the model's consideration on empirical 
grounds, which perhaps could make up for the shortage of the 
model's theoretical investigations. 
6.6.1. A test of the valuation models with the values for 
self-classified current health state of the Thai 
samples. 
The experience and remarks of Torrance et al (1982) that 
a valuation model might break down when it is applied to a 
large number of health states leads to an assessment of the 
precision of the estimates for some other health states 
produced by the two models. In the Thai survey, the values 
for the respondents' current health states and the self- 
classification of their current health states are used to 
create the values for other health states. The number of the 
additional health states f rom this combination process is 
expected to be considerable since the survey included two 
types of patient. However, one criticism of this method is 
the small number of samples in each of these health states. 
moreover, the difference between this method and the main 
valuation procedure might cause some doubt over the 
comparability of the former's result. 
There are 37 additional health states available from this 
process for the model test. The comparison between the 
interviewed values and predicted values for these health 
states from the aspect model are reported in Table 95. Only 
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Table 95 The comparison results between 
standardised interviewed values 
health states and the estimated 
aspect model. 
The estimates' precision. 
the median 
for current 
values from the 
Health 
state 
Median of 
the current 
health state 
value 
Estimated 
value 
Value 
differential* 
Number of 
samples 
11113 0.17 0.37 0.20 1 
11131 0.67 0.37 -0.30 4 
11311 0.17 0.31 0.14 1 
11123 -0.43 0.28 0.71 2 
11133 0.55 0.14 -0.41 2 
11132 0.15 0.28 0.13 2 
11212 0.82 0.47 -0.35 1 
11221 0.63 0.48 -0.15 14 
11231 0.58 0.24 -0.34 2 
11321 0.31 0.24 -0.07 2 
11331 0.00 0.12 0.12 1 
21112 0.70 0.57 -0.13 3 
21121 0.63 0.57 -0.06 19 
21131 0.75 0.29 -0.46 1 
21211 0.60 0.48 -0.12 3 
11222 0.65 0.35 -0.30 6 
11223 0.63 0.18 -0.45 1 
11232 0.41 0.18 -0.23 3 
11233 0.03 0.09 0.06 2 
11332 0.20 0.09 -0.11 2 
12122 0.79 0.31 -0.48 1 
21122 0.59 0.43 -0.16 23 
21123 0.65 0.21 -0.44 5 
21133 0.72 0.11 -0.61 3 
21212 0.17 0.36 0.19 1 
21221 0.36 0.36 0.00 8 
21231 0.23 0.18 -0.05 4 
21321 0.50 0.18 -0.32 3 
22121 1.58 0.32 -1.26 1 
12332 0.38 0.05 -0.33 1 
21222 0.56 0.27 -0.29 19 
21223 0.15 0.13 -0.02 2 
21232 0.39 0.13 -0.26 2 
21233 0.60 0.07 -0.53 4 
21333 0.00 0.03 0.03 1 
22221 0.62 0.20 -0.42 2 
22222 0.70 0.15 -0.55 2 
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Table 95 The comparison results between 
standardised interviewed values 
health states and the estimated 
aspect model (continued). 
B. The distribution of the discrepancy ranges. 
the median 
for current 
values from the 
Discrepancy range the number of the health states 
0.00 to ±0.05 4 
±0.06 to ±0.10 3 
±0.10 to ±0.15 7 
±0.16 to ±0.20 3 
±0.21 to ±0.25 1 
±0.26 to ±0.30 4 
±0.31 to ±0.35 4 
±0.36 to ±0.40 0 
±0.41 to ±0.45 4 
±0.46 to ±0.50 2 
< 0.51 or > 0.51 5 
total 37 
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46% of the health states are in a variation range between 0 
and ±0.20. (If the six previously tested health states are 
included, the size in this range rises to 55%. ) 
6.6.2. A test for the diminishing marginal values of the 
health states hypothesis with the Thai data. 
One of the contentious issues in the scaling procedure is 
that the values for the health states measured by most 
available scaling methods are thought to be unempirical and 
incompatible with rigorous systemic thinking (Llewellyn- 
Thomas et al, 1984). Boyle et al (1984) claim that most 
scaling methods available, except for standard gamble 
technique, lack the theoretical foundation of utility theory. 
Torrance et al (1982) regard their health state valuation 
result by the category rating method as merely values for 
health states. They acquired the utility values for those 
health states equivalent to those scaled by standard gamble 
technique by assuming that in each health state, the former, 
with an exponential power of 1.6, was equal to the latter. 
Since the feeling thermometer valuation method and the 
aspect model in this study are not directly based on the 
standard utility theory and to ensure that their results 
could be as good as those based on the standard theory, it is 
worth showing that some aspects of their outcomes could be 
anticipated from the theory and found in its related studies. 
one unique finding in the utility function, based on the 
expected utility theory found in various study areas, is the 
diminishing marginal utility. The existence of this property 
in the surveyed valuation and the valuation model would make 
them further compatible with the expected utility theory. 
There are two main methods to find out whether a utility 
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function has the property of the diminishing marginal 
utility. First, from the concave curve of a utility function, 
which implies mathematically declining marginal utility, the 
first derivative function with respect to the object in 
consideration (Xi) is positive and the second, negative. This 
can be demonstrated in Figure 4 and the equations below. 
U (Xi) =f (Xi) 
dU U, (Xi) fI (Xi) >0 
dXi 
d2U U // (Xi) f // (Xi) <0 
dXi2 
This testing approach is suitable for objects with a 
single attribute and for those with a possible function form. 
For the multiattribute objects like health states, there is 
a defining problem of variables, which require their 
differentiability. 
Secondly, for some ranges of a utility function, an 
average of the utility values for two magnitudes is less than 
the utility value for the average of the two magnitudes. 
According to Figure 4, the point C which represents the 
utility values for the average (Xj) of the two quantities 
(Xj-l and Xj+, ) is above the point D, the mean of the two 
utility values. 
The second proposition is far easier to modify for 
testing the hypothesis here although it may lack the 
generalisation and rigorous proof that the first one has. The 
difficulty of the adaptation of this approach to the health 
state valuation is to define consecutive or adjacent health 
states for the test. For example, according to a logical and 
rational ranking pattern, the health state 11122 has the 
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Figure 4: A utility function with the diminishing 
marginal utility hypothesis. 
U Cx) 
U(x. 1) 
U (X3) 
(U(x, 
-, 
)+U(X,., ))/2 
u(x3-l) 
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health states 11112 and 11222 as better and worse health 
states next to it. Also, the health states 11121 and 12122 
can be defined as its adjacent health states. In a 
multidimensional health status index model, it is possible 
that some individual health states have more than one set of 
their adjacent health states. As a result, there is no singly 
unique way but a variety of possibilities to form the test. 
Some are explored here. The basic form of the test, whatever 
the definition of the adjacent health states used, is derived 
as follows. 
The decline in the additional utility values for the 
health states can be expressed as follows. 
U(HSi. 1) - U(HSi) < U(HSi) - U(HSi-1) 
U(HSi. 1) + U(HSi-1) < 2U (HSi) 
U(HSi.,, ) + U(HSi-, ) <U (HSi) 
2 
where HSi.,,, HSi and HSi-, are any three consecutive or 
adjacent health states and HSi, I is healthier 
than HSi and HSi is healthier than HSi-, 
This investigation employs two methods to define adjacent 
health states. One definition is based on the number of the 
non-healthy dimensions in a health state. One of the three 
health states has at least two healthy dimensions. Another 
health state is similar to the previous health state except 
for the moderately severe level in only one of two healthy 
dimensions of the first health state. The third health state 
contains the moderately severe level in both healthy 
dimensions of the first health state, its other health 
dimensions are the same as those of the first health state. 
The other definition deals with the severity level in any 
one dimension. The basic health state has to have one healthy 
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dimension. The other two adjacent health states differ from 
it in a manner that one has the moderately severity level and 
the other, the extreme one in that dimension. This is 
provided that all other dimensions are identical. 
By using the values for the 43 health states compiled 
from the current health states of the Thai respondents, 
thirteen trios of the health states can be specified by each 
definition. Table 96 presents the results of these two tests. 
The outcome according to the severity degree arrangement 
confirms the hypothesis of the diminishing marginal values 
better than that based on the number of the non-healthy 
dimensions one. More than 60% of the health states in the 
former category satisfy the hypothesis while only 23% in the 
latter do. The aspect model highly complies with the 
hypothesis under the former definition (92% of the trios). It 
should be noted that the models are not consistent with the 
hypothesis for the one or two health states with multi- 
extremely severe dimensions. The values for these health 
states are nearer zero than one. This fact, correspondent to 
the concave curve of a typical utility function as shown 
above, implies that the declining marginal values of the 
health states occur in some health states whose values 
approach one. 
Therefore, it is highly likely that the diminishing 
marginal values exist in the health state valuation by the 
Thai evaluators with respect to the severity degree in any 
one dimension. The health state valuation may have a similar 
basis of judgement to the valuation for other objects' 
utilities. Due to the declining marginal values property 
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Table 96 :A test for the diminishing marginal values of the 
health states hypothesis with the Thai data. 
The number of the non-healthy dimensions arranqement. 
Health Health Health Health Health Survey Aspect 
state state state state state model 
with 1 with 2 with 3 with 4 with 5 
non- non- non- non- non- 
healthy healthy healthy healthy healthy 
dimen dimen dimen dimen dimen 
sion sions sions sions sions 
11113 11123 11223 x 
11123 11223 21223 x 
11133 11233 21233 x x 
11331 11332 12332 
11212 11222 21222 x x 
11212 21212 21222 x x 
21112 21122 21222 x 
21121 21122 21222 x 
21131 21231 21232 x x 
21211 21212 21222 x x 
21212 21222 22222 
21122 21222 22222 x x 
11222 21222 22222 x x 
Te number of the health states 3 5 
confirming the hypothesis is (23%) (38%) 
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Table 96 :A test for the diminishing marginal values of 
the health states hypothesis with the Thai data 
(continued). 
B. The severity level arrangement. 
Health state 
with no 
problems in 
the dimension 
concerned 
Health state 
with some 
moderate 
problems 
in the 
dimension 
concerned 
Health state 
with some 
extreme 
problems 
in the 
dimension 
concerned 
Survey Aspect 
model 
11113 11123 11133 x 
11131 11132 11133 x 
11311 11321 11331 
11212 11222 11232 
11132 11232 11332 
11221 11222 11223 
11231 11232 11233 
21121 21122 21123 x 
21211 21221 21231 x 
21212 21222 21232 
21221 21222 21223 
21231 21232 21233 x 
21133 21233 21333 x 
The number of the health states 8 12 
confirming the hypothesis is (61%) (92%) 
Notes / denotes the hypothesis is confirmed. 
X denotes the hypothesis is rejected. 
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available, the model could gain credibility in predicting the 
evaluators, health state valuation. 
In order to gain more support and generalisation of the 
hypothesis in the Thai data, more health states should be 
tested. A test on single respondent's own valuation for 
various health states should be attempted to complement the 
across-respondent test. And, like the models, value 
predictability, the hypothesis needs to be tested with data 
from various sources as well as in different populations. In 
addition, other forms of the hypothesis test should be sought 
and attempted. They could serve to validate the results 
discovered here. 
6.7. Suggestions for further investigations of the valuation 
models. 
6.7.1. More development areas needed for the existing 
valuation models. 
This analysis backs up the feasibility of modelling the 
respondents' valuation for health states and boosts 
confidence in the use of predicted values in cost-utility 
analysis of health programmes. Due to the models, moderate 
level of the estimation accuracy and, their better precision 
levels than the alternative approach based on the 
multiattribute utility theory, the models and their 
underlying concepts can be regarded as appropriate. They 
should gain further promotion in research. 
The consequences of the availability of models in cost- 
utility analysis are considerable. It could save a great deal 
of resources and effort in collecting- the valuation data. 
This would reduce the cost of conducting cost-utilitY 
analysis of many health programmes and lead to more uses of 
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this approach. The acceptance of the cost-utility analysis 
result would increase since it would be regarded to be based 
on a more scientific approach than before. 
The attractive points of the concept and models in this 
investigation are the small inaccuracies between the 
predicted and elicited values, uncomplicated methodology, the 
simplicity of the model operation and the small number of 
assumptions. In addition, the best model performs equally 
well for the eight different data sets. 
The imprecision of the predicted values for some 
unmeasured health states in cost-utility analysis may be 
dealt with by the sensitivity analysis. The maximum deviated 
values (in both directions) could be added to the estimates 
to make their lower and upper limits. This could ensure that 
the estimates used are highly likely to include the otherwise 
surveyed values in the analysis. 
The selection of which health states should be included 
in a valuation survey can play a role in assisting the model 
construction. For example, it is lucky that the EuroQol 
instrument used in this study included all the health states 
with only one-moderately severe level and the health state 
11122, which are the basic health states for the aspect 
model. For other alternative models, future data collections 
may incorporate other health states that are vital to them. 
Also, it may contain some key tested health states. It would 
be desirable if in a given Population the valuation for the 
tested health states is gathered in a different group of 
respondents from that providing the values for the basic 
health states. Thus the assessment of the model performance 
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would be more reliable. 
The current aspect model can be improved if future 
EuroQol survey questionnaires include other health states 
related to the parameter computation. For instance, the 
health states 11212,12112,21112,11221,12121,21121, 
12211,21211 and 22111 can provide the estimate for the 
number of the non-healthy dimensions parameter and be used 
for substantiation if the estimate is the same for all the 
dimensions involved as implicitly assumed. 
Similarly, the availability of the health states with 
only one-extremely severe level (i. e. 31111,13111,11311, 
11131 and 11113) can assess the validity of the assumption 
that the effect of an extreme level is counted twice the 
effect of the moderate counterpart in any dimension, given 
that every other thing is equal. If not, then the model 
should be adjusted and the parameters of a new model can be 
estimated by employing the data from these health states. 
With reference to the diminishing marginal values 
property found in the Thai valuation data, this property 
could be one of the criteria for the model selection. 
Provided that the aspect model fares well with the data 
from different populations based on the EuroQol instrument, 
the models and their underlying concepts (with any necessary 
modifications) should in the future be tested with the 
valuation data based on other health status indexes. 
6.7.2. Some essential criteria for testing the valuation 
models. 
Before the task of modelling the health state valuation 
proceeds any further in the future, the issue of establishing 
the criteria to assess the model performance and the rules 
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governing the methods and techniques employed in the model 
are essentially tackled. This could provide some direction 
and guidelines towards the model formulation. 
The following are some criteria used in this analysis and 
some suggested for future investigations. 
a) It is suggested that the precision test should be 
based on some health states which do not involve in the 
estimation process of the model. It does not matter whether 
they are in the same survey as those used in the estimation 
process or not. However, the test based on those in a 
separate survey may create a more rigorous conclusion. It is 
suggested in an unpublished note reporting the regression 
results of the valuation models by a researcher group at the 
Centre for Health Economics that the test should be based on 
respondents whose valuations are not employed in the model 
construction. 
b) Since it is impossible for any model to predict a set 
of the exact valuations (i. e. the discrepancy between the 
estimated and surveyed values is zero), discrepancy ranges 
should be used to determine the model's accuracy. The rule, 
therefore, is the higher number of the samples I valuations in 
lower discrepancy ranges the model can deliver, the better it 
is. A related criterion is to set the number of samples in 
some predetermined discrepancy ranges achieved by a model, 
whose predicted values are entitled to be used in cost- 
utility analysis. 
c) The model performance should be investigated on the 
basis of individual respondents' valuations in order to show 
its degree of the predictability for the selected 
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population's valuation. 
d) The ef f iciency criterion may be introduced into the 
model assessment. The less information and effort (implicitly 
involving cost) a model needs, the better it is provided that 
all models compared achieve a similar standard. For example, 
for a same survey, a model with a smaller number of "health 
state inputs" and, as a result, a larger number of health 
states available for a precision test, would be rated better 
than another model having more health state inputs and 
leaving over fewer tested health states, given other things 
equal. 
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Chapter 7 
conclusion 
This chapter examines some of the issues arising from the 
analyses in further detail. It discusses the obstacles 
encountered in the analyses, some solutions to which resulted 
in different courses of action from those planned. 
Limitations of the study are also assessed. It suggests the 
improvement in some aspects of the health-related quality of 
life valuation and other methodologies in cost-utility 
analysis. Issues for further research are also discussed. 
Finally, remarks about the prospect of the cost-utility 
approach in Thailand and at the international level are made. 
7.1. Conclusions. 
This study conducts the cost-utility approach in Thailand 
using the latest methodology. The survey of the health state 
valuation is feasible in the country, despite the fact that 
the health state measure used, the EuroQol instrument, was 
created and has been developed in the Western settings. It 
could be said that the experience of a measurement of the 
health-related quality of life with the resource allocation 
purpose is gained from the study as well. 
The results of cost-utility analysis are, as an 
illustration, applied to setting the priority ranks for the 
four health programmes and to assessing a proposed Thai 
health policy. They also point out that regarding the 
vaccination programmes, a rise in efficiency can be brought 
about by focusing the improvements in the vaccine 
effectiveness and the protection length. 
By adopting the steps, methodology and the health state 
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values in this study as a framework, the analysis of 
operational as well as national health programmes needs only 
appropriate data, which mainly are the clinical parameters, 
costs and health outcomes. Or it could be modified further by 
using the values from one's own survey and/or by employing 
other suitable methodology. 
The aspect model and the regression model are proposed to 
give the valuation required in this COSt-utility analysis. 
Their findings are also tested with the surveyed values. 
Though their performance is adequate, there are many 
possibilities to improve the models. 
Regarding the immediate goals, the investigation into the 
possible sources of bias finds some personal background 
effects on the health state valuation. However, in the 
standardised form, only the values of groups divided by 
different health experience are substantially significant in 
the interview survey. As with other studies, the impact 
should be identified with the issue of whose values should 
count. However, it is unimportant and insignificant as far as 
this cost-utility analysis is concerned since the value 
diversity does not change the conclusion of the priority 
ranking of the four health programmes. But it might be 
crucial to the health programmes with a dominant aspect of 
the quality of life. The choice of the value aggregation in 
this study is the median values due to the non-normal 
distribution of the samples' valuation. Considering all of 
these, the surveyed valuation data have a minimum of bias and 
a high degree of validity. The use of the valuation in the 
cost-utility analysis involves least implicitly value-laden. 
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Based on the common procedure and data collection, a 
conclusive result is obtained. For the TB control, the 
ambulatory curative care is more cost effective than the 
preventive care but not for the hospitalised one. As a 
diarrhoea control objective, the measles vaccination is more 
cost effective than the rotavirus vaccination. The 
vaccination budget would be well spent by giving the first 
priority to the measles vaccination, followed by the BCG 
vaccination and the last to the rotavirus vaccination. The 
overall priority ranking is: 1) the ambulatory short-course 
anti-TB treatment, 2) the measles vaccination, 3) the BCG 
vaccination, 4) the hospitalised short-course anti-TB 
treatment and 5) the rotavirus vaccination. 
The feasibility of the valuation surveys from a variety 
of populations across nations with the same EuroQol 
instrument justifies the possibility of utilising this 
health-related quality of life measure in different settings, 
though the values obtained could vary due to culture and 
population backgrounds. However, it is predicted that the 
different valuation between the Thais and the Europeans could 
reduce as Thailand experiences lower death rates, longer life 
and reviving people with extremely severe health states. This 
would encourage the international cooperation in developing 
a standard global health-related quality of life measure for 
the allocation objective and in investigating the underlying 
factors responsible for the valuation differential. 
The proposed valuation models work well on some 
international data sets but satisfactorily on others. More 
details of the data are needed to make better the estimation 
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and assessment. As with the health state measure, the 
ultimate object is a standard global valuation model, which 
could produce the appropriate valuation for a specific 
individual population. 
The study findings are basically consistent with other 
international studies. The significantly different results 
between the Thai and international studies (e. g. the priority 
rank for the rotavirus vaccination programme) could highlight 
the relevance of the domestic information in any country to 
its own efficiency assessment and priority- s ett ing method for 
the resource utilisation. 
7.2. Inquiries into some issues emerging from the analyses. 
This section examines four key issues stemming from the 
analyses. Some investigations show the importance of the 
quality of life component in this cost-utility analysis and 
the effects of private costs on the result. It discusses the 
implications of the choice of sample and the response rate in 
the valuation survey. 
a) The importance of the quality of life component in 
this cost-utility analysis. 
Since most of the health programmes in this study have 
more effect on life expansion than on quality of life 
improvement, it is worth investigating whether the additional 
effort is profitable on the compilation of the quality of 
life weighting data. Also, an examination shows the 
importance of the information to the economic assessment of 
both the health programmes in this study and health 
interventions in general. 
Compared with other arguments for contemplating cost- 
utility analysis given by Drummond et al (1987) such as the 
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substantial impact on the quality of life of some health 
interventions and an intention to compare one's study with 
other cost-utility studies, the need for combining morbidity 
and mortality into a common unit of the outcome measurement 
is of great relevance to this study. This means that the 
health programmes that af f ect both morbidity and mortality in 
principle should be entitled to be analysed by cost-utility 
methods. In the cost-utility analysis framework, morbidity 
usually affects the quality of life and mortality, the 
quantity of life or the life expectancy (Drummond et al, 
1987). As the objective of all health interventions is set to 
be enhanced length and quality of life, cost-utility analysis 
is supposed to be part of the analysis of all the social 
health resource allocation (Williams, 1987). 
Prescott et al (1983) point out some inadequacies of 
single measure of morbidity and of mortality. The former in 
terms of diseased cases prevented lacks the duration and 
extent of illness while the latter in the form of the number 
of deaths avoided omits the difference in the age at death. 
Moreover, the same authors show that a different 
effectiveness measure could produce a different conclusion 
and suggest a different course of action about efficient 
resource use. 
They advocate potential years of life gained as an 
alternative effectiveness measure, which could not only 
resolve some problems in the two measurements mentioned above 
but also unite morbidity and mortality into a single 
effectiveness form. 
Nevertheless, a key shortcoming of this measure remains. 
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It cannot distinguish the quality of life gained from 
avoiding diversified severity types and extents of different 
diseases by different interventions. Therefore, the outcome 
measurement in terms of the potential years of life gained is 
inferior to the quality-adjusted life years (QALYs) gained 
because of the lack in the quality of life valuation. 
However, the gain in this account should be justified by 
the cost of making the information available. This issue, 
which is one of the criteria against applying cost-utility 
analysis mentioned by Drummond et al (1987), is of concern 
for this cost-utility analysis. Considering the extra cost of 
gathering and incorporating the quality of life weightings in 
an analysis, a cost-utility study could be replaced by a 
cost-effectiveness one. For instance, if it is sufficient for 
cost-effectiveness analysis to produce the ranking outcome of 
health programmes and the quality of life weighting factor 
does not change the analysis conclusion, then there is no 
need to perform cost-utility analysis (Drummond et al, 1987) . 
Prescott et al (1983) give an example of uneven influences of 
the components constituting a composite health status measure 
as a guide to the disease priority-setting in a country. The 
disease priority ranking according to healthy days of life 
saved, which is the combination of morbidity and mortality, 
was dominated by the mortality component. 
However, in order to demonstrate that the quality of life 
preference does not have a significant effect on the 
comparison, it has to be available and proved to be trivial. 
Therefore, the argument does not assist in deciding whether 
or not the quality of life preference should be collected (if 
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cost-utility analysis is one of the options). It in fact 
suggests what type of the economic evaluation be presented 
when the impact of the quality of life preference on the 
analysis conclusion is known. 
The health programmes in this study affect both quality 
and quantity of life. The latter obtainable from these health 
programmes seems to outperform that from other health 
interventions such as the heart disease treatment because 
they save an almost maximum lif e expectancy at birth (except 
for the TB treatment). But the opposite is true for the 
former. 
However, this advantage is cancelled out between 
themselves. Therefore, their crucial difference lies on the 
quality of life. As seen in Chapter 4, the morbidity 
attributed to each disease is different in both type and 
magnitude. For instance, the complications for measles 
victims mainly involve mental disorders whereas those for 
diarrhoeal patients, the growth or development prospects. By 
contrast, TB patients at the advance stage encounter physical 
malformation. The afflicted survivors from these ailments are 
likely to lead lives with qualitative distinction. 
Without the quality of life weightings, the net health 
benefits from the measles vaccination and the TB treatment 
programmes are over-estimated while the health yields from 
the rotavirus and BCG vaccination programmes are under- 
estimated. The measles vaccination programme according to the 
cost per potential life year gained of 356.87 baht (US$14.29) 
becomes more cost-effective than its cost per QALY measure by 
18%. The cost-effectiveness of the TB treatment programme is 
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slightly improved (3%) in terms of the cost per potential 
life year gained (168.26 - 176.63 baht or US$6.67 -7.03 for 
the ambulatory option and 1416.71 - 1557.51 baht or US$56.13 
- 61.71 for the hospitalisation option) . The cost- 
effectiveness of the rotavirus vaccination programme based on 
the cost per potential life year gained, which is estimated 
at 3872.70 baht (US$153.70), worsens by 77% compared with its 
cost per QALY. The cost per potential life year gained of the 
BCG vaccination programme is 1093.80 baht (US$43.41), which 
is equal to 31% higher than the cost per QALY. 
The cost-effectiveness ranking based on the cost per 
potential life year gained is the same as that based on the 
cost per QALY. That is, as far as the comparison of these 
health programmes is concerned, it is adequate to use the 
cost per potential life year gained to rank their cost- 
effectiveness. This implies that the quality of life 
adjustment is not so important in the economic evaluation 
that it could alter the ranking outcome. 
It can be speculated that when these two cost- 
effectiveness measures are applied to other health 
programmes, whose cost-effectiveness estimates are ranked 
more closely, there is possibly a conflict in the ranking. 
The potential life year gained measurement would overstate 
the value of the interventions with a more severe impairment 
but understate that of those with a less severe one. 
However, the ranking is not the only function of the 
economic assessment, though a crucial one. The importance of 
the quality of life factor is evident in other aspects of the 
evaluation. The outcome based on the cost per potential life 
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year gained, which implicitly assumes a year in sickness the 
same for every illness, could be biased considerably against 
the rotavirus vaccination programme and moderately against 
the BCG vaccination programme but in favour of the measles 
vaccination programme. The difference in the estimates 
between the two cost-effectiveness measures, which is 
accounted for by the quality of life adjustment, demonstrates 
that this assumption does not comply with the quality of life 
aspect of these diseases from the people's perspective. For 
instance, the potential life year gained plays down the 
quality of life valuation for the rotavirus immunisation a 
great deal and for the BCG immunisation to a certain extent. 
But the opposite happens to the measles vaccination. 
The omission of the difference in the quality of life 
among the health interventions could mislead health decision- 
makers and policy-makers using the findings of cost per 
potential life year gained data. They may guide them to 
invest in the interventions that yield the greatest survival 
duration but generate poor quality of life. This could be in 
contrast to the objective of improving health. As a result, 
health resources could be wasted and the health objective 
unfulfilled. On the other hand, they could obtain a better 
and more relevant outcome by employing the cost per QALY. 
The use of the potential life year gained could lead to 
under-funding for the rotavirus and BCG vaccination 
programmes and over-funding for the measles vaccination and 
TB treatment programmes. By basing decisions on this 
measurement, the health budget required for the health 
programmes would be misjudged with respect to the desirable 
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health level. 
The value of the quality of life weighting data would 
become more apparent when these health programmes, which 
predominantly influence prolonging lives, are compared with 
others interventions that chiefly affect the quality of life 
improvement. The potential life year gained would fail to 
capture fully the health benefit of the latter programmes. 
More importantly, the availability of the quality of life 
adjustment would make the trade-off between the two types of 
the programmes easier, more explicit and more accurate. 
At present, the Thai health sector, like the health 
sector in most of other countries, has no clear outcome 
measurement of health interventions. Prescott et al (1983) 
note that in most countries, the health objectives are 
formulated on the basis of inputs or intermediate outcomes. 
The same authors also point out that in the quest for 
improvements in health status, developing countries have been 
awaiting more economic evaluation studies to guide them in 
the right direction. The need for appropriate health status 
measurement is undoubtedly central to the success of the 
economic assessments. If the quality of life variable is 
acceptably included in the outcome measurement in the Thai 
health sector, then the QALY would be a promising candidate. 
It can be concluded that although the cost-effectiveness 
ranking outcome of the four Thai health programmes based on 
the cost-utility analysis can be similarly predicted by the 
less-demanding, cost-effectiveness analysis using the 
potential life year gained, the superiority of the former 
over the latter is demonstrated in other aspects of the 
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resource allocation principle. The importance of the quality 
of life component is obviously seen throughout the health 
resource allocation process. 
To weight the value of the quality of life factor against 
its elicitation cost is in fact a matter of opinion. The two 
are not in a commensurable unit. Considering all the existing 
and potential merits of the quality of life weightings 
collected in this study, they are in the author's opinion 
worthwhile. 
b) The effects of the private costs on the analysis result. 
Many suggest that various definitions of the health 
programme cost (i. e. the viewpoints of the analysis) should 
be explored in the economic evaluation (Warner et al, 1982). 
Although some are not available or cannot be measured or 
valued, their inclusion should not be ignored. The conflict 
in the analysis perspective could withhold the health 
programmes implemented from achieving the predicted optimum 
level (Cohen et al, 1988). Torrance (1986) claims that the 
analysis based on the private viewpoint could be employed in 
predicting the likely participation of the recipients in 
health programmes. The private spendings are about 70% of the 
total health expenditures in Thailand (Roemer, 1991). On the 
face of it, the analysis with the private viewpoint could 
involve in a larger part of the resource allocation. Here the 
effect on the cost-effectiveness of the health programmes in 
this study is investigated from an analysis of the different 
viewpoints. 
The private costs incurred to an average vaccinee and his 
attendance and to an average TB patient are approximated from 
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the few Thai studies available. The costs compatible with the 
societal viewpoint are assumed to be the sum of the patient's 
and government's costs. 
In receiving a health care service, it is possible that 
a patient himself and the members of his family bear some 
costs. The private cost can be in both monetary and non- 
monetary forms. The lost productivity is one of the most 
difficult to be estimated accurately (Warner et al, 1982). It 
is widely acknowledged that the cost in the form of pain, 
anxiety or suffering due to a health care service exists but 
is immeasurable in monetary units. (Warner et al, 1982; 
Drummond et al, 1987). 
The travel cost and lost earnings are considered in this 
analysis as the costs borne by the vaccinees or patients and 
their families. It is assumed that the government provides 
the immunisations and TB treatments free of charge. The side 
effects of these services, which presumably cover all the 
physical, mental and social sufferings, were incorporated as 
the negative expected quality of life in the benefit side and 
will not count in the private cost side again. 
According to a study about the immunisation programmes in 
northern provinces of Thailand, a vaccination recipient on 
average expended a travel cost of around 5.19 baht (US$0.21) 
(the 1988 price level) and spent about 47 minutes in 
travelling to a health centre (Limtragol et al, 1989). 
The median travel cost to major provincial hospitals, 
including those in Bangkok, for TB treatment was found to be 
between 13.40 baht (US$0.53) and 19.60 baht (US$0.78) for the 
local patients and between 43 baht (US$1.70) and 62.30 baht 
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(US$2.47) for those outside the area on the basis of the 1988 
price level (Chavalittamrong et al, 1989). 
There are two factors responsible for the lower travel 
cost to a health centre than to a TB treatment site. First, 
the former is usually situated nearer the recipients, homes 
(i. e. nearby their villages) than the latter. Secondly, the 
availability of the former is far greater than that of the 
latter. 
The analysis by Chavalittamrong et al (1989) indicates 
that the TB patients I average lost earning because of absence 
from work so as to obtain the treatment is estimated to be 
about 95.00 - 126.68 baht (US$3.76 - 5.02) . Compared with 
their average income of slightly more than 2000 baht 
(US$79.24) per month, the income forgone is relatively high. 
This estimate is reasonable since in receiving the treatment 
a patient has to sacrifice 5% of his income (i. e. a day off 
from 22 working days). (According to the Thai minimum wage 
rate bill, the payment to employees is made on the basis of 
a working day. ) 
In actuality, a child is always accompanied by an adult 
to obtain a vaccination. Since all the study immunisation 
programmes are intended to render in the first year of a 
child's life, he loses no income. But an attendant bears some 
earning loss. It is supposed that his forgone income is 
equivalent to that incurred to the TB patientd. This 
assumption may be over-estimated on the grounds that the 
vaccination acquisition may not take a whole day and an 
attendant might not be in the labour force (e. g. housewife, 
unemployed or retired) - The unavailability of an analysis 
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about the attendant's characteristics makes it impossible for 
the estimate to be any more precise. 
Presumably there are no other family costs in all the 
health programmes in this study. It is also supposed that 
vaccinees go to health centres while TB patients travel to 
the TB treatment centres and hospitals. 
As BCG vaccinations are mainly given at birth, there is 
no travel cost or income loss for an attendant. Therefore, 
the private cost of a BCG vaccination becomes zero. 
A measles immunisation needs a trip for both a child and 
his attendant as well as causing a dayss earning loss. They 
amount to 105.38 - 137.06 baht (US$4.18 - 5.43) . The same 
private costs are applied to a rotavirus vaccination. The 
private cost per QALY of a measles immunisation varies from 
405.83 baht (US$16.06) to 527.46 baht (US$20.90). The figure 
for a rotavirus immunisation ranges from 5776.07 baht 
(us$228.85) to 7514.65 baht (US$297.73). 
For a visit to a TB treatment centre, a TB patient pays 
between 108.40 baht (US$4.29) and 188.98 baht (US$7.49). 
According to the analysis by Kamonratanakul et al (1990), 
seven visits are needed during the ambulatory treatment. This 
means that his expense of the treatment ranges from 758.80 
baht (US$30.06) to 1322.86 baht (US$52.41) .A patient with 
the hospitalised TB treatment would not expend travel costs 
but lose two months' income or 4180.00 - 5573.92 baht 
(US$165.61 - 220.84). 
He would obtain a QALY from the ambulatory treatment at 
a cost of 72.46 - 126.33 baht (US$2.87 - 5.01) on the 
2HRZ/4HR regimen or 81.23 - 141.61 baht (US$3.22 - 5.61) on 
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the 2HRZ/4H2R2 one. For the hospitalised treatment option, a 
QALY is valued at 399.18 - 532.29 baht (US$15.82 - 21.09) for 
the 2HRZ/4HR formula or 447.47 - 596.69 baht (US$17.73 - 
23.64) for the 2HRZ/4H2R2 one. With reference to the patient's 
viewpoint, the 2HRZ/4HR regimen is better than the 2HRZ/4H2R2 
one in both options of the treatment. 
The health programme ranking according to the cost per 
QALY dif f ers between the government Is and the patient Is 
viewpoints in all the programmes except for the rotavirus 
immunisation, which is rated as the lowest priority in both. 
The BCG vaccination and hospitalised TB treatment are more 
cost-effective based on the patient's cost than based on the 
government's cost. The former programme becomes the top 
priority and the latter one the third. By contrast, the 
ambulatory TB treatment and measles immunisation are less 
cost-effective in the private view than in the public one. 
They are the second and fourth ranks, respectively. 
The ranking based on the social viewpoint indicates that 
the top priority goes to the ambulatory TB treatment. The two 
regimen cost per QALY are very similar. The 2HRZ/4HR formula 
varies from 254.01 baht (US$10.06) to 307.88 baht (US$12.20) 
and the 2HRZ/4H2R2 one from 254.17 baht (US$10.07) to 314.55 
baht (US$12.46). The BCG vaccination programme comes second. 
its cost per QALY of 837.23 baht (US$33.23) derived from the 
social viewpoint is equivalent to that based on the 
government one. The third rank belongs to the measles 
immunisation, which costs 840.95 - 963.00 baht (US$33.32 - 
38.15) for a QALY. The priority for the hospitalised TB 
treatment is penultimate. Again, the 2HRZ/4HR regimen 
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(1855.35 - 1988.46 baht or US$73.51 - 78.78 per QALY) is 
cheaper than the 2HRZ/4H2R2 one (2048.34 - 2197.56 baht or 
uS$81.15 - 87.07 per QALY). The rotavirus vaccination 
programme has the last priority, whose cost-effectiveness is 
in a range of 7958.75 - 9697.33 baht or US$315.32 - 384.20 
per QALY. 
The cost per QALY ranking is similar between the social 
viewpoint and the government's one for most of these 
programmes. The difference is in the ranks of the BCG 
vaccination and measles vaccination programmes. The former 
has the second priority based on the social viewpoint but the 
third based on the government one. On the other hand, the 
social viewpoint ranks the latter the third but the 
government one, the second. 
The ranking derived from the social viewpoint is in 
contrast to that derived from the patient's viewpoint. The 
ambulatory TB treatment and BCG vaccination programmes, which 
are given the first and second priorities according to the 
social point of view, are in the reverse rank order based on 
the private counterpart. The opposite ranking between the two 
viewpoints also applies to the hospitalised TB treatment and 
measles vaccination programmes. Their priorities in the 
social point of view are the fourth and third, respectively. 
The differences in the ranking between the different 
points of view can be seen from the resource consumption 
pattern of the programmes. The cost differentials between the 
private and government viewpoints arise from the fact that 
the share of the private resources for the ambulatory TB 
treatment far exceeds that for the BCG vaccination and that 
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the private cost for the hospitalised TB treatment is less 
than the public one by 20%. The two sources contribute almost 
equally to the measles vaccination. The similar pattern also 
happens to the cost differentials between the private and 
social viewpoints. The government pays more than 50% for all 
the programmes' resources used except for the rotavirus 
immunisation programme. 
In terms of the percentage of the total resource 
consumption, the cost incurred to the average health service 
recipient is between 0-72% and to the government between 28- 
100%. The rotavirus vaccinees bear the maximum cost share 
whereas the BCG counterparts the least. By contrast, the 
government makes the greatest contribution to the service for 
the latter group and the lowest for the former group. 
There are two main criticisms for the private cost data. 
First, if there is an improvement in the transportation 
between health institutions and the health service 
recipients I homes and more rapid service provisions, then the 
income loss may not be as much as a day's earning. Therefore, 
the private cost and the correspondent cost per QALY decline. 
so does the cost per QALY to society. The impact on the 
ambulatory TB treatment would be more significant than the 
other services since it contains seven times the combined 
travel cost and income loss incurred to the others. The 
ef f ect would be of the most signif icance f or the hospitalised 
TB treatment owing to the reduction in the two months I income 
loss estimate. Secondly, the analyses on which these data are 
based did not controlled for the confounding impacts on the 
socio-economic factors. In addition, they included a small 
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sample of people. Therefore, the generalisation of the data 
is questionable. 
Hence, the results suggest, rather than conclude, that a 
different cost-effectiveness ranking of the health programmes 
could result from using a different viewpoint. However, with 
reference to any point of view, it is certain that the 
rotavirus immunisation programme possesses the lowest cost- 
effectiveness. 
Two observations emerging f rom. the above investigation 
can reinforce the justification of employing the government 
cost data as a principal viewpoint in this analysis. First, 
the analysis outcome based on the government viewpoint can to 
a large extent reflect that based on the social one. 
Secondly, the implementation of the health programmes in 
accordance with the patient Is viewpoint (and even the social 
one in some instances) may undesirably create bias against 
patients with low productivity loss (e. g. unemployed, poor 
and housewives) . The services for their illness are given 
lower priorities than they ought to be since the costs for 
their service acquisition are overstated. By contrast, the 
outcome derived from the government costs is advantageous due 
to avoiding this bias. The services provision is determined 
regardless of the clients' characteristics. 
c) The implications of the choice of sample in the valuation 
survey. 
The selection of the samples in this study is the value 
judgement of the analyst. There are at least two questions 
directly emerging from this decision. First, to what extent 
do the quality of life valuation data in this survey 
represent those of the subject groups in the whole Thai 
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population? This is necessary because the valuation data 
acquired are applied to the health programmes implemented at 
the national level. Secondly, how can the valuation data 
account for those of other subject groups unavailable in this 
analysis (e. g. politicians)? The valuation data of other 
subject groups should be tested whether the variation from 
various sources is significant and how it affects the 
analysis result. The second question would be a subject for 
future Thai cost-utility studies. 
The valuation data from the patients and healthy people 
in this study have yet to prove whether they could stand for 
the whole Thai population. The outcome may be with some doubt 
generalised to a national level. Since most of the variables 
in this study were not categorised in the same way as those 
available in the official sources, it is difficult to make 
the comparison. Some approximately comparable variables are 
shown here. Their distinctions vary from slightly to sharply. 
The unemployment rate of 6.3% in Thailand in 1987 (the 
latest data from Monthly Bulletin of Statistics of United 
Nations (1993)) is comparable to that of 7.0% found in the 
interview survey, though the data are in a few years apart. 
However, in the postal survey, the rate is lower than the 
official one by more than 4%. The median household income 
from the interview survey in this study is similar to the 
average household income surveyed in Bangkok in 1987 
(National Statistics Office, 1990) . On the contrary, that 
from the postal survey is about twice. The same source 
indicates that on average households in Bangkok earned more 
than twice that of all Thai households did in that year. 
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The illiteracy rate in Thailand in 1980 for the 
population over 15 years old was 12% and that for the 
population over 25 years old, 20.5% (United Nations, 1992). 
The interview survey, including only 9% of the illiterate 
respondents, under-sampled the illiterate population. Though 
the improvement in the Thai education system in the past 
decade may reduce the rate, it would not be as low as that 
found here. In addition, the postal survey omitted the 
illiterate people completely since its basic requirement is 
the literacy of the respondent. 
Some health care variables differ between the Bangkok 
population and the rest of the country. The Fact Finding 
Commission (1987) reports that during 1976 to 1978, on 
average a Bangkok resident spent on health care about three 
times as much as an average Thai did. The same source 
indicates that the urban people's rate of utilising health 
services from various public health facilities was about 
three times the rate of the rural people. 
So the quality of life weighting data of the populations 
in other locations of Bangkok as well as in other provinces 
throughout Thailand should be sought. Whether or not they are 
in contrast to the valuation in this study needs to be 
verified with respect to not only the background variables 
but also their health care ones. Their impact on the cost- 
utility analysis outcome is of great importance. 
Like the medial profession in most countries, the Thai 
counterpart has a substantial authority on national and local 
health policies. According to Roberts (1988), the British 
medical profession has a considerable influence in devising 
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health policy at regional level and at district one. The 
valuation data of the health administrators and policy-makers 
in the health profession group in this study are most likely 
to reflect the valuation of the public health policy-makers 
community. This is because a substantial proportion of the 
high-rank health officials in Ministry of Public Health 
participated in the survey. 
The government's intervention in most preventive care 
programmes is justified on the grounds that their investment 
would be sub-optimal if left to the market operation (Cohen 
et al, 1988). This implies that the government's health gain 
weightings for these programmes are of importance. Therefore, 
it is sensible to employ the government officials, valuation 
in the assessment of the immunisation programmes in this 
study. In addition, it could reflect the national interest, 
which may not be accounted for by an aggregate of 
individuals, valuations (Loomes et al, 1990). 
In 1988 there were 80% of the doctors in the country 
employed in the public sector and more than half of them 
worked in the Ministry of Public Health (Division of Health 
Statistics, 1988). About 90% of the doctors in the public 
sector also practised in the private sector (during their 
non-official hours) (Health Planning Division, 1990). The 
sample in the valuation survey is equal to 1.5% of the 
doctors in Ministry of Public Health and 0.6% of all the 
doctors available in the country at the time. Therefore, 
their view about the quality of life may relate not only to 
the public health resource allocation referred to above but 
also to the private counterpart through their private medical 
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practices. Their valuation data would be appropriate for 
cost-utility analysis of all public health programmes. Also, 
they could be applied equally well to the analysis at the 
national level as well as the individual practice one. 
Some argue for the quality of life valuation of the 
direct beneficiaries from the relevant health programmes. 
According to Drummond et al (1987), it is sensible because of 
the difference in the age-sex profiles between patients in 
some distinctive interventions (e. g. angina patients and 
scoliosis patients). Carr-Hill (1989) suggests that the 
appropriate sample of the valuation depends on the condition, 
patient and treatment under consideration. With reference to 
this view, the valuations of the bronchitis and cancer 
patients would only be applicable to their respective 
interventions. However, as discussed before, conducting a 
cost-utility study based on the valuation data specific to 
disparate groups of health service recipients is impractical 
and reduces its comparability. 
The sample choice becomes an issue as there is a 
significant difference in the valuation and in their cost- 
utility outcome between various subject groups categorised by 
some key variables (Drummond et al, 1987). It would not be 
problematic, if no difference emerges. By contrast, if there 
should be one, the analysis objective may be a criterion to 
select an appropriate group (i. e. on the basis of the 
viewpoint of the health officials or the patients in 
question). Gudex (1990) suggests that the discussion of the 
appropriate sample may be beneficial if the foundation of the 
health care system is of focus (e. g. its philosophy) . So far 
580 
most studies, including this one, have found no or slight 
differences in the valuation between subject groups (Drummond 
et al, 1987). 
d) The implications of the response rate in the valuation 
survey. 
The response rate in the interview survey indicates a 
bias against the health profession group but in favour of it 
in the postal survey. The low participation and response rate 
from this group may imply the resistance of some members to 
the health state valuation method and/or the methodology of 
cost-utility analysis and/or the cost-utility approach as a 
whole. Feldstein (1970) points out that health officials are 
likely to have more difficulty in the valuation than other 
respondent groups since they judge on the behalf of the 
public. 
In the United Kingdom, analysts also encounter the 
problem of the unwillingness of the health administrators in 
revealing their value judgements about health care issues, 
especially the health programme priorities (Normand, 1990). 
However, it is hoped that as the Thai health professionals 
understand the approach better, the cooperation would expand 
in the future. Also, it would make them overcome the 
difficulty in the decision-making over the rival health 
benefits conferred to distinctive beneficiaries from a 
variety of public health programmes. 
To enhance the response rate in general, as mentioned in 
the section about the problems encountering the EuroQol 
instrument in Chapter 2, the modifications in its design, 
particularly the dead state valuation, may be essential. 
Also, it is useful to reveal the factors responsible for the 
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lack in cooperation and motivation. Attempts should be made 
to rectify it accordingly. 
7.3. The shortcomings of the analyses. 
Due to no prior information about the likelihood of 
valuing some health states as "worse than death" by the Thai 
respondents, the interviewers were not prepared and trained 
for a modification of the time trade-off scaling method to 
cope with this matter. As a result, the values for some 
health states were impossible to compute (i. e. the health 
states with zero score) . This resulted in the incapability of 
a sensible comparison of the values from the two scaling 
methods due to insufficient number of observations. It also 
led to missing an opportunity to use the time trade-off 
scores in estimating the values for unmeasured health states 
to be used in the cost-utility analysis. Fortunately, the 
time trade-off scores were adequate for the analysis of the 
personal background effects. 
The postal survey encountered the problems of the 
patients I relocation and death, which resulted in the outcome 
biased towards the doctors and policy-makers. This could also 
beg the question about the difference in the valuation 
between the former patients (i. e. postal subjects) and 
current patients (i. e. interviewed subjects). 
The fact that the aggregation unit analysis has too small 
a number of observations is responsible for detecting no 
signs of the influences as opposed to the findings based on 
the individual counterpart. It is anticipated that as more 
health state valuations are available, the analysis could 
find the same biases. The variables tested are limited to 
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those observable, measurable and health-related. The other 
subjective impact sources might be escaped from the test. 
However, such a comprehensive analysis is too complicated to 
do at present. 
The interval property of the valuation obtained might be 
violated in some health states but not all. So it could 
partially affect the cost per QALY result to a slight extent. 
The vital setbacks for this cost-utility analysis rest on 
the estimation of some parameters. These problems are beyond 
the control of health economists since the parameters in 
question are studied in different disciplines. In most 
instances, economic evaluation studies have to depend upon 
secondary data published in other relevant areas. The 
methodology of clinical studies, the main purpose of which is 
to supply the information for the clinical decision-making, 
is sometimes incompatible with that of economic analysis. 
The outcome measurements for the health programmes in 
this study are unavailable. The uncooperation of the experts 
in this matter, the second best option, forced the study to 
take on the author's own opinion. Nevertheless, the value 
judgement used is made explicit and is therefore 
challengeable. The problem of the subjectivity does not 
affect the study result due to the insignificance of the 
health-related quality of life component in these health 
programmes. But it could cause a big problem for those with 
an important quality of life aspect. For them, a highly 
objective health outcome measurement has to be sought. 
7.4. The limitations of the study. 
According to neoclassical economics, the efficiency 
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allocation principle is based on the marginal (additional) 
unit (e. g. marginal cost and marginal benefit) . However, this 
study obtains only the estimates for the average costs and 
average effectiveness because they are the only data 
available. Therefore, the assumption of the equivalence 
between the average and marginal units is made. 
The clinical trials seem to go on concerning only average 
efficacy and effectiveness estimates. The economic analysis 
cannot do anything much about this. However, it might be 
possible to estimate the additional efficacy and 
effectiveness from the relationship of the sample size and 
the efficacy and effectiveness magnitudes in similar trials. 
Moreover, the approximation of the costs for the 
vaccination programmes from other vaccination programmes 
could possibly cause some inaccuracy. The differences in the 
vaccination costing with respect to demographical f actors and 
the programme size are not taken into account and allowed for 
(Creese, 1983). Though the lack of these data does not affect 
this study much, they are necessary for the analysis at the 
operational level. 
7.5. Some suggestions for cost-utility analysis. 
From the experience of this study, the following issues 
should be considered for the improvement in conducting a 
cost-utility analysis. They are arranged in order of the 
importance. 
a) The acceptable rules for the conversion of diseases 
and side effects into the health states and the health 
outcome measurement with a high degree of objectivity 
(notably the clinical trial basis) should be obtained. This 
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would result in more reliable, acceptable findings of the 
analysis. 
b) In order to increase its accountability and expand the 
scale of implications and applications, the estimation of the 
parameters should be wider (e. g. private costs), more 
appropriate (e. g. marginal costs and benefits) and more 
accurate (e. g. a directly estimated cost of the programmes 
concerned). 
c) More valuation models, based on the decision theory in 
particular, should be attempted. More surveyed valuation data 
for other health states can help develop much better models 
and test them accordingly. 
d) More parameter estimates under the Thai settings 
should be made available for the analysis, the results of 
which are intended to be utilised domestically. Gerard (1992) 
believes that the cost-utility analysis results are often 
ingeneralisable. 
e) The interview with the time trade-off scaling method 
should be able to deal with the worse-than-death states. As 
a result, the visual analogue scale and the time trade-off 
scaling techniques can be compared without any doubt. The 
effect of the latter on the cost per QALY result would be 
realised as well. 
7.6. issues for further research. 
Some major issues related to cost-utility analysis, 
demanding investigation, are as follows. Better understanding 
of them could strengthen the analysis and promote its 
applications. 
1) As ethical issue may prevent ideal clinical trials, 
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how the economic evaluation acquires its fundamental 
information which may be unavailable in the trials should be 
studied. 
2) The more familiarity with the health state 
classification may be the key to enhancing the health state 
valuation. A trial for this could be designed to train 
different groups of people (e. g. healthy people, patients and 
doctors) to think their health in terms of a health state 
classification, allow them to observe their own health with 
this for some time and ask them to characterise their past, 
present and any change in health with the health state 
descriptors. Also, it could test how viable the health state 
classification is. 
3) In order to make the estimates of the costs of the 
health programmes more reliable, the factors affecting the 
cost should be included in the cost estimation procedure, 
including a change in technology, programme size and time 
scale. In addition, the computation for the marginal cost is 
important too. 
4) Due to the conflict between the cardinal and ordinal 
forms in some health states evident from the personal 
background ef f ect analysis in this study, the property of the 
cardinal form such as the equal interval property could be 
challenged and should be investigated. 
5) The analysis of factors influencing valuations should 
be enlarged to health care factors and other subjective 
variables. An investigation should make it clear if the 
impact could arise from the content of the valuation 
instrument, the layout, the number of health states 
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simultaneously determined and the scaling method. Also, the 
division in the valuation between different health experience 
groups should be explained in more detail. 
6) What accounts for different valuations between 
different populations across countries, like that between the 
Thais and the Europeans as found in this study, is now being 
investigated. Culture and norms in the society are found to 
be the key factors (Hunt et al, 1987). The dynamic aspect of 
the differential, that is, a change in the different 
valuations due to perhaps information and medical technology 
changes, should be on the research agenda as well. 
7) Most EuroQol valuation surveys suffered the low return 
rate of the postal survey. A modified survey method for a 
rise in the rate should be sought and attempted. The support 
to the postal samples may have some substantial ef f ect on the 
incentive to cooperate. It could be in the form of a specimen 
of an answered health state valuation accompanying the 
questionnaire and a telephone follow-up giving explanations. 
The appropriately modified survey needs to be cost-effective 
and generate enough support to increase response rates. 
7.7. Concluding remarks. 
This study demonstrates the value of cost-utility 
analysis in examining the efficiency of the four health 
programmes in the Thai health care system. Its two vital 
functions are to point out the existence of inefficiency and 
to provide a means to efficiency. The analyses show that the 
outcomes of this cost-utility study have minimum bias, good 
validity and a low degree of subjectivity. The incorporation 
of cost-utility analysis in the priority-setting process of 
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the health resource utilisation is fully justified. In 
addition, the procedure reveals the vagueness, 
unsystematisation and inconsistency in the existing decision- 
making process. All of these support the acceptance of the 
cost-utility approach in the Thai health sector, advocate an 
assessment process of efficiency, and suggest the need for 
more cost-utility studies and the expansion in the analysis 
to all levels. 
Since cost-utility analysis at present is in the 
developmental stage, more studies of its various issues are 
needed. Their top priorities should be to solve current 
shortcomings and to settle a wide methodological variation. 
An economical way to do this is the worldwide collaboration 
on the study of cost- utility analysis and related issues. 
The development in some methodologies at the international 
level could facilitate domestic cost-utility studies and in 
turn the results from particular settings could be fed back 
to the methodological investigation. This also would promote 
both the quantity and quality of the approach across 
countries. The standard established procedure of this 
approach as well as that of the health state measurement 
might be acquired as a by-product. With such a collective 
effort, the cost-utility approach could become the dominant 
economic analysis for tackling questions of efficiency in 
health sectors. 
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Appendix I 
The questionnaire and questions of the health state 
valuation for the survey in Thailand. 
A questionnaire for the EuroQol health state valuation for 
the survey in Thailand. 
This is a survey of a health state valuation. The information from 
you would be used for a research only and it would not be exposed for 
other purposes. You may want to give an answer or may not. 
There are two parts in this questionnaire. The first is a general 
socio-economic information. The second is the scaling of your 
preference of health states. 
General definition. 
The last year in all questions you would meet means the duration 
between 1st January 1990 and 31st December 1990. 
Part T: Socio-economic information. 
Remark : Please tick (/) in the parenthesis in accordance with your 
conditions. 
1. Do you live in a urban area or a rural area? 
urban area 
rural area 
2. What is your age? 
Age 
- years. 
3. Sex () male () female 
4. How many years did (do) you study? 
Education 
- years. 
5. What is your current occupation? 
occupation 
6. What is your marital status? 
() single () married () divorced () widow ) other 
7. What is your estimated annual income in the last year? 
Annual income Baht 
8. What is your estimated household annual income? 
Household annual income Baht. 
9. if you did (do) not earn in the last year, how do you classify 
yourself as one of the following : 
() the retired () the unemployed a housewife 
10. How many visits to health care providers, for example, a 
hospital, a clinic, a doctor, a health centre, a drug store, 
and a traditional practitioner in the last year. 
Health care times. 
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11. How many people permanently living in the same house as you in the 
last year? 
Family size people. 
12. How long do you exercise and/or play sports regularly in a month 
during the last year? 
Time minutes each month. 
13. How many cigarettes on average do you smoke a day during the last 
year? 
Cigarette smoking cigarettes a day. 
14. Areý you :()a current smoker 
()a never smoker 
() an ex-smoker 
15. How many bottle of beer and/or 
week during the last year? 
Alcohol drinking 
liquor on average do you drink in a 
bottles a week. 
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Part II : The scaling method. 
We are trying to find out what people think about health. We are 
going to describe a few health states that people can be in. We want 
you to indicate how good or bad each of these states would be for a 
person like you. There are no right or wrong answers. Here we are 
interested only in your personal views. 
But f irst of all we would like you to indicate (on the next page) 
the state of you own health today. 
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By placing a tick (, 0 in at least one box in each group below, please 
indicate which statements best describe your own health state today. 
Mobility. 
I have no problems in walking about. 
I have some problems in walking about. 
I am confined to bed. 
Self-care. 
:I have some problems with self-care. 
:I have some problems washing or dressing myself. 
:I am unable to wash or dress myself. 
Usual Activities. 
:I have no problems in performing usual activity (eg. 
work, study, housework, family or leisure activities). 
:I have some problems in performing my usual 
activities. 
:I am unable to perform my usual activities. 
Pain/Discomfort. 
:I have no pain or discomfort. 
:I have moderate pain or discomfort. 
:I have extreme pain or discomfort. 
Anxiety/ Depression. 
:I am not anxious or depressed. 
:I am moderately anxious or depressed. 
:I am extremely anxious or depressed. 
Compared with my general level of health over the past 12 months, my 
health state today is 
Please tick one box 
Better 
Much the same 
Worse 
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To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked by 100 
and the worst state you can imagine is marked by 0. 
We would like you to indicate on this scale how good 
or bad is your own health today, in your opinion. 
Please do this by drawing a line from the box below 
to whichever point on the scale indicates how good or 
bad your current health state is. 
Best imaginable 
health state 
100 
7 
Your own health 
state today 
0 
0 
1 
0 
Worst imaginable 
health state 
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We now want you to consider some other 
health states. 
Remember, we want you to indicate how good 
or bad each of these states would be for a 
person like you. 
They are described, on either side of the 
scale, on the page opposite. 
When thinking about each health state 
imagine that it will last for one year. 
What happens after that is not known and 
should not be taken into account. 
Please draw one line from each box to 
whichever point on the scale indicates how 
good or bad the state described in that box 
is. 
It does not matter if your lines cross each 
other. 
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(Page 1 of the feeling thermometer) 
No problems in walking about 
No problems witb, selt-care 
some problems witb performing 
usual activities 
No pain or discomfort 
Not anxious or depressed 
No problems in walking about 
No problems with self-care 
No problems with performing usual 
activities (eg. work, study, house 
work, family or leisure activities) 
No pain or discomfort 
Not anxious or depressed 
Some problems in walking about 
No problems with self-care 
Some problems with performing usual 
activities 
Extreme pain or discomfort 
Moderately anxious or depressed 
No problems in walking about 
No problems witb self-care 
No problems witb performing usual 
activities (eg. work, study, bouse 
work, family or leisure activities) 
Moderate pain or discomfort 
Moderately anxious or depressed 
Best imaginable 
bealth state 
100 
No problems in walking about 
No problems with self-care 
No problems with performing usual 
activities (eg. work, study, house 
work, family or leisure activities) 
Moderate pain or discomfort 
Not anxious or depressed 
Some problems in walking about 
Some problems with washing or 
dressing self 
Some problems with performing 
usual activities 
Extreme pain or discomfort 
, _Extremely 
anxious or depressed 
Confined to bed 
Unable to wasb or dress self 
Unable to perform usual activities 
Extreme pain or discomfort 
Extremely anxious or depressed 
Confined to bed 
Unable to wasb or dress self 
Unable to perform usual activities 
Moderate pain or discomfort 
Not anxious or depressed 
Worst imaginable 
health state 
Please check that you have drawn one line from each box (that is, 8 lines in all) 
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(Page 2 of the feeling thermometer) 
In the same way as on the previous page, please indicate how good or 
bad these additional states are, by drawing a line form each box to a point 
on the scale. You will find that 2 of the these states (marked *) are 
repeated from the previous page. 
Best imaginable 
bealth state 
Some problems in walking about 
No problems with self-care 
No problems with performing 
usual activities 
No pain or discomfort 
Not anxious or depressed 
100 
No problems in walking about 
No problems with self-care 
No problems with performing usual 
activities (eg. work, study, house 
work, family or leisure activities) 
No pain or discomfort 
Moderately anxious or depressed 
*No problems In walking about 
No problems with self-care 
No problems with performing usual 
activities (eg. work, study, house 
work, family or leisure activities) 
No pain or discomfort 
Not anxious or depressed 
Unconscious 
No problems in walking about 
some problems with washing or 
dressing self 
No problems with performing usual 
activities (eg. work, study, house 
work, family or leisure activities) 
No pain or discomfort 
Not anxious or depressed 
Worst imaginable 
bealtb state 
Confined to bad 
Some problems with washing or 
dressing self 
Some problems with performing 
usual activities 
No pain or discomfort 
Not anxious or depressed 
'Confined to bed 
Unable to wash or dress self 
Unable to perform usual activities 
Extreme pain or discomfort 
Extremely anxious or depressed 
Some problems in walking about 
Some problems with washing or 
dressing self 
Unable to perform usual activities 
Moderate pain or discomfort 
Extremely anxious or depressed 
Please check that you have drawn one line trom each box 
(that is, 8 lines in all) 
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- In the previous pages we asked you to say how 
good or bad various health states are in your 
view. 
We would now like you to tell us how good or 
bad you feel the state "deadN is, compared with 
being in the other states for one year. 
Please turn back to pages 6 and 7 draw a line 
across the thermometer at the point you would 
locate the state "dead". 
Remember we would like you to do this on both 
pages 6 and 7. 
. Thank you for being so helpful. 
Did you find filling in this questionnaire 
very difficult 
fairly difficult 
fairly easy 
very easy 
Could you please let us know roughly how long 
it took you to complete minutes. 
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b. The questions for the valuation given by the interviewers in 
the time trade-off method session. 
In each question, You will be presented two choices and asked to 
choose the one that you would prefer. If you think the two choices are 
equal, please say so and both choices will be marked. Suppose that you 
have ten more years to live and will die after that. 
Time started for the time trade-off method 
ouestion 1. 
You have two choices. The first is that you have a perfect health 
which defines as no problems in walking about. No problems with self- 
care. No problems with performing usual activities ( eg. work, study, 
housework, family or leisure activities). No pain or discomfort. No 
anxious or depressed. And you live for 10 years. The second is that 
you have no problems in walking about. No problems with self-care. 
Some problems with performing usual activities. No pain or discomfort. 
Not anxious or depressed. And you live for 10 years. 
a) Which choice do you prefer? 
first choice go on the next step. 
second choice stop. 
b) If your first choice is changed from living 10 years to dying 
immediately and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
c) If your first choice is changed from dying immediately to 
living 9 year and other things are still the same, which choice do you 
prefer? 
first choice ; go on the next step. 
second choice ; stop. 
d) If your first choice is changed from living 9 years to living 
1 year and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
e) If your first choice is changed from living 1 years to living 8 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
f) If your first choice is changed from living 8 years to living 2 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
g) If your first choice is changed from living 2 years to living 7 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
h) If your first choice is changed from living 7 years to living 3 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
i) If your first choice is changed from living 3 years to living 6 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
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j) If your first choice is changed from living 6 years to living 4 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
k) If your first choice is changed from living 4 years to living 5 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; stop. 
both or indifference stop. 
Ouestion 2. 
You have two choices. The first is that you have a perfect health 
which defines as no problems in walking about. No problems with self- 
care. No problems with performing usual activities ( eg. work, study, 
housework, family or leisure activities). No pain or discomfort. No 
anxious or depressed. And you live for 10 years. The second is that 
you have some problems in walking about. No problems with self-care. 
some problems with performing usual activities. Extreme pain or 
discomfort. Moderately anxious or depressed. And you live for 10 
years. 
a) Which choice do you prefer? 
first choice go on the next step. 
second choice stop. 
b) If your first choice is changed from living 10 years to dying 
immediately and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
c) If your first choice is changed from dying immediately to 
living 9 year and other things are still the same, which choice do you 
prefer? 
first choice ; go on the next step. 
second choice ; stop. 
d) If your first choice is changed from living 9 years to living 
1 year and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
e) If your first choice is changed from living 1 years to living 8 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
f) If your first choice is changed. from living 8 years to living 2 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
g) If your first choice is changed from living 2 years to living 7 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
h) If your first choice is changed from living 7 years to living 3 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
i) If your first choice is changed from living 3 years to living 6 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
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j) If your first choice is changed from living 6 years to living 4 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
k) If your first choice is changed from living 4 years to living 5 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; stop. 
both or indifference stop. 
Ouestion 3. 
You have two choices. The first is that you have a perfect health 
which defines as no problems in walking about. No problems with self- 
care. No problems with performing usual activities ( eg. work, study, 
housework, family or leisure activities). No pain or discomfort. No 
anxious or depressed. And you live for 10 years. The second is that 
you have no problems in walking about. No problems with self-care. No 
problems with performing usual activities (eg. work, study, housework, 
family or leisure activities). Moderate pain or discomfort. Moderately 
anxious or depressed. And you live for 10 years. 
a) Which choice do you prefer? 
first choice go on the next step. 
second choice stop. 
b) If your first choice is changed from living 10 years to dying 
immediately and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
c) If your first choice is changed from dying immediately to 
living 9 year and other things are still the same, which choice do you 
prefer? 
first choice ; go on the next step. 
second choice ; stop. 
d) If your first choice is changed from living 9 years to living 
1 year and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
e) If your first choice is changed from living 1 years to living 8 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
f) If your first choice is changed from living 8 years to living 2 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
g) If your first choice is changed from living 2 years to living 7 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
h) If your first choice is changed from living 7 years to living 3 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
i) If your first choice is changed from living 3 years to living 6 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
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j) If your first choice is changed from living 6 years to living 4 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
k) If your first choice is changed from living 4 years to living 5 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; stop. 
both or indifference stop. 
Ouestion 4. 
You have two choices. The first is that you have a perfect health 
which defines as no problems in walking about. No problems with self- 
care. No problems with performing usual activities ( eg. work, study, 
housework, family or leisure activities). No pain or discomfort. No 
anxious or depress . And you live for 10 years. The second is that you 
have no problems in walking about. No problems with self-care. No 
problems with performing usual activities (eg. work, study, housework, 
family or leisure activities). Moderate pain or discomfort. Not 
anxious or depressed. And you live for 10 years. 
a) Which choice do you prefer? 
first choice go on the next step. 
second choice stop. 
b) If your first choice is changed from living 10 years to dying 
immediately and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
c) If your first choice is changed from dying immediately to 
living 9 year and other things are still the same, which choice do you 
prefer? 
first choice ; go on the next step. 
second choice ; stop. 
d) If your first choice is changed from living 9 years to living 
I year and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
e) If your first choice is changed from living 1 years to living 8 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
f) If your first choice is changed from living 8 years to living 2 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
g) If your first choice is changed from living 2 years to living 7 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
h) If your first choice is changed from living 7 years to living 3 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
i) If your first choice is changed from living 3 years to living 6 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
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j) If your first choice is changed from living 6 years to living 4 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
k) If your first choice is changed from living 4 years to living 5 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; stop. 
both or indifference stop. 
Ouestion 5. 
You have two choices. The first is that you have a perfect health 
which defines as no problems in walking about. No problems with self- 
care. No problems with performing usual activities ( eg. work, study, 
housework, family or leisure activities). No pain or discomfort. No 
anxious or depress . And you live for 10 years. The second is that you 
have some problems in walking about. Some problems with washing or 
dressing self. Some problems with performing usual activities. Extreme 
pain or discomfort. Extremely anxious or depressed. And you live for 
10 years. 
a) Which choice do you prefer? 
first choice go on the next step. 
second choice stop. 
b) If your first choice is changed from living 10 years to dying 
immediately and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
c) If your first choice is changed from dying immediately to 
living 9 year and other things are still the same, which choice do you 
prefer? 
first choice ; go on the next step. 
second choice ; stop. 
d) If your first choice is changed from living 9 years to living 
1 year and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
e) If your first choice is changed from living 1 years to living 8 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
f) If your first choice is changed from living 8 years to living 2 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
g) If your first choice is changed from living 2 years to living 7 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
h) If your first choice is changed from living 7 years to living 3 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
i) If your first choice is changed from living 3 years to living 6 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
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j) If your first choice is changed from living 6 years to living 4 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
k) If your first choice is changed from living 4 years to living 5 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; stop. 
both or indifference stop. 
Ouestion 6. 
You have two choices. The first is that you have a perfect health 
which defines as no problems in walking about. No problems with self- 
care. No problems with performing usual activities ( eg. work, study, 
housework, family or leisure activities). No pain or discomfort. No 
anxious or depressed. And you live for 10 years. The second is that 
you are confined to bed. Unable to wash or dress self. Unable to 
perform usual activities. Extremely pain or discomfort. Extremely 
anxious or depressed. And you live for 10 years. 
a) Which choice do you prefer? 
first choice go on the next step. 
second choice stop. 
b) If your first choice is changed from living 10 years to dying 
immediately and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
c) If your first choice is changed from dying immediately to 
living 9 year and other things are still the same, which choice do you 
prefer? 
first choice ; go on the next step. 
second choice ; stop. 
d) If your first choice is changed from living 9 years to living 
1 year and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
e) If your first choice is changed from living 1 years to living 8 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
f) If your first choice is changed from living 8 years to living 2 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
g) If your first choice is changed from living 2 years to living 7 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
h) If your first choice is changed from living 7 years to living 3 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
i) If your first choice is changed from living 3 years to living 6 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
j) If your first choice is changed from living 6 years to living 4 
years and other things are still the same, which choice do you prefer? 
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first choice ; stop. 
second choice ; go on the next step. 
k) If your first choice is changed from living 4 years to living 5 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; stop. 
both or indifference ; stop. 
Ouestion 7. 
You have two choices. The first is that you have a perfect health 
which defines as no problems in walking about. No problems with self- 
care. No problems with performing usual activities ( eg. work, study, 
housework, family or leisure activities). No pain or discomfort. No 
anxious or depressed. And you live for 10 years. The second is that 
you are confined to bed. Unable to wash or dress self. Unable to 
perform usual activities. Moderate pain or discomfort. Not anxious or 
depressed. And you live for 10 years. 
a) Which choice do you prefer? 
first choice go on the next step. 
second choice stop. 
b) If your first choice is changed from living 10 years to dying 
immediately and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
c) If your first choice is changed from dying immediately to 
living 9 year and other things are still the same, which choice do you 
prefer? 
first choice ; go on the next step. 
second choice ; stop. 
d) If your first choice is changed from living 9 years to living 
1 year and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
e) If your first choice is changed from living 1 years to living 8 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
f) If your first choice is changed from living 8 years to living 2 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
g) If your first choice is changed from living 2 years to living 7 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
h) If your first choice is changed from living 7 years to living 3 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
i) If your first choice is changed from living 3 years to living 6 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
j) If your first choice is changed from living 6 years to living 4 
years and other things are still the same, which choice do you prefer? 
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first choice ; stop. 
second choice ; go on the next step. 
k) If your first choice is changed from living 4 years to living 5 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; stop. 
both or indifference stop. 
Ouestion 8. 
You have two choices. The first is that you have a perfect health 
which defines as no problems in walking about. No problems with self- 
care. No problems with performing usual activities ( eg. work, study, 
housework, family or leisure activities). No pain or discomfort. No 
anxious or depressed. And you live for 10 years. The second is that 
you have some problems in walking about. No problems with self-care. 
No problems with performing usual activities (eg. work, study, 
housework, family or leisure activities). No pain or discomfort. Not 
anxious or depressed. And you live for 10 years. 
a) Which choice do you prefer? 
first choice go on the next step. 
second choice stop. 
b) If your first choice is changed from living 10 years to dying 
immediately and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
c) If your first choice is changed from dying immediately to 
living 9 year and other things are still the same, which choice do you 
prefer? 
first choice ; go on the next step. 
second choice ; stop. 
d) If your first choice is changed from living 9 years to living 
1 year and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
e) If your first choice is changed from living 1 years to living 8 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
f) If your first choice is changed from living 8 years to living 2 
years and other things are still the same, which choice do you prefer? first choice ; stop. 
second choice ; go on the next step. 
g) If your first choice is changed from living 2 years to living 7 
years and other things are still the same, which choice do you prefer? first choice ; go on the next step. 
second choice ; stop. 
h) If your first choice is changed from living 7 years to living 3 
years and other things are still the same, which choice do you prefer? first choice ; stop. 
second choice ; go on the next step. 
i) If your first choice is changed from living 3 years to living 6 
years and other things are still the same, which choice do you prefer? first choice ; go on the next step. 
second choice ; stop. 
j) If your first choice is changed from living 6 years to living 4 
years and other things are still the same, which choice do you prefer? 
605 
first choice ; stop. 
second choice ; go on the next step. 
k) If your first choice is changed from living 4 years to living 5 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; stop. 
both or indifference ; stop. 
ouestion 9. 
You have two choices. The first is that you have a perfect health 
which defines as no problems in walking about. No problems with self- 
care. No problems with performing usual activities ( eg. work, study, 
housework, family or leisure activities). No pain or discomfort. No 
anxious or depressed. And you live for 10 years. The second is that 
you are unconscious. And you live for 10 years. 
a) Which choice do you prefer? 
first choice go on the next step. 
second choice stop. 
b) If your first choice is changed from living 10 years to dying 
immediately and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
c) If your first choice is changed from dying immediately to 
living 9 year and other things are still the same, which choice do you 
prefer? 
first choice ; go on the next step. 
second choice ; stop. 
d) If your first choice is changed from living 9 years to living 
I year and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
e) If your first choice is changed from living 1 years to living 8 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
f) If your first choice is changed from living 8 years to living 2 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
g) If your first choice is changed from living 2 years to living 7 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
h) If your first choice is changed from living 7 years to living 3 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
i) If your first choice is changed from living 3 years to living 6 
years and other things are still the same, which choice do you prefer? first choice ; go on the next step. 
second choice ; stop. 
j) If your first choice is changed from living 6 years to living 4 
years and other things are still the same, which choice do you prefer? first choice ; stop. 
second choice ; go on the next step. 
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k) If your first choice is changed from living 4 years to living 5 
years and other things are still the same, which choice do you prefer7 
first choice ; stop. 
second choice ; stop. 
both or indifference ; stop. 
ouesti2n 10. 
You have two choices. The first is that you have a perfect health 
which defines as no problems in walking about. No problems with self- 
care. No problems with performing usual activities ( eg. work, study, 
housework, family or leisure activities) . No pain or discomfort. No 
anxious or depressed. And you live for 10 years. The second is that 
you have no problems in walking about. Some problems with washing or 
dressing self. No problems with performing usual activities (eg. work, 
study, housework, family or leisure activities) . No pain or 
discomfort. Not anxious or depressed. And you live for 10 years. 
a) Which choice do you prefer? 
first choice go on the next step. 
second choice stop. 
b) If your first choice is changed from living 10 years to dying 
immediately and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
c) If your first choice is changed from dying immediately to 
living 9 year and other things are still the same, which choice do you 
prefer? 
first choice ; go on the next step. 
second choice ; stop. 
d) If your first choice is changed from living 9 years to living 
1 year and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
e) If your first choice is changed from living 1 years to living 8 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
f) If your first choice is changed from living 8 years to living 2 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
g) If your first choice is changed from living 2 years to living 7 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
h) If your first choice is changed from living 7 years to living 3 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
i) If your first choice is changed from living 3 years to living 6 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
j) If your first choice is changed from living 6 years to living 4 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
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k) If your first choice is changed from living 4 years to living 5 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; stop. 
both or indifference stop. 
Ouestion 11. 
You have two choices. The first is that you have a perfect health 
which defines as no problems in walking about. No problems with self- 
care. No problems with performing usual activities ( eg. work, study, 
housework, family or leisure activities). No pain or discomfort. No 
anxious or depressed. And you live for 10 years. The second is that 
you have no problems in walking about. No problems with self-care. No 
problems with performing usual activities (eg. work, study, housework, 
family or leisure activities) . No pain or discomfort. Moderately 
anxious or depressed. And you live for 10 years. 
a) Which choice do you prefer? 
first choice go on the next step. 
second choice stop. 
b) If your first choice is changed from living 10 years to dying 
immediately and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
c) If your first choice is changed from dying immediately to 
living 9 year and other things are still the same, which choice do you 
prefer? 
first choice ; go on the next step. 
second choice ; stop. 
d) If your first choice is changed from living 9 years to living 
1 year and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
e) If your first choice is changed from living 1 years to living 8 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
f) If your first choice is changed from living 8 years to living 2 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
g) If your first choice is changed from living 2 years to living 7 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
h) If your first choice is changed from living 7 years to living 3 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
i) If your first choice is changed from living 3 years to living 6 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
j) If your first choice is changed from living 6 years to living 4 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
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k) If your first choice is changed from living 4 years to living 5 
years and other things are still the same, which choice do you prefer7 
first choice ; stop. 
second choice ; stop. 
both or indifference stop. 
Ouestion 12. 
You have two choices. The first is that you have a perfect health 
which defines as no problems in walking about. No problems with self- 
care. No problems with performing usual activities ( eg. work, study, 
housework, family or leisure activities). No pain or discomfort. No 
anxious or depressed. And you live for 10 years. The second is that 
you are confined to bed. Some problems with washing or dressing self. 
some problems with performing usual activities. No pain or 
discomfort. Not anxious or depressed. And you live for 10 years. 
a) Which choice do you prefer? 
first choice go on the next step. 
second choice stop. 
b) If your first choice is changed from living 10 years to dying 
immediately and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
c) If your first choice is changed from dying immediately to 
living 9 year and other things are still the same, which choice do you 
prefer? 
first choice ; go on the next step. 
second choice ; stop. 
d) If your first choice is changed from living 9 years to living 
1 year and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
e) If your first choice is changed from living 1 years to living 8 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
f) if your first choice is changed from living 8 years to living 2 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
g) If your first choice is changed from living 2 years to living 7 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
h) If your first choice is changed from living 7 years to living 3 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
i) If your first choice is changed from living 3 years to living 6 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
j) If your first choice is changed from living 6 years to living 4 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
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k) If your first choice is changed from living 4 years to living 5 
years and other things are still the same, which choice do you prefer7 
first choice ; stop. 
second choice ; stop. 
both or indifference ; stop. 
ouestion 13. 
You have two choices. The first is that you have a perfect health 
which defines as no problems in walking about. No problems with self- 
care. No problems with performing usual activities ( eg. work, study, 
housework, family or leisure activities) - No pain or discomfort. No 
anxious or depressed. And you live for 10 years. The second is that 
you have some problems in walking about. Some problems with washing or 
dressing self. Unable to perform usual activities. Moderate pain or 
discomfort. Extremely anxious or depressed. And you live for 10 
years. 
a) Which choice do you prefer? 
first choice go on the next step. 
second choice stop. 
b) If your first choice is changed from living 10 years to dying 
immediately and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
c) If your first choice is changed from dying immediately to 
living 9 year and other things are still the same, which choice do you 
prefer? 
first choice ; go on the next step. 
second choice ; stop. 
d) If your first choice is changed from living 9 years to living 
1 year and other things are still the same, which choice do you 
prefer? 
first choice ; stop. 
second choice ; go on the next step. 
e) If your first choice is changed from living 1 years to living 8 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
f) If your first choice is changed from living 8 years to living 2 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
g) If your first choice is changed from living 2 years to living 7 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
h) If your first choice is changed from living 7 years to living 3 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; go on the next step. 
i) If your first choice is changed from living 3 years to living 6 
years and other things are still the same, which choice do you prefer? 
first choice ; go on the next step. 
second choice ; stop. 
j) If your first choice is changed from living 6 years to living 4 
years and other things are still the same, which choice do you prefer? first choice ; stop. 
second choice ; go on the next step. 
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k) If your first choice is changed from living 4 years to living 5 
years and other things are still the same, which choice do you prefer? 
first choice ; stop. 
second choice ; stop. 
both or indifference ; stop. 
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Appendix Il 
The calculation for the health state valuation 
by the time trade-off method. 
For each question, the health state value can be estimated from 
the choice a subject chose in each step as below. Indifference point 
is measured at the mean of the two successive years. 
Stop at step a). There is an inconsistency of the subject' 
preference. 
Stop at step b). The health state has a negative or zero 
value. 
Stop at step c). Indifference point is 9.5. 
The value is 0.95. 
Stop at step d). Indifference point is 0.5. 
The value is 0.05. 
Stop at step e). Indifference point is 8.5. 
The value is 0.85. 
Stop at step f). Indifference point is 1.5. 
The value is 0.15. 
Stop at step g). Indifference point is 7.5. 
The value is 0.75. 
Stop at step h). Indifference point is 2.5. 
The value is 0.25. 
stop at step i). Indifference point is 6.5. 
The value is 0.65. 
Stop at step j). Indifference point is 3.5. 
The value is 0.35. 
Stop at step k). For the first choice, 
Indifference point is 4.5. 
The value is 0.45. 
For the second choice, 
Indifference point is 5.5. 
The value is 0.55. 
For both (or indifference between both) 
Indifference point is 5.0. 
The value is 0.5. 
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Appendix III 
The questionnaire for experts' clinical judgement survey 
on the diseases and health programmes of this study. 
a. A questionnaire set for measles 
Vital clinical findincrs about measles, 
its complications and its vaccine side effects 
The following are the update and vital clinical features of measles, 
its complications and its vaccine side effects, which would assist your 
evaluation. 
a. Clinical feature Reference 
-coryza, conjunctivitis and cough 7 
for 3-7 days 
-rash for 4-6 days 7 
-fever for 2-4 days, malaise, listless- 3,2 
ness, acute catarrh, photophobia, head- 
ache, nose bleeding 
-irritability, constitutional disturbance 3,2 
vomiting and diarrhoea 2-3 days 
-febrile convulsions 3 
-by the end of about a week after its 2 
first appearance, any trace of eruption 
scarcely remains. In favourable cases, 
convalescence produces rapidly, the 
patients feel perfectly well. 
b. Complications 
-gastrointestinal complications include 3 
diarrhoea, vomiting, dehydration, stoma- 
titis, thrush, protein-losing entero- 
pathy, true appendicitis and mesenteric 
adenitis with abdominal pain 
-central nervous system mainly involves 3 
encephalomyelitis which causes fever, 
vomiting, drowsiness, convulsion and 
coma in a rapidly progression rate. The 
consequences are optic nerve damage, 
permanent mental disorders and severe 
neurological damage (epilepsy and para- 
lysis). Recently it has been reported of 
subacute sclerosing panencephalitis. 
-otitis media 1,7 
-respiratory complications include 3 
pneumonia, empyema, bronchitis, pneumo- 
thorax and mediastinal 
-development retard I 
-life-long handicap 1 
-malnutrition 7 
-pancreatitis 6 
-1 in 400 children has major handicap 4 
like blindness due to vitamin A 
deficiency 
-haemorrhagic measles (bleeding) 3 
-other complications includes epistaxis, 3 
cervical and mediastinal adenitis, 
purulent conjunctivitis, urinary tract 
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Reference 
infection, severe impetigo, disseminated 
intravascular coagulapathy, myocarditis 
and measles hepatitis. 
-death 
c. Side effects 
-no serious side effects 1 
-severity of measles in vaccinees 
8 
involves malaise, sore eyes, running 
nose and few spots lasting for 1 day 
-15 % have minor reactions with fever, 5 
rash and Koplik spots. Few have 
transient diarrhoea and cough 
-mild fever and rash for 1-3 days in 7,3 
up to 15 % of vaccinations 
-encephalitis occurs I in a million doses 7 
-neurological disorder 1/1000000 doses 4,3 
-encephalitis and/or encephalopathy 4 
0.3/1000000 doses 
-death 0.7/1000000 doses 6 
-permanent serious handicap 0.5/1000000 4 
doses 
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Moreover, according to your experience, if there are other key 
clinical findings which are not listed above but are included in your 
evaluation, could you please describe them below. 
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Instructions : 
1. You are asked to provide information about measles from your 
experience with regarding its major impact, in general cases, on 
patients' health states, the complications and the side effects of 
vaccination. 
2. The disease prognosis that you will find later in this 
questionnaire is referred to a common clinical outcome (s) of the disease 
with accompanying duration (s) in the typical patients. The first period 
of sick means the first time that the disease produces significantly 
clinical outcome. 
3. The complication prognosis is referred to a less common 
clinical outcome (s) of the disease but more serious illness than usual. 
Among many possible complications, a maximum of three important 
complications, which are categorised into immediate, intermediate and 
long-term periods, is requested. (That is, you may give none, 1,2 or 3 
disease complications. ) The first period of complication means the first 
time that clinical outcomes of the disease complication occur. 
4. The side effect prognosis is referred to an adverse clinical 
outcome (s) arising from the vaccination against measles. Among many 
possible side effects, a maximum of three important side effects, which 
are categorised into immediate, intermediate and long-term periods, is 
requested. (That is, you may give none, 1,2 or 3 vaccine side effects. ) 
The first period of side effect means the first time that clinical 
outcomes of the vaccine side effect occur. 
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b. A questionnaire set for rotavirus diarrhoea 
Vital clinical findings about rotavirus and its vaccine side effects 
The following are the update and vital clinical features of 
rotavirus diarrhoea and its vaccine side effects, which would assist your 
evaluation. 
a. Clinical feature 
-the severity of infection ranges from 
asymptomic to mild diarrhoea to a severe 
condition with sometimes fatal dehydra- 
tion. 
-68 % of patients have fever 
-64 % have vomiting 
-91 % have dehydration 
-explosive and watery diarrhoea lasting 
for 5-7 days 
-loss of absorptive capacity in the 
small intestine 
-malnutrition 
-35 % of patients with less than 2 years 
old have mild dehydration 
-9 % of patients with less than 2 years 
old involve moderate dehydration 
-on average, 5-12 days per episode (8 day 
mean) 
b. Side effects 
-of 25 vaccinees, 1(4 %) had fever, 
1(4 %) had vomiting and 2(8 %) seen 
by a paediatrician during 28 days after 
vaccination without giving their 
problems. 
Reference 
2 
2,3 
2,3,4 
1,2,3 
4 
4 
1 
1 
1 
3 
6 
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Moreover, according to your experience, if there are other key 
clinical findings which are not listed above but are included in your 
evaluation, could you please describe them below. 
625 
Instructions : 
1. You are asked to provide information about rotavirus diarrhoea 
from your experience with regarding its major impact, in general cases, 
on patients' health states and the side effects of vaccination. 
2. The disease prognosis that you will find later in this 
questionnaire is referred to a common clinical outcome (s) of the disease 
with accompanying duration (s) in the typical patients. The first period 
of sick means the first time that the disease produces significantly 
clinical outcome. 
3. The side effect prognosis is referred to an adverse clinical 
outcome (s) arising from the vaccination against rotavirus diarrhoea. 
Among many possible side effects, a maximum of three important side 
effects, which are categorised into immediate, intermediate and long- 
term periods, is requested. (That is, You may give none, 1,2 or 3 
vaccine side effects. ) The first period of side effect means the first 
time that clinical outcomes of the vaccine side effect occur. 
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c. A questionnaire set for infant tuberculosis 
Vital clinical findings about tuberculosis in infants 
and the BCG vaccine side effects 
The following are the update and vital clinical features of 
tuberculosis in infants and the BCG vaccine side effects, which would 
assist your evaluation. 
a. Clinical feature Reference 
-The large majority of children do not mani- 1 
fest clinical symptoms following infection. 
-In a small proportion a mild non-specific 1 
feverish illness occurs at the time of 
tuberculin conversion (winitial fever*). 
-occasionally erythema nodosum or phylycte- 1 
nular conjunctivitis develops. 
-Then comes the primary complex. Haemotoge- 
nous dissemination resulting in miliary 
tuberculosis or in tuberculosis meningitis 
or bronchial dissemination resulting in 
bronchopneumonia, tend to occur within the 
next six months and most cases of this 
nature develop within year of the first 
infection. Local complications from the 
primary complex, such pulmonary segmental 
collapse or obstructive emphysema come a 
little later, usually 6 to 18 months after 
infection and may persist much longer. 
-The same applies to the complications of I 
cervical and mesenteric adenitis. Individual 
organ tuberculosis, such as those of the 
bones and kidneys come even later : two or 
more years after tuberculin conversion. 
-Finally chronic pulmonary tuberculosis comes 
many years after the first infection. In 
comparison between young and older children, 
if the first infection occur in adolescence, 
the adult type of pulmonary tuberculosis 
is likely to follow soon. 
b. Side effects 
-a small red tender swelling appears at the 2 
site of immunisation 
-abscess or lymph glands swelling may develop 2 
-death rate from BCG infection after routine 2 
vaccination is between 0.2 and 1 per 1000000 
vaccinees. 
References 
1. J. O. Foster and G. C. Arneil (1973), Textbook of Paediatrics 
Longman groups limited. 
2. UNICEF (1985) Assignment Children : Universal Child Immunisation 
by 1990, Geneva. 
631 
Moreover, according to your experience, if there are other key 
clinical findings which are not listed above but are included in your 
evaluation, could you please describe them below. 
632 
Instructions : 
1. You are asked to provide information about tuberculosis from your 
experience with regarding its major impact, in general cases, on infant 
patients' health states and the side effects of BCG vaccination. 
2. The disease prognosis that you will find later in this 
questionnaire is referred to a common clinical outcome (s) of the diseaýe 
with accompanying duration (s) in the typical patients. Since 
tuberculosis involves chronic illness, its prognosis is divided into 
three ranges : immediate, intermediate and long-term periods. The first 
period of sick means the first time that the disease produces 
significantly clinical outcome. 
3. The side effect prognosis is referred to an adverse clinical 
outcome (s) arising from the vaccination against tuberculosis. Among many 
possible side effects, a maximum of three important side effects, which 
are categorised into immediate, intermediate and long-term periods, is 
requested. (That is, you may give none, 1,2 or 3 vaccine side effects. ) 
The first period of side effect means the first time that clinical 
outcomes of the vaccine side effect occur. 
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d. A questionnaire set for adult tuberculosis 
Vital clinical findings about adult tuberculosis, anti-tuberculosis 
chemotherapy treatment and the treatment side effects 
The following are the update and vital clinical features of 
tuberculosis in adults and anti-tuberculosis chemotherapy side effects, 
which would assist your evaluation. 
a. Clinical feature Reference 
-usually unnoticed initially 6 
-the time from infection to conversion of the 2 
tuberculin skin test is 6 to 8 weeks; 
demonstrating primary lesions. 
-although most cases of active disease 2 
present with pulmonary disease, virtually 
any organ may later be affected, and signs 
and symptoms vary accordingly. 
-5-8 weeks from initial contracting the 1,3,4,5 
infection having signs of malaise, 
discomfort, fever, night sweats, weight loss 
breathlessness, pain in side or shoulder, 
cough, abundance of sputum, blood spitting, 
a primary lesion in lung, anorix, lassitude, 
strength loss, actual emaciation, chest pain 
female amenhorroea and male impotence 
-the disease develops with uncertain rate, 1,3,4,5 
depending on the patient's condition. The 
symptoms are mainly an increase of those 
present in the first stage, increasing cough 
and the spit is thick and yellow. The patient 
is much weaker, greatly lost in weight, 
swing fever, vomiting and diarrhoea. A key 
sign is the falling in the chest over the 
excavated area. 
-the advanced stage may progress within 1,3,4,5 
the six months which includes organs 
damages, serious debilitation, 
disfiguring and crippling. Large cavities 
have formed in the lung, troublesome 
diarrhoea, haemorrhage, extreme emaciation, 
bed-sores, swing temperature, excessive 
sweats, cough. All through the disease, 
there is often a curious mental state known 
as the spes phthisica, the sufferer being 
buoyed up by the daily recurring belief that 
he is better, and is beginning to recover. 
-death is highly possible if untreated 3,4,5 
b. Side effects 
-side effects of isoniazid are peripheral 2 
neuritis, hepatitis, hypersensitivity 
-side effects of hepatitis, febrile reaction, 2 
purpura (rare) 
-side effects of streptomycin are 8th nerve 2 
damage, nephrotoxicity 
-side effects of ethambutol are optic 2 
neuritis (reversible with discontinuation of 
drug; very rare at 15 mg/kg), skin rash 
-side effects of pzrazinamide are hyperurice- 2 
mia, hepatotoxicity 
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Moreover, according to your experience, if there are other key 
clinical findings which are not listed above but are included in your 
evaluation, could you please describe them below. 
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Instructions : 
1. You are asked to provide information about tuberculosis from your 
experience regarding its major impact on adult patients' health states, 
anti-TB chemotherapy treatment and its side effects. 
2. The disease prognosis that you will find later in this 
questionnaire is referred to a common clinical outcome (s) of the disease 
with accompanying duration (s) in the typical patients. Since 
tuberculosis involves chronic illness, its prognosis is divided into 
three ranges : immediate, intermediate and long-term periods. The first 
period of sick means the first time that the disease produces 
significantly clinical outcome. 
3. In this study, a short course (6-month chemotherapy) is 
considered. The regimen consists of isoniazid 300 mg/d + rifampicin 450- 
600 mg/d + pyrazinamide 1500-2000 mg/d daily for 2 months and isoniazid 
300 mg/d + rifampicin 450-600 mg/d daily for another 4 months. The 
treatment prognosis is referred to a common clinical outcome (s) arising 
from the treatment against tuberculosis. For the comparable purpose to 
the disease prognosis, the treatment prognosis is also classified into 
three. ranges : immediate, intermediate and long-term periods. 
The first period of treatment is the first time that the patient 
seeks the treatment and, presumably, at the same time that the regimen 
is administered to the patients. It should be noted that in order for 
consistency between the disease and treatment prognoses, the first period 
of the treatment prognosis would be matched with a sick period of the 
disease prognosis. 
4. The side effect prognosis is referred to an adverse clinic 
outcome (s) arising from the treatment against tuberculosis. Among many 
possible side effects, a maximum of three important side effects, which 
are categorised into immediate, intermediate and long-term periods, is 
requested. (That is, you may give none, 1,2 or 3 treatment side 
effects. ) The first period of side effect means the first time that 
clinical outcomes of the treatment side effect occur. 
643 
IV po to to to to pri pyj a r- po pt r- IV plu ou po 'a u .0 ý ol Do su 0 P) P S)i ps p En A) (n pf pf A) P) PO 0 0) rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr rr 
m MMM mmm mmm M(DM 
rr cr rT rr rr rr rr rr rr cr lb rr rr rr rr rr rt rT 
n0n H. H. H. P. rr : I, pi rr : 3* V P. : 31 :: r 
0 0 cn ui At Al Ph (4 H. P (n SD P) M ol A) 00 uI .40 La (A U) (n (n C: (D :1 9: m n (D 
p 
:3 >4 00 (D 5 :3 :1 rr tn ý-- rr 0 tn :3 m 
ýL o cr C6 r? X00 , P0W P- 0 - op 00 :100 03 o " (D rf M rj m El r- (D tr 5 El 
ts (D " lu " (D a ý- (A (D 11 In '0 ý-- Ma (D '0 
(n 5 0) :3 m tl p M0M m 0 V 0 (D CT X 51 P )j- 'a . -0 a0 M 10 0 ý- m ý- (D cl, :3 rr "0 (D 0- rr " 0. CL " U. (A 0 l< ý-- 0 (D 00n- ý- 00 ý- 0 ý- rr r- L< r- a0 u- rr tQ (D tj (D tr rx (D P) 
cn P) W 0 'a ?I 'o ý- P- - ýl :ý ý- 5 0 ý- N rr :1 11) ý-- W (D (D < SD (D (D X :30 :1 Fl- 11 N P- :Cý, - cn ýl :c tr 5 P- X" :1 1-. ul rr 0 :1 :r ca P. (D M :3 0 ý, - 0M 0 ý-- ?I rr 11 C0 CL ? -1 00 (D ; -;, PC 0t :r 
Ul r- (D "0 ýl :1w- (D " SD 
C4 a 9L El (A (1) F. - 0 ý-- 0- " n, a- to : 3' (D x 0 (D (4 ý-- 0 P. (D rr 0 " P. s)) P. " in 0w" (a pi z" M :3 :3 mw 00 rr -, " Ll ýl cn tQ o (D 0. (D El 0- :: r, 0 l< P- co 2) 
'a (D CL M ýf (D , :3 0 pi :1 0) 
1-1 '13 - 0" 11 to 0" rD Q tr 
(D " "0 z 0 
En (D rr " C: Z0 : 3, (D 11 P r- 
(n 0 . rr cn Q r- I- (n " Ur rr (D (13 (A ul (D (D 0 
io. (D (D -, I. - U) r_ 
:C:;, " cn rT (a 0 (D 
0 :rx ul ol rr (D 
0 
rr 
(D 
C3 0 D C3 C3 00C C3 C3 C3 C3 00 0 C3 C3 
C C3 00 C3 C3 C3 C3 C3 C3 C3 C C3 C3 C3 CU w 
0 C3 0013 C3 C3 C3 C C3 C3 C3 C3 C3 C3 0 C3 w 
C3 C3 C3 C C3 C3 0 C3 C3 C3 C 0 C3 0 C3 MC 
0 13 0 C3 C3 C3 0 C3 a C2 a C3 C3 C3 C3 0 C3 Ln 0 
;v 
C C3 C C3 C3 C3 C3 C3 C3 C3 13 C3 0 C3 C3 0 C3 aN 
10 
(D 
C3 C3 C3 C3 0 C3 C3 C C3 C3 0 C3 CC C3 C3 C -4 
0 
9L 
C3 C 0 C3 C3 00 C3 0C C3 C3 0 C3 C3 C3 C3 cc) (D 
(D 
;v 
C C3 C3 C3 C3 0 C3 C3 aDC C3 C3 C3 *C3 C3 U w 
C C3 C3 C3 C3 C3 C3 0 C3 C C3 C3 C3 C3 C3 C3 C 
ý-A 
(3 
0 C C3 0 13 C3 C3 C CM C3 D C3'b 0 C3 D 
IFZ 
C3 --C3 13 C3 0 Ci DC C3 C3 13 C3 CC D0C w 
0 
rr (4 
A' m (D M 
rr P) P) 
M U) M 
U) MM 
tn mV 
rr C6 " 
pf ý'- 0 
rt su U: l 
M rr Z 
M0 
cr 0 
: 1, tr, 9L ý, - 
(D H. 01 
rr (n :raM 
(D H. 0) 
0 U) 
10 m (D 
su 0) 
rT M 
H. (D tl 
m0 
:: a tQ 
rr " :3 
00 
(n 0 cn 
(D 
rr 
P. 
cn 0 
,a 
M 
o Aý- ia. a 
.a 
,a 
rr 
(D 
17 
0 
(D 
0 
(D 
0 
(D 
z 
rr 
0 
rr 
:r 
M 
(D 
rr 
n, 
rr 
m 
644 
to of ovi A) NI Ila to 0) Al p tic PIC po 1 to z ru 
t-h z 10 10 PO to Pa po plo 
rr rr rr rr rt 
1 )p P) 
rr rr rr 
Pi cn p cn A) 
rr r- rr rr 
0) A) ol 
rr rr rr 
0) 0 A) 
(D 
)- 
(D 
). -. P. Fl. 
MMM 
)l. ý.. P. ý, - A) ),. ý, - P. P. P. 
rr rr rr 
H. ý'. H. 
:3 0 :1 :3 :3 
mmm 
:3zz 
(D ý- M ýý ý- M 
z :3 1< :3 
MM (D 
:3 :3 :3 
M (D (D 
3 rr CT f"r rr rr cr rr rr rr 0 rr 0 r? rr rr rr 
: ts z 
rr rr rr 000 
W. ý11 P. ti, : 71 :r P. rr :: r* rr P. tr :: r 
p P) p M H- 
M :3 P. (D P. (D 
S)i 
:3 X00 (D ;I ýl :1 rr (A H. rr ýl :: I (n 0 
0 
0 tn :: 1 
$"1 
n 
0 
rr CL rr 
" 
x00 ol P- 0WP. 0 000 :300 
:3 
(D 
M 
rr i2l tr (D 5 r_ (D tr 5 "5 
ul 
" P) 
50 
"Ma 
D ) 
I. - (a (D "M " (D 10 P. (D "a rr 
0 (D rr 
( "0 
5 P) I- 
M* (D 
'a - -0 
M 
V0 
:1 
(1)10 0 
:r 
P. ý- (D 
l 
(D rr :3 rr " A) m tr rr " 0, ial " rx (n 0 
0 
<0 
r 
M 
a0 
000- 00 1- 0 ý-- rr 
w . w 10) a ? It 
tr rr to m 
a"H. -U 
m 
U 
rr tx m 
0 ý- ýl 
P) 
cr z lu P. ID (D (D 0) (D (D Z0 :5P. M " ;I (A -5 t tr 5 x 
0 
:1P. 
0 to 
"w CT 0 :3 
0 P- , 
:r (4 )- (D 0 :3 
r- 0 11 100 
" 
ý- M ;, Vc 
CT 
0 :C ,r 
11 
- :C M r- (D 
(410 
"0 
11 5 
:3 En ,M 
- 
"p :3 lb 
0 ý.. CL rh :;, 10 - cn U) CL : 1* (D Fý X, 0 (D 
" fn 
M 1--o 
00" 
H. (D rr 0 
(A t1l r ti 
ti il. ý-A 
D 
: 1) 
M fn 00 rr - -, " si 5 
( :1" 
cn Q0 
ý- 
X LQ (D 11 (D =1 0 :r0 I< P- U) S)) P. IC (D $1 
' 
"5 (D :3 0" z 0) " 0 0 Q 0 11 (D Q t3l m" "0 :3 0 (n (D rr " 
T 
Z :: 1 0 (D il z C ul to r- P. to " tr rr 
9L (D 
ul W 
: 7* fD 
(D (D 
U) 
0 
Z 
. 0- H. :C (a rr 
Ea 0 (D . Fl. 
rr (D 
P. 0 
(D 
rr (a 
H. (D 
(D 
to 
13 13 C3 0 C3 C3 13 13 C3 C3 C3 C3 C3 13 C3 M C3 
C3 D C3 D 13 13 C3 D C3 C3 13 C3 DD C3 C3 C3 tj 
C3 13 C3 C C3 C3 C3 13 C3 C3 D C3 13 C3 D C3 C3 w 
C3 C C3 D C3- C3 C3 D C3 C3 13 13 13 13 C3 C3 13 ol. 
C3 C3 D C3 13 0D0 a0 13 13 C3 C3 0 C3 13 (n 0 
PV 
0Ma 13 13 0 C3 C3 0 13 00 * 13 00 C', 
,a 
(D 
C3 0 000 000 13 0 13 0a0 13 13 13 -3 
0 
0 0 00a C3 00 000 0 C3 0 000 co 0 
rr 
0 0 00 '13 000 00 13 000 000 ko 
" 0 000 C3 00 13 0 C3 0 13 13 000 CD 
" 0 000 13 00 0 13 Q C0 13 00 13 
01 -- 01 0 C3 01 000 00 C3 0 C3 0 0 
(D (4 hi- 
:e rT (D 
rr 
:r rr 
(D (D 
rr 
tr 
(D 
'Ö (D (D 
%» p 131 
rr 0 (1) 
H- (D (D 
0 
:1 10 10 
rr hi fi 
00 
(Q (Q 
w- zy :i 
000 
bl (4 
:: r rr 
10 
(D H- 
0 P) 
ti 
0 
10 
rr 
(D 
0' 
0 
x 
(D 
0 
?l 
pl 
(D 
ul 
10 
0 
>j 
i3A 
(D 
t: 1 
0 
rr 
: 21 
(D 
645 
10 0 10 0) 
to 10 I'd to po po or: Portz PC to to po pri IV po A) 11) 0) A) 0) V ID (n A) p ul 0) Al 0) 0) p) ps 0) rT rr cr rr rr rr rr rr rr z- rr El 0 rr rr rr rr rr rr 
M M mmm M (D M (D MM MMM (D (D (D 
rr rr rr rr rr rr cr rr rr P) rr rT rr rr rr rr rr 
000 
H. P. P. ý.. Jý. tr :: r :f P. rr v rr :r P. V tr H. :r :r (a (4 W00 p) 1)) P) AI to ID p MW U) V) En m9 :3 m P. 0 0 (D :3 >4 00 m 0 rr M )- rr 0 0 U) 0 0 cn :3 (D 0) 0 (Ir CA rr >4 00 0 H- 0 cn H. 0 000 Z00 i2b 0 M (D rr 9L vm5zm tr 5 "5 :j (D "P " (D IV ýý Cn (D "0 '0 " (D 115 H- (D 'a rr (A 5 A) :3 (D "0 M, (D. N (D :3 :r 0 (D FT x 5 0) P. _ a0 'a 0 (D '0 0 H. M ý, - (D rr :3 cr ?10 (D Ur rr " tr CL "w V) 0 F- 0 M 00n- ý- 00 ý- 0 ý- rr r- a0 V rr QM tr (D rr tr m Al 
(n 0) 10 ?1 10 ý- P. -5 :ý"5 0 "5 (r :1 01 P. 0) (D m< 0) (D m x :10 :3W. 11 " ý] P. :c p- (n El tr -: i H-X N 0 ý, - " (1) rr 0 :j :rW P* (D U) :$ 0 s- 0 ca 0 1- PI r? ti %= 0 11 m00 ti P- (D ;, v 10 0 :c :r ca r- (D "0 cn - (D (a PC 
0 1-1 
91 5 
H. 9L " 
- 11 
:r `0 1 En pt rL t: r (D ;v 0m En H- 0 (D cr 0 " P. ý- s- ti ca 0 (A " 0 r- " (D :3" :3 CL to 00 rr 015 in tQ 0 ; lr Q (D M (D ýl 0 :r0 1< 0 0) 10 (D 91 "5 (D PI - Z; 0" Z P) 
" '0 - 0 tt 5Q 0 rl (D Q tj* (D " "0 11. ýr :: % 0 (4 ID rr " r- 00 :r (D ýL 0) r- w (a . CT 0Q r- H- w" v r1l (D M 
ýl (D 
cn ca 
: 3, (D 
(D (D 
En 
0 
.z P. :C::; ' (n rr cn 0 (D 
r-I 
0 ýr IV rr (D 
0 
M 
rr (n P* (D 
(D 
w- P-h 
C a 0 13 0 El 13 C3 000 0 E3 C C3 C3 D Ln 
C3 13 D0 C3 13 13 13 13 0 13 aaa E3 C3 0 co 
C3 C3 0 C3 C3 C3 C3 C3 CD C3 C3 D C3 C3 0 13 
ý-A 
(n 
C3 D D00 0 C3 C3 0a C3 13 C3 13 C3 C0 
C3 0 000 0 C3 M 1: 1 C3 C3 C3 C3 C3 C3 C3 13 Ln 0 
C3 C C3 C C3 13 C3 C3 C3 CC C3 C3 C3 C3 13 13 C) 
PO 
(D 
rl 
H. 
0 C3 00 C3 C3 C3 C3 00 C3 C3 a 13 C3 C3 C3 
LI) 
Lq 
0 
9L 
C3 C3 C3 C0 00D C3 0 C3 DD C3 C3 C3 C3 
a,. 
C> (D 
0 0 C3 C3 C3 C3 13 0 13 0 C3 0 C3 C C3 C3 C3 Ln 
- C3 C3 C3 C3 C3 C3 C3 D 00 C3 a0 C3 C3 C3 C 
Ln 
Cl 
0 C3 C3 C3 C3 C C3 0 a 13 C3 C3 (3 C3 0C0 
tn 
Ln 
ID 0 C3 C3 0 000 1C C3 C3 C3 C3 0 10 C3 C3 
Ch 
4b 
(4 po 0-3 
rr :r 
ID MM 
rr A) 
M0 ý4 
(D 0 
:3 
rr I 
0 cr 
:c rr (D 
:r (D 
(D H. 
rr U) 
Va (D 
(D ti. 01 
00 
, t3 (D (D 
0p 
rr Ma 
H- (D " 
(D 0 
:1 "a Q 
rr " :3 
00 
0 cn 
0 l< 
rr 
n 0 PV ;, v p. :: l 
,aQ 
(D 
0 
ýl 
N 
0 
rr 
(D 
ol 
0 
>4 
(D 
0 
(D 
rn 
10 
0 
z 
CL 
(D 
:s 
rr 
rr 
0 
rr 
Z* 
(D 
:r 
(D 
rr 
:r 
646 
I 
to A) 110 A) lu 
PTJ "0 
su i 
to to pu po r- po " r. ro IV 110 po po 110 po 
l 
s t A) A) P) 0) ib ul P) p) in pi ol 0) pf 0 0) 0 r r rT rr r? rr rr rr rr rt r. rr cr r? rr rr rr rr rr 
(D m (D 
:3 :j 
M (D 
:1 ts :1 
m (D m 
:j :% :3 
(D ý- m ý- ý- m 
:3 :j L< :1 
(D (D (D 
1 1 
M (D (D 
rr rr rr rr rr rr rr rr rr 0) rr 0) rr 
:: : :3 
rr rr rr 
:1 :3 :3 
rr rr rr 000 
VVV P. rr :r rr :r P. :r tr 0) P) P) (A H. p 1'. P) 0pp (4 Al P) U) (n UI -4 (n .4 En C: H. (D P. (n (n z 0 ta (D X00 (D 5 :3 :3 rt w P. rr :3 :3 (4 z n 0 (n :3 
n o rr m rr " (D X00 r al H. 00 )--o P) 00 00 ýL r tr M5Z (D ' tr 5 rh ý 
:3 MP 
(n (D " (n a 
(D 
I-- (D '0 (D Pa rr (D 
1 
(D 0 (D rr >4 5 A) ýJ- 0,0 10 0 (D V0 P* ý-4 (D P- (D rr :3 rr 11 A) (D tor rr tj Jýr ji " tr 0 l< ý- 0 M 000- ý- 00 ý- 0 ý- rr a0 Ur rl, to M Ix M rr 0- (D 0) 0 10 " 10 ý- I-- -5 :ý ý- 5 0 ý- 5 rr 0) H. P (D (D ý4 ID (D (D :30 :3 i'l g H. (n 5 s. X (n rr o :3 : 3, 0 0 cn 0 11-111 rr 91 r- 0m 00 ti P- (D X'a 0 
M C: (D 0 El :1 En (D 
0a 5 -" 0M 0 P- CL " 'o lr ." fl 'J' (D N0 (D M ý, - 0 P. (D rr 0 " ý'- Pý p " (A 0 U) " (n ti r- " (D V" ý- C, (a 00 rr " CL 5 (A Q0 ; Izl Q (D 0. (D 5o. : 3,0 l< P- w 9) P. 'a M 9L "5 0 t-I :: 0 1-1 Mj - 0" ti 51 to 0" (D to tr (D " P-1 0 :r :3 0 Cn (D rr 0 ýr (D 11 0z 
co (A r- W- En IM U, rr (D M 
C4 (D 
cn to 
PV (D *l, 
(D (D 
I-- (a r- 
:: ý ýr ? -t, (a rr En 0 (D P. 
0 tr PV 
rr (D 
0 
(D 
rr cn 
H. (D 
(D 
Lo t-h 
0 E3 D 13 D C3 13 C3 C3 C3 C3 ao c3 c3 a r3 
1: 3 0 C3 C3 M C3 00 DC E3 D C3 C3 0D0 
C C3 C3 C3 C3 13 0 C3 13 13 C3 C C3 D C3 D C3 
C3 C3 C3 C3 D C3 C C3 a0 13 C3 00 C3 C3 C3 
(D 
0 
rr 
13 C3 a0 13 M0 C3 C3 a C3 0 C3 D 13 D0 Ln 
rr 
C3 C3 13 C3 C3 C3 0 C3 C3 C3 13 0 C3 0 C3 U C3 m 
a 
(D 
D C3 0 C3 0 C3 0 C3 C3 [3 0 DC C3 C C3 C3 
0 
C3 C3 C3 C3 C3 C3 C3 0 E3 0 C3 C3 MC C3 C C3 co (D 
(D 
;v 
D 13 C3 C3 C3 C3 C3 C3 C3 0C C3 C3 C3 C3 D Cl ko 
C3 0 C3 C3 C3 C C3 C3 0 C3 C3 C3 C3 (3 C3 C3 C3 
P" 
0 0 C3 C3 C3 C3 C3 C3 C3 C3 0 13 C3 0 C3 C3 C3 
C3 I - C3 I a C3 01 C3 C3 C3 101: 3 0 C3 C3 C3 I C3 0 C3 
(n 'a 0 ý1' rT ý- m 
0) MM 0) 
rr Al rr 
(D (4 
tn M (D 
:3 
I, - En (D rr 
rp 11 
ID H. 
:c rr 0 
(D rr 0 
(D 
n cr rr o 
N W 
rr M )ý. :r rr A) (n (D " rr 
(D 5 
1c; 0) (D 
P) rr :3 
rr cr 
m :I 
:3 rr 
rr 0 
10 tQ 
)II tl 
ý--o 0 
14.0 
(D to 
9) 
0 tr 
ýr K 
rr rr 
(D 0 
0) IV rr P- 
5 :3 
(D Ul 
0 
rr P- 
:3 
,a 
(D 0) 
" 10 
0 PI 
PI 0 
.a 
(T 
(D 
v 
0 
x 
(D 
0 
(D 
En 
10 
0 
:3 
CL 
(D 
:I 
rr 
rr 
0 
rr 
: 31 
(D 
:r 
M 
rr 
V 
I. 1 647 
ov 
0 
po 
A) Pli a to P tu pv to to 
Z po " r- 10 PC 10 to lu to to 0 P) 0) ol p 0) U) p§ (n A) A) p 0) 0) p pi cr rr rr rr rr rr rr rr rr r- r? r- rr rr cr rr r? rr rr W. M ýj. (D )ý. ý'. P. P. Fj. Fj. ý- p Fi. ý-- A) ý, - )I. ý. 4. P. P. ýJ. :3 z (D MM ts :1 :3 (D (D (D :3 :10 (D ý- M F- ý- M 0 :3I, < :3 MMM 0 :1 :3 M (D :3n:: l rr rlr rr rr rr rr rr rr rr 0) rr P rr rr rr rr rr rr rr 000 
1- P. H. ýr -Ir : 71 P. rr :r rr :f P. :rv P. :r : 3- 0 W ul ul WP0 V) P. A) P. p U) A) A) cn P SD 
r- (D 5 :: 1 n :1 x00 m5 :3 0 rt w H. rr :50 :3 0m :3 M 0 rr 12, rr >4 00 * p $1.0 w P- 0 l 000 :100 p 0 "M rf 134 o m5 r- (D tr 5 "5 :3 (D " P) " (D 10 ý- 0 (D " tn '0 1-. - (D '0 1-- (D 'a lb ý (D tl P) (D - (D PI (D :j :: rl n m rr 50P. a ._ 0 10 0 M 'a 0 Jý. t. -I M H. (D rr :3 rr ti 0) (D tr rr " Ur ýL "v 0 0 ,< ý- 0 (D 000- ý-- 00 ý- 0 ý- rr r- l< r- 10 0 tr rr to (D I: r (D rr ix M P m Al (a Plo 11 a ý- P- *5 :c ý- -! 1 0 1-5 rr 0 ý,. P) (D (D < P (D (D :30 :3 H- 12, N5 ý-- (a ;3 tr BI H- X I-t :3P. " U) rr 0 :1 :: F, (n (D (a 0 t, - 00 0 P. 1-t rr 11 r- 0 in, ?100 P- (D ;, Vrj 0 ,c -Ir CA r- (D "0 Z (n " (D " 0) 
Colo la, 5 -" cn ca 0 t-I H- CL m :: F, 10 - to " M : 1' (D 0 (D (1) s-- 0 P... (D rr 0 
" EQ 0 (A M to 1.1 r_ (D :J CL (a 00 rr " si En tQ 0 
(D 11 (D ýj 0. : 71 0 l< V) 0) '0 (D 91 "5 (D M, Z 0" :3 SD 1.1 PC 0 Q 0 (D QV (D M "0 :: 1 0 
Ca (D rr " r- :30 :r (D 91 0) C: (n ul . rr (a Q r- P. cn " tr rr (D En 
11 (D 
r- [a to 
:rM 
(D (D 
En 
0 
C: 
)a. :ý :r (n rr (A 0 (D P. 
0 : 71 PV 
rr (D 
0 
0 
(D 
rr (A 
P. (D 
(D F- 
ca t-h 
M C3 Cl C3 D M0 C3 93 - C3 C3 13 DD DC C3 
C3 C3 C3 C3 D CC C3 C3 C 13 C3 C3 C3 C3 C3 C3 w 
C3 C3 C3 C3 C3 C3 C3 C C3 M0 C00 DCQ w 
C C3 C3 C0 C3 C3 C3 0 C3 D C3 C3 D C3 C3 C3 
C3 D C3 C3 C3 C3 C3 C3 C3 C3 C3 0 C3 C3 C3 C3 C3 Ln (D 
0 
C3 C3 C3 C3 C3 M C3 C3 C3 C C3 Q C3 C3 C C3 C3 0) 
C3 0 00 C3 0 C3 C3 C3 C3 C3 C3 0 C3 C3 C3 C3 -4 0 z 
C3 C3 C3 C3 C3 C3 C3 C C3 ci C3 C3 C3 C3 C3 C3 C3 co - 
C C3 D Cl C3 C3 C3 C3 C3 0 C3 C3 C3 C3 a C3 C3 ko 
C3 C3 C3 C3 C3 C3 C3 D C3 13 C3 C3 C3 C3 C3 0 C3 
C3 C3 C3 C3 C3 C3 C3 C3 d, C3 C3 Q C3 C3 C3 C3 C3 ý-A 
C3 -- D C3 C3 C3 'C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 
rr 1ý 
P, M (D 
rr P 
(D U) 
Ul (D :3 
rr 
rr 
:c rlr (D 
:r (D 0. 
0 rr lu 
: 1, rr (D M 
rr 
=* rr rr 
(D "" 
(D (D 
rr rr 
rr 55 
ý'- (D (D 
(D :30 
:1 CT rr 
rr 
1010 
00 
En to Q 
00 
:5M (n 
P. P. 
(D (a M 
0) 
0 til 
.= l< 
PC rr 
(D 
o 
-0) to 
,a 
? I. 
0 
rT 
(D 
0 
0 
(D 
En 
Ic 
0 
z 
rr 
cr 
0 
(D 
rr 
648 
, IV po a "Cl tic to ov PC po Z po "Z ra "a PC po po po po 0) 0) 000 0PP P) ti) pWp P) of P) A) A) p I 
rr rr rr rr rr rr rr rT rr C: rr rr rr rr rr rr rt rt 
m M mmm MMM M t- M I-- (D (D M (D MM (D :1 :s :3 :3 :j :%o0 :3 :J 1< :3 :: % :3 :j 0 :3 :3 rr rr rlr rr rr rr rr rr rr ID rr A) rr rT rr rr rr rt rr 
00 () 
P. (T : 11 ti rr :: r 
to ti) (n 0 cn P) 0 P) M P. p H. P) p P) , tA A) ID 
91 Z (D ý :3 
0 ul w <0 ý-A <0 r- ý, - (D P- M En r_ Ul (n n 
(D :3 x00 (D 5 :3 :% (n PI- rlr " :1 (4 :$ 0 ul :1 
:z 
m 0 rr 0. rr x00 P) 0 En ýJ- 0 P) 00 z00 0 "M rr 9L al m5cm tr 5 m5 :1 (D ? 'I P) " (D 1c; ý- (a (D PI U) 'a ý- (D a (D 10 rr (n 5 0) P M Pi P) (D - (D ?J (D ?I :r 0 m rr 5 P) P. V -0 "a 0 (D a0 ý-- M P. (D rr 0 rr H P) (D 0' rr " 0' 0,1-1 0 0 ,< F- 0 (D 000- ý- 001. - 0 rr r_ 1< r- 'cl 0 tr rr Q (D (D rr tr (D P) (A 0) w A) a" 'a ý- P- -0 :5 0 ý- ýl rr :3 0) 1... P) (D (D P (D M >4 :10 0 P- CL 5 (n 5 :4 
P'. X" 0 H. " (n rr 0 :3 :rWH. M U) :3 0 P- 0 (n 0 cr a Z0 CL "00 H- (D ; lvo 0 :c :r - ý- :ý (n r- M "0 5 :3M- (D ti P zi 0) (410 11 5 -" (n (n 0". F- C6 " ::; ' 10 - En " Cl : ýr (D :C;, v PI 0 ID (a F-- 0 (D rr 0 " P. 1. - 0) H- tj cn 0 (1) " (A a JI (D Z" ý- z ýL rn 00 rr ia, 5 WQ0 PV to M CL (D El o :r0 l< I,. w 0) 'o (D 51 m ;5 MM. :3 0" :3 0) 
ti 10 0" ?I IQ 0 Ft (D to v M F1 1.1 0 :3 0 cn (D rr " r_ :10 : 1' (D 11 A) S: cn En . rr (A LQ r- H- (n " ol rr rD (n r- to w (D (D 0 CL (D S)i :: r M '-ý ý- (n r- 
. ýL I- : E: ::; ' t-11 (a rr cn 0 (D 
rr (D 
0 
(D 
(D 
(D 
C3 0 (3 C3 D DDD C3 13 C3 a C3 C3 13 C3 C3 Ln 
C3 C 0 C3 13 C3 0 C3 C3 0 C3 C3 D C3 C3 0M 
H 
a 
C3 13 C3 Cl 13 C3 M C3 C C3 C C3 E3 C 13 13 C3 Ln 
13 C3 C3 C3 C3 13 C3 C3 cl EY C3 UC C3 C3 C3 C3 
w 
a 
C3 C3 C3 C3 C3 C3 C3 C CC0 C3 0 C3 0 C3 C3 un "o 
(D 
a C3 C3 C3 C3 C3 13 0 13 C3 C3 C3 C3 C 13 C3 C3 a 0 
C3 C3 C3 C3 C3 D C3 C3 C C3 C3 C3 C C3 C3 C3 C3 Ln 
(D 
C3 C3 C3 C3 13 C3 C3 C3 C3 13 C3 C3 C3 C3 C3 C3 C3 C) 
C3 C3 C3 C3 C3 D C3 C3 C3 C3 C3 C3 C3 C C3 Cl 13 
Ob 
Ln 
C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 D C3 C C3 C3 
Ln 
CD 
C C3 Cl C3 C3 C3 C3 C3 C3 C3 C3 C3 Cl 0 C3 C3 C3 
Ln 
Ln 
C3 D C3 C C3 C3 C3 C3 C3 C3 13 C3 C3 C C3 C3 C3 
a% 
CD 
rr >- 
P (D (P 
rt Z) 
(D U) >- 
(n ID 0 
rT 1 
9» rr 
K rT 
:: r (D 
rr 
ýr rt 
(D M 
rr 0 
131 rr Pi 
(P tl C 
(D 5 
10 p (0 
IN rr :i 
rr rr 
(D Z; 10 
te rr m 
rr 0 
10 (Q 
p- ki :i 
tli 00 
.N0 (n 
V 
rr (D 
f. H. 
0 
lö 
rr 
(D 
01 
0 
x 
(D 
0 
(D 
(n 
10 
0 
(D 
rr 
0 
rr 
(D 
:r 
(D 
649 
Ili 0) pla 1)) to III to IV po po 
110 r_ ru m 9: 113 po po Ila PO to po 
(It rr 
00 101 r A) Do 0 0m lb pwv 0) 0) A) 10) P 0, r rr rr rr r? cr rt r- cr a r- rr rT ril rr cr rT rr 
M 
:3 
M 
:3 
(D M (D 
:1 :3 :1 
MM (D 
:1 :1 :3 
(D (D I-J M 
:1 :% L< :3 
MMM 
3 
(D M (D 
rr cr rr rr rr rr rr rr rt rT P, rr 
: 0 :3 
rr rT rr 
:3 :3 :1 
rr rr rr 
n00 I... V :r :r Fl. cr " rr :r w I- :r 0 (A WM (A ju JD P) to H. I-A) 000 La P) 0) 
Pj C m zi :3 
W (4 (n 14 0 ý_j < CA 
r- I- M 1- 
Mw 
9: 
14 (A 
(D 
0 
x00 (D 5 :1 :3 rr M P_ (Ir :1 :1w :3 n 0w :j 
1", 
0 
0 
cr m rr 
ti 
>4 00 p P_ 0 to F_. 0 P00 :300 
m rr in. tr mV r_ m tr ýl ", 5 ý_j :I M" ID "M C) I- rA (D rl 0 'Cl ý_ (D 113 P. (D 'a rl* (n 5 A) P m 11 P (D - (D (D :3 tr 0 m rr ýl o) ý.. 'a -0 a0 m 10 0 t- M I- (D rr 0 rr "0 (D tr rr " tr CL " 0, 0 0 ,<1. - 0 (D 000-ý. - 00 ý_ 0 ý_ rr r_ 
(n 
L< r_ 
ol 
10 0 
D1 
tr cr 10 m tr (D rr tr (D 0) w 
:1 A) 
I 0" 
P. 0 
a 1_11.. 5 
(D (D 
:E ý_ ýl 
D 0 ý_ El rr X :90 :3 P- CL "5 (D 
I 
0 ýl :c 
(D 
tr El P. 
(D 
t'. X 1.1 
0 ý-- 
:3P. 
0 (4 
r% (4 rr 0 -, r M Fl. (D (n :3 
sz 0 11 "00 
0 P. " 
P. M X-0 cr 0 :c:: r 
ýl 
- P_ :c CA a (D 
(010 
"0 
11 5 
5 ::, M, (D 
- 
" P) :3 sli 
0 M" : 7,10 - fn 
U) ta 
:r (D 0 (D V) 1- 0 )- M rr 0 " P) 1- " (n 
aw 
0 (n " 
00 rr 
W 9: 
-, r1h m 
(D :: I " 
(n tQ o 
ý_ :3 
M 11 (D El 0 ýr 0 ý< (n P) 
PV Q 
P. 11 " El 
0" 
(D 
5Q 
0 Ili 
0 '"t (D 
:: 3 P) 
t t-I 0 H. :r :3 
Q tr 
0 (A (D 
(n 0 
rr " 
. rr 
0 :30:: 1' 
tQ J= )- 
(D a C: 
(D M 
11 (D 
cn m 
, 
w" 
(D (D 
tr rr 
0. 0) r (D '-ý 
:C:: r 
ý. - (a r_ 
cr 0 (D 
P) -1 "" Z: 0 :: rl ; Nl 
rr (D 
W. 0 
fD 
rr (a 
P. (D 
(D L- 
t-h 
C3 D C3 E3 C3 DM0 C3 M0 13 C3 13 
TO 
C3 E3 
0 13 13 C3 0 D C3 D 0 C3 0 C3 0 13 C3 D C3 w 
C3 M C3 DD D C3 C3 C3 C3 0 a 13 0 C3 C3 C3 P_ 
fl 
rD 
C3 D C3 D C3 C3 C3 C3 C3 C C3 0 C3 C3 C3 C3 C3 l0b (D 
0 C3 C3 C3 0 C3 C 13 C3 13 C C3 C3 C3 C3 C3 0 Lrl 
(D 
0 
rr 
C3 a C3 C3 C3 C3 C3 13 C3 0 C3 C3 C3 C3. C3 C3 C3 CTA 
1c; 
(D 
C3 C3 0 13 0 0 C3 C3 C0 C3 C3 C3 C3 0 C3 C3 -3 
0 
ýL 
C3 C3 00 13 C3 C3 0 0 C3 C3 13 C3 C3 00 C3 cc) (D 
(D 
D 0 C3 0D C3 00 C3 0 C3 C3 C3 C3 C3 0 C3 ko 
C3 C3 C3 C3 C3 C3 C3 0 C3 C3 C3 C3 0 C3 C3 C3 C3 
0 0 C3 C3 C3 00 13 13 C3 0 C3 C3 C3 0 C3 C3 
I C3 I -01 
D C3 C3 I C3 C3 DI a C3 '13 C3 C3 C3 C3 C3 C3 
0 lu lu 10 q : il rr k- )- k- :: r (D 
pi (D (D (D (0 
rT 
(D ID (D (b 
ta r? 
rt rr 5 
IN ti p p. (D 
:e rr n rr iD :i : 21 (D ti (D rr rr 
p. (D 
ft tr rr 0 tr (D : yl u) )l. 
(D (D )-. CL 
rr rt 91 (D 
: 31 0 li, 10 (D 
(D H- H- M ID 
91 00 (D Mh 
10 (D tr mm 
p0P P"h (D 
rT (D P- 12» (D (1 
w- mM k4. n rr 
(D mh (D rr 0 
N (D 
rr n (D rr 
rt p-h l< 
Mh 
(D 0 
U, pö C) m 
m rr 
s'. 0 rr 
(D 0 w- (4 
l< jzý 
m t]ý (D 
k.. k< 
91 (0 
(D rr r1h 
p- Mih 
(D C) (D 
(D N 
0 (C 
0 
lö CL 
(D P 
fi >O Z) 
p. lö 5 
0 pl 0 
ýL 0 :1 
. 10 ta 
10 
0 
(D (D 
0 
ýI 
fl. 
(D 
m 
lö 
0 
(D 
:C 
rr 
rr 
0 
rr 
: 71 v 
(D (D 
C> 
650 
A 
to p to p ro pa 10 ol Tj to 'a to r: to r- Po 110 po po po Pic to 0 of 
l 
ID 0P A) 0 01 U) P lb P) P) 0) Al 0 rr rt r r rr Irr rr CT r? rr r- rr a r- fT rr r? rt rr rr rr 
M MMM MMM M I--, M J-f M (D M (D M (D M 
rr rr r? rr r? rr rr rr rr A) rr 0) rr rt rt rr rr rr rr 000 
P. P. ýJ. P. : 3, :r :r P. rr :r" cr : 71 P- :r :r W. :r :r W M 0 (n 0 A) pP fA ý-- p P- 10 0 ol 0) (n Al P) 
C: M ;1 :3 
P 
:3 >4 00 0 rr 0 P. rr :I :: I ca :3 
0 
0 (n :3 
iab n 0 rr 13, rr H x00 0 1ý. 0MH. 0 01 00 z00 (D rt 11 tr M El Z (D tr 5 rh 51 :3 m"P "Ma ý- (1) (D ti (n 'o ý- (D 'a P. m po rT m ýP :3 m"p M-M (D :1 :r 0 (D rr x ýl p I- 'o . -0 "0 (D 'a 0 1- 1-- M I-- (D rr :3 rr ti lb M U, cr " in, PI ty, (n 0 1. - 0 (D 000- ý- 00 0 ý- rr r- 
(a 
< r- 
A' 
10 0 
t tr rr to M t V rr tr (D P V) P o" o5 :ý P- 5 o 1--5 rr :3 SD p. P) (D M P) (D (D M X :10 :3 1- il "5 (n El -C tr 5 
), - X" 0 W- 
:3 1-. 0 V) " (n rr 0 :3 0 1-- :rU, P- M (A z0 CL "0n " )It fl. (D Prlo, rr 0 :c :r M - ý-- :C (11 r- M 
1 
"0 (D " P) Z 0) V) 0 
0 
Q. -3 
ý. - a I-h tr. .0- to ? 
"% (A Ea 
M Zf' (D 
I- 
: ý: PV M0M M P. - 0 1- (D rr 0 " P- ý- A) ý,. " (a 
(I En 
0W" 
00 rr 
(A r- 1.1 
1ý1 t-h CI. 
(D Z" 
(A Q0 
ý- :1 
M OA (D 50 : 3,0 I< ul P) 
10 m 11 " El (D t-t ý :1 0" " T; - M" 
0" 
"0 
5 ul j- :T 
0" (D 
1 Q tr (n M 
cn to 
cr " 
rr 
r- =I o : 1* 
(n QC "- 
: 
(D 0. 
0 
0) r- 
MM ca W 
En " 
(D (D 
tr rr 
0 
rr 0 (D 
P, " ýl zi 
0 :r tQ 
cr (D 
0 
(D 
(D 
W 
0 0 Doo C3 0 C3 D D E3 C3 C0 C3 
C3 a 0D0 D00 D E3 0 13 C3 0 C3 C3 C3 w 
C3 0 0 13 D C0 C3 C3 DC 0 C3 C3 C3 13 C3 w 
(D 
C3 0 D C3 C3 00 C3 0D C3 CCC C3 C3 C3 (D 
0 C3 C3 C3 0 C3 C3 C3 0D 13 C3 a C3 C C3 C3 vi 
(D 
0 
rr 
C3 0 0 -C3 C3 13 C3 0 C3 C3 C3 13 C3 C3 C3 0 C3 c-, (D 
C3 C3 C3 C3 0 C3 C3 0 C3 0 C3 C3 C3 C3 C3 C3 C3 0 ýl 
0 C3 C3 C3 0 C3 C3 C3 13 C3 C3 0 C3 C3 C3 D C3 co 
F 
0 
:I 
rr 
C a DC0 C3 Cl D C3 C3 13 C3 C3 C3 C3 0 C3 
a C DD C3 DD0 C3 C3 C3 13 C3 C3 C3 C3 C3 
D D C3 13 D C3 C3 C3 a C3 C3 C3 C3 C3 C3 C3 13 
0 - C3 0 C3 0 C3 00 a C3 D C3 C3 C3 00 C3 I. -& m 
10 110 W (D MMm 
" IV of of mw,, " (n. m (D M :3 
13. (n M 
r 
C? (D rt 
$I, cn 'o, cr 0 rr (D 
M 3, 
0 cr rr 01. 
:3. :7. (D : 3' rr 
(D (D (D 
rr 
: 31 (A : 3- V (n 
(D tl- tl- "H 
, il cn 0 C: '0 fD tJ* (D 
P) A) 
rr (D Cr (D 
(D 
" (D (D 
rr 0 (D rr 0 
(I m 
(n Mo 
0 
rr 
rr 
(D :I IX H. 
0 ilt (n 
rn 
(D (D 
cr 
M "' " 
"0M 
pt ý5,0 
1- rr 
rt, "I 
0 
,a :50 (D 0. " of 
010 5 
In'? -I 0 00 
Q 
rr 
(D 
,a 
ol P) 
0 rr 
X P. 
(D (D 
rr 
0 
10 
i'l 
rr 
rr 
0 
rr 
:ra 
ID 
.0 40 
P-0 Q 
rr CD 
651 
I 
113 c Pt r_ lu 110 
rt rr rr rT rr rt rr 
Al En 
rr rr cr 
op SI) 
rr rr rT rr rr rr 
(D 
:3 
M 
:1 
MMM 
:3 :j :3 
M (D (D 
:3 :1 :3 
M 1-4 M )-J M 
:1z l< :1 
M (D M 
1 
M (D M 
rr cr rr rr rr rr rr rt rr lb rr P rr 
: :3 :3 
rlr rr rr 
:1 :1 :j 
rr rr rr 000 
H, 
(n tn 
H. H. rr : 71 ti cr tr :: r :r 
w (A ta III p ol (n P- lb H. p (n 0) P) 
ýL C: M ýl tl 
(A 0 14 <0 1- -4 cn 
r: 1- m ý-- 
cn w 
r M si, :3 >4 00 , Mg :3 :1r? 0 P- rr :3 - :3 cn :% n 0M :3 n o rf M (T M (D >4 0 A) )1- 00 ý-- 0 ' lu 00 :300 
:s m" ID 
rr 0. 
" (D a 
0 M5 r- M 
ý- 0 (D " CA 'a 
tr 5 
ý- (D 'o 
"5 
ý', (D Tj 
Fý 
:1 m PI p M, M M :1 tl 
rr 
:r n M rr X 5 Pj I-, - a . -0 'a 0 (D '0 0 1- 
0 
1. - (D P. 
I< 0 
(D rr P 
(D 
rr N lb (D tr rr " tr in, I-t rx 
z r_ 113 0 
00n- ý- a' rr to (D 00 1-- tr (D 0 ý- T m S)) tn 0 4ý 11 'Cl ý-- I.., - -5 :ý ý- 5 
( TT m 
0 ý- 5 :3 0) ý.. P) (D M lb (D rr X :10 :1 
0 0 
HI En rT 0 ts 
. 0 
:rP. (D 0 
a0 CL 00 
H " 
ý- m ; nl a 
rr 
0 :C : r, 
ýL 
- P- LO r_ (D 
CA a 
0 
5 
:sm (D 
- 
S)) 
0 1.... M rh 
" 
:ra-m P-ti 
En to 
CL :r (D :c ; -v 0M W 1-- 0 H, (D rr 0 SD 1- " (a 
m rA 
0 rA " 
0n rr 
m r- " 
I'll CL 
(D 0 ? --tt 
w tQ 0 
ý- zi 
* m J1 m 50 :r0 l< ;q ta 
M ia, 
ýa 
" El 
0" 
(D 
5 to 
0 
M" "0 H, :r 
0 ?1M 
:3 Q rx m 
w 
CT 
. 
0 
-'r r: P- 
mm 
0 
0) c 
rD CO 
C M co W 
cn " 
(D ID 
tr rr 
0 A Cl 
0 :: r (D ý- (a 
P-h (A 
r: 
0 (D F... 
rr 
?IH. Z 
('r (D 
0 
(D 
rr (A 
P. 
ID (D 
M 1-ý t"ll 
0 D C3 D C3 C3 C3 C3 C3 aD - C3 C3 0 C3 C3 C3 Ln 
0 C3 DD C3 D0D D 13 E3 D 13 - C3 C3 C3 0 
ý-4 
Cl 0 DDD DD0 C3 C3 U DD0 13 Cl C3 
to. 
(D 
C3 D C3 C3 C3 C3 0 C3 0 C3 C3 C3 C3 C3 C3 C3 C3 (D 
C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 0 C3 C3 C3 (D C3 o 
rr 
C3 C3 CD C3 C3 D C3 C3 C3 C3 C3 C3 C3 C3 C 3C (D 
C3 C3 C3 C3 C3 C3 D C3 00 C3 C3 C3 C3 C3 C3 C 0 Ln ja. 
cl C D C3 C3 C3 D C3 C3 C0 C3 C3 C3 C3 . C, q- C3 C3 CD (D 
A) 
C3 C3 D C3 C3 C3 C3 C3 13 a C3 C3 C3 C3 C3 C3 C3 
42. 
Lq 
C3 D DD C3 C3 D C3 C D C3 C3 0 C3 C3 CM M a 
0 D C3 D0 C3 C3 C3 C3 **C3 C3 D C3 C3 C3 C C3 (TI Ln 
D[ -C D0 C3 13 C C3 C3 C3 C3 C3 C3 0 D C3 C3 CD 
w 
(D (D (D (D rt Pi P) P) 
(D (4 ul u) >- 
(n (D (D (D 0 
rt iD rr 
P) (n p rT 
r-r 0 rr (b 
(D 
rr 
: 7' (D Zi' (4 
(D (D 
rt rr 
: 2,0 (D 
(D p. 
Mm 0 (D 
10 (D tý m% 
D) (4 p rh 
(T (D Pl 0* (D 
F- m rl k- 0 
(D Ph (D >- rr :j (D bl. 
rr 0 (D rr 
rr 
N.. 
(D 0 
,ö0A, 
N0 rr 
g» 0 
:; * H- (D 0 
0 mm F-- 
OL '9 
(D (D 
rr mt 
(D w- m 
Mh 0 (D 
mi X, 0 
(D rr 
rr (Q t-h 
0 
p* 
lö 
(D 
hi 
w. PO P) 
O'a 
-5 
). 1 0 
0 :1 
1C3 (C 
rT 
Z) : Z- rr (D 
0 
1Z5 
C» ý3i 
0 
(D 
0 
(D 
0 
10 
12. 
rr 
rr 
0 
rr 
: Z- 
(D (D 
:;, 
pl 
(D b--b 
CD 
652 
Appendix IV 
An early version of the EuroQol instrument. 
a. The statements of the health dimensions. 
Mobility. 
1. No problems walking about 
2. Unable to walk about without a stick, crutch or 
walking frame 
3. Confined to bed. 
Self-care. 
1. No problems with self-care 
2. Unable to dress self 
3. Unable to feed self 
Main activity. 
1. Able to perform main activity (e. g. work, study, 
housework) 
2. Unable to perform main activity 
Social relationships 
1. Able to pursue family and leisure activities 
2. Unble to pursue family and leisure activities 
Pain 
1. No pain or discomfort 
2. Moderate pain or discomfort 
3. Extreme pain or discomfort 
Hood 
1. Not anxious or depressed 
2. Anxious or depressed. 
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b. The valuation measurement. 
IILST IMAGINABLE IILALTII !: ýMTE 
-, loor- 
- t1o problems in walking about 
- No problems with self care 
- Unable to perform mnin activity 
(t. g. work. study. housa? --, -ýork) 
- Able to pursue family and 
leisure activities 
- Moderate pain or discomfort 
- Not anxious or depressed 
- No problems in walking about 
- No problems with self-care 
- Able to perform main activity 
(eg. work. study. housework) 
- Able to pursue family and 
leisure activities 
- No pain or discomfort 
- Not anxious or depressed 
- No problems in walking about 
- No problems with self-care 
- Unable to perform main activity 
(eg work. study. housework) 
- Unable to pursue family and 
leisure activities 
- Modcrate pain or discomfort 
- Anxious or depressed 
- Unnblc to wnIk without n sLi(: k-. 
crutch or walking frnme 
- Unable to dress scir 
- Unable to pcrrorm mnin ncLiviLy 
(eg work. study. housework) 
- Unable to pursue ramily and 
leisure activities 
- Extreme pain or discomrort 
- Anxious or depressed . 
95 
90 
B5 
80 
75 
70 
65 
60 
55 
50 
45 
40 
35 
30 
25 
20 
Is 
10 
- No problems in wr%lkitig tibout 
- No problems with .; cir-cnt-a 
- Able Lo pr%vrot-m mniti nctivity 
(n. g. work, sLmly. housework) 
- Able Lo ptivsm. rt,. iiy ato 
lelsurc ncLivitics 
- Modevnte pnin or disco, rort 
- Anxious or depresscd 
- Unable to walk about wiLhout a 
stick. crutch or wnlkitig rrnme 
- No problems'with scir-cm-a 
- Utirible to perrorm main nCLivity 
(ý-r, work. study. housr-4ork) 
- Unable to pursue ramny and 
letsurc ncLivitics 0 1-*. xtr(, mf! pnin or discomf'ort 
Anxious or dcpvcssed 
I- Being Dend 
.j0- C- 
- 
WORST IMAGINABLE HEALTH STATE 
cotirim. -ii to in-ti Unnille to recti svir 
uonwe to milill ; %C. Li%, ILY 
(#-g wovk. study. limmework) 
- Ilimble- IL) Imr. -me I*nnilly mid 
leLsurc nctiviLies 
- 1-*. xtrcmc pnin or discontrovt 
- Anxious or depressed 
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BUST IMAUINAIII. I. IIL:, %L: 1'11 STA-m 
-1 loo F 
- No problcms In walkitig about 
- No probl,!: ms with self-cnre 
- Able perrorm main activity 
(e.;. work. study. housework) 
- Able! to' pursue ramily and 
Icistire activities 
- Maderate. pnin or dIsc6m. "arL 
- Not anxious or depressed 
- No problems In walking nbout 
- No problims with scir-care 
- Unnble to perform main nctivity 
(eg. work. study. housework) 
- Unnble to pursue family and 
leisure activities 
- Extreme pain or discomfort 
- Anxious or depressed 
I 
Being Dead 
95 
90 
B5 
80 
75 
70 
65 
60 
55 
50 
- No problems in wnlking obout 
- No problems with scIr-cave 
- Unable to parrot-m main EtcLivity 
(e. g. work. study. housework) 
- Able to pursue rnmny ww 
1cistire nctivities 
- Extreme pniti or discomrot-L 
- Not atixious or depressed 
- No problems in walking about 
- Po problems witi, seir-cnre 
- Able to pcrrorm main activity 
feg work. study, housework) 
- 
ýble 
to pursue rnmily and 
leisure activities 
- No pain or discomrort 
- Anxious or depressed 
45 
40 
35 
30 
- No problems in walking about 
- No problems with selr-care 
- Unable to perform main activity 
(eg work. study. housework) 
- Unnble to pursue ramily nnd 
leisure activities 
- Moderate pain or discomfort 
- Anxious or depressed 
25 
- Conrined to bed 
- Unable Ln drc. ss %Clr 
- Unable Lo pnrrorm main activity 
(eg work. sLudy. housework) 
- Unable tp purs; m ramily nr)d 
leisurew ncLivftins 
- r:. xLl-cmc pain or discomrovt 
- Anxious or depressed 
- Unable to wnlk without a stick. 20 crutch or walking rrame 
- Unable to reed seir 
15 Unable to perrorm main activity 
(eg work. study. housework) 
Unable to pursue ramLly and 10 leisure activities 
Extreme pain or discomrovt 
5 Anxious or depressed 
oL 
WORST IMACUNAULE )IF. ALI*ll STATC 
Source : The EuroQol Group (1990). 
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Appendix v 
The predicted values of 243 health states according to 
the EuroQol classification by the aspect and 
the regression models based on the Thai interviewed 
standardised data. 
Health 
state 
Median value of 
the individual 
predicted values 
by the aspect 
model 
the predicted 
value by the 
regression 
model 
11111 - 0.71 
11112 0.74 0.63 
11113 0.37 0.55 
11121 0.75 0.66 
11122 0.56 0.58 
11123 0.29 0.50 
11131 0.36 0.61 
11132 0.29 0.53 
11133 0.15 0.45 
11211 0.63 0.60 
11212 0.48 0.53 
11213 0.25 0.45 
11221 0.48 0.55 
11222 0.34 0.47 
11223 0.17 0.40 
11231 0.25 0.50 
11232 0.17 0.42 
11233 0.08 0.34 
11311 0.31 0.50 
11312 0.25 0.42 
11313 0.13 0.34 
11321 0.25 0.45 
11322 0.17 0.37 
11323 0.08 0.29 
11331 0.14 0.40 
11 32 0.08 0.32 
11333 0.04 0.24 
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The predicted values of 243 health states according to 
the EuroQol classification by the aspect and 
the regression models based on the Thai interviewed 
standardised data. (continued). 
Health 
state 
Median value of 
the individual 
predicted values 
by the aspect 
model 
the predicted 
value by the 
regression 
model 
12111 0.55 0.60 
12112 0.44 0.52 
12113 0.23 0.44 
12121 0.42 0.55 
12122 0.30 0.47 
12123 0.15 0.39 
12131 0.22 0.50 
12132 0.15 0.42 
12133 0.07 0.16 
12211 0.37 0.49 
12212 0.26 0.42 
12213 0.13 0.34 
12221 0.25 0.44 
12222 0.19 0.36 
12223 0.10 0.29 
12231 0.12 0.39 
12232 0.10 0.31 
12233 0.05 0.23 
12311 0.19 0.39 
12312 0.13 0.31 
12313 0.06 0.23 
12321 0.12 0.34 
12322 0.10 0.26 
12323 0.05 0.18 
12331 0.06 0.29 
332 0.05 0.21 
12333 0.03 0.13 
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The predicted values of 243 health states according to 
the EuroQol classification by the aspect and 
the regression models based on the Thai interviewed 
standardised data. (continued). 
Health 
state 
Median value of 
the individual 
predicted values 
by the aspect 
model 
the predicted 
value by the 
regression 
model 
13111 0.27 0.49 
13112 0.23 0.41 
13113 0.12 0.33 
13121 0.22 0.44 
13122 0.15 0.36 
13123 0.07 0.28 
13131 0.12 0.39 
13132 0.07 0.31 
13133 0.04 0.23 
13211 0.17 0.38 
13212 0.13 0.30 
13213 0.06 0.23 
13221 0.12 0.33 
13222 0.10 0.25 
13223 0.05 0.17 
13231 0.06 0.28 
13232 0.05 0.20 
13233 0.03 0.12 
13311 0.10 0.28 
13312 0.06 0.20 
13313 0.03 0.12 
13321 0.06 0.23 
13322 0.05 0.15 
13323 0.03 0.07 
13331 0.03 0.18 
1 332 0.03 0.10 
13333 0.01 0.02 
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The predicted values of 243 health states according to 
the EuroQol classification by the aspect and 
the regression models based on the Thai interviewed 
standardised data. (continued). 
Health 
state 
Median value of 
the individual 
predicted values 
by the aspect 
model 
the predicted 
value by the 
regression 
model 
21111 0.75 0.62 
21112 0.59 0.54 
21113 0.30 0.46 
21121 0.58 0.57 
21122 0.41 0.49 
21123 0.20 0.41 
21131 0.29 0.52 
21132 0.20 0.44 
21133 0.10 0.36 
21211 0.50 0.52 
21212 0.36 0.44 
21213 0.18 0.36 
21221 0.34 0.47 
21222 0.26 0.39 
21223 0.13 0.31 
21231 0.17 0.42 
21232 0.13 0.34 
21233 0.07 0.26 
21311 0.2G 0.41 
21312 0.18 0.33 
21313 0.09 0.26 
21321 0.17 0.36 
21322 0.13 0.28 
21323 0.07 0.20 
21331 0.08 0.31 
21 3 0.07 0.23 
21333 0.03 0.15 
659 
The predicted values of 243 health states according to 
the EuroQol classification by the aspect and 
the regression models based on the Thai interviewed 
standardised data. (continued). 
Health 
state 
Median value of 
the individual 
predicted values 
by the aspect 
model 
the predicted 
value by the 
regression 
model 
22111 0.43 0.51 
22112 0.30 0.43 
22113 0.15 0.35 
22121 0.29 0.46 
22122 0.22 0.38 
22123 0.11 0.30 
22131 0.15 0.41 
22132 0.11 0.33 
22133 0.06 0.25 
22211 0.25 0.41 
22212 0.19 0.33 
22213 0.10 0.25 
22221 0.19 0.36 
22222 0.13 0.28 
22223 0.07 0.20 
22231 0.09 0.30 
22232 0.07 0.23 
22233 0.03 0.15 
22311 0.12 0.30 
22312 0.10 0.22 
22313 0.05 0.15 
22321 0.09 0.25 
22322 0.07 0.17 
22323 0.03 0.09 
22331 0.05 0.20 
22 3 0.03 0.12 
22333 0.02 0.04 
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The predicted values of 243 health states according to 
the EuroQol classification by the aspect and 
the regression models based on the Thai interviewed 
standardised data. (continued). 
Health 
state 
Median value of 
the individual 
predicted values 
by the aspect 
model 
the predicted 
value by the 
regression 
model 
23111 0.23 0.40 
23112 0.15 0.32 
23121 0.15 0.35 
23122 0.11 0.27 
23123 0.06 0.19 
23131 0.07 0.30 
23132 0.06 0.22 
23133 0.03 0.14 
23211 0.12 0.30 
23212 0.10 0.22 
23213 0.05 0.14 
23221 0.09 0.25 
23222 0.07 0.17 
23223 0.03 0.09 
23231 0.05 0.19 
23232 0.03 0.12 
23233 0.02 0.04 
23311 0.06 0.19 
23312 0.05 0.11 
23313 0.03 0.03 
23321 0.05 0.14 
23322 0.03 0.06 
23323 0.02 -0.02 23331 0.02 0.09 
23332 0.02 0.01 
2 0.01 -0.07 23113 0.07 0.24 
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The predicted values of 243 health states according to 
the EuroQoI classification by the aspect and 
the regression models based on the Thai interviewed 
standardised data. (continued). 
Health 
state 
Median 'Value of 
the individual 
predicted values 
by the aspect 
model 
the predicted 
value by the 
regression 
mode 1 
31111 0.36 0.53 
31112 0.30 0.45 
31113 O. IG 0.38 
31121 0.29 0.48 
31122 0.20 0.40 
31123 0.10 0.32 
31131 0.15 0.43 
31132 0.10 0.35 
31133 0.05 0.27 
31211 0.26 0.43 
31212 0.18 0.35 
31213 0.09 0.27 
31221 0.17 0.38 
31222 0.13 0.30 
31223 0.07 0.22 
31231 0.08 0.33 
31232 0.07 0.25 
31233 0.03 0.17 
31311 0.13 0.33 
31312 0.09 0.25 
31313 0.04 0.17 
31321 0.08 0.28 
31322 0.07 0.20 
31323 0.03 0.12 
31331 0.04 0.22 
313 2 0.03 0.15 
31333 0.02 0.07 
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The predicted values of 243 health states according to 
the EuroQol classification by the aspect and 
the regression models based on the Thai interviewed 
standardised data. (continued). 
Health 
state 
Median value of 
the individual 
predicted values 
by the aspect 
model 
the predicted 
value by the 
regression 
model 
32111 0.23 0.42 
32112 0.15 0.34 
32113 0.07 0.26 
32121 0.15 0.37 
32122 0.11 0.29 
32123 0.06 0.21 
32131 0.07 0.32 
32132 0.06 0.24 
32133 0.03 0.16 
32211 0.12 0.32 
32212 0.10 0.24 
32213 0.05 0.16 
32221 0.09 0.27 
32222 0.07 0.19 
32223 0.03 0.11 
32231 0.05 0.22 
32232 0.03 0.14 
32233 0.02 0.06 
32311 0.06 0.22 
32312 0.05 0.14 
32313 0.03 0.06 
32321 0.05 0.16 
32322 0.03 0.09 
32323 0.02 0.01 
32331 0.02 0.03 
32 0.02 0.03 
32333 0.01 -0.04 
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I Illifil II 
The predicted values of 243 health states according to 
the EuroQol classification by the aspect and 
the regression models based on the Thai interviewed 
standardised data. (continued). 
Health 
state 
Median value of 
the individual 
predicted values 
by the aspect 
model 
the predicted 
value by the 
regression 
model 
33111 0.12 0.31 
33112 0.07 0.23 
33113 0.04 0.15 
33121 0.07 0.26 
33122 0.06 0.18 
33123 0.03 0.10 
33131 0.04 0.21 
33132 0.03 0.13 
33133 0.01 0.05 
33211 0.06 0.21 
33212 0.05 0.13 
33213 0.03 0.05 
33221 0.05 0.16 
33222 0.03 0.08 
33223 0.02 0.00 
33231 0.02 0.11 
33232 0.02 0.03 
33233 0.01 -0.05 
33311 0.03 0.11 
33312 0.03 0.03 
33313 0.01 -0.05 
33321 0.02 0.05 
33322 0.02 -0.02 
33323 0.01 -0.10 
33331 0.01 0.00 
33332 0.01 -0.08 33333 0.00 -0.15 
Notes : 1. The value of health state 11111 is assumed to 
be 1.00 in the computation of the aspect 
model. 
2. The values are rounded up at 0.005. So in some 
health states, identical reported numbers, 
in fact, are different when extended the 
digits. For example, health states 23331 and 
23332 are reported to have the value of 0.02 
but their scores are 0.023 and 0.017; 
respectively. 
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